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Abstract 
 
Several long non-coding RNAs (lncRNAs) have been identified to play key, rate-
limiting roles in malignancies, and the mechanisms involved are now being 
elucidated. This study addressed the roles of NEAT1 and MIAT lncRNAs, in breast 
cancer.  
The short isoform NEAT1 _1 was found to be significantly up-regulated in 
advanced stages of breast cancer samples and in the ER/PR +ve and HER –ve 
molecular subtype, where its expression correlated positively with that of its 
neighbouring gene, MALAT1. NEAT1 transcripts in breast cancer cell lines were 
detected in both nuclear and cytoplasmic compartments. Silencing of cytoplasmic 
NEAT1 led to an increase in the expression of nuclear NEAT1, where such 
overexpression inhibited apoptosis and increased cell survival. Consistent with 
this, siRNA and ASO mediated knockdown of NEAT1 transcript levels decreased 
cell survival and migration and promoted cell death induced by different apoptotic 
stimuli including chemotherapeutic agents and UV-C irradiation. Reduced NEAT1 
expression levels were also associated with changes in the expression of genes 
involved in the regulation of cell proliferation and survival. More importantly, it was 
found that NEAT1_1 regulates gene expression in cis and trans.  
MIAT expression levels were significantly increased in triple negative breast 
cancer samples and its expression correlated with NEAT1 expression. In breast 
cancer cell lines, MIAT expression was found to correlate with the expression of 
the transcription factor Oct4. MIAT down-regulation in breast cancer cells 
enhanced the basal apoptosis level and inhibited short and long-term survival. 
Induction of cell death by UV-C irradiation and chemotherapeutic drugs was also 
augmented in cells transfected with MIAT specific siRNA. 
Taken together, the outcome of this study reveals important roles for NEAT1 and 
MIAT lncRNAs in breast cancer. Future work should explore the potential of these 
lncRNAs in the development of therapeutic drugs and as diagnostic and 
prognostic markers.    
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Chapter 1 
Introduction  
 
 1.1 Anatomy and physiology of the breast 
 
The breasts are bilateral prominent structures that lie in front of the chest above 
the pectoralis major and serratus muscles. They are attached to the skin by a layer 
of connective tissues known as cooper’s ligaments, where neoplasm of the breast 
might affect them and causing a retraction of the overlying skin (Mace︠a and 
Fregnani, 2006). Each breast extends vertically from the collarbone (clavicle) to 
the sixth rib edge and horizontally from the middle breastbone (sternum) to the 
mid-axillary line below the armpit. The center of each breast has a dark skin area 
called nipple surrounded by a circular pigmented dark skin area called the areola. 
Areola skin is characterised by appearance of little bumps that are related to 
modified sebaceous glands, which moisturise the nipples during breastfeeding 
(Darlington, 2015). 
Structurally, breast tissues consist of glandular tissues, which are formed by 15-20 
lobes that are separated by adipose and connective tissues (Cooper’s ligaments). 
These connective tissues provide support to the breast (Ellis and Mahadevan, 
2013). Each lobe is made up of multiple smaller lobules, in which milk-secreting 
glands (alveoli) are found.  Milk produced in the alveoli passes into a series of 
small ducts or tubules that drain toward the apex of the nipple (Ellis and 
Mahadevan, 2013). At birth, the mammary glands are not developed and appear 
as a slightly elevated region in the chest. The female breast begins to develop with 
the onset of puberty by forming the lobules and their ducts, and increasing fat 
deposition leading to an increase in breast size. The size and pigmentation of the 
areola and nipple also increase during the onset of puberty (Ellis and Mahadevan, 
2013). The development of the breast during puberty is under the influence of 
oestrogen and progesterone hormones. Estrogen affects the growth of the ducts 
 while progesterone stimulates the growth of lobules (Ellis and Mahadevan, 2013). 
Notably, mammary gland tissues development start at puberty and is completed 
during pregnancy and lactation. During menopause, atrophy in the glandular tissue 
occurs, in addition to a decrease in breast consistency as a result to the reduction 
in collagen amounts (Ellis and Mahadevan, 2013).  
In addition, the breast contains nerves, blood vessels and lymphatics, which drain 
the fluid to the axillary and internal thoracic lymph nodes. Approximately, 75% of 
breast lymphatic fluids drain to the axillary lymph nodes while the remaining 25% 
passes to the internal thoracic lymph nodes (Darlington, 2015; Neville and Neifert, 
1983; Ellis and Mahadevan, 2013).  
 
1.2 Aetiology and histopathology of breast cancer 
Breast cancer is a heterogeneous group of diseases that results from a multistep 
process of accumulating genetic alterations of several proto-oncogenes and 
tumour-suppressor genes as well as other genetic changes including 
chromosomal rearrangements and copy number amplifications (Osborne et al, 
2004).  Breast cancer comes in several clinical and histological forms and 
represents the most common worldwide disease and the leading cause of death 
among women in less developed countries (Cancer, I.A.F.R.O. 2013). According 
to British cancer statistics (2014), the incidence of breast cancers in United 
Kingdom represents 15% of all new cases of cancer (UK, C. R. 2014). Higher 
incidence of breast cancer is reported in women with early onset of menarche and 
late menopause, low number of pregnancies in addition to their first full term 
pregnancy after age of 40 and short duration of breastfeeding (van den Brandt and 
Goldbohm, 2002; UK, C. R. 2014). Breast cancer risk factors include frequent 
 exposing to ionizing radiation at a younger age, excessive alcohol consumption, 
high body mass index and the use of exogenous hormones such as hormonal 
replacement therapy (UK, C. R. 2014). 
According to Histopathological examination, breast cancer can either be in situ 
(localized in their site of origin), or invasive carcinoma (invade the underlying 
tissues) (Pinder, 2010). Carcinoma in situ is an epithelial hypertrophy of the ducts 
and lobules without invading the basement membrane. About 20-25% of all breast 
cancers are ductal carcinoma in situ (DCIS), while 1-2 % represents lobular 
carcinoma in situ (Pinder, 2010; Tuzlali, 2016; Cutuli et al, 2015).  
Although, the invasive breast cancers (ductal and lobular carcinoma) differ in their 
morphological characteristics as well as in their metastatic ability, both of them 
develop from the duct-lobular junction and represent the most common breast 
cancer types (Turashvili et al, 2007). In contrast to invasive ductal carcinoma, 
lobular carcinoma represents 15% of all invasive breast cancers and metastasizes 
markedly to the gastrointestinal system, gynaecologic organs, and peritoneum 
(Turashvili et al, 2007; Borst and Ingold, 1993; Winn et al, 2016; Gatza and Carey, 
2016).   
 
1.3 Classification of breast cancer  
Breast cancer is a heterogeneous disease that comes with distinct 
histopathological, biological and molecular subtypes leading to disparate response 
to therapeutics and clinical outcomes. Such classification is clinically important as 
it allows informed decision regarding treatment, management and determines the 
prognosis (Viale, 2012; Rakha & Green, 2017; Brenton et al, 2005). 
Histopathological classification is considered as a worldwide reliable method of 
 subdividing breast cancer in two types, ductal and lobular carcinoma. Although, 
the basic importance of this classification is to give an idea about the 
morphological characteristics of breast cancer, but it has a minimum clinical 
application particularly in choosing the suitable method of management. The 
histopathological identification of breast carcinoma together with the tumour size 
and grade represent the basic outline of a pathological report (Viale, 2012). The 
biological classification of breast cancer is based on their molecular signature i.e. 
expression of protein biomarkers and gene expression profiles. Such classification 
provides information for treatment decision and choosing appropriate therapeutic 
strategies such as systematic hormonal therapy and chemotherapy (Viale, 2012; 
Rakha & Green, 2017). The classification used conventionally for patient 
prognosis and management is based on the expression of the classical 
immunohistochemistry markers namely oestrogen receptor (ER), progesterone 
receptor (PR) and human epidermal growth factor receptor 2 (HER2) (Viale, 2012; 
Rakha & Green, 2017). However, high-throughput technologies like gene 
expression profiling and microarray analysis led to the identification of further at 
least five molecular breast cancer subtypes: luminal, normal breast-like, HER2, 
and basal-like (Brenton et al, 2005; Vidal et al, 2016).  The luminal subtype is 
further sub-categorised into type A and B. Both subtypes are ER positive and 
represent 65-70% of breast cancers. However, the characteristic profile of luminal 
type A includes low ratio of Ki-67 (≤14%), a p53 mutation rate of 13% and an 
excessive expression of ER related genes such as GATA binding protein 3 
(GATA-3), X-box binding protein 1 (XBP-1), forkhead box A1 (FOXA1) and Alcohol 
dehydrogenase 1B (ADH1B) (Zhang et al, 2014; Sørlie et al,2001). Whereas 
luminal type B is characterised by a  high level of ki-67 (≥ 14%), frequent p53 
mutation rate (~40%) and high expression of proliferation- related genes such as 
 Cyclin B1(CCNB1), Marker Of Proliferation Ki-67 (MKI67) and myeloblastosis 
oncogene-like 2 (MYBL2) (Zhang et al, 2014a; Sørlie et al,2001). The 5-year 
survival rate of luminal type A is 95% and approximately 50% for luminal type B 
breast cancer (Zhang et al, 2014a; Sørlie et al, 2001). 
Basal-like subtypes are known to be ER, PR and HER2 negative (triple negative) 
and likely to be grade 3 tumour (Wu et al, 2012). These types of tumours account 
for 60% to 90% triple negative cases (Liedtke et al, 2008; Bertucci et al, 2006) and 
are of particular interest due to their aggressive clinical course and the lack of any 
form of standard targeted systemic therapy (Badve et al, 2011). The gene 
expression profiles of these tumours mimic that of the normal breast myoepithelial 
cells and basal epithelial cells of other parts of the body.  Such gene expression 
profiles include lacking or low expression of ER, PR and HER2, and high 
expression of basal epithelial cell markers such cytokeratins 5, 6, 14, 17 and 
EGFR (epidermal growth factor receptor or HER1) (Carey et al, 2006; Wu et 
al,2012). These tumours also shows high expression levels of proliferation related 
genes and are more probable to have low expression levels of BRCA1 and to 
harbour TP53 mutation (Carey et al, 2006; Wu et al, 2012).  
Similar with basal cancers, HER2 overexpression tumours are likely to be of grade 
3 tumours (Weigelt et al, 2010; Voduc et al, 2010). HER2 tumours display two 
patterns of gene expression. The first one is the high expression of HER2 and lack 
of ER expression (HER+/ER-). The second pattern of HER2 positive tumours is 
the expression of ER (HER2+/ER +) (Carey et al, 2006). The tyrosine kinase 
 HER2 receptor is encoded by the HER2 gene, which is a proto-oncogene located 
on chromosome 17q21 (Yersal and Barutca, 2014). Activated HER receptors 
undergo dimerization and transphosphorylation on the tyrosine residues of their 
intracellular domains. The phosphorylated tyrosine residues interact with 
 numerous intracellular signaling molecules, leading to activation of a number 
signaling pathways that lead to the activation of transcription factors which 
regulate many genes involved in cell proliferation, survival, differentiation, 
angiogenesis, invasion and metastasis (Barnes and Kumar, 2004; Gutierrez and 
Schiff, 2011). Clinically and biologically, HER2-positive tumours display aggressive 
behavior, are highly proliferative and more than 40% have TP53 mutations. These 
tumours account for 15-20% of breast cancer subtypes and are characterised by 
the high expression levels of genes associated with the HER2 pathway (Barnes 
and Kumar, 2004; Gutierrez and Schiff, 2011). These tumours show relative 
resistance to hormonal agents and an increased sensitivity to certain cytotoxic 
agents such as doxorubicin (Yersal and Barutca, 2014). Doxorubicin sensitivity 
has been possibly due to amplification of topoisomerase-2 gene which is located 
near the HER2 locus on chromosome 17 and is the target of this drug (Ross et al, 
2003; Gabos et al, 2006). However, the advances in translational science have led 
to the development of a large spectrum of HER targeted therapies. 
Normal breast like tumours are poorly characterised. They account for about 5%-
10% of all breast cancers and usually do not respond to neoadjuvant 
chemotherapy (Yersal and Barutca, 2014). They are characterised by high 
expression of genes related to adipose tissues presenting an intermediate 
prognosis between luminal and basal-like tumours (Perou et al.,2000; Smid et 
al.,2008). These tumours can also be classified as triple negative due to the lack 
of ER, PR and HER2 expression. However, they are not considered basal type 
because they lack the expression of cytokeratins 5 and EGFR (HER1) (Yersal and 
Barutca, 2014).Table 1.1 summaries the characteristics of breast cancer subtypes.  
 
 
  
 
                             Table 1.1 The molecular taxonomy of breast cancer     
 
 
Currently, the use of endocrine therapy is considered the best choice for the 
treatment of breast cancer with ER and PR overexpression, while systematic 
Molecular 
subtype 
Tumour characteristics  References 
Luminal A  
ER positive. 
Excessive expression of ER related genes GATA 
binding protein 3(GATA-3), X-box binding protein 
1(XBP-1), Forkhead box A1(FOXA1) and Alcohol 
Dehydrogenase 1B (ADH1B). 
Low expression of Ki-67 (≤14%). 
P53 mutation rate of 13%. 
5-year survival rate is 95% . 
Zhang et al, 
2014a; 
Sørlie et 
al,2001 
Luminal B 
ER positive.  
High expression of proliferation- related genes such 
as CCNB1, MKI67 and (MYBL2). 
High expression of ki67 (≥ 14%). 
P53 mutation rate of 40%. 
5-year survival rate is 50%. 
Zhang et al, 
2014a; 
Sørlie et 
al,2001 
basal-like 
ER negative. 
Represents 10-15% of breast cancers. 
High expression of genes related to the basal 
epithelial cells (cytokeratins 5, 6, and 17).   
Low expression of BRCA1. 
Brenton et 
al, 2005; 
Zhang et al, 
2014a 
Carey et 
al,2006  
Wu et 
al,2012 
HER2 
(ERBB2+) 
 
Represents 10 % of breast cancers 
Two patterns of expression similar to basal like 
tumours and to luminal type B breast tumour.  
Brenton et 
al, 2005; 
Zhang et al, 
2014a 
Carey et 
al,2006  
Normal 
breast-like 
cells 
Highly expression of genes related to adipose 
tissues.  
Perou et 
al,2000 
Smid et 
al,2008 
 chemotherapy is considered as the best choice for the treatment of HER2 positive 
tumours (Viale, 2012 ; Rakha & Green, 2017). For ER positive and HER2 negative 
breast tumours, the option of using chemotherapy with endocrine therapy is 
determined according to the tumour size and grade, the rate of proliferation 
(determined by the immunohistochemically staining of ki67 antigen), distant 
metastasis and lymph node involvement (Viale, 2012 ; Rakha & Green, 2017). 
Gene signatures have been developed as predictors of response to therapy and 
the protein and non-protein products of the genes that are directly involved in the 
development of breast cancer are potential targets for the development of novel 
specific and effective therapeutics. 
 
1.4 Stages of breast cancer 
The TNM (Tumour, Node, Metastasis) staging is a scoring system for evaluating 
the predictive factors of breast cancer management (Benson, 2003; Bagaria et al, 
2014; Brierley et al, 2016). This grading system involves the determination of  the 
tumour state according to their size, axillary or local lymph node involvement and 
whether they are invading to the nearby tissue or distant metastasis 
(Benson,2003; Bagaria et al,2014; Brierley et al,2016).  However, this system is 
not sufficient to predict a suitable treatment for a certain type of breast cancers, 
particularly, the triple negative subtype (TNBC). According to the TNM staging 
system, the stages of breast cancer range from 0 to IV (0 to 4). Table 1.2 
summarises the TNM stages depending on the combination of tumour size (T), 
lymph node status (N) and metastasis (M). 
 
 
 Table 1.2 The TNM stages of breast cancer (Whitman et al,  2006) 
 
 
 
1.5 Grades of the breast cancer 
 
The histological grading of breast cancer is responsible for assessing the 
prognostic factors of the tumour. This grading uses certain criteria that determine 
the degree of tumour cell differentiation such as cell morphology (glandular or 
Stage Characteristics 
Stage 0 (Tis, N0, M0) 
Non-invasive cancer. 
Localised in the ducts and lobules without spreading to 
the axillary lymph nodes. 
Stage 1A (T1, N0, M0) 
Small size of tumour.  
Invasive but has not spread to the lymph nodes. 
Stage 1B (T1, Nmic, 
M0). 
Nmic refers to lymph 
nodes seen by 
microscope only 
Tumour size is larger than 0.2 mm and less than 2mm.  
Spread to the lymph nodes. 
 
Stage llA: 
1-T0, N1, M0 
2-T1, N1, M0 
3- T2, N0, M0 
1-No evidence of breast tumour but it has spread to the 
lymph nodes.  
2-Tumour size less than 20mm and has spread to the 
axillary lymph nodes.  
3-Tumour size is between 20-50mm and has not spread 
to the axillary lymph nodes. 
Stage llB: either 
1-T2, N1, M0 
2- T3, N0, M0 
1-Tumour size is between 20-50mm and has spread to 
1-3 axillary lymph nodes  
2-Tumour size is larger than 50mm without spreading of 
cancer cells to the lymph nodes. 
Stage lllA 
(T0, T1, T2, T3, N2, M0) 
The tumour presents in any size. 
Spread to 4-9 axillary lymph nodes but no distant 
metastasis. 
Stage lllB 
(T4, N0,N1 or N2, M0) 
The tumour spread to the chest wall causing 
inflammation or ulceration with or without involvement of 
axillary lymph nodes. 
No distant metastasis. 
Stage lllC 
(any T, N3, M0) 
The tumour presents in any size. 
Spread to 10 or more axillary lymph nodes without 
distant metastasis. 
Stage lV 
(any T, any N, M1) 
Tumour presents in any size. 
Tumour has metastasised to different parts of the body. 
 tubular), nuclear pleomorphism and the rate of mitosis by detecting the level of Ki-
67, which increases in proliferating cells  (Sainsbury et al, 1994; Rakha et al, 2008; 
Rakha & Green, 2017).  
Accordingly, three grades are currently used and these include grade 1, 2 and 3. 
Grade 1 (low grade or well differentiated) is characterised by the appearance of 
large number of differentiated cells in well-organized pattern and low rate of 
mitosis. Grade 2 (intermediate or moderately differentiated) involves the 
appearance of abnormal cells, which look different from normal cells (variation in 
size and shape of the cells as well as the nucleus become larger and darker) and 
have a faster rate of growth (Rakha et al, 2008; Elston et al, 1999). Grade 3 (high 
grade) is characterised by the presence of poorly differentiated or undifferentiated 
cells with irregular pattern and high rate of proliferation. Table 1.3 provides 
summary of the grades of breast cancer and their characteristics. 
Table 1.3  The grades of breast cancer (Sainsbury et al, 1994; Rakha et al, 2008; Rakha & 
Green, 2017) 
 
 
 
Grade Characteristics 
Grade 1 
Low grade or well differentiated. 
Large number of differentiated cells in well-organized 
pattern and low rate of mitosis. 
Grade 2 
Intermediate or moderately differentiated  
Cells look different from normal cells and their growth 
rate is increased.  
Grade 3 
High grade or poorly differentiated. 
Cells are poorly differentiated or undifferentiated cells 
with irregular pattern and characterized by immense 
rate of proliferation. 
 1.6 Long non-coding RNA  
The Encyclopaedia of DNA Elements (ENCODE) Consortium, an international 
research consortium aiming to identify the functional elements in the human 
genome sequence, confirms that 80.4% of human genome displays some 
functionality in at least one cell type. Their data interpreted main features about 
the organisation and function of the human genome, including the annotation of 
coding and noncoding regions and identify the regulatory elements controlling 
chromatin accessibility, transcription factor binding and DNA methylation (Qu and 
Fang, 2013). Their results revealed that many of these regulatory elements 
interact with one another to form a network that affects gene expression (Qu and 
Fang, 2013). Results from the ENCODE project included the annotation of 20,687 
protein-coding genes, 33,977 noncoding transcripts and 9640 long non-coding 
RNA (lncRNA) genes (Qu and Fang, 2013).  
The term non-coding RNA (ncRNA) is regularly used to describe RNA that does 
not encode a protein. Although it has been generally assumed that most genetic 
information that specifies biological form and phenotype is expressed as proteins, 
increasing number of evidence suggests that the majority of the genomes of 
mammals is in fact transcribed into ncRNAs, many of which are alternatively 
spliced, may be processed into smaller products and have a very wide range of 
biological functions. ncRNAs are a class of naturally occurring RNA molecules, 
transcribed from non-protein coding genes and possess a fundamental role in cell 
biology (Mattick and Makunin,2006;  Marchese and Huarte,  2014).  They are 
predominantly associated with eukaryotes and reported to encompass many 
varieties of RNAs that have specific but non-coding functions (Mattick and 
Makunin, 2006). These ncRNAs are reported to comprise important roles in 
 underpinning the highly controlled, complex pathways involving gene expression 
and are significant in disease, particularly cancer (Mattick and Makunin, 2006). 
ncRNAs include housekeeping ncRNAs (examples include ribosomal RNA, 
transfer RNA, small nuclear and nucleolar RNAs) and regulatory ncRNAs which 
contribute to the regulation of cellular differentiation and developments by their 
effects on gene expression at transcriptional and posttranscriptional levels (Dinger 
et al, 2008; Prasanth and Spector, 2007). Regulatory ncRNAs are generally 
subdivided according to their length into two classes, either small non-coding 
RNAs composed of 18-200 nucleotides or long non-coding RNAs (lncRNAs) which 
are described as transcripts longer than 200 nucleotides (Mattick and Makunin, 
2006; Wang and Chang, 2011).  Examples of small ncRNAs include microRNAs 
(miRNAs) and small nucleolar RNAs (snoRNAs). miRNAs are one of the most 
studied small ncRNAs which act as endogenous post-transcriptional silencing 
effectors. They serve as guides for either the cleavage or translational inhibition of 
complementary mRNA target transcripts (Amaral and Mattick, 2008). Their 
regulatory roles in several critical biological processes such as cellular 
proliferation, differentiation and developmental timing are well established and 
several evidence support their involvement in cancer and many other diseases 
(Amaral and Mattick, 2008). Small nucleolar RNAs (snoRNAs) act as guide for 
post-transcriptional modification of ribosomal RNAs (rRNA) and some spliceosome 
RNAs. These post-transcriptional modifications are very important for the 
production of efficient and accurate ribosomes, the cell’s protein synthesis 
machinery (Lestrade and Weber, 2006). In addition, the importance of snoRNAs in 
controlling fate and its role in oncogenesis have been recently highlighted 
(Reviewed by Williams and Farzaneh, 2012).  
 LncRNAs, which represent the focus of this thesis, have received attention due to 
their tissue- and developmental-specific expression patterns and their functional 
importance in many physiological and pathological processes (Quinn and Chang, 
2016). The improvement in RNA sequencing and computational prediction 
techniques have resulted in the identification of large numbers of these lncRNAs 
(more than 16.000) and will undoubtedly lead to a further increase in their number  
(Spector, 2017).  Similar to mRNAs, lncRNAs are RNA polymerase II transcripts, 
processed via capping at the 5’ end polyadenylated at the 3’ end and spliced. 
They are predominately located within the nucleus, but they can also be found in 
the cytoplasm (Dinger et al, 2008). Unlike mRNAs and other small ncRNAs, 
lncRNAs are poorly conserved between related species and because of this it has 
been initially suggested that these transcripts are not of functional importance 
(Wang and Chang, 2011; Ponjavic et al, 2007). However, their strong cell-type 
specific and temporal expression has confirmed their importance and the fact that 
they are under transcriptional control rather than “transcriptional noise” (Cabili et 
al, 2011; Mattick and Makunin, 2006; Ponjavic et al, 2007). It is now well 
established that several lncRNAs play key roles in the control of multiple biological 
processes, such as gene expression, epigenetic regulation, chromatin remodeling, 
organ or tissue development, and innate immune response (Quinn and Chang, 
2016). Accumulating evidence has further supported their roles in many cellular 
functions relevant to the process of ageing including cellular response to stress, 
proliferation, differentiation, quiescence, senescence and death (Spector, 2017). 
Consequently, mutations and deregulation of these lncRNAs have been 
associated with the development and progression of many human diseases, 
including cancer, autoimmune diseases and cardiovascular diseases. Accordingly, 
lncRNAs provide interesting novel opportunities as potential biomarkers for 
 disease diagnosis, treatment and prognosis, and new therapeutic strategies 
(Spector, 2017).  
 
1.6.1 Types of long noncoding RNAs 
LncRNAs can be divided into three subclasses: natural antisense transcripts 
(NATs), intronic long non-coding RNAs and long intergenic non-coding RNA 
(lincRNAs) (Moran et al, 2012).   
 
1.6.1.1 Natural antisense transcripts (NATs) 
NATs belong to a large class of lncRNA that have transcripts complementary to 
other RNAs. NATs are, as their name implies, transcripts coded from the opposite 
strand of a protein-coding gene in the antisense direction, of which around 40% of 
coding genes express these lncRNAs (Moran et al, 2012; He et al, 2008). There 
are two main NAT categories: cis-NATs and trans-NATs. cis-NATs are antisense 
RNA transcribed from a single locus, due to the existence of a physical overlap of 
two genes in different strands, usually having specific targets in a one-to-one style. 
On the other hand, trans-NATs are RNAs transcribed from different loci, displaying 
imperfect complementarities; therefore, they are able to aim at many sense targets 
forming complex regulation networks (Lavorgna et al, 2004).  Antisense-
overlapping lncRNAs have a tendency to undergo fewer splicing events and the 
basal expression levels in different tissues and cell lines can be either positively or 
negatively regulated (Moran et al, 2012; He et al, 2008). These lncRNAs can use 
transcriptional and post-transcriptional gene regulatory mechanisms to carry out a 
wide variety of biological roles. They can form duplexes with their corresponding 
mRNA counterpart to either induce or inhibit their translation (Lavorgna et al, 
 2004) and they have been implicated in epigenetic silencing of functionally 
important genes (Morris et al,   2008 ; Morris, 2009).  An important example of a 
functional NAT is ANRIL, a lncRNA involved in cancer progression (Gibb et al, 
2011a). ANRIL is a 3.8 kb-long antisense transcript to the INK4 locus that spans 
an estimated region of 30–40 kb at chromosome 9p21 and its expression 
correlates with INK4a epigenetic silencing (Gibb et al 2011a; Li and Chen, 2013). 
The INK4 locus encodes three tumour suppressor genes that are reported to be 
silenced in prostate cancer. ANRIL is reported to be an initiating factor in cancer 
formation by causing abnormal silencing of the INK4 (El Messaoudi-Aubert et al, 
2010; Pasmant et al, 2007). Studies have shown that ANRIL mediates INK4a 
transcriptional repression in cis by acting as scaffold molecule and interacting with 
the Pc/Chromobox 7 (CBX7) protein, a member of the Polycomb Repressive 
Complex 1 (PRC1) associated with the remodeling and manipulation of chromatin 
(Yap et al, 2010). 
 
1.6.1.2 Intronic lncRNAs   
Intronic lncRNAs are transcripts contained within introns of protein coding genes in 
either the sense or antisense direction and are released during pre-mRNA 
processing by the action of spliceosomes (Moran et al, 2012). These lncRNAs 
have the same tissue expression as their corresponding protein-coding genes and 
function either by acting as a regulator of alternate splicing of the protein transcript 
or by being involved in transcript stabilisation (Moran et al, 2012). Some of these 
lncRNAs possess a long half-life in the cytoplasm allowing them to contribute to 
the regulation of translation (Mattick and Gagen, 2001; Hesselberth, 2013). 
 
 For instance, SAF, a lncRNA transcribed from the opposite strand of intron 1 of the 
human FAS gene, is involved in regulating the expression of FAS alternative splice 
variants through pre-mRNA processing (Yan et al, 2005). Overexpression of SAF 
lncRNA in the human T-leukemic cell line Jurkat did modulate the expression of 
different FAS protein soluble forms, making cells more resistant to FAS-mediated 
apoptosis (Yan et al, 2005; Louro et al, 2009). 
Intronic sense and antisense lncRNAs may regulate the expression of a 
neighbouring protein-coding gene through a phenomenon termed transcriptional 
interference, which prevents initiation complex recruitment or transcriptional 
elongation (Mazo et al, 2007). Evidence has been provided that in human, a 
partially intronic lncRNA, produced from the genomic locus encoding dihydrofolate 
reductase (DHFR), directly interacts with the major promoter, decreasing the 
expression of the protein-coding RNA (Martianov et al, 2007). Another work 
showed that long spliced intronic antisense transcripts, overlapping the promoter 
of the progesterone receptor gene (PGR), are necessary for activation of PGR 
expression (Schwartz et al, 2008).  
 
1.6.1.3 Long intergenic non-coding RNAs (LincRNAs)   
LincRNAs, unlike NATs and Intronic lncRNAs, are transcribed in regions outlying 
protein-coding genes (Moran et al, 2012; Cabili et al, 2011). They were previously 
considered “JUNK DNA” that has no functional importance. However, studies have 
shown that these lncRNAs play a myriad of functions that range from epigenetic 
regulation to post transcriptional genetic modulations. Their roles have been 
demonstrated in embryonic stem cell pluripotency, cell proliferation and immune 
surveillance (Amit et al, 2009; Moran et al, 2012). The abnormal expressions some 
 of these lincRNAs in a number of cancer suggest that they may play a  role in the 
formation and progression of different types of cancer ranging from solid tumours 
to leukaemia (Tsai et al, 2011). 
Compared to mRNA expression, lincRNA expression is generally more variable 
between tissues (Derrien et al, 2012) and many of them have been reported to be 
preferentially expressed in brain and testis (Ravasi et al, 2006;  Cabili et al, 2011). 
The expression of some of these lincRNAs is reported to be regulated by 
transcription factors such as p53 and NFҡB (Amit et al, 2009; Moran et al, 2012).  
For instance, lincRNA-p21 is transcribed from a region ~15 kb upstream of p21 
and mediates apoptosis in a p53-dependent manner upon DNA damage response 
(Huarte et al, 2010). 
Another lincRNA, P21 associated ncRNA DNA damage activated (PANDA), is 
transcribed from the ~5 kb upstream region of p21 in an antisense orientation to 
p21. Similar to p21, the expression of PANDA is also induced by DNA damage 
and activated in a p53-dependent manner (Huarte et al, 2010).  
While many of these lincRNAs are found mostly in the cytoplasm, some are almost 
exclusively found in the nucleus such as Gas5, Xist, MALAT1, NEAT1, and 
MIAT20 (Kino et al, 2010; Hutchinson et al, 2007 ; Sone et al,  2007; Spector, 
2017).  
 
1.6.2 Functions of lncRNAs  
LncRNAs demonstrate a wide range of functional and structural roles and are 
involved in many biological processes (Gibb et al, 2011b). They have been  
implicated in a number of gene-regulatory roles, such as chromosome dosage-
compensation, imprinting, epigenetic regulation, cell cycle control, cell death 
 (apoptosis) nuclear and cytoplasmic trafficking, transcription, translation, RNA 
splicing, nuclear organisation, cell differentiation and others. In many cases, 
transcription of lncRNA can negatively or positively affect the expression of nearby 
or distant genes (cis- or trans- acting lncRNA). Antisense lncRNAs are able to 
hybridise to the overlapping sense transcript and block recognition of the splice 
sites by the spliceosome, thus resulting in the generation of an alternatively 
spliced transcript or degradation of the transcript. In many cases, lncRNAs 
regulate the activity or localization of proteins and serve as organizational 
frameworks of subcellular structures. Some lncRNAs are processed to yield small 
RNAs such as miRNAs, piwi RNAs, and other less well-characterized classes of 
transcription regulators ((Mercer et al, 2009; Wang and Chang, 2011; Figure 1.1).  
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 1.1 functions of lncRNAs. The figure summarises mechanisms of actions of lncRNAs 1) 
LncRNAs transcribed from an upstream noncoding promoter (orange) can negatively (1) or 
positively (2) affect the transcription of the gene located downstream (blue) by inhibiting RNA 
polymerase ll recruitment or inducing chromatin remodeling, respectively. (3)Antisense 
lncRNA transcript (purple) is able to hybridize to the overlapping sense transcript (blue) and 
block recognition of the splice sites by the spliceosome, leading to the production of 
alternatively spliced transcript. (4) In some cases, hybridization of the sense and antisense 
transcripts can activate RNA interference pathway allowing dicer to generate endogenous 
siRNAs. (5) LncRNA (green) can bind to specific protein in partners and modulate the activity of 
the protein. (6) Some lncRNAs serve as a structural component that allows a larger RNA-
protein complex to form cellular structures or alter where the protein localises in the cell (7). 
(8) Long ncRNAs (pink) can be processed to yield small RNAs such as miRNAs (Wilusz et al, 
2009). 
 The main ways in which these lncRNAs exert their effects can be described by 
four mechanistic models, including acting as signals, decoys, guides or scaffolds 
(Wang and Chang, 2011; Deniz and Erman, 2017).  
 
1.6.2.1 LncRNAs as signals 
LncRNAs can act as a signal in regulation of gene expression since they are 
characterised by cell-type specific expression that occurs in a specific time and 
place in addition to their ability to respond to different external stimuli (Figure 1.2) 
(Wang and Chang, 2011). 
A number of lncRNAs was found to be activated in response to specific stimuli and 
subsequently activated or down regulated the corresponding subsets of genes 
(Wang and Chang, 2011; Moran et al, 2012). These signal lncRNAs appear to 
have critical roles in epigenetic regulation, whereby transcriptional silencing of 
groups of genes on a particular chromosome is mediated by interactions with the 
chromatin or by the recruitment of chromatin-modifying proteins (Wang and 
Chang, 2011; Moran et al, 2012). Some lncRNAs can bind the transcription factors 
themselves, in order to regulate gene expression, resulting in the inability of the 
transcription factor to bind its target sequence (Wang and Chang, 2011; Moran et 
al, 2012). 
 
 
 
 
 
                                         
             
 
Signal lncRNA expression cannot only act as markers of transcriptional elements 
and their abundance, but also as a reflection of spatio-temporal gene regulation 
(Wang and Chang, 2011; Moran et al, 2012). The best example is Xist, which is an 
lncRNA about 17kb in length, involved in the inactivation of female X chromosome. 
Initially, during female cell differentiation, a small region within Xist known as Rep 
A (Repeat A) binds to one of the X chromosomes in the X inactivation center (Xi) 
in association with Polycomb Repressive Complex 2 (PRC2). This will lead to 
further repression in the Xist gene on the intended X chromosome, causing a 
whole silence of the chromosome in cis (Brosnan and Vionnet, 2009). Meanwhile 
Tsix, which is an antisense lncRNA, plays an important role in protecting the other 
X chromosome from silencing by the repressive effect of Rep A through preventing 
their binding to the Xi (Moran et al, 2012).  
 
1.6.2.2 LncRNAs as decoys   
Different non-coding RNAs were found to interact and some lncRNAs 
demonstrated binding capabilities to miRNAs, consequently preventing further 
 Figure 1.2 LncRNAs exert their effects by diverse mechanisms. LncRNAs can act as a signal 
and serve as a molecular signal to regulate transcription in response to various stimuli. The 
figure demonstrate that the presence of lncRNA serve as indicator of transcriptional activity to 
enhance gene expression, by recruiting   transcription factors and altering the chromatin 
states. Adapted from Wang and Chang (2011) 
 binding of the miRNAs to their target mRNAs (Wang and Chang, 2011; Moran et 
al, 2012). It was found that lncRNAs could also act as decoys to remove 
transcription factors from gene promoters to prevent binding and transcription 
(Figure 1.3) (Wang and Chang, 2011).  In this case, the function of the lncRNAs is 
probably as a negative regulator of a specific effector to control transcription 
repression (Wang and Chang, 2011). These lncRNAs act as molecular decoys in 
order to regulate gene transcription, post-transcriptionally, thus protein synthesis 
and possible in a tissue-specific capacity (Wang and Chang, 2011; Moran et al, 
2012). 
 
                   
 
Growth Arrest 5 (GAS5) is a lncRNA reported to act like a “riborepressor" of the 
glucocorticoid receptor (GR). It binds to the DNA-binding domain of the GR by 
acting as a decoy glucocorticoid response element (GRE), thus competing with 
DNA GREs for binding to the GR and modulating the transcriptional activity of the 
GR (Kino et al, 2010). P21 associated ncRNA DNA damage activated (PANDA) is 
another lncRNA that act as a decoy and prevents the p53-mediated apoptosis 
because of DNA damage (Hung et al, 2011). PANDA inhibits the expression of 
apoptotic genes by sequestering the transcription factor NF‐YA of its promoters 
Figure 1.3 LncRNAs exert their effects by diverse mechanisms. The figure shows how lncRNA 
can act as decoy. In this case, lncRNA binds to the transcription factor inhibiting its binding to 
the promoter and titrating them away from chromatin. Adapted from Wang and Chang (2011) 
 (Hung et al, 2011). Studies have shown that inhibiting the interaction between 
PANDA and NF‐YA interaction leads to an increased transcription activity of NF‐
YA and restored apoptosis. 
 
1.6.2.3 LncRNAs as guides 
Epigenetic factors can determine cellular identity by modulating specific gene 
expression in both cis and trans, using enzymes to modify the chromatin, either 
activating or repressing the gene (Moran et al, 2012). LncRNAs potentially have a 
role in guiding these epigenetic factors, for example, directing chromatin-
remodelling complexes to their specific loci where they exert their effect 
(Figure1.4) (Moran et al, 2012). The process by which this occurs has yet to be 
elucidated, however, one suggested mechanism is that some lncRNAs may bind 
the chromatin first and mediate binding of chromatin-modifying complexes by 
acting as a docking station (Chu et al, 2011). The other one is proposed by the 
interaction of DNA-binding proteins to lncRNA, which in turn guiding them to their 
target sites in chromatin (Kanhere and Jenner, 2012). Guiding lncRNAs have been 
found to be involved in important biological processes including, X inactivation and 
roles in the establishment of chromatin states (Wang and Chang, 2011).  
                     
Figure 1.4 LncRNAs exert their effects by diverse mechanisms. The figure shows that  lncRNA 
can act as guides by  recruiting  chromatin-modifying enzymes to the target genes, and thus 
contribution to tissue-specific gene expression. Adapted from Wang and Chang (2011) 
 Both AIR (Antisense to insulin-like growth factor type 2 receptor (Igf2r)) and 
HOTAIR (HOX Antisense Intergenic RNA) are examples of lncRNAs that act as 
guides for the regulation of gene expression.  Air  is a 108 kb, polyadenylated, 
non-coding RNA that transcribed from an antisense promoter located in intron 2 of 
the Igf2r (insulin-like growth factor type 2 receptor) in the mouse chromosome 17 
(Hung and Chang, 2010 ; Bonasio et al, 2010). The Igf2r gene cluster contains 
three imprinted genes: Igf2r, Slc22a2, and Slc22a3. Unlike Igf2r, Slc22a2, and 
Slc22a3 maternal transcription, AIR is only expressed from the paternal allele 
(Nagano et al, 2008).  Expression of the AIR results in a "cloud" nuclear pattern 
over the imprinted DNA locus during embryonic development of the placenta and 
the adult heart (Hung and Chang, 2010; Bonasio et al, 2010).  HOTAIR is located 
at the boundary of two chromatin domains in the HOXC locus. HOTAIR is 
transcribed antisense to the HOXC genes. HOTAIR distally regulates the 
chromosomal domain in trans on HOXD locus (Rinn et al, 2007; Biswas and 
Desai, 2017). Another study revealed that the 5′ domain of HOTAIR physically 
interacts with PRC2 methylase and increases its activity, which facilitates histone 
H3 lysine-27 trimethylation on the HOXD locus and results in silencing of the 
HOXD gene (Rinn et al, 2007). 
 
1.6.2.4 LncRNAs as scaffolds 
LncRNAs can interact with chromatin-modifying complexes, transcription factors 
and splicing factors to form ribonucleoprotein complexes, acting to some extent as 
a scaffold. Such ribonucleoprotein complexes may act on chromatin to affect 
histone modifications, or may play a structural role and stabilise nuclear structures 
or signaling complexes (Figure 1.5) (Wang and Chang, 2011; Moran et al, 2012). 
 The function of scaffold lncRNAs is essential to provide an infrastructure allowing 
proteins and various transcriptional factors to assemble around in order to carry 
out their effect (Khalil et al, 2009; Wang and Chang, 2011). This class of lncRNAs 
must presumably possess different binding domains to allow the degree of 
coordination to occur, and in the binding of the constituents bring these effector 
molecules together to result in their interaction (Wang and Chang, 2011). In many 
cases, the disruption of these scaffold lncRNAs leads to detrimental biological 
effects inferring theses lncRNAs are required for co-localisation and for the precise 
dynamics of interactions to occur (Khalil et al,  2009; Taft et al,  2010). 
 
            
 
 
  
                               
 
Figure 1.5 LncRNAs exert their effects by diverse mechanisms. The diagram shows how 
lncRNA can act as molecular scaffolds for protein complexes to form ribonucleoprotein 
complexes. Such complex is shown to act on chromatin to affect histone modifications. 
Adapted from Wang and Chang (2011) 
 An example of lncRNA that acts as a scaffold is ANRIL, an antisense non-coding 
RNA transcribed from INK4 locus, which encodes three tumour suppressors 
(p15INK4b, ARF and p16INK4a).  Studies have revealed that ANRIL is able to 
bind to chromobox 7 (CBX7) within the PRC1 complexes, leading to the 
repression of the expression of the genes located on the INK4 (Kotake et al, 2011; 
Yap et al, 2010).  
LncRNAs that act as scaffolds and bring together different proteins or bridging 
protein complexes includes Nuclear Enriched Abundant Transcript (NEAT1) and 
Metastasis-Associated in Lung Adenocarcinoma Transcript (MALAT1) (Guttman 
and Rinn,2012).  Both NEAT1 and MALAT1 bind multiple proteins localising to the 
paraspeckles and nuclear speckles, respectively (Clemson et al, 2009; Sunwoo et 
al, 2009; Murthy and Rangarajan, 2010; Spector, 2017). 
 
 1.7 The hallmarks of cancer 
Cancer is defined as the uncontrollable division and proliferation of abnormal cells 
forming malignant growths, which are caused by mutations involving DNA 
(Hudson, 2011). These cancerous cells proliferate rapidly, resist apoptosis and 
can metastasize to various parts of the body, making cancer a challenging disease 
to treat (Hudson, 2011). Although there are many different types of cancer, all 
cancer cells share six biological capabilities that are acquired during the multistep 
development of a tumour; these shared characteristics known as the six hallmarks 
of cancer, which aid carcinogenesis (Hanahan and Weinberg, 2000).   
The most fundamental trait of cancer cells is their ability to proliferate without a 
controlled signalling input. This is possible by several mechanisms, including the 
increase in growth factor production such as vascular endothelial growth factor 
 (VEGF) and transforming growth factor (TGF) (Hanahan and Weinberg, 2000). 
Cancer cells can also increase the number of receptors on their cell surface and 
structurally alter existing ones in order to enable cancer cell signalling, which 
causes other cells to proliferate out of control (Hanahan and Weinberg, 2000). The 
second important hallmark of cancer cells is the ability to evade growth 
suppression. In normal cells, proliferation is a highly controlled process, in which 
different signals are involved in specific phases of the cell cycle (Hanahan and 
Weinberg, 2000). In particular, the G1 phase of the cell cycle is a vital point in 
which anti-growth signals have the ability to block proliferation and prevent further 
growth. However, most cancer cells can evade these signals in order to continue 
proliferating (Hanahan and Weinberg, 2000). The two most common tumour 
suppressors down regulated in cancer include the retinoblastoma protein (Rb) and 
p53. The loss of these tumour suppressor genes aids cancer cells in their third 
distinctive trait of replicative immortality (Hanahan and Weinberg, 2000). Normal 
cells possess an intrinsic mechanism, which blocks cell division to a certain limit. 
However, cancer cells have the ability to overexpress telomerase, which allows 
the cells to continue to proliferate (Hanahan and Weinberg, 2000).  In addition to 
their ability to proliferate out of control, cancer cells also have the ability to resist 
apoptosis by down regulating signalling pathways, through the over expression of 
anti-apoptotic (E.g. Bcl -2) and the silencing of pro-apoptotic proteins (E.g. Bax/ 
Bak). The extrinsic pathway in particular is widely implicated in tumour formation 
and is triggered from within the cell because of DNA damage (Hanahan and 
Weinberg, 2000). 
A critical trait of cancer cells required for the progression of cancer is the ability to 
activate metastasis and tissue invasion (Hanahan and Weinberg, 2000). This is a 
key component in the spreading of cancer from the primary site to distant organs. 
 The process involves changes to the ways in which cells attach to other cells and 
to the extracellular matrix (Hanahan and Weinberg, 2000). There are several steps 
involved, including local tissue invasion, intravasation, transition through the blood 
and lymphatic tissue and finally colonisation in foreign tissues. Finally, in order to 
maintain tumour growth and metastasis, cancer cells have the ability to induce 
angiogenesis, the formation of new blood vessels (Hanahan and Weinberg, 2000). 
Tumour angiogenesis is a multi-step process, which involves signalling from 
several pro-angiogenic growth factors such as VEGF.  Angiogenesis enable the 
tumour to grow and expand through the delivery of oxygen and nutrients to the 
cells and it is suggested that metastatic cells can migrate through the new tumour 
vessels into the circulation allowing them to colonize other tissues (Hanahan and 
Weinberg, 2000).  
 
1.8 LncRNAs and cancer 
There is a number of evidence that implicates lncRNAs in a wide range of cancers, 
as the expression levels of many have been found to be dysregulated in cancer 
cells (Hudson, 2011; Moran et al, 2012). A substantial amount of the evidence 
acquired so far suggests that lncRNAs play important roles in each of the 
hallmarks of cancer and therefore contribute to the carcinogenesis process, 
invasion and metastasis. Some lncRNAs are classified as oncogenic transcripts 
because their expression has been reported to increase in many cancers.  
Identified oncogenic or pro-oncogenic lncRNAs include prostate cancer antigen 3 
(PCA3), prostate cancer gene expression marker 1 (PCGEM1), and prostate 
cancer associated ncRNA transcript 1 (PCAT1) which are highly expressed in 
prostate cancer, posing as attractive biomarkers Reviewed by (Bolton et al, 2014). 
 PCGEM1 is also overexpressed in breast cancer (Ginger et al, 2006).  KRASP, 
HULC, HOTAIR, MALAT1/NEAT2, p15AS, ANRIL, H19, SRA1, p21NAT, and 
RICTOR have also been described as oncogenic lncRNAs (Nie et al, 2012). Their 
oncogenic effects attributed to the abnormal posttranscriptional gene regulation, 
like increasing the alternative splicing of mRNA, or epigenetic control by chromatin 
modification. For example, HOTAIR interacts with Polycomb repressive complexes 
2 leads to suppressing PRC2 and increase H3K27 trimethylation, which in turn 
leads to silencing the metastatic suppressive genes (Nie et al, 2012). On the other 
hand, some lncRNAs show decreased expression in cancers and therefore are 
suggested to   function as tumour suppressors. These lncRNAs include  MEG3, 
GAS5, LincRNA-p21, PTENP1, TERRA, CCND1/Cyclin D1, and TUG1 (Nie et al, 
2012). MEG3 transcript is also reported to act as a a positive regulator of p53 
protein, it stimulate p53- dependent transcription from p53-responsive promoter 
(Nie et al, 2012). Therefore, the loss of MEG3 can lead to a loss of P53 
transcription. Some of these lncRNAs may have oncogenic and/or tumour 
suppressive effects depending on the cellular context. For example, XIST 
transcript is upregulated in some male cancers, but down-regulated in female 
cancers (Weakley et al, 2011).  
Accumulating evidence suggests that some lncRNAs have critical roles in 
carcinogenesis by regulating tumour cell proliferation.  A particular example of 
these lncRNAs is the steroid receptor RNA activator (SRA) (Lanz et al, 1999). 
SRA expression is reported in normal and malignant human mammary tissues. 
However, elevated levels of SRA are found in breast tumours and the increased 
SRA levels might contribute to the altered ER/PR action that occurs during breast 
tumorigenesis (Leygue et al, 1999). Increased SRA expression leads to an 
increase in cellular proliferation (Yan et al, 2016). The lncRNA, PCAT-1 (prostate 
 cancer associated transcript 1) was identified to be upregulated in a subset of 
metastatic and high-grade localized prostate cancers (Fu et al, 2006). 
Overexpression of PCAT-1 causes an increase in LNCaP prostate cancer cell 
proliferation, whereas its siRNA mediated knockdown caused a 50 % reduction in 
cell proliferation rate and resulted in the upregulation of genes associated with 
mitosis and cell cycle (Prensner et al, 2011). Another example of lncRNA that alter 
cell proliferation is small nuclear RNA7SK also known RN7SK (Yang et al, 2001; 
Chiappetta et al, 1996). RNA7SK regulates the transcription elongation by binding 
to the positive transcription elongation factor b (P-TEFb) and inhibiting its positive 
effects on RNA polymerase II transcription elongation (Nguyen et al, 2001; Yang 
et al, 2001). RNA7SK also interacts with the transcription factor and chromatin 
regulator HMGA1 (high mobility group AT-hook 1) which regulates the expression 
of growth related genes. RNA7SK compete with HMGA1 binding to DNA and 
therefore inhibiting its function (Chiappetta et al, 1996; Chiappetta et al, 2001). A 
number of studies have implicated lncRNAs in the inhibition of tumour suppressor 
genes and therefore allowing the cell to acquire the ability to evade growth 
suppressors. Five ncRNA fragments have been shown to interact with the tumour 
suppressor PSF (Li et al, 2009). PSF protein is involved in repressing the 
transcription of proto-oncogenes by binding to their regulatory regions. Li et al. 
(2009) identified these lncRNAs in a screen aimed at identifying RNA that interact 
with PSF. Their results showed that these lncRNAs promote the release of PSF 
from the human proto-oncogene GAGE6 regulatory region resulting in an 
activation of GAGE6 expression (Li et al, 2009). Increased expression of these 
RNA fragments in human melanoma cell line promoted their tumorigenic 
phenotype, confirming their role in tumorigenesis and the importance of lncRNA-
protein interaction (Li et al, 2009). ANRIL, an antisense non-coding RNA in the 
 INK4 locus, is another lncRNA reported to inhibit the activity of tumour suppressor 
genes (Kotake et al, 2011). ANRIL functions by interacting with SUZ12 
(suppressor of zeste 12 homolog), one of the subunits of the Polycomb repression 
complex 2 (PRC2) promoting the recruitment of the PCR2 complex to the well-
known tumour suppressor gene p15 (INK4B) supressing its expression (Kotake et 
al, 2011).  Silencing of ANRIL expression in WI38 normal embryonic lung cells 
leads to an increase in the expression of p15 (INK4B) and inhibition of cell 
proliferation (Kotake et al, 2011). ANRIL also interacts with a subunit of Polycomb 
repressive complex 1 (PRC1), CBX7 (chromobox resulting in the recruitment of 
PRC1 to the p16 (INK4A)/p14 (the tumour suppressor ARF) locus and subsequent 
silencing of this gene locus by H3K27-trimethylation (Yap et al, 2010). Both, CBX7 
and ANRIL are overexpressed in human prostate cancer, highlighting the 
importance of such interaction for tumour development (Yap et al, 2010). 
 In addition to lncRNAs that act as oncogenes, others act as tumour suppressors. 
These include GAS5 (Growth Arrest-Specific 5) and lincRNA-p21. GAS5 was 
originally isolated due to its increased levels in growth-arrested mouse NIH3T3 
fibroblasts (Schneider et al, 1988). Further studies supported these findings by 
showing that in human leukemic cells, the level of GAS5 expression increased in 
density-induced cell cycle arrest and greatly reduced in actively growing cells 
(Coccia et al, 1992). GAS5 expression has been shown to be altered in many 
cancers including prostate and breast cancers (Pickard and Williams, 2014). 
GAS5 has been showed to act as a “riborepressor”:  Its exon 12- encoded 
sequence contains hairpin structure that contains two glucocorticoid response 
elements (GRE) -like sequences, termed GRE-1 and GRE-2, which are 
complementary to each other (Raho et al, 2000; Muller et al, 1998). These 
sequences interact with the DNA binding domain of the glucocorticoid receptors, 
 thus competing with the GRE in the genome for binding to these receptors. This 
leads to the suppression of several responsive genes including cellular inhibitor of 
apoptosis 2 (cIAP2) and consequently sensitizes cells to apoptosis (Raho et al 
2000). Another example of a lncRNA that acts as tumour suppressor is lincRNA-
p21 which was identified in the attempt to identify novel ncRNA involved in the 
regulation of TP53 function (Huarte et al, 2010).  LincRNA-p21 is a p53 target 
gene with its gene located directly next to the p21 (Cdkn1a) gene on mouse 
chromosome 17.  Its expression has been shown to be activated upon DNA 
damage in different mouse tumour models (Huarte et al, 2010).  LincRNA-p21 
associates with the RNA binding protein hnRNP K and mediates its binding to its 
target gene. hnRNP K is a transcriptional repressor. Binding of lincRNA-p21 to 
hnRNP K leads to gene silencing and the induction of apoptosis (Huarte et al, 
2010). LincRNA-p21 appears to be conserved and is induced in human fibroblasts 
after DNA damage induction. Further studies have shown that lincRNA-p21 is 
down-regulated in human prostate cancer, and low levels of lincRNA-p21 
correlated with high disease stage and prediction of poor survival (Wang et al, 
2017b). Low expression level of lincRNA-p21 was found to correlate with low 
expression of p53-associated genes (Wang et al, 2017b). In vivo studies showed 
that overexpression of lincRNA-p21 inhibited prostate cancer cell proliferation and 
long-term survival partly by regulating p53 downstream gene expression and by 
promoting apoptosis (Wang et al, 2017b).  
The above examples clearly support a role for lncRNAs in two traits of cancer:  
sustaining proliferative signalling and evading growth suppressors. LncRNAs also 
play a role in enabling replicative immortality, the third hallmark of cancer, which is 
also related to cell proliferation. This trait is due to the fact that tumour cells avoid 
the shortening of telomeres and cell senescence by expressing the specialised 
 enzyme telomerase which is able to add telomeric repeat to the end of the 
chromosome (Shay and Wright, 2000). The lncRNA TERRA (telomeric repeat-
containing RNA) transcripts are derived from several subtelomeric loci. TERRA 
localises to telomeres and is involved in telomeric heterochromatin Formation 
(Deng et al 2009). TERRA is believed to act as a negative regulator of telomerase 
(Redon et al 2010). TERRA binds to its interacting protein partner hnRNP A1 and 
together with POT1 (protection of telomeres 1), they act to displace RPA 
(replication protein A) from telomeric ssDNA after DNA replication, i.e. shortening 
of telomere, to promote telomere capping and preserve genomic integrity (Flynn et 
al, 2011). TERRA supresses the activity of the telomerase, therefore low 
expression levels of TERRA transcription is necessary for the telomerase function 
and telomere lengthening.  Accordingly, low expression level of TERRA is reported 
in telomerase-positive cancer cells (Ng et al, 2009).  In fact, TERRA is 
downregulated in many cancers, providing a possible link to the longevity of 
cancer cells by telomerase-mediated lengthening of telomeres (Ng et al, 2009). 
Resisting cell death is another hallmark of cancer. A number of lncRNAs have 
been identified has been showed to play an important role in the control of cell 
death decision. PCGEM1 (Prostate-specific transcript 1) is a prostate tissue-
specific and prostate cancer-associated lncRNA involved in inhibiting apoptosis 
(Petrovics et al, 2004). Overexpression of PCGEM1 in LNCaP cells lead to 
delayed induction of P53 and p21(Waf1/Cip1) and subsequent inhibition of 
apoptosis (Petrovics et al, 2004) .The PCGEM1-associated anti-apoptotic 
responses was reported to be androgen-dependent, as androgen-independent 
variants  of LNCaP cells did not exhibit this effects (Petrovics et al, 2004). SPRY4-
IT1 is another lncRNA involved in the control of cell death. SPRY4-IT1 is derived 
from an intron of the SPRY4 (Sprouty RTK Signalling Antagonist 4) gene. SPRY4-
 IT1 is predominantly localized in the cytoplasm of melanoma cells, and its 
knockdown results in defects in cell growth, differentiation and higher rates of 
apoptosis in melanoma cell lines (Khaitan et al, 2011). 
LncRNAs have been implicated in the fifth hallmark of cancer, which allows the 
tumour cells to invade and form distant metastases. The lncRNA MALAT1 
(Metastasis-Associated Lung Adenocarcinoma Transcript 1, MALAT1) has been 
shown to be involved in metastasis and therefore it is considered as a prognostic 
marker for metastasis and patient survival in non-small cell lung cancer (NSCLC) 
(Ji et al, 2003). MALAT1 is extremely abundant in many human cell types and is 
highly conserved across several species highlighting its functional importance 
(Gutschner et al, 2011). MALAT1 is retained in the nucleus and specifically 
localises to nuclear speckles which play a role in pre-mRNA processing 
(Hutchinson et al, 2007).  Studies have shown that MALAT1 regulates alternative 
splicing of pre-mRNAs by modulating the levels of active serine/arginine splicing 
factors (Tripathi et al, 2010). High expression level of MALAT1 is associated with 
metastasis in NSCLC patients. It is also up-regulated in several cancers including 
lung cancer, uterine endometrial stromal sarcoma, cervical cancer and 
hepatocellular carcinoma (HCC) (Ji et al, 2003). Studies have shown that MALAT1 
promotes cell motility through transcriptional or post-transcriptional regulation of 
metastasis-related genes. Additionally, MALAT1 has also been shown to support 
proliferation and invasion of cervical cancer cells and its knockdown in CaSki cells 
led to an upregulation of caspase-8 and -3 and Bax and the downregulation of Bcl-
2 and Bcl-xL (Guo et al, 2010).  HOTAIR (HOX Antisense Intergenic RNA) is 
another lncRNA involved in cancer metastasis. HOTAIR is a 2.2 kb lncRNA 
transcribed in antisense direction from the HOXC gene cluster (Rinn et al, 2007). It 
plays an important role in epigenetic regulation of gene expression by interacting 
 and recruiting the PRC2 to the HOXD locus which leads to transcriptional silencing 
across (Martianov et al, 2007). HOTAIR also interacts with another histone 
modification complex, the LSD1/CoREST/ REST complex, which coordinates 
targeting of PRC2 and LSD1 to chromatin for coupled histone H3K27 methylation 
and K4 demethylation (Tsai et al, 2010). HOTAIR expression is deregulated in 
different types of cancer (Yang et al, 2011b). In human breast cancer, HOTAIR is 
overexpressed and its expression positively correlates with metastasis and poor 
outcome. HOTAIR depletion inhibits invasiveness in epithelial cancer cells and its 
overexpression alters H3K27 methylation via PRC2 and therefore alters target 
gene expression leading to increased cancer invasiveness and metastasis (Gupta 
et al, 2010). 
HOTAIR levels are increased compared with non-cancerous and its high 
expression is considered as an independent prognostic marker for HCC 
recurrence and shorter survival (Yang et al, 2011b).  In addition, HOTAIR 
suppression in liver cancer cells sensitizes cancer cells to tumour necrosis factor α 
induced apoptosis and to the chemotherapeutic drugs cisplatin and doxorubicin 
(Yang et al, 2011b).Another hallmark of cancer is acquiring the ability to induce 
angiogenesis. The lncRNA αHIF is a natural antisense transcript (NAT) 
complementary to the 3' untranslated region of the hypoxia inducible factorα 
(HIF1α). αHIF negatively regulates the expression of HIF1α, a critical regulator of 
angiogenesis (Rossignol et al, 2002). Overexpression of αHIF triggers HIF1α 
mRNA decay (Uchida et al, 2004). αHIF transcripts are detected in several human 
cancers and it is considered  a marker for poor prognosis in breast cancer (Uchida 
et al,2004).  Another NAT associated with angiogenesis is termed sONE or eNOS 
antisense (NOS3AS) which regulates the expression of nitric-oxide synthase  
(eNOS) in a post-transcriptional manner under normoxia and hypoxic conditions 
  (Fish et al, 2007).  
Over all, the presented evidence strongly supports the functional importance of 
long ncRNAs and provides mechanistic understandings how lncRNAs can 
contribute to the hallmark capacities of cancer cells. 
 
1.9 Long non-coding RNAs in breast cancer  
Several lncRNAs have been reported to play an important role in various 
mechanisms that contribute to the development of breast cancer, including 
tumorigenesis, proliferation, apoptosis, invasion, angiogenesis and drug 
resistance. Among these lncRNAs, seven have been investigated intensively. 
These include HOTAIR, MALAT1, H19, BCAR4, SRA, XIST and GAS5 (Wang et 
al, 2017a).  
Increased expression levels of HOTAIR have been reported in primary breast 
cancer (Gupta et al, 2010). Further studies have shown that HOTAIR promotes 
breast cancer metastasis and can be used as metastatic biomarker (Chisholm et 
al, 2012; Sørensen et al, 2013). According, to its radio-genomic feature, HOTAIR 
overexpression leads to elevation the ERF (enhancing rim fraction) score, a 
quantitative dynamic contrast material-enhanced (DCE) breast magnetic 
resonance (MR) imaging biomarker, and hence increase the possibility of 
detection early metastasis in breast cancer (Wang et al.,2016a).  
As discussed above, HOTAIR acts as scaffold and binds to different functional 
complexes leading to the modification of specific histone proteins and 
epigenetically controlling gene expression. The 5’ end of HOTAIR binds to PRC2 
facilitating H3K27 methylation and the silencing of targeted genes (Sørensen et al, 
2013). On the other hand, the binding of 3’ end of HOTAIR to the LSD1/ 
 CoREST/REST complex leading to the demethylation of H3K4 and the activation 
of genes expression (Tsai et al, 2010). Many genes affected by the changes in 
HOTAIR expression are involved in different cell signalling pathways (Gupta et al, 
2010). One of the HOTAIR targets genes is miR-568, which controls the 
expression of nuclear factor of activated T cells 5 (NFAT5) (Li et al, 2014b). 
Epigenetically silenced miR-568 leads to the increased expression of NFAT5, 
which activates the expression of several metastatic-related genes, such as 
S100A4 and VEGF-C (vascular endothelial growth factor C) and promotes the 
epithelial-mesenchymal transition (EMT) and angiogenesis of breast epithelial 
cells (Li et al, 2014b). 
In addition to its function in the regulation of alternative splicing of pre-mRNA, 
MALAT1 was reported to form a repressive complex with the RNA-binding protein 
HuR, which is involved in the regulation of CD133 expression. CD133 is a cancer 
cell stem marker CD133 that promotes the EMT-program in various cancers, 
including breast cancer (Latorre et al, 2016). Accordingly, HuR silencing MCF-7 
breast cancer cells resulted in an increase in N-cadherin (CDH2) and CD133 
expression with a migratory and mesenchymal-like phenotype (Latorre et al, 
2016). MALAT1 also interacts with Polycomb 2 protein leading to the activation of 
the transcription of growth related genes (Yang et al, 2011a). Both full length 
MALAT1 and an alternatively spliced variant of MALAT1 were found to be highly 
expressed in ER positive cell lines (Latorre et al, 2016; Ellis et al, 2012).  
Breast cancer anti-oestrogen resistance 4 (BCAR4) is a lncRNA associated with 
tamoxifen resistance (Meijer et al, 2006).  Overexpression of BCAR4 causes 
tamoxifen resistance in tamoxifen-sensitive breast cancer cells, anchorage-
independent cell growth and an increase in the phosphorylation of ERBB2 (HER2), 
indicating the involvement of ERBB2 signalling pathway in BCAR4 mediated 
 effects (Godinho et al, 2011; Godinho et al, 2010). BCAR4 is reported to increase 
cell migration by regulating the transcription of glioma-associated oncogene 
homolog 2(GLI2)-dependent target gene (Godinho et al, 2010). The C-C 
chemokine ligand 21 (CCL21) and its receptor, chemokine receptor 7 
(CCL21/CCR7) promotes growth and metastasis of many tumour types including 
breast cancer (Tutunea-Fatan et al, 2015). The important role of BCAR4 in 
CCL21-induced hypo-phosphorylation of RNA Pol II Ser5 was further 
demonstrated in mouse models where locked nuclear acid (LNA) was used to 
target BCAR4 resulted in the hyper- phosphorylation of RNA polymerase II (Pol II) 
Ser5 and suppression of breast cancer metastasis in mouse models (Xing, et al., 
2014).   
H19 is an imprinting lncRNA involved in breast cancer.  In humans, this lncRNA is 
transcribed from the maternal allele located on chromosome 11p15.5 (Pachnis et 
al, 1984; Zemel et al, 1992).  Accumulating evidence demonstrates an oncogenic 
role for H19 in breast cancer.  Overexpression of H19 MDA-MB-231 cells 
promotes anchorage independent growth (Lottin et al, 2002).  In addition, injection 
of H19-transfected cells into nude mice leads to an increase in tumour progression 
(Matouk et al, 2007).  Studies have also demonstrated increased levels of H19 
expression in either invasive breast cancer or ductal carcinoma in situ (DCIS) 
compared with normal adjacent breast tissues (Zhang et al, 2015).  A number of 
evidence supports a role for H19 in multiple stages of tumour progression 
including proliferation and metastasis (Raveh et al, 2015). Overexpression of H19 
which is mediated by the binding of the transcription factor E2F1 to its promoter,  
leads to accelerated G1-S transition and cell cycle progression (Berteaux et al, 
2005). H19 stimulates tumour cell proliferation by down-regulating tumour 
suppressors such as p57kip2 or up-regulation of oncogenes such as cyclin E2, 
 facilitating the transcription of angiogenic genes or inhibits apoptotic-related genes 
(Raveh et al, 2015).  Additionally, H19 was found to be highly expressed (ten-fold 
higher) in ER-positive breast cancer compared to ER-negative tumour tissues 
(Sun et al, 2015). Inhibition of  ER in luminal progenitors lead to a decrease in  
H19 expression and smaller colony formation, highlighting the presence of ER-
H19 axis in ER positive breast cancer cells involved in promoting cell survival ( 
Basak et al, 2015).   
The lncRNA SRA modulates the function of ER and PR steroid receptors, it is also 
involved in breast cancer (Klinge et al, 2004). SRA mediates the transactivation of 
the steroid receptors by binding to their N-terminal AF1 (activation function 1 
domain) and forming a co-active complex with SRC-1 (steroid receptor co-
activator 1) (Lanz et al, 1999). Genes affected by SRA includes these involved in 
cell proliferation and apoptosis. In addition, SRA is a part of nuclear receptor-
mediated transcription and miRNA processing (Redfern et al, 2013). It also 
interacts with the RNA helicase P68 and participates in CTCF (CCCTC-binding 
factor) - mediated chromosome organisation (Yao et al, 2010). SRA expression 
levels in breast cancer is much higher than its level in normal breast tissues (Lanz 
et al, 1999). Several SNPs (single nucleotide polymorphisms; rs10463297, 
rs801460) in SRA genes have been identified to be associated with an increase 
susceptibility to breast cancer (Yan et al, 2016). SRA transcript is subject to 
differential splicing in addition to the lncRNA product, some of the splice variants 
encode a conserved protein, the SRA protein (SRAP). SRAP is highly expressed 
in primary breast tumours (Emberley et al, 2003). Studies have shown that SRAP 
is expressed in breast cancer and that its levels could be used as a predictive 
marker in younger patients with ER-positive/node-negative breast cancer (Yan et 
al, 2009). Microarray studies have shown that SRAP expression is increased in 
 both ER positive and ER negative breast cancer. However, the results showed 
that the high level of SRAP expression was associated with poor prognosis in ER 
positive breast cancer patients (Yan et al, 2009). 
While the lncRNAs discussed above play an oncogenic role in breast cancer, 
GAS5 is one of the lncRNAs that act as tumour suppressor. GAS5 encodes 
different splice variants of non-coding transcripts as well as small nucleolar RNAs 
(snoRNAs), microRNAs, and PIWI-interacting RNAs (Xu et al, 2016).  GAS5 
accumulates in growth-arrested cells due to interaction with the mechanistic 
Target of Rapamycin (mTOR) pathway and through nonsense-mediated decay (Lv 
et al, 2016). In active growing cells, GAS5 mRNA is degraded through the 
nonsense-mediated RNA decay (NMD) pathway (Yamashita et al, 2009).  The 
involvement of GAS5 in human cancers was first studied in breast cancer, when it 
was found to be downregulated in breast cancer tissues (Mourtada-Maarabouni et 
al, 2009). Further studies reported GAS5 is found to be downregulated in various 
cancers and its low expression levels were often found to be predictive of poor 
prognosis in cancer patients (Hayes and Lewis-Wambi, 2015). Moreover, GAS5 
silencing was found to promote breast cancer cell proliferation and its 
overexpression promoted apoptosis and inhibited cell growth in different types of 
cell including breast cancer cells (Mourtada-Maarabouni et al, 2008; 2009).  
The involvement of XIST in breast cancer is now well documented.  XIST plays an 
essential role in X-chromosome silencing in female cells. XIST is expressed in all 
female somatic cells. However, the loss of X inactivation and expression of XIST 
transcript have been noticed in breast and ovarian cancers (Pageau et al, 2007). 
XIST expression was found to be significantly reduced in breast cancer tissues 
compared with normal breast tissues (Huang et al 2016). XIST interacts with 
SHARP/SPEN and SMRT co-repressor and acts as decoy preventing histone 
 deacetylase 3 (HDAC3) from binding to the promoter of PH domain and leucine-
rich repeat phosphatase 1 (PHLPP1), so that PHLPP1 is transcribed. PHLPP1 is a 
phosphatase, which dephosphorylates AKT leading to the inhibition of its activity 
and decreased cell growth and viability. Proteins such as BRCA1 (breast cancer 1) 
and the stem cell pluripotency transcription factors NANOG and Oct4 (octamer-
binding transcription factor 4) are involved in the regulation XIST expression 
(Galupa and Heard, 2015). In addition to the seven lncRNAs discussed above, 
recent studies have identified novel lncRNAs associated with breast cancer. These 
include LINP1, LINK-A (long intergenic non-coding RNA for kinase activation) and 
NKILA (NF-Kappa B interacting lncRNA).  LINP1 which is overexpressed in human 
TNBC (triple negative breast cancer), is involved in the regulation of the non-
homologous end joining pathway (NHEJ) (Zhang et al, 2016b). LINP1 acts as a 
scaffold and linking Ku80/70 and DNA-PKcs to broken ends and thereby 
enhancing the repair of DNA double-strand breaks. LINK-A plays an important role 
in the glycolysis reprogramming of TNBC (Lin et al, 2016). LINK-A interacts with 
breast tumour kinase (BRK) and leucine-rich repeat kinase 2 (LRRK2), promoting 
their phosphorylation and activation of HIF1α (Hypoxia-inducible factor 1-alpha). 
Active HIF1α promotes transcriptional programs resulting in the activation of 
glycolysis reprogramming in TNBC (Lin et al, 2016). NKILA is up regulated by NF-
κB, which is critical link between inflammation and cancer. NKILA binds to NF-κB 
/IκB and prevent NF-κB activation. NKILA is essential to prevent over-activation of 
NF-κB pathway in inflammation-stimulated breast epithelial cells. Low NKILA 
expression is associated with breast cancer metastasis and poor patient prognosis 
(Su et al, 2015).  
In conclusion, an increasing number of evidence supports a crucial role for 
lncRNAs in the development and progression of breast cancer and highlights the 
 potential of these lncRNAs as therapeutic targets in addition to diagnostic and 
prognostic (Cerk et al, 2016; Liu et al, 2016). LncRNAs have been shown to be 
involved in affecting epigenetic regulation, chromatin remodelling, gene expression 
and signalling pathways that demonstrated to affect various processes in breast 
cancer events. These include cell proliferation, cell survival, metastasis, 
angiogenesis and response to therapy. Therefore, characterization of lncRNAs 
modes of action will allow their future use for therapeutic purposes and as 
potential biomarkers for diagnostic and prognostic purposes.  
The above information has outlined some examples of lncRNAs involved in breast 
cancer. The focus of this thesis is to investigate the roles of the two nuclear non-
coding RNAs, Nuclear Enriched Abundant Transcript 1 (NEAT1) and Myocardial 
Infarction Associated Transcript (MIAT) in breast cancer. Therefore, the biology of 
these two lncRNAs will be outlined below. 
 
1.10 NEAT1 (Nuclear Enriched Autosomal Transcript 1)  
Nuclear Enriched Abundant Transcript 1 (NEAT 1), also known as Virus Inducible 
Noncoding RNA (VINC) or MEN ε/β RNA (Multiple Endocrine Neoplasia ε/β), is a 
long noncoding RNA encoded on chromosome 11q13.1 by the multiple endocrine 
neoplasia locus. Its chromosomal location is separated from its genomic neighbor 
MALAT1 by just 55 kb (Figure 1.5) (Hutchinson et al, 2007). MALAT1 also called 
NEAT2 (Nuclear enriched Abundant Transcript 2) was one of the first lncRNAs 
that was demonstrated to be associated with a disease, namely non-small cell 
lung cancer (NSCLC) (Hutchinson et al, 2007). MALAT1 was subsequently 
identified to play a pivotal role in cell proliferation, migration, and invasion by 
regulating processes such as alternative splicing, nuclear organization, epigenetic 
 control of gene expression (Hutchinson et al, 2007; Tripathi et al, 2010). NEAT1 
shows no homology with NEAT2 but both lncRNAs have been shown to be highly 
conserved within the mammalian lineage, which suggests that they have 
significant function (Hutchinson et al, 2007). In addition to another lncRNA 
GOMAFU/MIAT (Myocardial Infarction Associated Transcript), both NEAT1 and 
NEAT2 are examples of long noncoding RNAs that accumulate abundantly within 
the nucleus as RNA components of specific nuclear bodies (Clemson et al, 2009). 
NEAT1 is a stable intergenic lncRNA molecule, transcribed by RNA polymerase II 
into an unspliced structure containing a polyadenylated tail motif at the 3’ end of 
the sequence. It is specifically found within the paraspeckles nuclear 
compartments, where it localises (Clark and Mattick, 2011; Clemson et al, 2009).  
There are thought to be at least two isoforms of NEAT1; a small, widely expressed 
3.7 kb isoform (Hutchinson et al, 2007) NEAT1_1 and a much larger, 23 kb 
isoform termed NEAT1_2 (Clark and Mattick, 2011) which is expressed at slightly 
lower levels. Interestingly, the NEAT1_2 isoform contains a conserved tRNA-like 
structure, which can be cleaved by RNaseP to generate long and short ncRNA 
(Clark and Mattick, 2011; Cornelis et al, 2016). The expression levels of both 
transcripts are up-regulated upon differentiation of human embryonic stem cells 
(Chen and Carmichael, 2009), muscle differentiation (Sunwoo et al, 2009) and in 
vitro neuronal differentiation (Mercer et al, 2010). The function of NEAT1 is unique 
for a lncRNA molecule and therefore is thought to have an important role in the 
biology of the cell. It is essential in the formation of paraspeckles, the distinct 
nuclear structures that localise within the sub- compartments of the nucleus 
(Clemson, et al, 2009; Cornelis et al, 2016). 
 
    
 
1.10.1 NEAT1 and nuclear paraspeckles  
Nuclear paraspeckles are mammalian specific ribonucleoprotein nuclear bodies 
named due to their speckled appearance and they are approximately 0.5-1 
Microns in size and their number between 5-20 foci per nucleus (Fox and Lamond, 
2010; Clark and Mattick, 2011). Paraspeckles are located in the interchromatin 
nucleoplasmic space within the cell, near to but distinct from splicing factor-
enriched nuclear speckles (Bond and Fox, 2009). Figure 1.6 shows fluorescent 
images of the stained paraspeckles within the nuclei and their relation to other 
nuclear speckles found in the adjacent area. 
 
 
 
 
 
 
 
 
Figure 1.5 Chromosomal location of the NEAT1 gene. NEAT1 gene is located on chromosome 
11q13.1, about 55kb nearby to MALAT1 locus. NEAT1 transcribed into NEAT1_1 (short isoform) 
and NEAT1_2 (long isoform). Adapted from Bond and Fox, 2009.  
    
  
 
The relationship between NEAT1 and paraspeckles can be seen by their 
correlation in expression levels, an increase in the level of NEAT1 expression 
results in an increased number of paraspeckle bodies within the cell (Clemson et 
al, 2009; Cornelis et al. 2016). NEAT1 is essential for the formation of 
paraspeckles since NEAT1 knockout mouse were found to be devoid of 
paraspeckles and showed a loss in female fertility. Knockout females were not 
able to form the corpus luteum in a stable proportion resulting in infertility, as well 
as a lactation defect (Nakagawa, et al, 2014; Standaert et al, 2014).  The 
suppression of NEAT1 using small interference RNAs (siRNA) eliminates the 
presence of paraspeckles but does not affect the expression of other nuclear 
structures such as Cajal bodies or nuclear speckles (Clemson et al, 2009). 
Interestingly, a recent study has dissected the role of the two NEAT1 isoforms by 
Figure 1.6 Visualised Paraspeckles. (A) The combined interference contrast and fluorescence 
micrograph of HeLa cells stained with anti-PSPC1(anti-paraspeckles protein 1)  reveals the 
paraspeckles (green) as nucleoplasmic domain, which distinct from nucleoli (stained with B23 
antibody; red). (B) HeLa cells showing reorganization of the DBHS protein PSPC1 (green) to 
perinucleolar caps after treatment with actinomycin D to inhibit RNA Pol II transcription. (C) 
HeLa cell stained with anti-PSPC1 (green), anti-SC35 (red), and DAPI (blue) to show the 
relationship between paraspeckles abutting nuclear speckles in the interchromatin space. (D) 
TEM image of a HeLa cell section immune gold labelled with anti-PSPC1. The labelled IGAZs 
are usually found in close proximity to the interchromatin granules (ICGs; nuclear speckles). 
This image is adapted from the Bond and Fox, 2009. 
 using CRISPR-Cas9 genome editing to create total NEAT1 knockout cell line, cell 
line with expression of short isoform NEAT1_1, and cell line that express twofold 
more of NEAT1_2 long isoform (Li et al, 2017b). This study has provided evidence 
that the long NEAT1 isoform, NEAT1_2 is the major component of the 
paraspeckles while NEAT1_1 is not and co-localises in numerous non-
paraspeckles foci named "micro speckles," suggesting that it may carry 
paraspeckles-independent functions (Li et al, 2017b). 
 
1.10.2 Function of paraspeckles 
Paraspeckles are stress-induced nuclear bodies. Their function is to retain RNA 
molecules edited through processes such as Adenosine-Inosine editing (Clark and 
Mattick, 2011; Clemson, et al, 2009; Cornelis et al, 2016).  They also function to 
sequester the transcription/splicing factor SFPQ, thereby depleting SFPQ from 
promoters and affecting expression of critical immune genes (Hirose et al, 2014; 
Imamura et al, 2014). It is therefore suggested that paraspeckles act as a 
sequestration ‘sponge’ for proteins (Mang et al, 2017). Such sequestration 
mechanism is similar to other nuclear structures such as nucleoli that retain certain 
cell cycle regulators and nuclear stress bodies that trap specific splicing factors 
(Visintin and Amon,2000; Biamonti and Vourc'h,2010) . Paraspeckles proteins are 
common in both human and mice cells, and contain the structures required for 
cellular functions including the splicing of pre-mRNA, nuclear retention of RNA and 
the regulation of transcription (Clark and Mattick, 2011; Clemson, et al, 2009).  
The involvement of paraspeckles in mRNA regulation has been shown to be due 
to the protein p54 forming complexes, which causes adenosine-inosine edited 
RNA molecules to be retained within the nucleus, therefore storing molecules, 
 such as splicing factors (Hutchinson et al, 2007). A molecule found in 
paraspeckles, which suggests its involvement in pre-mRNA splicing, is CFIm68, a 
pre-mRNA 3’ end-processing factor, which would facilitate the release of any 
transcripts retained by p54 through the cleavage of these molecules (Clemson et 
al, 2009). 
 
1.10.3  Paraspeckles proteins  
The paraspeckles contain more than 40 RNA binding proteins assembled on the 
scaffolding RNA NEAT1 (Naganuma et a, 2012).  Almost all these proteins have a 
role in transcriptional and post-transcriptional gene regulation and have DNA or 
RNA binding domains (Naganuma et al, 2012).  Some of these proteins are 
members of the multifunctional Drosophila Melanogaster behaviour/human 
splicing proteins (DBHS family) (Bond and Fox, 2009). These proteins contain 
RNA recognition motifs (RRM) and RNA binding domains required for their 
localisation to the paraspeckles and are usually used as markers for the 
paraspeckles (Clemson et al, 2009; Clark and Mattick, 2011). 
They are reported to form heterodimers and extended long oligomers, which are 
essential for the formation of the paraspeckles (Clemson et al, 2009; Clark and 
Mattick, 2011). siRNA mediated knockdown of two of the DBHS proteins, NONO 
(Non-POU domain-containing octamer-binding) and SPFQ (Splicing factor proline 
and glutamine rich), resulted in the loss of paraspeckles in Hela cells, providing 
evidence that NONO and SPQF are essential for the formation and stability of 
paraspeckles (Sasaki et al, 2009; Naganuma et al, 2012). In addition, of NONO 
and SPQF, five other proteins were identified to be essential for the formation and 
the integrity of the paraspeckles. These include RBM14 (RNA binding motif protein 
 14), HNRNPK (Heterogeneous nuclear ribonucleoprotein K), DAZAP1 (DAZ 
associated protein 1), FUS (Fused in sarcoma) and HNRNPH3 (Heterogeneous 
nuclear ribonucleoprotein H3) (Naganuma et al, 2012).  
 
1.10.4 Formation of paraspeckles  
The formation of paraspeckles may occur initially during the transcription of 
NEAT1 by RNA polymerase II, once at least two foci of the RNA are present, 
before dispersing into distinct locations within the nucleus as the NEAT1 
transcripts are released (Clemson et al, 2009). This diffusion of the structures 
occurs in response to the movement of NEAT1 foci away from chromosome 11 
and its site of transcription, into the nucleus (Hutchinson et al, 2007).  
 As the cells progress through the cell cycle, the levels and location of both the 
NEAT1 RNA foci and the paraspeckles change (Clemson et al, 2009). The foci are 
the large localised structures of the RNA, which are widely distributed throughout 
the cell (Hutchinson, et al, 2007). During the interphase stage of the cycle, NEAT1 
RNA and the paraspeckles appear in a bipolar formation. In the early G1 stage of 
the cycle, there are only low numbers of NEAT1 RNA foci, which are located close 
to the transcription sites. The levels of the paraspeckle proteins such PSP1 
(PSPC1, paraspeckle protein component 1), NONO and SPQF within the 
paraspeckle begin to rise as the cell cycle progresses, allowing the structures to 
be identified. This correlates with the simultaneous increase in NEAT1 RNA foci 
due to the transcription of gene that immediately results in visible NEAT1 foci 
(Clemson et al, 2009). The correlation between the two structures as they 
progress through the cell cycle indicated how closely related their functions are. 
This can be further demonstrated through the disassembly of the paraspeckle 
 bodies due to the transcriptional arrest of NEAT1, and their inability to reassemble 
unless NEAT1 RNA is present (Clark and Mattick, 2011). 
 
1.10.5 NEAT1 function 
In addition to its role in the formation and maintenance of paraspeckles, NEAT1 
plays an important role in regulating different cellular functions (Lo et al, 2016a). It 
has been reported to play a critical role in mouse mammary gland development 
(Lo et al, 2016a). Recent studies implicated NEAT1 in adipogenesis (Gernapudi et 
al, 2016). The study identified a microRNA-140(miR-140)/NEAT1 non-coding RNA 
signalling networks involved in adipogenesis. Down-regulation of miR-140 results 
in suppression of NEAT1 expression. Furthermore, adipocyte-derived stem cells 
isolated from miR-140 knockout mice showed a strong reduction in their 
adipogenic capabilities, which was associated with a decrease in the expression 
level of NEAT1. Transfecting NEAT1 into the cells restored the adipogenesis 
process and differentiation (Gernapudi et al., 2016) These results suggest that 
targeting NEAT1/miR-140 axis could be a potential target in the prevention or 
treatment of obesity. 
NEAT1 has been reported to be significantly up regulated in Huntington’s disease 
(Johnson, 2012). NEAT1 have been associated with drug addiction. For instance, 
NEAT1 up-regulation was detected in the nucleus accumbens of heroin abusers 
(Johnson, 2012). NEAT1 was also identified as one of the RNA that binds to TDP-
43, a predominantly nuclear RNA-binding protein that forms inclusion bodies in 
frontotemporal lobar degeneration and amyotrophic lateral sclerosis (Tollervey et 
al, 2011). The significance of these results is unclear as the NEAT1 knockout mice 
are viable, despite the absence of paraspeckles (Nakagawa et al, 2011). Further 
 studies in model organisms will be required to determine the significance of 
NEAT1 in the neurodegenerative process.  
During the course of this study, a number of evidence has emerged implicating 
NEAT1 in oncogenesis. A number of studies have identified NEAT1 function as an 
oncogene in multiple types of cancer, including breast cancer. NEAT1 
overexpression has been reported in different types of solid tumours like 
malignancies of digestive system, hepatocellular carcinoma, lung cancer and 
oesophageal squamous cell cancer (Yang et al,2017; Xiong et al ,2017; Guo et al, 
2015; sun et al, 2016; Chen et al, 2015). Its mode of action is not very clear,  but it 
has been reported that in non-small lung cancer (NSCLC) the contribution of 
NEAT1 in progression of this cancer via its role as a competing endogenous RNA 
(ceRNA) (Sun et al, 2016). NEAT1 overexpression caused a repression of has-
miR-377-3p and prevented its effect on the transcription factor E2F3 resulting an 
increase in the expression levels of E2F3 which plays a crucial role in enhancing 
the progression of NSCLC (Sun et al, 2016). In gastric cancer, NEAT1 was found 
to be overexpressed in gastric cancer tissues and cell lines, and its expression 
positively correlated with clinical stage, histological type, lymph node metastasis, 
and distant metastasis (Song et al, 2017). Cox regression analyses also showed 
that NEAT1 overexpression was a poor independent prognostic factor for gastric 
cancer patients (Song et al, 2017). In vitro studies showed that NEAT1 silencing 
significantly suppressed the gastric cancer cell migration and invasion and 
reduced epithelial-mesenchymal transition (EMT)-associated proteins expression 
(Song et al, 2017). 
NEAT1 involvement in breast cancer has also been reported during the course of 
the current study. NEAT1 is reported to be a direct transcriptional target of 
hypoxia-inducible factor 2 (HIF-2) in a number of breast cancer cell lines and in 
 solid tumours and its levels were shown to dramatically increased in hypoxia 
(Choudhry et al, 2015). Induction of NEAT1 in hypoxia was associated with an 
increase in cellular proliferation, improved clonogenic survival and reduced 
apoptosis, all of which are hallmarks of increased tumorigenesis (Choudhry et al, 
2015). NEAT1 was found to be highly expressed in breast cancer tissues and its 
high expression was closely related to the tumour size and lymph node metastasis 
(Choudhry et al, 2015; Zhang et al, 2017b). In vitro studies have also shown that 
NEAT1 silencing caused a decrease in cell proliferation and metastasis in breast 
cancer cells and decreased the protein expression levels of EMT-associated 
proteins (Zhang et al, 2017b). More interestingly, recent genomic studies have 
shown that NEAT1 promoter carry recurrent mutations in breast cancer. Such 
mutations affect the protein binding to the NEAT1 promoter leading to the 
alteration of expression levels (Rheinbay et al, 2017).   
While high expression levels of NEAT1 was reported in different solid tumours and 
was associated with poor prognosis, other studies have shown that NEAT1 is 
down-regulated in oesophageal cancers, retinal cancers and acute promyelocytic 
leukaemia where it promotes leucocyte differentiation ( Gibb et al, 2011b; 
Johnson, 2012; Gao et al,2016). NEAT1 expression levels were found to be 
considerably down-regulated in leukaemia patient samples compared with those 
from healthy donors (Gao et al, 2016).  NEAT1 low expression levels were also 
reported in leukemic cell lines such as K562, THP-1, HL-60 and Jurkat, which 
goes along with the expression observed in leukemic patients (Gao et al, 2016). In 
addition, NEAT1 overexpression in K562 and THP-1 leukemic cells leads to the 
inhibition of ATP-binding cassette G2, which is involved in promoting the 
mechanism of multidrug resistance to the chemotherapy, and alleviated the 
multidrug resistance induced by cytotoxic agents (Gao et al, 2016). In addition to 
 the evidence discussed above, the importance of NEAT1 in the regulation of cell 
death and survival is also highlighted by its identification as a potential gene that 
control cell survival using an unbiased functional screen to identify genes  
regulating apoptosis (Williams et al, 2006). Such screen has identified several 
genes, each of which opened up a venue for apoptosis research. One of the 
genes identified using this approach was the lncRNA GAS5 which plays very 
important role in the control of cell death and survival (Mourtada-Maarabouni et al, 
2009; Mourtada-Maarabouni et al, 2010). Based on the accumulating evidence of 
the significant role of NEAT1, It is therefore important to study its function in the 
control of programmed cell death and survival and its involvement in cancer. 
 
 1.11  MIAT (Myocardial Infarction Associated Transcript)  
MIAT is one of the noncoding RNAs associated with nuclear structures namely 
nuclear bodies (Ishizuka et al, 2014). MIAT was previously known as RNCR2 
(retinal non-coding RNA2) and GOMAFU. Increasing number of evidence confirms 
the role of MIAT lncRNA in a number of cellular processes, like the formation of 
nuclear bodies (Ishizuka et al, 2014) and neurogenic commitment (Aprea et al, 
2013). In addition MIAT lncRNA is involved in a number of diseases and cellular 
processes, including myocardial infarction (Ishii et al, 2006; Liao et al, 2016), 
diabetic retinopathy (Vausort et al, 2014), microvascular dysfunction (Yan et al, 
2015) and paranoid schizophrenia (Rao et al, 2015). MIAT was originally identified 
in the neurons of the mouse retina and was later found to be highly expressed in 
the nervous system throughout development and its expression was reported to 
continue into adulthood (Sone et al, 2007). It was later found to be conserved 
among higher vertebrates, including human and chicken, in terms of both its 
 nuclear localisation and expression pattern in the nervous system (Sone et al, 
2007; Tsuiji et al, 2011).  MIAT gene is located on chromosome 22q12.1, about 9-
10 kb alternative spliced transcript, and its transcript has the characteristics of 
mRNA, which include 5’ capping, polyadenylation at the 3’ ends and splicing. 
However, unlike protein coding mRNA, MIAT transcript escapes nuclear transport 
and accumulates within the nucleus, where it forms a unique nuclear structure 
(Sone et al, 2007; Sattari et al, 2016; Xuefeng et al, 2017). 
 
1.11.1 Role of MIAT in cardiovascular, microvascular and related 
diseases 
The association of MIAT with cardiovascular diseases was first highlighted by 
identifying a single nucleotide polymorphism in the human homologue associated 
with an increased risk of myocardial infarction. Hence, the gene has been named 
myocardial infarction associated transcript instead of GOMAFU (Ohnishi et al, 
2000). Further clinical trials studies comparing 414 myocardial infarction (MI) 
patients with 86 healthy volunteers have shown that patients with ST segment 
elevation myocardial infarction (STEMI) had lower expression levels of MIAT 
compared to those with non- ST segment elevation myocardial infarction 
(NSTEMI). Among all the cardiovascular risk factors, expression of MIAT was 
positively associated only with smoking (Vausort et al, 2014). Xuefeng et al. (2017) 
showed that MIAT acts as a pro-fibrotic factor in MI. The studies demonstrated 
that MIAT expression level in cardiac muscles increased myocardial attack. MIAT 
acts as a sponge for miR-24. An increase in MIAT leads to the decrease in miR-24 
and the increase in the expression levels of miR-24 target genes including the 
fibrosis- related regulators, Furin (furin, paired basic amino acid cleaving enzyme) 
 and TGF-β1 (transforming growth factor beta 1), leading to an increase in cardiac 
fibrosis and hence insufficiency in cardiac function (Xuefeng et al, 2017). 
Accordingly, MIAT knockout caused an up-regulation in miR-24, which prevented 
fibrosis and enhanced cardiac function (Xuefeng et al, 2017). Therefore, 
normalisation of MIAT expression post-myocardial infarction can be considered as 
a therapeutic target that could lead to the decrease in fibrosis and the 
improvement in cardiac function (Xuefeng et al, 2016; Liao et al, 2016). 
MIAT was also reported to play an important role in the regulation of mammalian 
retinal cell differentiation (Rapicavoli et al, 2010). A number of evidence has 
implicated MIAT lncRNA in the development of microvascular dysfunction. Studies 
have shown that MIAT expression level is increased in the retina of diabetic rats 
and humans and in vitro experiments demonstrated that its expression was 
induced by high glucose (Yan et al, 2015). Decreasing the expression level of 
MIAT in diabetic rats led to the improvement in the visual functions, the reduction 
in the pro-inflammatory proteins related to diabetes mellitus and the decrease in 
endothelial inflammatory responses, suggesting that inhibition of MIAT expression 
might improve retinal vessel impairment (Yan et al, 2015). MIAT was shown to 
function in retinal endothelial cell as a competing endogenous RNA (ceRNA) 
which acts as a sponge for miR-150-5p leading to an increase in the expression of 
vascular endothelial growth factor (VEGF), a miR-150-5p target gene and the 
maintenance of  retinal and corneal vascularization  (Jiang et al, 2016b; Yan et al, 
2015).  Recent studies have shown that MIAT is associated with the development 
of age-related cataract as it was found to be specifically up-regulated both in the 
plasma fraction of whole blood and aqueous humour of cataract patients (Shen et 
al, 2016).  The studies showed that MIAT knockdown in human lens epithelial cells 
suppressed tumour necrosis factor-α expression, stimulated of an atypical growth 
 of these cells and increased the rate of migration, suggesting a potential role of 
MIAT in Posterior capsule opacification (PCO)-related pathological process. This 
result elucidates the role of MIAT in the pathological process of posterior capsule 
opacification (PCO), a post-operative complication of cataract (Shen et al, 2016). 
 
1.11.2 Role of MIAT in neuronal development and mental 
disorders  
In addition to its expression in different types of neurons and through the 
neurogenesis process, MIAT has been reported to be involved in neuronal 
development and its abnormal expression might result in particular nervous 
dysfunction (Sone et al, 2007; Ishizuka et al, 2014). Microarray analysis of 
transcripts associated with neural stem cell proliferation and differentiation 
revealed that MIAT is expressed during neurogenesis an oligodendrocyte lineage 
specification (Mercer et al, 2010). Further studies have showed that MIAT controls 
the differentiation of neural progenitors, the survival of new neurons and the 
splicing of Wnt7b, a protein involved in different steps of neurogenesis, indicating 
the importance of MIAT in neuronal commitment and survival (Aprea et al, 2013).    
Studies performed by Barry et al. (2014) to investigate the role of MIAT in SZ 
pathogenesis involved stimulation of the neuronal depolarization using mouse 
primary cortical neurons and determining the changes in gene expression 
associated with such stimulation at different time points.  Their results showed that 
MIAT was one of the most strongly down-regulated non-coding transcripts at 
different time points. Down-regulation of MIAT expression in human-induced 
pluripotent stem cells derived neurons was shown to result in alternative splicing 
patterns that resemble those observed in SZ for the two SZ-associated genes 
 disrupted–in-schizophrenia 1 (DISC1) and receptor tyrosine-protein kinase 
(ERBB4) ( Barry et al,2014). MIAT was shown to be important in anxiety, a 
common symptom in SZ.  Spadaro et al. (2015) have investigated the relationship 
between MIAT (Gomafu) expression and anxiety-like behavior in mice. The studies 
reported that MIAT was significantly down-regulated in fear conditioned group of 
mice and siRNA mediated silencing of MIAT in the pre-limbic region of the 
prefrontal cortex enhanced fear response during behavioral training (Spadaro et 
al, 2015). However, the fear enhancement caused by down-regulation of MIAT 
disappeared after 24h, indicating that MIAT has no effect on long-term memory 
(Spadaro et al, 2015). The study showed that MIAT down-regulation leads to its 
dissociation from BMI1, a key member of the Polycomb repressive complex 1,  
and relieves its repressive control over the schizophrenia-related gene crystallin 
beta 1 (Crybb1) promoter, resulting in an increase in Crybb1 gene expression. 
Collectively, these results highlight the importance of MIAT in neuronal function 
and strongly suggest that their dysregulation in MIAT expression and function may 
contribute to the development of neurological and neuropsychiatric disorders. 
 
1.11.3 Role of MIAT and cancer 
Evidence implicating MIAT in cancer is now emerging. MIAT is selectively up-
regulated in neuroendocrine prostate cancer, which is the most lethal prostatic 
neoplasm (Crea et al, 2016).  MIAT has been shown to interact with Polycomb 
genes enhancing histone modification and playing a role in cancer cells' plasticity, 
thereby promoting the emergence of metastatic, drug-resistant neoplasms (Crea 
et al, 2016). Data mining aimed to perform lncRNA profiling on a cohort of 213 
glioblastoma patients from The Cancer Genome Atlas as well as independent data 
 sets from the Gene Expression Omnibus (GEO), identified six-lncRNA signature 
that were significantly associated with the overall patient survival (Zhang et al, 
2013). These lncRNAs include ART1, MGC21881, GAS5, PAR5, and MIAT 
(Zhang et al, 2013). MIAT expression was reported to be significantly down-
regulated in glioma brains compared to normal and its expression of MIAT was 
found to be associated with long survival (Zhang et al, 2013). While MIAT 
expression in glioblastoma is associated with long survival and appears to act as a 
tumour suppressor, recent studies have reported MIAT overexpression in an 
aggressive form of chronic lymphocytic leukaemia (CLL) (Sattari et al, 2016). The 
studies showed up-regulation of MIAT in lymphoid but not in myeloid cell lineage 
with mature B cell phenotype. MIAT was found to be significantly up regulated in 
primary leukemic cells from patients with aggressive form of CLL carrying either 
17p-deletion, 11q-deletion, or Trisomy 12. Furthermore, upregulated MIAT levels 
were associated with rapid death cases (Sattari et al, 2016).  The mouse 
homologue of MIAT has been shown to bind to Oct4 gene (octamer-binding 
transcription factor 4), a marker of stemness, leading to an increase in Oct4 
expression (Mohamed et al, 2010; Zeindene et al, 2014). Oct4 also binds to MIAT 
and positively regulates its transcription in mouse embryonic stem cells, and thus, 
they constitute a regulatory feedback loop (Mohamed et al, 2010). The relationship 
between MIAT and Oct4 was investigated in malignant B cells. The results showed 
that siRNA mediated down-regulation of MIAT in malignant B cell lines was 
associated with a concomitant downregulation of Oct4 (Sattari et al, 2016). These 
results indicated that as in mouse embryonic stem cells, MIAT in malignant B cells 
positively regulates Oct4 transcription and Oct4 regulated MIAT expression, and 
thus both molecules make up a positive feedback loop and are essential for cell 
survival (Sattari et al, 2016). These studies highlighted the anti-apoptotic role of 
 MIAT in malignant mature B cells and its potential as a biomarker for 
aggressiveness of chronic lymphocytic leukemia 
 
1.12 Aims and objectives   
Currently, the study of LncRNAs is becoming one of the most popular fields in the 
biological and medical sciences. LncRNAs have emerged as important regulatory 
molecules in developmental, tumour suppressor and oncogenic pathways and 
other diseases. Some of these lncRNAs can regulate cell survival and cell death, 
suggesting a key role for these molecular regulators. Others have become 
diagnostic markers and potential therapeutic targets. Understanding of the 
mechanism(s) by which lncRNAs regulate cell death survival will lead to new 
markers of cancer diagnosis and identification of novel therapeutic targets. The 
aims of this study are to investigate the role of two nuclear lncRNAs, NEAT1 and 
MIAT/GOMAFU in the regulation of cell death and survival of breast cancer cells. 
The present study specifically investigates the functional activity of NEAT1 and 
MIAT in breast cancer cells and aims to address the gap in our understanding of 
the role and mechanisms of action for these two lncRNAs. 
 
 
 
 
 
 
 
 
  
 
 
 
                       
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 2 
 Materials and Methods 
 
 2.1 Materials 
2.1.1. Cell culture, transfection and functional analysis 
The human breast cancer cell lines MCF7 and MDA-MB-231 were purchased from 
ATCC-LGC Promochem (Teddington, UK). RPMI-1640 growth medium containing 
[phenol Red as pH indicator (# R0883), L-glutamine (# G7513), sodium pyruvate 
(# S8636), HEPES Buffer (# H0887), gentamicin (# G1272)], Trypsin/EDTA (# 
59418C) and Phosphate-buffered saline (PBS) (# 101584397) were from Sigma-
Aldrich Company Ltd. (Gillingham, UK). Foetal bovine serum (FBS) (# FB-1001S) 
was from Biosera (East Sussex, UK). Some NEAT1 siRNAs (Nominated according 
to their targeting site) were obtained from Qiagen (Crawley, UK), NEAT1a (ID: 
2163122, # S105189751), NEAT1c (ID: 2163121, # S103682126). Ambion Select 
NEAT1 siRNAs were obtained from Life Technologies Ltd (Paisley, UK). NEAT1, 1 
(ID: s238175, # 4399665) and NEAT1, 2 (ID: s238174, # 4399666). MIAT2 siRNA 
(ID: 2164377, #SI04314919), MIAT3 siRNA (ID: 2163124, # SI00582799) were 
purchased from Qiagen (Crawley, UK).  All siRNAs were HPLC purified, annealed 
and ready to use. Silencer®siRNA labelling kit-Cy3 (#1632) and Negative Control 
siRNA (# AM4635) were purchased from Life Technologies. The Negative Control 
siRNA has no significant sequences similar to mouse, rat, or human gene 
sequences. Custom antisense oligonucleotides were ordered from GE Healthcare 
Dharmacon Inc., Little Chalfont, UK. The single stranded RNA/DNA 
oligonucleotides were converted to the 2’ hydroxyl form and desalted. 
The following kits were obtained from Merck Millipore: Muse cell count and viability 
kit (# MCH100102), Muse annexin V and dead cell kit (# MCH100105) and Muse 
cell cycle kit (# MCH100106). The MTS assay (CellTiter 96 AQueous One Solution 
Cell Proliferation Assay) was from Promega (Southampton, UK). HiPerFect 
 transfection reagent (# 301704) was from Qiagen and the Nucleofector solution 
(Mirus Ingenio®kit, # MIR 50115) was from Mirus Bio LLC, Madison, WI, USA. The 
chemotherapeutic drugs (Docetaxel, 5-Fluorouracil, Nutlin-3a and Mitoxantrone) 
were purchased from Sigma-Aldrich Company Ltd (Gillingham, UK). 
 
2.1.2 Materials for RNA isolation and gene expression analysis 
TRIzol (#15596018), TaqMan assays, Random primer (# N48190-011) and 
Ribonuclease inhibitor were from Life Technologies Ltd. SensiFast Probe Hi-ROX 
kit was from Bioline (London, UK), RQ1 RNase-free DNase was from Promega 
(Southampton, UK). Omniscript Reverse Transcription (RT) Kit, (# 205111) was 
from Qiagen. Ribonuclease inhibitor (Invitrogen, # 10777-018).RQ1 DNase 10x 
Reaction Buffer (# M198A), RQ1 RNase-free DNase (# M 610A) and RQ1 DNase 
stop reaction (# M199A) were purchased from Promega (Southampton, UK).  
Isopropanol and Ethanol were purchased from Fisher Scientific UK Ltd 
(Loughborough, UK). Chloroform was from BDH laboratory supply, England.  
RT2 Profiler PCR Array (96-Well Format) for Human Cell Cycle (# 330231 PAHS-
020A) and Human Breast Cancer (# 330231 PAHS-131ZA), RT2 First Strand Kit 
(# 330401) and RT² SYBR® Green qPCR Mastermix  (# 330520) were purchased 
from QIAGEN. TissueScan™ Cancer and Normal Tissue cDNA Arrays (# 
BCRT102) were purchased from OriGene (Rockville, USA).  
2.2 Methods 
2.2.1 Cell culture 
Two types of breast cancer cell lines MCF7 and MDA-MB- 231 were used in this 
study. Both cell lines were derived from plural effusion of patients with breast 
 cancer. The first cancer cell line MCF7 was established in 1973 in the Michigan 
cancer foundation and is characterized by low level expression of the proliferation 
marker Ki67 and high hormonal sensitivity via expression of oestrogen receptor 
(Soule, et al, 1973). In contrast, the triple negative MDA-MB- 231 cell line lacks the 
expression of oestrogen, progesterone and HER2 receptors and shows high 
expression level of  Ki67 (Cailleau et al, 1974; Holiday and Speirs, 2011).  
Cells were routinely cultured in complete RPMI-1640 growth medium 
supplemented with 10% heat inactivated foetal calf serum, 2mM L-glutamine and 
200 µg/ml gentamycin.  Cells were incubated at 37o C in a 5% CO2 humidified 
incubator. After a confluence of 80% ,cell detachment were proceeded by rinsing  
the flask with 3 ml of Phosphate buffered saline (PBS)  followed by adding 2 ml of 
0.25% Trypsin /EDTA minutes before returning the flask to the incubator for 3- 5 
minutes to facilitate detachment of the cells. An equal volume of medium was 
added to the flask to inactivate the trypsin and the content of the flask was 
transferred to a 15 ml centrifuge tube and centrifuged at 300 x g for 5 minutes in 
order to get a pellet. The supernatant was discarded and the cell pellet was re-
suspended in fresh RPMI medium and seeded into new flasks. 
 
2.2.2 Freezing and thawing of MCF7 and MDA-MB-231 cell lines 
 MCF7 and MDA-MB-231 cells were stored for long period at -140°C in liquid 
nitrogen. Cells were re suspended in 1ml of cryoprotectant medium (40% FBS, 
50% complete RPMI growth medium and 10% dimethyl sulphoxide (DMSO). 
before transferring them to a cryo-tube. They were immediately stored in an 
isopropanol chamber at -80 before being transferred to liquid nitrogen for long-
term storage.  For the recovery of the cells, the cryopreserved cells were thawed 
 at 37˚C and re-suspended in 10 ml of RPMI complete medium. Cells were 
centrifuged at 300 x g for 5 min and re-suspended with appropriate volume of 
RPMI complete growth medium and maintained in a 5% CO2  humidified incubator 
at 37˚C.  Cell lines were replaced with fresh stocks from liquid nitrogen after a 
maximum culture period of 2 months.  
 
2.2.3 siRNA labelling  
To determine siRNA transfection efficiency, siRNA duplexes were labelled with 
Cy3 using the Cy3 Silencer TM siRNA labelling kit, following the manufacturer’s 
instructions. The Cy3-labelling siRNA reaction was prepared in a sterile, nuclease-
free tube and with a limited exposure to light for the entire procedure. The reaction 
consisted of 18.3µl of nuclease free water, 5 µl of 10x labelling buffer, 19.2 µl 
siRNA (20 µM) and 7.5 µl of Cy3 labelling reagent (100 µM) which was added last. 
After mixing by vortexing, the labelling reaction was incubated at 37˚C for 1hr. 
Labelled siRNAs were stored in freezer at -20˚C. 
 
2.2.4 Optimisation of Transfection by HiPerFect transfection 
reagent  
To obtain the highest transfection efficiency with minimal effects on cell viability, 
optimisation trials for HiPerFect transfection reagent were carried out for every cell 
line using Cy3 labelled scrambled siRNA, according to the supplier protocol. 
Breast cancer cells were plated at a concentration of 1.5 x 105 cells/well in a 6-well 
plate with added 2.5 ml growth medium and incubated at 37°C for 30 minutes. 
siRNA complex was prepared in 0.5 ml Eppendorf tube by mixing  different 
volumes of HiPerFect reagent  with 6 µl of 7.68 µM Cy3 labelled siRNA diluted in 
 94 µl Opti-MEM I. Opti-MEM I is a reduced serum media which is ideal for cationic 
lipid transfection. It is buffered with HEPES and sodium bicarbonate; and 
supplemented with hypoxanthine, thymidine, sodium pyruvate, L-glutamine, trace 
elements, and growth factors. Each complex was added drop-wise to the cells in a 
6 well plate before being incubated at 37˚C in a 5% CO2. The efficiency of 
transfection was determined after 72 hr using fluorescence microscopy. 1ml cells 
transfected with Cy3 labelled negative siRNA were centrifuged at 300 x g for 6 
minutes. Supernatant was discarded and the pellet washed with 1ml of PBS.  Cells 
were centrifuged as above, and re-suspended in 20 µl of RPMI medium. The 
whole sample was placed on a slide and covered with a coverslip and viewed 
under the microscope.  Transfection efficiency was calculated as percentage of 
transfected cells from all cells by counting transfected cells holding a red 
fluorescent signal as a result of the successful transfection with Cy3 labelled 
siRNA, using Nikon Eclipse E400 Binocular Fluorescence Microscope with FITC 
filter (Figure 2.1). Viability was determined using vital dye staining, as described in 
section 2.2.7.1. The results showed that HiPerFect did not affect cell viability.  
High transfection efficiency was obtained using 4.5 µL of transfection reagent, 
(83.5% and 90% in MCF7 and MDA-MB-231) respectively (Table 2.1).  
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2.1 Optimisation of transfection by HiPerFect transfection reagent. Different 
volumes of HiPerFect transfection reagent was used with Cy3 labelled siRNA. Transfection 
complexes were added into MCF7 and MDA-MB-231 cells. The efficiency of transfection 
and cell viability were determined 72h post transfection. The transfection efficiency was 
determined by counting the fluorescent cells per 100 cell in the field. While, cell viability 
was calculated according to the equation:    % of viability= [viable cells/ total cells] x 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell line 
Volume of the          
transfection 
reagent 
Transfection 
efficiency  72 
hours post- 
transfection 
         Cell viability 
Viable cells  
X105 cells/ml 
Total cells 
X105 cells/ml 
    % 
MCF7 
1.5 µL 
3 µL 
4.5 µL 
73% 
67% 
83% 
10.3 
17.8 
19.5 
11.5 
19.7 
21.6 
89% 
90% 
90% 
MDA-MB-
231 
1.5 µL 
3 µL 
4.5 µL 
64.3% 
72% 
90% 
12 
15.5 
20.2 
14.3 
19.6 
23.2 
84% 
79% 
87% 
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  B) 
 
       
 
 
Figure 2.1 A representative image of transfection efficiency in breast cancer cells using 
HiPerfect transfection reagent. (A) The transfection efficiency of MCF7 cells and (B) MDA-MB-
231cells, 72 hours post-transfection. The transfection was carried out using 4.5 µl of HiPerfect 
transfecting reagent and the images were taken using fluorescent microscope. Magnification 
x200  
 
 2.2.5 RNA interference by small interference RNA (siRNA)  
Cells were transfected with gene specific Ambion Select or Qiagen siRNAs using 
HiPerFect transfection reagent or Nucleofection. Controls received negative 
control siRNA. Details on the gene specific siRNAs and their target location are 
presented in Table 2.2 and Table 2.3.  
Transfection using HiPerFect transfection reagent was carried out according to 
standard protocol (Qiagen, 2010). Breast cancer cells were seeded in 6 well plate 
(1.5 x105 cells/well) and incubated at 37°C for 30 minutes. siRNA  and HiPerFect 
complex was prepared in 0.5 ml Eppendorf tube by mixing 4.8 µl of 20 µM of either 
(-)siRNA or gene specific siRNA and 95.2 µl Opti-MEM I. The mixture was 
vortexed before adding 4.5 µl of HiPerFect transfection reagent and mixed gently 
by pipetting. The mixture was incubated at room temperature for 10 minutes 
before being added in a dropwise manner whilst swirling the plate. Cells were 
incubated at 37˚C for 72 h in 5% CO2. Efficiency of transfection and the levels of 
gene expression were determined 72h post transfection by fluorescence 
microscopy and qRT- PCR, respectively. Harvested cells were re-plated 24h for 
functional analysis and assessment of cell survival.  
Nucleofection was also used for the transfection of siRNAs.  MCF7 and MDA-MB-
231 were nucleofected with gene specific siRNA or negative control siRNA using 
Ingenio electroporation solution. The cells were sub-cultured one day before 
Nucleofection. On the day of the nucleofection, 2 x 106 cells were re-suspended in 
100 µl of Ingenio electroporation solution and 5 µl of .siRNA (3.3 µM). Cell 
suspension was transferred into nucleofector certified cuvettes and was 
nucleofected using Amaxa™ Nucleofector™ II, P-020 and X-013 for MCF7 
(ATCC) high efficiency and MDA-MB-231 (ATCC) respectively. Cells were 
recovered and plated in 5 ml RPMI medium in 6-well plates. The plate was 
 incubated in a humidified incubator at 37°C and 5% CO2 for 48h. 48h after 
transfection 2.5x105 of the transfected cells were trypsinised counted and re-plated 
for further 24 and 48 hours before assessment of the cell survival. 
 
 
 
 
 
 Name 
Sequence 
ID 
Cat. No. 
Targeting 
site 
Target sequences (5’-
-3’) 
NEAT1 
siRNAs 
NEAT1a 
NR_00280
2 
SI0518975
1 
445-465 
5’-
GCCGGGAGGGCTAA
TCTTCAA-3’ 
NEAT1c 
NR_00280
2 
SI0368212
6 
3310-3330 
5’-
CTGCGTCTATTGAAT
TGGTAA-3’ 
NEAT1,
1 
gb/GQ859
162.1 
S238175 
12013-
12033 
5’- 
TGCTGCCAAAATAGA
ATAA-3’ 
NEAT1,
2 
gb/GQ859
162.1 
S238174 
12084-
12104 
5’- 
GACTGTAATTGGTAC
AGTA -3’ 
NEAT1 
(ASOs) 
NEAT1,
1 
NR_13101
2.1 
GEHCU-
000379 1934-1953 
5’-
GCAGATTACTAGGA
GAAGGG-3’ 
NEAT1,
2 
NR_13101
2.1 
GEHCU-
000380 
3163-3182 
5’-
AATGAGCCAAGACT
AGAGGG-      3’ 
siRNAs 
Sequence 
ID 
Cat. No. 
Targeting 
site 
Target sequences (5’-3’) 
   
MIAT2 
NR_00349
1 
SI0431491
9 
6488-6508 
5’-
GCGGGUCUUUCCUACGC
UATT-3’ 
   
MIAT3 
NR_00349
1 
SI2040728
31 
9735-9755 
5’-
GGAGUCUACUGAACAUC
AATT-3’ 
Table 2.2 Details of NEAT1siRNAs and Antisense Oligonucleotides (ASOs) and their 
target sequences. 
 
Table 2.3 MIAT siRNAs and their target sequences  
 A)  NEAT1 siRNAs
 
B) NEAT1 Antisense Oligonucleotide 
 
C) MIAT 2 and MIAT 3 siRNAs
 
 
Figure 2.2 Schematic diagram representing the targeting sites of small interference RNAs 
(siRNAs), antisense oligonucleotide (ASO) and TaqMan Gene Expression Assay. (A) 
Represents the targeting sites of NEAT1 siRNAs, in which the targeting sites of N1a 
(SI05189571) and N1c (SI03682126) are (445-465) and (3310-3330) respectively. While, the 
targeting sites for N1, 1(s238175) and N1, 2 (s238174) are (12013-12033) and (12084-12104) 
respectively (Qiagen). (B) Represents the targeting sites of NEAT1 antisense Oligonucleotides 
and in both NEAT1 short and long isoforms, in which the targeting site for N1, 1 and N1, 2 are 
(1934-1953) and (3163-3182) respectively (NCBI). (C) Shows the targeting sites of MIAT 
siRNAs, where the target sites of M2 (SI04314919) and M3 (SI00582799) are (6488-6508) and 
(9735-9755) respectively (Qiagen). The green shaded area represents the TaqMan Gene 
Expression Assay location (for both primers and probe). 
 
 2.2.6 Nucleofection of antisense oligonucleotides 
The antisense oligonucleotides (ASOs) consisted of DNA and RNA 
phosphorothioate-modified oligonucleotides containing selective phosphorothioate 
backbone modifications (as indicated by * and 2’ O-methyl RNA bases (indicated 
by ‘m’ as presented in Table 2.2). Cells at density of (2 × 106) in 0.1 ml Ingenio 
electroporation solution were nucleofected with 5 pmol oligonucleotide using 
programmes P-020 and X-013 for MCF7 and MDA-MB-231 respectively. Then, the 
cells were re-plated in 3 ml RPMI medium in 6-well plates. The plate was 
incubated in a humidified incubator at 37°C and 5% CO2 for 48h. 
 
2.2.7 Determination of apoptosis and cell survival  
2.2.7.1 Vital dye exclusion assay  
Cell viability was determined by vital dye staining using trypan blue and a 
haemocytometer. The intact membranes of the live cells exclude the vital dye and 
appear bright under light microscope. Whereas, dead cells absorb trypan blue dye 
through their damaged membrane and selectively show to have blue colour. 20 µl 
of the cell suspension was mixed with an equal volume of 0.4% trypan blue stain. 
Cell suspension was loaded in the edge of the chamber between the coverslip and 
the groove in the chamber and allowed to be drawn into the chamber by capillary 
action. Viable and non-viable cells were counted under the light microscope and   
cell number per ml was calculated using the following equation: 
“Average Number of Cells in four large squares X dilution factor X 104” 
 
 2.2.7.2 Cell viability using flow cytometry 
Total and viable cell counts were determined by flow cytometry using the Muse® 
Count and Viability Assay kit and the Muse system, a mini flow cytometer. The 
Muse Count and Viability reagent contains two DNA binding dyes, which allow the 
differential staining of viable and non-viable cells based on their membrane 
integrity and permeability to these dyes. One of the DNA-binding dyes in the 
reagent specifically stains the nucleus of dead and dying cells ,the cells that have 
lost their membrane integrity. This parameter is used to discriminate between the 
live cells (that do not take up the dye) from the stained non-viable or dying cells 
and is displayed on the Muse system as “VIABILITY”. The other dye is membrane-
permeant and stains the DNA in all viable nucleated cells with a nucleus (MuseTM 
user’s guide, # MCH100102,). This parameter is used to discriminate cells with a 
nucleus from debris and non-nucleated cells. The Muse™ System counts the 
stained nucleated events and uses the cellular size properties to distinguish 
cellular debris from cells to determine a precise total cell count. Using these data, 
the Muse™ Count and Viability Software Module automatically performs 
calculations and displays data in two dot plots (Figure 2.3). 
Determination of total and viable cell number of transfected cells using the Count 
and Viability Assay was carried out following the manufacturer’s instructions. 
Trypsinised cells were diluted 20 fold with the reagent (for example, 20 μl of cell 
suspension into 380 μl of Muse Count and Viability Reagent). Cells were allowed 
to stain for a minimum of 5 minutes at room temperature and were counted using 
the Muse cell analyser.  
 
   
                    
 
 
2.2.7.3  MTS cell viability assay 
Cell viability was also determined using The CellTiter 96® AQueous One Solution 
Cell Proliferation Assay (MTS assay). The CellTiter 96® AQueous One Solution 
Reagent contains tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) and an 
electron coupling reagent (phenazine ethosulfate; PES).  The enhanced chemical 
stability of PES allows it to be combined with MTS to form a stable solution. The 
MTS tetrazolium compound is bio-reduced by NADPH or NADH produced by 
dehydrogenase enzymes in metabolically active cells, resulting in the development 
of coloured soluble formazan product in tissue culture medium (Cell Proliferation 
Assay, Promega). 
Figure 2.3 The output of Muse displaying the results of the number of viable cells and 
viability.  These results are obtained after completion of acquisition using the Muse™ Cell 
Count and Viability Software, which automatically performs calculations and displays data in 
two dot plots. 
 
 MTS assay was performed by directly adding 20 μl of the MTS solution to the cells 
cultured in 96 well plates. Cells were incubated for 1-3 h at 37ºC in 5% CO2 before 
recording the absorbance at 490nm with the multi plate reader TECAN (Infinite). 
 
2.2.7.4 Determination of apoptosis using flow cytometry  
Apoptosis level was measured by flow cytometry using Apoptosis was the  Muse 
cell analyser  system and  the Muse® Annexin V and Dead Cell Assay kit. The 
characteristics physiological changes that occur because of the initiation of 
apoptosis include the externalization of phosphatidylserine (PS) to the cell surface, 
cleavage and degradation of specific cellular proteins, condensation of nuclear 
chromatin, and the loss of membrane, which occurs in the late stage (Kerr et al, 
1972). PS is a membrane component that normally localised in the internal side of 
the cell membrane. PS translocate to the outer side of the membrane in the early 
events of the apoptosis process (Kerr et al, 1972). Annexin V is a calcium-
dependent phospholipid-binding protein with a high affinity for PS, and can readily 
bind to externalised PS and can therefore label early apoptotic cells (Kerr et al, 
1972). 
The Muse™ Annexin V and Dead Cell assay utilizes Annexin V to detect 
externalised PS on apoptotic cells. The assay also contains a fluorescent dead cell 
marker, 7-aminoactinomycin D (7-AAD) which is used as an indicator of cell 
membrane structural integrity. 7-AAD is excluded from live, healthy cells, as well 
as early apoptotic cells.  Using this assay allows the distinction between four 
populations of cells (MuseTM user’s guide, # MCH100105). As present in Table 2.4 
and Figure 2.4  
 
  
 
  
The level of apoptosis was measured using the Muse™ Annexin V and Dead Cell 
assay according to the manufacturer’s instructions. 100 μl of Trypsinised cells 
were mixed with 100 μl of Muse® Annexin V and Dead Cell reagent. The mixture 
was incubated for 20 minutes at room temperature in the dark before data 
acquisition using the Muse cell analyser system. 
 
 
 
 
                 
Types of cell population Annexin V Dead cell maker (7-AAD) 
non-apoptotic cells -ve -ve 
early apoptotic cells +ve -ve 
late stage apoptotic and dead cells +ve +ve 
nuclear debris -ve +ve 
Table 2.4 The distinction of cell population after using Muse™ Annexin V and 
Dead Cell assay. Annexin V was used to detect externalised PS on apoptotic cells 
and 7-aminoactinomycin D (7-AAD), a fluorescent dead cell marker, which was an 
indicator of cell membrane integrity. 
 .  
 
2.2.8 Cell cycle analysis    
Cell cycle analysis was carried by flow cytometry using the Muse™ Cell Cycle 
Assay and the Muse cell analyser. The assay reagent consists of a mixture of the 
nuclear DNA intercalating stain propidium iodide (PI) and RNAse A.  PI allows the 
discrimination between the cells at different stages of the cell cycle, based on their 
differential DNA content. The use of RNAse in the reagent increases the specificity 
of DNA staining (MuseTM user’s guide, # MCH100106). Resting cells in G0/G1 
phase contain two copies of each chromosome. As cells enter the cell cycle, they 
start the synthesis of other copies of their chromosomal DNA (S phase). The 
increase in the DNA content will result in the increase in fluorescence intensity 
from PI Fluorescence intensity increases until all chromosomal DNA has doubled 
Figure 2.4 A display of the ratio of apoptotic and dead cells after completion of data 
acquisition by Muse. The Muse™ Annexin V & dead cell Software automatically performs 
calculations and displays data in two dot plots 
 in G2/M phase. At this stage, cells in the G2/M cells fluorescence with twice the 
intensity of the G0/G1 population. The G2/M cells eventually divide into two 
daughter cells (MuseTM user’s guide, # MCH100106). The Muse Cell Cycle 
Software Module performs calculations automatically and displays the data in two 
plots. The DNA content index and cell size index is displayed as dot plot. DNA 
content index histogram is also displayed with markers available to analyse the 
cell populations in each phase of the cycle Figure 2.5.   
 
                
 
 
 
Figure 2.5 A display of the percentage of cells in different phase of cell cycle using the 
Muse.  After completion of data acquisition, the Muse™ cell cycle Software automatically 
performs calculations and displays data in histogram and dot plots. 
 
 The transfected cells were harvested 48 hours post-transfection and re-plated in 
fresh medium 2 × 105 cells/well in a 6-well plate. Following incubation for 24 hours, 
1 million cells were washed in PBS before re-suspending the pellet in 200 µl PBS. 
Cells were then fixed in 1 ml ice cold (70% ethanol / 30% PBS) while vortexing at 
medium speed. Cells were stored at –20°C for at least 3 hours prior the cell cycle 
analysis. On the day of the analysis, cells were centrifuged for 5 minutes at 300 x 
g. The supernatant was discarded and the cell pellet was re-suspended in 200 µl 
of Muse Cell Cycle Reagent.  
Cells were incubated for 30 minutes in the dark and data acquisition was carried 
out using the Millipore Muse cell analyser.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
2.2.9 Anchorage- dependent clonogenic assay 
The effects of gene silencing on the long-term survival was determined by 
assessing the ability of the cells to form colonies. Anchorage- dependent 
Clonogenic assay was carried out 48 hours post-transfection. Cells were seeded at 
a density of 1 x 103 cells/well in triplicate in a 6-well plate in 2 ml RPMI 1640 
medium containing 10% conditioned growth medium. Plates were incubated at 
37°C in 5% CO2 for 2-3 weeks. Number of the colonies was determined after 
staining with crystal violet stain (0.5% (w/v) in methanol) for 10 minutes. 
 
2.2.10 Cell migration 
The migration ability of MCF7 and MDA-MB-231 cells was assessed using the in 
vitro scratch assay.  The technique is based on creating a "scratch" in the cells 
grown in monolayer. Using light microscope, images are captured at the beginning 
and at regular intervals during cell migration to close the scratch. Captured images 
 are compared and used to quantify the migration rate of the cells (Liang et al, 
2007). Cells transfected with gene specific siRNAs were plated in 6-well plate at a 
density of 2 x105 cells/ml in RPMI 1640 growth medium. Cells were incubated in 
5% CO2 at 37ºC until they reached 80%-90% confluence. A scratch line was made 
using 10 µl pipette tip with RPMI 1640 growth medium and the plates were rinsed 
to remove detached cells, followed by the addition of 3 ml medium. The gap 
generated by the scratching was measured at zero time before incubating the cells 
in 5% CO2 at 37ºC. Measurement of the distance between the two edges of the 
wound was measured at 18 hours interval using the light Microscope. The 
percentage of the wound closure was calculated using the following formula: 
 
 
 
 
2.2.11 Induction of cell death and cell survival assays 
After transfection, cells were trypsinised before being irradiated with Ultraviolet-C 
(UV-C). 0.8 x 105 cells were exposed to the UV-C light, using a UVG-54 hand-held 
lamp (UVP, Cambridge, UK). The used dose was 40 J/m2 for MCF7 and MDA-MB 
231 cells. Cells were then collected washed in RPMI 1640 growth medium and re-
suspended with appropriate volume of growth medium, and re-plated in 6-well 
plate’s cell survival assay at 24 and 48 hours. 
For drug treatments, the post transfect cells were cultured for minimum 20 h in 96 
well plates at 0.8 x105 cell/ml, before addition of 5-fluorouracil (5-FU; 175 M), 
docetaxel (10 M), Nutlin-3 (5 M), mitoxantrone (50 µM) or vehicle (0.25 % 
(Pre-migration) area – (Migration) area 
area 
(Pre-migration) area 
  
X 100 
 dimethyl sulphoxide). Cells were cultured for 48 h post-treatment and cell viability 
was assessed using the CellTiter 96® Aqueous One Solution Cell Proliferation 
Assay (MTS assay) (Section  2.2.7.3). However, the growth inhibitory effect of 
chemotherapeutic drugs in MCF7 and MDA-MB-231 was determined at 24h and 
48h of drug treatment and calculated according to the equation. 
 
% of cytotoxicity= 100- [OD490 of treated sample / OD490 of untreated 
sample   (vehicle)] x 100 
 
2.2.12 RNA isolation    
Total RNA was isolated from the parental cells and the transfected cells in order to 
determine gene expression; using TRIzol. TRIzol is a monophasic solution of 
phenol and guanidinium isothiocyanate that simultaneously solubilizes DNA and 
RNA and denatures proteins. Addition of chloroform after solubilisation allows 
phase separation of the DNA, RNA and proteins. Proteins are extracted to the 
organic phase, DNA resolves at the interface, whereas the RNA remains in the 
aqueous phase. After transferring the aqueous phase, RNA can be recovered by 
precipitation with isopropyl alcohol (Chomczynski and Sacchi,.1987)Cells were 
lysed by adding 1 ml of TRIzol and the cell lysate was pipetted several times to 
ensure sufficient cell disruption. 200 µl of chloroform was added 5 minutes post 
incubation at room temperature. The samples were shaken vigorously for 15 
seconds before being incubated for 5 minutes at room temperature followed by 
.centrifugation at 15,000 x g for 15 minutes at 4°C, This step allows the separation 
of a clear upper aqueous layer which contains the RNA, an interphase and a red 
 lower organic layer which contains the DNA and proteins. The upper aqueous 
layer containing the RNA was collected in another tube to be precipitated by 
adding 0.5 ml cold isopropyl alcohol. After incubation for 10 minutes at room 
temperature, the samples were centrifuged at 15000 x g for 15 minutes and at 
4ºC. The supernatant was discarded and the formed pellet was washed once by 
adding 1 ml of 75% ethanol, vortexing and centrifuging at 10000 x g for 5 minutes 
at 4°C. The resultant pellet was air-dried for 10 minutes, before being re-
suspended in RNAs free water, pure deionized water that prepared via certain 
processes without adding any chemical additives (Qiagen, 2008). The integrity of 
the isolated RNA was assessed by gel electrophoresis and by determining the 
ratio of absorbance at 260 nm and 280 nm using NanoDrop 1000 
spectrophotometer (Thermo, scientific). 
Furthermore, purification of cytoplasmic RNA from animal cells using the RNeasy 
Mini Kit (Qiagen). According to the manufacturer’s instructions, the purification 
steps started by lysis of cultured cells at density of 106 with 175 µl of 
precooled(4⁰C) buffer RLN (a non-ionic detergent that lysis the cell membrane 
without affecting the nucleus) and prepared from (50mM TrisCl,pH 8, 140mM 
NaCl, 1.5mM MgCl2, 0.5%(v/v) Nonidet P-40 (1.06 g/ml). After 5 min of incubation 
in ice the homogenised cells were centrifuged at 4⁰C for 2 min to precipitate the 
nucleus, the supernatant was transferred t to another centrifuge tube where 350 µl 
of buffer RLT was added (a guanidine-thiocynate containing lysis buffer) with 430 
µl of ethanol. After that, 700 µl of the sample were transferred into the RNeasy 
mini spin column placed in 2ml collection tube and centrifuged. This was followed 
by the addition of 700 µl of buffer RW1 and centrifugation to wash the spin column 
membrane. Frequent washing followed this step using 500 µl of buffer RPE, a 
washing buffer, and the final step was adding 30-50 µl of RNase free water to the 
  spin column membrane and centrifuge for 1 min to elute the RNA. The obtained 
RNA was stored at -80oC. 
 
 2.2.12.1 Gel electrophoresis 
The integrity of RNA was determined by gel electrophoresis which allows the 
examination of the 28S and 18S ribosomal RNA bands. The upper ribosomal band 
(28S in eukaryotic cells and 23S in bacterial cells) should be about twice the 
intensity of the lower band (18S in eukaryotic cells. 1% standard agarose gel was 
prepared by using 0.5 g of agarose and 50 ml of TAE buffer (Tris base, acetic acid 
and EDTA with the final composition of 40 mM Tris acetate; 1 mM EDTA; pH 8.2 - 
8.4). The mixture was then microwaved for 2 min on high power. After cooling, the 
gel was poured into a casting tray after adding 4µl of Ethilium bromide and left to 
set.  Samples of RNAs were prepared by adding 2µl of loading buffer to 1µg of 
RNA (Final volume 7 µl). The gel was run on 98 Volt for 35 minutes before being 
visualised with UV light box and photographed (Figure 2.6).   
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Figure 2.6 A representative gel Electrophoresis of RNA samples. RNA extracted from MCF7 
and MDA-MB231 transfected cells including control (mock control), negative control, and 
transfect cells with N1a and N1c siRNAs. The figure shows a 2:1 intensity ratio between 
28S(5kb) and 18S (2kb) rRNA in the hyperladder, a molecular weight marker composed of RNA 
fragments of known length, which is considered a benchmark for intact RNA. 
 2.2.13 Real time RT-PCR (RT-qPCR) 
 
2.2.13.1 Reverse transcription 
Reverse transcription (RT) was carried using the Omniscript Reverse Transcription 
kit from Qiagen. 2 μg of total cellular RNA was reverse transcribed using Omni 
script RT kit (Qiagen. # 205111), Random primer (Invitrogen # N 48190-011) and 
Ribonuclease inhibitor (Invitrogen.  #10777-018), following the manufacturers’ 
instructions.  RNA samples were first treated at 37ºC for 30 minutes with 3 µl of 
RNase-free DNase (Promega) to remove any residual DNA in the samples. 
Following the incubation, 1 µl of RQ1 DNase stop solution was added to the 
samples and the samples were further incubated for 10 minutes at 65ºC.then, the 
reverse transcriptase mixture was  added to the samples as illustrated in table 2.5 
and further incubate at 37 ºC for 1h. After that, the cDNA samples were kept in -20 
ºC. 
 
 
 
 
 
 
 
 
 
 
 
 
Component Volume in µl / reaction 
10X buffer RT 2 µl 
dNTP Mix(5mM each dNTP) 2 µl 
Random primer 10  µM 2 µl 
RNase inhibitor (10 units/ µl) 1 µl 
Omniscript Reverse Transcriptase 1 µl 
RNase free water variable 
Total reaction volume 20 µl 
Table 2.5 The reverse transcriptase mixture 
 2.2.13.2 Real time PCR 
The real time PCR (qPCR) was carried out using SensiFast Probe Hi-ROX kit and 
gene specific TaqMan Gene Expression Assays. Table 2.7 contains information on 
the different assays used. The real time PCR (qPCR) was carried out using 
SensiFast Probe Hi-ROX kit, gene specific TaqMan Gene Expression Assays and 
the ABI Prism 7000 sequence detection system (Warrington, UK). Table 2.7 
contains information on the different assays used. Each PCR reactions contained 
1 µl (10 ng) of cDNA, 10 µl Sensifast, 1 µl TaqMan Gene Expression Assays and 8 
µl nuclease free water in a final volume of 20 μl. A standard curve was included 
with each run to allow relative quantitation. A standard curve was made by 
preparing serial dilution of 0.1–30 ng cDNA (prepared from cDNA from different 
types of breast cancer cells) (Table 2.6). Nuclease-free water containing 100 ng/μl 
yeast tRNA was used as a diluent; it acts as a carrier molecule that adheres to 
nucleic acid binding sites in the micro centrifuge tube and prevents binding of the 
nucleic acid of interest. Input amounts of samples were calculated from their 
respective threshold cycle (CT) values, using the standard curves generated with 
each assay. Data were expressed relative to 18S rRNA.  
 
 
 
 
 
 Table 2.6 Serial dilution of standards that prepared from cDNA from different types of 
breast cancer cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Standard Conc.ng/ µl µl Standard µl dilution 
S1 30 50 116.7 
S2 10 60 120 
S3 3 50 116.7 
S4 1 60 120 
S5 0.3 50 116.7 
S6 0.1 60 120 
Probe RefSeq ID 
Exon 
Boundary 
Assay 
location 
NEAT1   
Short isoform 
NR_028272.1 Hs03453534_s1 1-1 3310 
NEAT1  
long isoform 
NR_131012.1 Hs01008264_s1 1-1 7996 
MIAT NR_003491.3 Hs00402814_m1 5 1864 
MALAT1 NR_002819.3 Hs00273907_s1 1-1 4952 
Table 2.7 The details of TaqMan gene expression assay specific for human 
NEAT1 (short and long isoforms), MIAT and MALAT1 expression. 
  
 
RT-qPCR was also performed on TissueScan™ Cancer and Normal Tissue cDNA 
Arrays using Breast Cancer cDNA Array II. The array is ready-to-use panel of 
cDNA samples derived from patients with breast cancer of different stages, grades 
and hormone receptors expression together with cDNA samples derived from 
healthy individuals. The panel contains 48 samples and includes 5-normal and 43 
breast cancer samples. The samples were collected from females of 31-84 year of  
A) NEAT1 probes 
 
 
B) MIAT 
 
Figure 2.7 Schematic diagrams representing the location of Taqman gene expression 
assay. (A) Represents the location of NEAT1 probes that cause amplification of short 
isoform (Hs03453534_s1) and long isoform (Hs01008264_s1) respectively. (B) Represents 
the location of MIAT Taqman probe (Hs00402814_m1), which results in the amplification 
of exon 5 (Thermofisher scientific for gene expression assay).  
 
 age with breast cancer of grade 3-9 according to Nottingham grading system. The  
tumour ranges from carcinoma in situ to metastatic ductal or lobular 
adenocarcinoma of the breast. The panel contains samples of different stages; 11-
stage I, 8-IIA, 6-IIB, 8-IIIA, 2-IIIB, 4-IIIC, 4-IV. The panel contains samples show 
different hormone receptor expression; some are oestrogen positive, progesterone 
positive, oestrogen/progesterone positive, HER2 positive, triple positive or triple 
negative. For each assay, a standard curve of threshold cycle (CT) value versus 
log input standard cDNA was constructed by linear regression, and the equation of 
the line was used to calculate input amounts of samples from their respective CT 
values. Data were expressed relative to 18S. 
 
2.2.14 RT2 profiler PCR array 
The effects of NEAT1 expression on the other genes was determined by using the 
RT2 Profiler PCR Array (96-Well Format) kit for Human Cell Cycle (# 330231 
PAHS-020A), which define the expression of 84 genes responsible for positive and 
negative cell cycle regulation (cell cycle – Qiagen). While, Human Breast Cancer 
array ( # 330231 PAHS-131ZA) responsible for profile the expression of 84 genes  
that involved in dysregulation of signal transduction and other biological processes 
of breast cancer (Breast Cancer – Qiagen). Following the manufacturers’ 
instructions, 25 μl of the PCR component mixture was added to each well 
containing a dried array of the RT2 profiler plate. The plate tightly covered with 
optical thin wall 8-Cap strips to be run in PCR cycling program (ABI Prism 7000 
sequence detection system) as in Table 2.7.  
 
  
                            Table 2.8 The cycling program for RT2 Profiler PCR Array 
 
 
 
 
 
 
2.3 Statistical analysis  
Data are presented as mean ± slandered error of the mean (S.E.), where (n) 
represent the number of experiments. Statistical analysis was determined by 
Student’s t-test and two-way ANOVA with Bonferroni’s multiple comparison test 
(MCT) using the Graph Pad 7 software. The results of Real-Time PCR were 
analysed by using the standard curve method.  A p-value of   <0.05 was 
considered to be statistically significant. Web-based PCR Array Data analysis 
software at www.SABioscience.come was used to analyse RT2 profiler assay 
results. The results of RNA sequencing were analysed by using the IPathway 
Guide for Next-gen pathway analysis at www.advaitabio.com.  
 
 
 
 
 
Cycles Duration Temperature 
1 10min 95 ◦C 
40 
15 s 
1 min 
95 ◦C 
60 ◦C 
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 Chapter 3 
Expression analysis of 
NEAT1 and MIAT in breast 
cancer
 3.1 Introduction 
Despite its heterogeneous characteristics, breast cancer is one of the few cancer 
types in which molecular classification has successfully been utilised for the use of 
personalised therapies, leading to significant improvements in disease-specific 
survival (West et al, 2001). Gene expression profiling has allowed the 
classification of breast tumours into the well-known major subtypes that exhibit 
different response to treatment, risk of disease progression, and preferential organ 
sites of metastasis. While the ER and PR positive luminal types respond well to 
hormonal intervention and HER2+ tumours can be effectively controlled with a 
diverse array of anti-HER2 therapies, the molecular-based signature for the basal-
like TNBC tumours is still lacking and only 20% of these tumours respond well to 
standard chemotherapy. Determining the specific gene expression signature of 
different breast cancer types, including TNBC, is very important because it will 
allow the identification of specific diagnostic and prognostic biomarkers that will 
provide a more precise classification of the disease (West et al.,2001). Indeed, 
many multi-gene prognostic signatures from microarray gene expression analysis 
of either mRNA or miRNA levels were recently shown to predict prognosis and 
metastatic risk with greater accuracy than the traditional prognostic criteria (Bao 
and Davidson, 2008; Perou et al, 2000). In addition to their diverse functional 
roles, accumulating evidence confirms that the expression of many lncRNAs is 
dysregulated in multiple human cancers (Fu et al, 2016; Qian et al, 2016; Arun et 
al, 2016). The expression of some of these lncRNAs is also associated with 
cancer metastasis and prognosis (Arun et al, 2016; Fu et al, 2016). These include 
HOTAIR, which is upregulated in primary breast tumours and its overexpression is 
associated with enhanced breast cancer metastasis (Zhang, et al,2014).  MALAT1 
 expression levels have been found to be elevated in many solid tumours, such as 
lung (Schmidt et al, 2011), liver (Lai et al, 2012), and prostate cancers (Ren et al, 
2013). Several lncRNA signatures have also been developed as novel predictors 
of survival in glioblastoma multiform (Zhang et al, 2013), breast cancer (Meng et 
al, 2014) and colorectal cancer (Hu et al, 2014). The aims of this chapter are to 
investigate if NEAT1 and MIAT expression levels are altered in breast cancer. The 
expression levels of the two lncRNAs were therefore evaluated in samples from 
different stages of breast cancer. 
  
3.2 Methods  
The expression of NEAT1, MIAT and MALAT1 were determined in the 
commercially available TissueScan qPCR Breast Cancer Disease Panels II 
(BCRT102), as described in Section 2.2.13.2. The panel was purchased from 
OriGene Technologies. Breast cancer complementary DNA (cDNA) array included 
48 samples covering cDNA from 5-normal, 11-Stage I, 14-II, 14-III and 4-IV 
samples, whose clinical and pathological features are freely available at the 
following address: http://www.origene.com/qPCR/Tissue-qPCR-Arrays.aspx.  
Real-time PCR was conducted using SensiFast Probe Hi-ROX kit and TaqMan 
gene expression assays. Assay codes for Hs99999901_m1 for 18S, 
Hs03453534_s1 for NEAT1 short isoform (NEAT1_1), Hs01008264_s1 for the 
long isoform of NEAT1 (NEAT1_2), Hs00273907_s1 for MALAT1 and 
Hs00402814_m1 for MIAT) were employed as recommended by the 
manufacturers and were run on an ABI Prism Sequence Detection System model 
7000. Assays usually contained 10 ng sample cDNA in a final volume of 20 μl. A 
standard curve, comprising 0.1–30 ng cDNA (prepared from MCF7, MDA-MB 231, 
 T47D,MDA-MB 361and Hs58T cells) was included with each run to allow relative 
quantitation. For each assay, a standard curve of threshold cycle (CT) value 
versus log input standard cDNA was constructed by linear regression, and the 
equation of the line was used to calculate input amounts of samples from their 
respective CT values. Data were expressed relative to 18S rRNA. The expression 
levels of NEAT1, MALAT1 and MIAT were determined in both tumour and normal 
tissue samples and then differentiated according to their clinical stages and 
molecular classification of breast tumour.  Data were analysed by one-way 
analysis of variance with Bonferroni's multiple comparison test for post hoc 
analysis of selected groups, depending on the number of groups to be compared. 
Homogeneity of variance was checked by Bartlett's test. Correlation between 
expression levels of the three long non-coding RNAs was analysed using 
Pearson’s linear correlation after outliers had been removed by Grubs test. Two-
sided P-values were calculated, and a probability level of less than 0.05 was 
chosen for statistical significance. 
  
3.3 Results 
3.3.1 Expression of NEAT1 transcripts in breast cancer 
To analyse the expression of NEAT1 transcripts in breast cancer, NEAT1 short 
and long isoform transcript levels in samples from the Breast Cancer Disease 
Panels II (BCRT102) from OriGene, were assayed by real-time PCR. The assay 
used Taqman gene expression assays targeted against the two different isoforms 
of NEAT1, and 18S as endogenous control gene. The use of 18S was verified in 
preliminary experiments, which showed that the mean of its expression levels was 
found to be similar in tumour and normal samples (respective mean ± S.E. values 
 were 14.2±0.36 and 13.3±0.29). Levels of the short isoform of NEAT1 (NEAT1_1) 
in tumour samples, relative to 18S, were significantly increased compared to the 
normal breast samples. The results revealed up to 4 fold increase in the 
expression levels of NEAT1_1 in tumour samples (Figure 3.1A). Interestingly, the 
degree of increase in the levels of NEAT1_1 varied according to the clinical stages 
of breast cancer (Figure 3.1B). While there was a 7 fold increase in the transcript 
levels in samples from patients with stage lll and stage lV disease compared to 
control samples, only a 3 fold increase was seen in the samples from patients with 
stage I and stage II disease (Figure 3.1B). Stratification of patients into groups 
according to the molecular subtypes confirmed statistically significantly higher 
levels of NEAT1_1 in the breast cancer samples positive for both ER and PR and 
negative for HER2 when compared to normal breast tissue (Figure 3.1C). There 
was no statistical difference between NEAT1_1 expression levels in triple positive 
samples and samples from normal tissues. Whereas, the level of NEAT1_1 was 
significant lower in TNBC samples (Figure 3.1C).  
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Figure 3.1 The expression levels of NEAT1 short isoform (NEAT1_1) in normal and breast 
cancer samples. Expression levels of NEAT1_1 were normalised to the levels of 18S. A) In the 
complete data set (n=48), NEAT1_1 levels are increased (*P< 0.0001) in tumour (n=43) relative 
to normal tissue samples (n=5). B) A subset of the data showing increased transcript levels  of 
NEAT1_1 which is significant in patients with stages I-II disease (*P<0.05; n=25) and highly 
significant in stage III-IV disease (**P<0.001; n=18). C) Relative NEAT1_1 expression levels 
following stratification of samples into groups according to molecular subtypes. Results showed 
a significant (*P< 0.05) up-regulation of NEAT1_1 in ER, PR +ve & HER-ve samples and highly 
significant downregulation (**P< 0.01) in TNBC. (One way Anova test with Bonferroni's multiple 
comparisons)  
 The expression levels of the long isoform of NEAT1 (NEAT1_2) were also 
determined in the samples from the Breast Cancer Disease Panels II (BCRT102).  
The results revealed a lower level of NEAT1_2 in breast cancer samples when 
compared to samples from normal breast tissues but the statistical analyses were 
not significant (Figure 3.2 A). Further analysis showed that the expression level of 
NEAT1_2 is lower in all the stages of the disease compared to the control; 
however, the decrease in the expression levels was not statistically significant 
(Figure 3.2B).  Analysis of the levels of NEAT1_2 in the different molecular 
subtypes of breast cancer showed a decrease in the levels of NEAT1_2 in the 
different subtypes in comparison to the normal tissue samples; however, such 
decrease was statistically significant only in TNBC samples (Figure 3.2C). 
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Figure 3.2 The expression levels of NEAT1_2 in breast cancer. (A) The results of the full data 
set (n=48) showed an insignificant down regulation of NEAT1_2 in breast tumour (n=43) 
samples compared to control (n=5).   (B) A slight decrease in the expression levels in all the 
stages of breast cancer, such decrease was not statistically significant. (C) The expression 
levels of the long isoform showed reduced expression in all molecular subtypes of breast 
cancer, however such down-regulation was statistically significant only in TNBC (*P< 0.05) . 
(One way Anova test with Bonferroni's multiple comparisons) 
 3.3.2 Expression of MIAT lncRNA in breast cancer 
To examine whether the mRNA expression levels of MIAT exhibit changes in 
breast cancer, the Breast Cancer Disease Panels II was used to determine MIAT 
levels in breast cancer and normal tissues. Real time PCR was performed using 
TaqMan gene expression assay targeted at MIAT gene and 18S, which was used 
as endogenous control gene. The results revealed that the overall mean of MIAT 
expression levels was slightly lower in breast tumour compared with the mean of 
MIAT expression levels in normal breast tissues; however, the results were not 
statistically significant (Figure 3.3A). Figure 3A (scattered figure) shows that some 
breast tumour samples express high levels of MIAT compared to the control. 
Further analysis of the data revealed higher MIAT expression levels in stage I and 
II of breast tumour samples. However there was no statistical significant between 
the expression of MIAT in control samples and samples from stage I and II.  MIAT 
expression levels were slightly lower in the advanced stages of the disease, stage 
III and stage IV (Figure 3.3B). Examination of MIAT expression in the different 
molecular subtypes of the disease showed that compared to the normal breast 
samples, MIAT expression is not changed in the triple positive (ER,  PR and HER2 
positive) samples, significantly reduced in ER, PR +ve, HER –ve breast cancer 
subtypes and significantly increased (2 fold increase) in TNBC (Figure 3.3C). 
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Figure 3.3 MIAT expression levels in breast cancer. The level of MIAT lncRNA was 
determined in 43 tumour samples and compared to 5 normal breast tissue samples.  A)  
MIAT expression showed no significant change in the full data sets of breast tumour 
compared to normal. B) Analysis of the data revealed that there is a highly significant 
(**P<0.01) downregulation of MIAT lncRNA in stage lll-lV disease. C) Stratification of MIAT 
expression levels according to the molecular subtypes showed the variation in MIAT 
expression according to the molecular breast cancer types. A highly significant (***P< 0.001) 
overexpression of MIAT was found in TNBC, and a significant (**P< 0.01) downregulation in 
ER, PR +ve & HER-ve breast cancer. (One way Anova test with Bonferroni's multiple 
comparisons) 
 
 3.3.3 Correlation analysis of NEAT1, MALAT and MIAT expression 
levels 
Neat1 gene is located 55 kb upstream from the lncRNA MALAT1/NEAT2. The two 
genes share common regulatory DNA elements and their expression is reported to 
be co-regulated in certain tissues such as the intestine and colon (Nakagawa et al, 
2012). It was therefore important to determine if there is a relationship between the 
two lncRNAs in breast cancer. In order to determine if there is a correlation 
between the expression of NEAT1 and MALAT1, the expression levels of MALAT1 
in breast cancer samples and normal tissues samples in the OriGene breast 
cancer array (BCRT102) was determined using real time PCR and 18S as 
endogenous control. As shown in Figure 3.4A, MALAT1 expression levels were 
more than two fold higher in breast cancer samples compared to control (**P< 
0.01). This up-regulation is significant (*P< 0.05) in stage l-ll and highly significant 
(**P< 0.01) in stage lll-lV, as illustrated in Figure 3.4B. The results also showed 
that similar to NEAT1, the expression levels of MALAT1 were significantly up-
regulated in ER, PR +ve, HER –ve breast tumour subtype samples and 
significantly down-regulated in TNBC samples (Figure 3.4C).  
To explore the correlation between each of the NEAT1 isoforms and MALAT1, a 
Pearson’s linear correlation test was performed. The results revealed there was 
positive correlation (****P< 0.0001) between NEAT1 _1 and NEAT1_2 isoforms 
with MALAT1 expression as shown in (Figure 3.5A and B) respectively, suggesting 
that MALAT1 expression might be positively regulated by NEAT1 or both lncRNAs 
might be involved in one pathway.  
Analysis of the NEAT1_1 and MIAT expression levels showed positive significant 
(*P< 0.05) correlation (Figure 3.6A). Similarly, there was a highly significant 
 correlation (****P< 0.0001) between MIAT and NEAT1_2 expression, as shown in 
(Figure 3.6B).     
C o n tro l T u m o u r
0
1 5
3 0
4 5
6 0
7 5
M
A
L
A
T
/1
8
s
**
C
o n
tr
o l
T u
m
o u
r
0
5
1 0
1 5
M
A
L
A
T
/1
8
s
**
C
o n
tr
o l
S t
a g
e  
l- l
l
S t
a g
e  
ll l
- lV
0
1 0
2 0
3 0
4 0
5 0
M
A
L
A
T
/1
8
s
**
*
C
o n
tr
o l
S t
a g
e  
l- l
l
S t
a g
e  
ll l
- lV
0
5
1 0
1 5
2 0
M
A
L
A
T
/1
8
s
**
*
C
o n
to
ro
l
T r
ip
le
 +
v e
E R
,P
R
+ v
e&
H
E R
-v
e T
N
B
C
0
5
1 0
1 5
2 0
2 5
M
A
L
A
T
/1
8
s
*
*
C
o n
to
ro
l
T r
ip
le
 +
v e
E R
,P
R
+ v
e&
H
E R
-v
e T
N
B
C
0
5
1 0
1 5
M
A
L
A
T
/1
8
s
*
*
A )
B )
C )
 
 
 
 
Figure 3.4 The expression levels of MALAT1 lncRNA in breast cancer.  A) The results revealed 
significant increase in the expression levels in breast tumour samples (n=43) compared to the 
control (normal breast tissue n=5) (**P< 0.01).  B) Represents the expression stratified 
according to breast cancer stages, which showed a significant (*P< 0.05; n=25) and highly 
significant (**P< 0.01; n=18) increase in MALAT1 expression levels in stage l-ll and stage lll-lV, 
respectively.  C) Further analysis of the results according to the molecular subtypes of the 
cancer revealed a significant (*P< 0.05) increase in MALAT1 expression ER, PR +ve & HER-ve 
and a significant down-regulation in TNBC (*P< 0.05). (One-way Anova test with Bonferroni’s 
multiple comparisons) 
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Figure 3.6 Correlation analysis of NEAT1 isoforms and MIAT lncRNA expression in breast cancer 
samples. (A) The result shows a significant positive correlation (*P< 0.05) in the expression levels 
of NEAT1 short isoform and MIAT. (B)  Revealed a highly significant positive correlation 
(****P<0.0001) in the expression of NEAT1 long isoform and MIAT in breast cancer samples.   
 
 
 
 
 
Figure 3.5 Correlation analysis of NEAT1 isoforms and MALAT1 lncRNA expression in breast 
cancer samples. The analysis of correlation coefficient was done by Pearson’s linear test.(A 
and B) The results show significant positive correlation (****P< 0.0001) in the expression 
levels of NEAT1 short and long isoform with MALAT1 respectively.  
   
 
 
 
downregulation in TNBC. (Unpaired t test with Welch's correct). 
 
 3.4 Discussion 
 
Comprehensive analysis of lncRNAs gene expression in multiple human tissues 
showed that their expression is tissue-specific and lower than the protein coding 
genes (Derrien et al, 2012). Expression of lncRNAs has been reported to be 
deregulated in many cancers (Malih et al, 2016). Such expression in a tissue and 
disease specific manner makes them ideal candidates to be used as diagnostic 
and prognostic biomarkers for different cancers including breast cancer, and could 
contribute to the improvement in the management of the disease (Fu et al, 2016; 
Malih et al, 2016). So far, HOTAIR, H19 and KCNQ1OT1 lncRNAs were 
considered as the important biomarkers in breast cancer diagnosis, in which 
HOTAIR  and H19 show a high expression rate in invasive carcinoma (IC) rather 
than ductal carcinoma in situ (DCIS), while HOTAIR and KCNQ1OT1 lncRNAs 
show high expression in tumour cells (Zhang, et al.,2015). Wu et al. (2016) 
reported a number of tissue specific lncRNAs that are associated with breast 
cancer development. The expression of these lncRNAs correlated with a set of 
mRNAs. This co-expression of lncRNAs-mRNAs complexes contributes to the 
control gene expression that might be a factor in the imitation of breast cancer. 
One of these lncRNAs is AC145110.1 which is encoded on chromosome 8p12. 
AC145110.1 was found to be co-expressed with 127 mRNAs, and such 
expression differs in tumour and normal breast tissues (Wu et al, 2016). 
Accordingly, the present study revealed a specific expression pattern of the two 
nuclear lncRNAs, NEAT1 and MIAT in breast cancer.  
This study revealed that MIAT and NEAT1 are differentially expressed in different 
stages of the disease and different molecular subtypes. The results revealed 
distinct NEAT1 signatures in breast cancer. NEAT1 expression levels showed a 
 moderate increase in stage I and II disease and a significant up-regulation in the 
advanced stages, stage III-IV disease. This suggests that overexpression of 
NEAT1 is important at the earliest stages of breast oncogenesis and may play a 
crucial role in the transition from pre-invasive to invasive growth. The present work 
also demonstrates for the first time that the two NEAT1 isoforms display a 
difference in their expression in breast cancer and confirms that the two isoforms 
might exert different functions. NEAT1_1, the short isoform, was found to be up 
regulated in breast cancer and the increase in the expression was strongly 
associated with the advanced stages of the disease (stage III-IV) and with ER, PR 
+ve and HER (-) subtype of the disease.  NEAT1_1 was found to be significantly 
down regulated in TNBC. However, the long isoform NEAT1_2 showed no 
changes in breast cancer apart from significant down-regulation in TNBC, similar 
to the NEAT1_1.  Results presented in this chapter also confirm a role for MIAT in 
breast cancer.  MIAT was found to be slightly down regulated in the advanced 
stages of the disease (stage III-IV) and an increase in its expression was 
associated with TNBC. However, it is worth noting that the number of TNBC 
samples is small and therefore more studies required to confirm these 
observations.  
Many studies have shown that NEAT1 is extensively expressed in human tissues, 
particularly after being exposed to a stress factor like proteasome degradation and 
viral infection (Barry et al, 2017). In addition, overexpression of NEAT1 in different 
tumours and particularly breast cancer was confirmed in different studies (Qian et 
al, 2016; Choudhry et al,2015). However, in this study, a variation in expression of 
NEAT1 isoforms in breast cancer was identified. A significant overexpression of 
NEAT1 _1 in tumour samples was observed, while NEAT1 _2 expression levels 
did not show major changes. These findings highlight the fact that the two isoforms 
 might be involved in different cellular function. Indeed, Li et al, (2017b) have 
successfully dissected the function of the two isoforms using CRISPR-Cas9 
genome editing approach. The study confirmed that only the long isoform is the 
essential component of the paraspeckles, whereas the short isoform was found to 
co-localise in non-paraspeckle structures called microspeckles and may carry 
paraspeckle-independent functions (Li et al, 2017b). Variations in NEAT1 isoforms 
expression have also been reported in different cell types in various tissues 
(Nakagawa et al, 2011).  NEAT1 _1 is widely expressed in different cell types, 
whereas strong expression of NEAT1 _2  was found to be associated with  
prominent paraspeckle formation and restricted to a sub-population of cells in 
certain tissues, particularly in the digestive tissues such as the stomach and colon, 
where natural cell loss occurs (Nakagawa et al, 2011). Chai et al. (2016) have 
provided more evidence to support a differential expression pattern for the two 
isoforms. The study showed the interaction between HuR, an RNA binding protein, 
and the miR-124-3p is responsible for regulation of NEAT1 _1 stability and 
therefore its expression level. A dysregulation of HUR- miR-124-3p axis leads to 
an increase of NEAT1_1 expression in ovarian cancer (chai et al, 2016). An 
increase in HuR expression and activity promote ovarian cancer cells growth and 
invasion by enhancing the over expression of NEAT1 _1, whilst an increase in 
miR-124-3p expression leads to the decrease in NEAT1 _1 expression levels and 
inhibition of ovarian cancer cell growth (chai et al, 2016). Furthermore, Wu et al. 
(2015) have also confirmed the overexpression of NEAT1 _1 in advanced stages 
of colorectal cancer and in metastatic tissues.  The overexpression of NEAT1_1 
was associated with poor prognosis of the disease, whereas NEAT1_2 expression 
level was not affected ( Wu et al.,2015).  
 Stratification of NEAT1_1 expression levels according to the molecular subtypes of 
breast cancer confirmed a predominant increase of NEAT1_1 ER, PR +ve and 
HER –ve subtype and a significant decrease in TNBC subtypes. The increase of 
NEAT1_1 in ER, PR +ve and HER –ve subtype might be explained by the fact that 
ER is a transcriptional regulator of NEAT1 (Chakravarty et al, 2014).  ERα is 
reported to regulate the transcription of different lncRNAs involved in prostate 
cancer including NEAT1 (Chakravarty et al, 2014; Romano et al, 2010). ERα has 
also been shown to regulate NEAT1 expression in prostate cancer which was the 
most significantly overexpressed lncRNA in prostate cancer and its expression 
was associated with prostate cancer progression (Chakravarty et al, 2014; 
Romano et al, 2010; Lin et al, 2004). Chakravarty et al. (2014) have shown that 
knockout of NEAT1 compromised the expression of ERα target genes, suggesting 
that NEAT1 is not only a downstream target but also a mediator of ERα signalling 
in prostate cancer cells. It is therefore possible that the interaction of NEAT1 and 
ER observed in prostate cancer is also present in breast cancer. Accordingly, the 
decrease of NEAT1_1 expression levels in TNBC might be due to the fact that 
these tumours are ER negative and therefore NEAT1 levels are decreased. 
However, further studies are required to confirm these findings because of the 
small sample size.  
MALAT1 was first identified as a prognostic marker in early-stage metastasizing 
lung cancer (Wu et al, 2016). In addition, MALAT1 suppresses expression of anti-
metastasis genes such as MIA2 (melanoma inhibitory activity 2) and ROBO1 
(roundabout 1), while induces pro-metastasis genes including LPHN2 (latrophilin 
2) and ABCA1 (ATP-binding cassette, sub-family A, member 1) to accelerate 
metastasis (Gutschner et al, 2013). MALAT1 is overexpressed in different solid 
tumours including lung, breast, colon, hepatocarcinoma, pancreatic and prostate 
 cancer (Tripathi et al, 2013; Meseure et al, 2016; Ma et al,2015).  Both NEAT1 and 
MALAT1 genes are located on chromosome 11q. NEAT1 gene is located 55 kb 
upstream from the MALAT1. The expression of both genes is demonstrated to be 
co-regulated in certain tissues such as the intestine and colon and certain cancers 
such prostate cancer (Nakagawa et al, 2012). The present study confirmed that 
there is a correlation of the NEAT1 and MALAT1 expression in breast cancer. 
Similar to NEAT1_1, MALAT1 was found to be up regulated in ER, PR +ve and 
HER –ve subtype and its levels decreased in TNBC subtype.  MALAT1 cellular 
effects on the alternative splicing of pre-mRNA lead to an aberrant expression of 
genes that are responsible for cell cycle regulation, thereby enhancing the 
proliferation of tumour cells (Tripathi et al, 2013). MALAT1 is an oestrogen 
dependent transcript and its expression was regulated by oestrogen receptors, 
mainly ERα and ERβ in breast and prostate cancer respectively (Aiello et al, 
2016). Therefore, such interaction might explain the overexpression of MALAT1 
lncRNA in ER, PR +ve and HER -ve samples and its decrease in TNBC. 
Nonetheless, the co-expression patterns in NEAT1_1 and MALAT1 gene 
expression suggest a coordinated dysregulation of these nuclear lncRNA loci in 
cancer.  
Analysis of MIAT expression in the breast cancer samples suggested that MIAT 
might be down-regulated in stages III-IV of the disease and its levels showed a 
significant increase in TNBC samples. Further experiments are required to confirm 
the up-regulation in TNBC because of the small sample size. However, the results 
are in agreement with other studies. Previous work has already implicated MIAT in 
cancer. Crea et al. (2016) reported a significant relationship between MIAT 
lncRNA expression and neuroendocrine prostate cancer (NEPC), an androgen 
receptor (AR)-negative metastatic neoplasm. Therefore, this finding might explain 
 the reason of MIAT upregulation in TNBC, which is characterized by negative 
endocrine receptors (estrogen and progesterone, and HER2), and by being highly 
metastatic and resistant to most of the chemotherapeutic treatments and 
presented with poor prognosis (Zhang et al, 2012). The other possible cause of 
MIAT overexpression could be related to the over expression of tumour necrosis 
factor (TNFα) in triple negative breast cells, a pro inflammatory cytokine that 
promotes tumour growth (Pileczki et al., 2012). Jin et al (2017) revealed a positive 
correlation between MIAT and TNFα expression in osteogenic differentiation of 
human adipose-derived stem cells (hASCs) (Jin et al, 2017).  
Furthermore, MIAT lncRNA shows a significant positive correlation with NEAT1 
isoforms. Such observations could be related to the role of MIAT lncRNA in 
promoting the expression of Oct4 mRNA. Oct4 is reported to promote and 
enhance the expression of NEAT1 and MALAT1 lncRNAs via 
Oct4/NEAT1/MALAT1 pathway in lung cancer (Nobil et al, 2017; Jen et al, 2017). 
In addition, Ling et al (2012) found a high expression levels of Oct 3/ 4 in MCF7 
and MDA-MB-231 breast cancer cells. Therefore, this evidence might explain the 
positive correlation in NEAT1 and MIAT expression in breast cancer.  
In summary, this study indicates that the expression of the two nuclear lncRNAs, 
NEAT1 and MIAT is dysregulated in breast cancer and suggests that these 
lncRNAs might be involved in the initiation and progression of breast cancer. The 
study also highlights a difference in the expression of short and long isoform of 
NEAT1. The study confirmed an interesting correlation between the expression of 
nuclear lncRNAs MALAT1 and MIAT with NEAT1. Both NEAT1 and MALAT1 
genes are located on chromosome 11q which is often dysregulated in cancer and 
the results presented in this chapter highlight the possibility of the presence of a 
coordinated dysregulation of these nuclear lncRNAs loci in cancer. Further studies 
 are required to investigate the potential use of these as diagnostic and prognostic 
biomarkers due to the variation in their expression, depending on breast cancer 
stages and molecular subtypes.   
 
 
Chapter highlights  
1. The expression pattern of NEAT1 _1 was different from that of NEAT1 _2 in 
breast cancer sample 
.  
2. NEAT1_1 short isoform is significantly up-regulated in breast cancer. Such 
expression was increased in advance stages of breast cancer and in ER, PR 
+ve, HER –ve molecular subtype 
.  
3. The results showed a small but significant down-regulation of MIAT lncRNA  in 
stage lll-lV of breast cancer and in ER, PR+ve, HER –ve samples. However, 
MIAT expression levels were significantly increased in TNBC 
.  
4. There was a significant positive correlation in expression between NEAT1and  
MALAT1 lncRNAs  in breast cancer.  Both NEAT1_1 and MALAT1 lncRNAs 
were up-regulated in ER, PR+ve, HER –ve molecular subtype of breast cancer 
and significantly down-regulated in TNBC. A significant positive correlation was 
found between NEAT1 and MIAT expression levels 
.  
5. NEAT1, MALAT1 and MIAT lncRNAs have the potential to be used as 
diagnostic and prognostic biomarkers because of the variation in their 
expression, according to breast cancer stages and molecular subtypes. 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
         
 
 
 
 
 
 
 
 
 
Chapter 4 
The role of Nuclear Enriched 
Abundant Transcript 1 (NEAT1) 
in breast cancer 
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4.1 Introduction 
Evidence presented in Chapter 3 suggests that NEAT1 is implicated in breast 
cancer. NEAT1 short isoform was found to be significantly up regulated in breast 
cancer cells. Its expression was increased in advance stages and in ER, PR +ve, 
HER –ve molecular subtype of the disease. An increasing number of studies have 
implicated NEAT1 in the regulation of cell survival (Lo et al, 2016a; Choudhry et al, 
2015; Ke et al, 2016). NEAT1 was identified independently as a candidate 
regulator of apoptosis using an unbiased functional screen to identify genes 
regulating apoptosis (Williams et al, 2006). Such screen has identified several 
genes including the long non-coding RNA GAS5, which plays very important role 
in the control of cell death and survival (Mourtada-Maarabouni et al, 2009; 
Mourtada-Maarabouni et al, 2010). 
NEAT1 was found to be significantly up-regulated during hypoxia in breast cancer 
cells and was characterised to be a direct transcriptional target of hypoxia-
inducible factor in breast cancer cells (Choudhry et al, 2015). The study confirmed 
the hypoxic induction of NEAT1 expression, which was accompanied by an 
increase in the formation of nuclear paraspeckles (Choudhry et al, 2015).  
Furthermore, an interaction between NEAT1 and the RNA binding protein FUS 
(Fused in sarcoma/translocated in liposarcoma) have been described in breast 
cancer cells by Ke et al. ( 2016). In which, FUS has the ability to bind with NEAT1 
forming a complex that is important for maintaining the survival of breast cancer 
cells (Ke et al, 2016). Another important interaction between NEAT1 and miR-548 
has been reported, where overexpression of miR-548 leads the suppression of 
NEAT1 expression resulting in an increase the apoptotic cell death of breast 
cancer (Lo et al, 2016a; Ke et al, 2016). Thus, NEAT1 overexpression participates 
 in breast cancer tumorigenesis via enhancing cell proliferation and reduction in 
apoptosis (Lo et al, 2016a). Therefore, it was of interest to study the functional 
effects of NEAT1 down-regulation on the survival of breast cancer cells.    
The aims of this chapter are to study the functional effects of NEAT1 silencing on 
the cell survival of two breast cancer cell lines which include oestrogen receptor 
positive MCF-7 and the TNBC, MDA-MB-231. Therefore, The specific aims are to 
determine: i) the effects of silencing NEAT1 on breast cancer cell survival, ii) the 
implications of reduced NEAT1 expression on the breast cancer cell response to 
chemotherapeutic agents and UV treatment, iii) the effects of NEAT1 silencing on 
the expression of MALAT1 and BAD, two genes located on the same chromosome 
 
4.2 Material and methods 
4.2.1 RNA interference  
MCF7 cells were transfected with specific siRNAs targeting NEAT1 long isoform 
using the HiPerFect transfection reagent, as described in section 2.2.5. 
Nucleofection was also used to transfect MCF7 and MDA-MB-231 with NEAT1 
specific siRNAs or NEAT1 antisense oligonucleotides (ASO) which target both the 
short and long isoforms, as explained in section 2.2.5 and 2.2.6 respectively. 
Information about the specific NEAT1 siRNAs and NEAT1 ASO are presented in 
Table 2.2 
. 
 
 4.2.2 Functional analysis: determination of cell survival, 
apoptosis, cell cycle profile and cell migration 
After transfection, cells were harvested by trypsinization then re-plated at 2x105 
cells into 6 well plates. Cells were cultured for further 24 and 48h before being 
trypsinzed to determine cell survival and apoptosis as described in section 2.2.7. 
Long-term survival was determined by re-plating transfected cells in culture 
medium supplemented with 10% (v/v) cell-conditioned medium in 6-well plates. 
Cells were cultured for 2-3 weeks before counting the colonies after staining with 
crystal violet as present in section 2.2.9. Cell cycle analysis was carried out 24h 
post re-plating as described in section 2.2.8.   
Cell migration was performed as detailed in section 2.2.10. Initially, measurement 
of the wound area was taken from four places using Image J software to document 
the pre-migration area of the cell-free detection zone. The distance across each 
wound was then measured in four places at 18 h and 36h or until wounds were 
completely closed. 
 
4.2.3 Induction of cell death and cell survival assays 
At 48 h post transfection with Antisense oligonucleotide (ASO), cells were 
trypsinised and treated with Ultraviolet-C (UV-C) irradiation prior to plating as 
present in section 2.2.11.  Cell survival and apoptosis were assessed after 24 and 
48h as described in section 2.2.7. Long-term survival was assessed by colony 
forming assay as in section 2.2.9, which was performed following irradiation. 
  Regarding drug treatment, transfected cells were cultured for 20 h before addition 
of each of the chemotherapy drug as in section 2.2.11. Cell viability was 
determined by MTS assay where sample absorbance readings at 490 nm (A490) 
were corrected for the appropriate medium plus drug blank values.  The growth 
inhibitory effects of chemotherapeutic drugs were determined at 24h and 48h post 
drug treatment and calculated according to the following equation: 
% of cytotoxicity= 100- [OD490 of treated sample / OD490 of untreated 
sample   (vehicle)] x 100 
 
4.2.4 Real time RT-PCR  
Total RNAs were isolated from 1x106 of transfected MCF7 and MDA-MB231 cells 
as in section 2.2.12. Cytosolic and nuclear RNAs were isolated as explained in 
section 2.2.12.  TaqMan gene expression assays (Table 4.1) were used on cDNA 
prepared by random hexamer priming and Omniscript, as described in section 
2.2.13.  Reactions (20 µl) contained 50 ng sample cDNA or 0.1–30 ng of standard 
cDNA (prepared from MCF7, MDA-MB-231, T47D, MDA-MB 361 and Hs5T cells). 
Endogenous gene expression levels of samples were calculated from their 
respective threshold cycle (CT) values using standard curves generated with each 
assay. Data were expressed relative to 18S rRNA. 
 
 
 
 
 
  
 
 
 
 
 
 
4.3 Results 
4.3.1 The effects of NEAT1 siRNAs on the survival of breast 
cancer cell using cationic lipid-mediated siRNA delivery 
system 
To examine the effects of reduced NEAT1 expression on breast cancer cell 
survival, NEAT1 siRNAs were employed to silence endogenous NEAT1 
expression. Two different siRNAs targeting the long isoform (NEAT1,1 siRNA 
targets nucleotides at position 12013-12033 and NEAT1,2 siRNA targets 
nucleotides at 12084-12104) were employed. Initially, HiPerFect transfection 
reagent was used for siRNA delivery. HiPerFect is a blend of cationic and neutral 
lipids that enables effective siRNA uptake and efficient release of siRNA inside 
cells, resulting in high gene knockdown even when using low siRNA 
Probe RefSeq ID Exon Boundary 
Assay 
location 
NEAT1 (short) NR_131012.1 Hs03453534_s1 1-1 3310 
NEAT1 (long) NR_131012.1 Hs01008264_s1 1-1 7996 
MALAT NR_002819.3 Hs00273907_s1 1-1 4952 
BAD NM_004322.3 Hs0018893_m1 1-2 524 
XIAP NM_001167.3 Hs00745222_s1 2-2 441 
Table 4.1 TaqMan gene expression assays. The table contains the details and 
locations of the different gene specific TaqMan gene expression assays used in this 
study. 
 concentrations and has minimal cytotoxicity effects (Qiagen, 2010). Such method 
of transfection is used routinely in the lab for siRNA delivery and was found to be 
efficient (Maarabouni et al, 2008). Therefore, it was chosen as a method for 
transfecting NEAT1 specific siRNA into MCF7 cells. RNA was isolated from MCF7 
cells 72h post-transfection and RT-qPCR was carried to assess the level of 
NEAT1 silencing in these cells. Surprisingly, RT-qPCR results showed that 
compared to control, endogenous expression levels of NEAT1 long and short 
isoforms were significantly increased in the cells transfected with each of the two 
NEAT1 siRNAs (Figure 4.1 A and B). Since the RT-qPCR primers and the probe 
are located in the short isoform of NEAT1, the possibility that the siRNAs used 
might have caused a decrease in the expression levels of the long isoform and 
such decrease led to the increase in the expression levels of the short isoform.  
To this end, another TaqMan gene expression assay targeting the long isoform 
was used to determine the level of NEAT1 expression in these transfected cells. 
The results confirmed that both NEAT1 siRNAs also caused significant increase in 
the levels of NEAT1 long isoform expression as illustrated in (Figure 4.1 B). 
siRNAs delivered via Cationic lipid polymers are reported to be released in the 
cytoplasm and do not reach the nucleus.  
Therefore, a cellular fractionation was performed to isolate the cytoplasmic from 
nuclear NEAT1 transcripts was carried out to assess the levels of NEAT1 
expression in the cytoplasmic and nuclear fraction. The results revealed that 
although there was a significant up-regulation in the nuclear NEAT1 levels, there 
was a significant down-regulation in the cytoplasmic NEAT1 levels, as shown in 
Figure 4.1C and D respectively.  Overall, these observations suggest that NEAT1 
siRNAs delivered via lipid polymers mediated transfection have silencing effects 
on the expression levels of cytoplasmic NEAT1 transcripts in MCF7 cells 
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Figure 4.1 The effect of NEAT1 specific siRNAs on NEAT1 expression in MCF7 using cationic-
lipid polymers mediated transfection. NEAT1 expression was determined by RT-PCR 72h post 
transfection with the negative siRNA or one of the NEAT1 siRNAs (N1, 1 and N1, 2). (A) There 
was a significant (*P<0.05 and ***P<0.001; n=4) increase in NEAT1 expression in transfected 
cells respectively when use NEAT1 assay located on NEAT1_1. (B) Demonstrates the 
significant (*P<0.05; n=4) elevation in NEAT1 expression particularly in transfected cells with 
N1,2 siRNA, after using NEAT1 assay that located on NEAT1_2 only. (C and D) represent the 
nuclear and cytoplasmic NEAT1 expression respectively. Although, there was a significant 
(**P<0.01; n=4) up-regulation in nuclear NEAT1 expression particularly in cells transfected 
with N1,2 siRNA. There was a significant (*P<0.05 and **P<0.01; n=4) down-regulation in 
cytoplasmic NEAT1 expression in transfected cells respectively. Unpaired t test.   
 In the next set of experiments, the effects of elevated expression of nuclear 
NEAT1 on cell survival were investigated following the transfection of NEAT1 
siRNAs using the cationic-lipid mediated transfection. The results showed that the 
decrease in the cytoplasmic and increase in the nuclear NEAT1 expression levels 
caused significant increase in the number of total and viable cells as displayed in 
Figure 4.2 A and B respectively. Such increase was associated with an 
enhancement in the long-term survival of these cells evidenced by an increase in 
their colony forming ability (Figure 4.2 C). 
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Figure 4.2 The effects of NEAT1 specific siRNAs on the basal cell survival of MCF7 cells using 
cationic-lipid polymer mediated transfection.  MCF7 Cells were transfected with negative 
siRNA or one of the NEAT1 siRNAs (N1, 1 and N1, 2). Cells were harvested at 72 h post-
transfection and re-plated for colony forming assay as well as for cell survival assessment after 
a further 24 h. Flow cytometry were used for determining the number of total and viable cells. 
(A and B) represent the number of total and viable MCF7 cells respectively. There was a highly 
significant (****P<0.0001; n=4) increase in number of cells as compared with the negative 
control. (C) Shows the number of colonies formed in long-term clonogenic assays. A significant 
(**P <0.01; n=4) elevation in the number of colonies compared with the negative control. (D) 
An example image of clonogenic assay plates after crystal violet staining. (Unpaired t-test) 
 
 Besides the elevation in number of total and viable cells, overexpression of 
nuclear NEAT1 transcripts lead to a significant reduction in the percentage of 
apoptotic cells in comparison with the negative control as presented in (Figure 4.3 
A). Previous studies have shown that down-regulation of paraspeckles associated 
proteins also negatively affected NEAT1 expression, These proteins include HECT 
Domain E3 Ubiquitin Protein Ligase 3(HECTD3), RNA Binding Motif Protein 
14(RBM14), Zinc Finger Protein 24(ZNF24), Non-POU Domain Containing 
Octamer Binding (NONO) and X-linked inhibitor of apoptosis protein (XIAP) (Fong 
et al, 2013). XIAP regulates apoptosis by inhibiting caspases (Eckelman et al, 
2006), it was therefore necessary to investigate whether the increase in nuclear 
NEAT1 expression had an effect on the levels of XIAP leading to the decrease in 
the basal apoptosis level. Indeed, the results showed that increase in nuclear 
NEAT1 expression levels was associated with an up regulation of XIAP expression 
levels as shown in Figure 4.3 B. 
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Figure 4.3 The effects of NEAT1 specific siRNAs on basal cellular apoptosis in MCF7 cells 
using Cationic lipid polymers-mediated transfection. MCF7 cells were transfected by 
HiPerFect transfection reagent using the negative siRNA or one of the NEAT1 siRNAs (N1, 1 
and N1, 2). Cells were harvested at 72 h post-transfection and re-plated 24h for assessment 
of apoptosis. Muse cell analyser and Muse Annexin V and dead cell kit were used for 
determining the percentage of apoptosis. (A) Shows the apoptotic ratio, where there was a 
highly significant (****P<0.0001 and ***P<0.001; n=4) decrease in the percentage of 
apoptosis as compared with the negative control. (B) Represents the cellular expression levels 
of XIAP, in which there was a highly significant (**P<0.01, *P<0.05; n=4) increase in XIAP 
expression for those MCF7 cells transfected with N1, 1 and N1, 2 siRNAs respectively. 
Unpaired t-test with Welch’s correction. 
 
 4.3.2 The effects of NEAT1 specific siRNAs on the survival of 
MCF7  breast cancer cells using nucleofection mediated 
delivery  
One of the major limiting factors in successful targeted silencing of nuclear 
transcripts is the direct delivery of the siRNAs into the cell nucleus. Previous 
studies have shown that siRNA delivered by both liposome and cationic polymers 
is localised in the cytoplasm (Berezhna et al, 2006). It was therefore important to 
use another method of transfection in order to investigate whether the results 
described above were due to the lack of siRNA delivery to the nucleus. 
Nucleofection, an electroporation-based transfection method, uses a combination 
of electrical parameters with cell-type specific reagents enabling nucleic acid 
substrates delivery not only to the cytoplasm, but also through the nuclear 
membrane and into the nucleus (Aluigi et al, 2006). Therefore, using Nucleofection 
could result in a direct silencing effect on nuclear NEAT1 transcripts.  Two types of 
NEAT1 siRNAs (N1a and N1c) were used targeting different sites on the short and 
long isoforms of NEAT1 (Table 2.2). MCF7 cells were nucloefected with NEAT1 
specific siRNAs (N1a and N1c). In addition, the scrambled siRNA (negative 
siRNA) was used as control.  The expression level of NEAT1 was determined at 
48h post transfection using two different NEAT1 gene expression assays that can 
detect the short and the long isoforms of NEAT1.  Results showed that 
nucleofection of MCF7 with both types of siRNA resulted in a significant NEAT1 
down- regulation compared to control (Figure 4.4 A and B). 
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NEAT1 silencing led to a significant reduction in the number of total and viable 
cells at 24h and cell viability at 48h  of re-plating  versus negative control (Figure  
4.5 A, B and C). Down-regulation of NEAT1 expression levels also caused a 
decrease in long-term cell survival, which is illustrated by a significant reduction in 
the number of colonies formed as presented in Figure 4.5 D. 
 
 
 
  
Figure 4.4 The expression levels of NEAT1 in transfected MCF7 cells with NEAT1 siRNAs 
using Nucleofection. Cellular NEAT1 levels were determined by RT-qPCR 48h post 
transfection with the negative siRNA or one of the NEAT1 siRNAs (N1a and N1c). (A) 
Represents the expression levels of cellular NEAT1 after using NEAT1 assay that located at 
the position 3310 (short isoform), where there was a significant (*P<0.05 and ***P<0.001; 
n=5) downregulation in cells transfected  with N1a and N1c siRNAs,  respectively. (B) A graph 
showing the NEAT1 expression levels using NEAT1 assay that located at the position 7996 
(long isoform). There was a significant (*P<0.05; n=5) down-regulation in cells transfected 
with N1a and N1c siRNAs. Unpaired t-test 
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Figure 4.5 The effects of NEAT1 silencing on the short and long-term survival of MCF7 
cells.  MCF7 Cells were transfected with negative siRNA or one of the NEAT1 siRNAs (N1a 
and N1c). Cells were harvested at 48 h post-transfection, re-plated for colony forming assay 
and assessment of cell survival after a further 24 and 48h. Flow cytometry was used to 
determine the number of total and viable cells and the percentage of viability. (A and B) 
represent the number of total and viable MCF7 cells respectively at 24h re-plating, which 
showed a statistically significant decrease (**P<0.01 and *P<0.05; n=5). (C) Shows a 
significant reduction in the percentage of viability at 48h of cell re-plating (*P<0.05; n=5). (D) 
The percentage of colonies formed in long-term Clonogenic assay, which is significantly 
decreased as compared to the negative control (***P<0.001 n=5). (E) An example image of 
Clonogenic assay plates after crystal violet staining. Unpaired t-test 
 Basal level of apoptosis was also assessed and it was found that NEAT1 down-
regulation caused statistically insignificant elevation in the percentage of basal 
apoptosis after 48h of re- plating (Figure 4.6). 
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Figure 4.6 The effect of NEAT1 down-regulation  on basal cell apoptosis in MCF7 cells.  
MCF7 Cells were transfected by nucleofection using the negative siRNA or one of the 
NEAT1 siRNAs (N1a  and N1c).  Cells were harvested 48 h post-transfection and re-plated 
for assessment of apoptosis after a further 24h (the data not present) and 48h. Muse cell 
analyser using the Muse Annexin V and dead cell kit measured the apoptosis level.  There 
was insignificant elevation in the percentage of apoptosis after 48h of re-plating. 
Unpaired t-test with Welch’s correction. 
 
 
 Further experiments were carried out to investigate whether the growth 
suppression produced by NEAT1 down-regulation was due to apoptosis, to cell 
cycle arrest, or to both. A cell cycle analysis was performed using propidium iodide 
staining and flow cytometry. The results revealed that the proportion of cells in 
NEAT1 down-regulated cultures is consistently higher in G1 phase than that in the 
controls and the percentage of cells in S phase is consistently lower, suggesting 
that NEAT1 down-regulation might cause arrest the cells in G1 phase (Figure 4.7). 
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Figure 4.7 Effects of NEAT1 silencing on the cell cycle profile of MCF7 breast cancer 
cells.  MCF7 cells were transfected with Negative siRNA or one of the NEAT1 siRNAs (N1a 
and N1c) that target the short and long NEAT1 isoforms. Cells were harvested 48h post 
transfection and re-plated for further 24h for cell cycle analysis. Cell cycle analysis involved 
quantifying DNA content by propidium iodide staining of fixed cells and fluorescence flow 
cytometry. There was a significant elevation in percentage of cells in G1 phase (**P<0.01 
n=5) and a highly significant reduction in the ratio of cells in S phase (***P<0.001; n=5).  
Unpaired t-test 
 
 4.3.3 The effects of NEAT1 specific siRNAs on the triple negative  
MDA-MB-231 breast cancer cells 
To examine the effects of NEAT1 silencing on the survival of the triple negative 
breast cancer cell line MDA-MB-231. MDA-MB-231 cells were nucleofected with 
NEAT1 specific siRNA (N1a  and N1c). NEAT1 siRNAs significantly reduced 
NEAT1 transcript levels by up to one-third of control as in (figure 4.8). This 
decrease in NEAT1 levels was associated with a significant reduction in the 
number of total and viable cells (Figure 4.9) at 24 and 48h of re-plating 
respectively. Furthermore, the reduction in NEAT1 transcript levels was also 
associated with a decrease in the cellular long-term survival as shown by a 
significant reduction in the number of colonies formed (Figure 4.9E). 
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Figure 4.8 The effects of NEAT1 specific siRNAs on NEAT1 expression levels in MDA-MB-
231 cells using Nucleofection as transfection method. Cellular NEAT1 levels were 
determined by RT-qPCR 48h post transfection with the negative siRNA or one of the 
NEAT1 siRNAs (N1a and N1c). The results of cellular NEAT1 expression after using NEAT1 
assay that located at the position 3310 showed a highly significant down-regulation in the 
cells transfected with N1a and N1c siRNAs (****P<0.0001; n=4).Unpaired t-test  
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Figure 4.9 The effects of NEAT1 silencing on the basal survival of triple negative breast 
cancer cells MDA-MB-231.  MDA-MB-231 Cells were transfected with negative siRNA or 
one of the NEAT1 siRNAs (N1a and N1c).  The cells were harvested 48 h post-transfection 
and re-plated for colony forming assay and assessment of cell survival after a further 24 
and 48h by flow cytometry. (A and B) represent the number of total MDA-MB-231 cells at 
24 and 48h of re-plating respectively, in which there was a significant (*P<0.05; n=4) 
reduction in total cells. (C and D) reveal the significant (***P<0.001,**P<0.01, *P<0.05  
n=4) reduction in number of viable MDA-MB-231 cells at 24 and 48h of re-plating 
respectively. (E) Number of colonies formed in long-term clonogenic assays (*P<0.05 and 
**P<0.01 n=4). (F) An example image of Clonogenic assay plates after crystal violet 
staining. Unpaired t-test   
                            
 
 
 In spite of its effects on short term and long-term viability, silencing of NEAT1 
expression levels had no effect on the basal apoptosis levels (results not shown). 
However, the reduction of NEAT1 expression levels affected the cell cycle profile 
of MDA-MB-231 and resulted in a significant increase in the percentage of cells in 
G1 phase and a concomitant decrease in cells in S and G2/M phases (Figure 
4.10) 
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Figure 4.10 Effects of NEAT1 silencing on the cell cycle profile of MDA-MB 231 breast 
cancer cells.  Cell cycle analysis was performed 48h post transfection and 24h post re-
plating. Cell cycle analysis was performed by the propidium iodide staining of fixed cells 
and fluorescence flow cytometry. There was a highly significant (***P<0.001 n=4) 
elevation in the percentage of cells in G1 phase and reduction in cells in S phase (*P<0.05 
and ***P<0.001 n=4) and G2/M (*P<0.05). Unpaired t-test. 
 
 4.3.4 The effects of NEAT1 specific antisense oligonucleotides 
(ASOs) on the survival of breast cancer cells 
In order to confirm the silencing effects on cell survival observed using NEAT1 
specific siRNAs, further experiments were carried out using NEAT1 specific 
antisense oligonucleotides (ASOs).   The mechanisms of ASO action in silencing 
of target RNA differ than the siRNA-mediated silencing (Watts & Corey, 2012). 
ASO is a single stranded that binds the target RNA to start its effect. While, siRNA 
is double stranded that needs further processing after association with RNA-
induced silencing complex (RISC) to eliminate the passenger strand and keep the 
guide strand to bind to  the complementary RNA target leading to its silencing 
(Figure 4.11) (Watts & Corey, 2012). In these experiments, the effects of NEAT1 
specific ASOs on the silencing of NEAT1 and cell survival were investigated. 
 
 
 
Figure 4.11 A diagram illustrating the comparison between ASO and siRNA 
mechanisms of action. (A) Represents the mechanisms of ASOs action delivered as a 
single-stranded oligonucleotide to bind to complimentary strand of  their target RNA. (B) 
Shows the mechanism of siRNAs effects, which is delivered as duplex and taken up by 
Argonaute (AGO) part of the RNA-induced silencing complex (RISC). The diagram was 
adapted from Watts and Corey ( 2012) . 
 
 
 MCF7 and MDA-MB231 cells were nucleofected with NEAT1 specific ASOs or a 
control ASO. NEAT1 transcript levels were determined using RT-qPCR 48h post 
Nucleofection. Both NEAT1 specific ASOs caused significant down-regulation of 
NEAT1 transcript in MCF7 (Figure 4.12 A) and MDA-MB-231 (Figure 4.12 B) 
compared to the control. The expression of NEAT1 neighbouring gene, MALAT1 
was also determined to find out if there is a correlation between the expressions of 
both genes. Indeed the results showed that NEAT1 down-regulation was 
associated with a decrease in MALAT1 expression in MCF7 and MDA-MB-231 
cells (Figure 4.12 C and D). Such down-regulation in MCF7 cells was associated 
with a significant decrease in the number of total and viable cells at 24h of re-
plating, but had no effects on long term survival (Figure 4.13). In MDA-MB-231, 
ASO mediated down-regulation of NEAT1 caused a significant decrease in the 
number of viable cells detected after 24h (Figure 4.14 A), an increase in the basal 
apoptosis level  (Figure 4.14 B ) and a decrease in the long term survival shown 
by a low number of colonies (Figure 4.14 C). The effects of NEAT1 silencing on 
breast cancer cell migration were also investigated. In comparison with the 
negative control, only MCF7 cells transfected with N1,2 ASO showed  a significant 
inhibition of cell migration at 36h only  (Figure 4.15 A ). In MDA-MB-231 cells, ASO 
mediated silencing caused a highly significant reduction in the rate of cell 
migration at 18h (Figure 4.15 B), no significant changes in this ratio after 36h of re-
plating (results are not shown) 
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Figure 4.12 The effect of NEAT1 specific ASOs on NEAT1 and MALAT1 cellular expression 
in MCF7 and MDA-MB-231 cells. The expression levels were determined by RT-qPCR 48h 
post transfection with negative ASO or one of the NEAT1 ASO (N1,1 and N1,2). (A and B) 
The results of cellular NEAT1 expression after using NEAT1 assay that located at the 
position 3310 showed a highly significant and significant (***P<0.001 and **P<0.01; n=4) 
down-regulation in both MCF7 and MDA-MB-231 cells respectively as compared with 
negative control. (C and D) represents the cellular MALAT1 expression in MCF7 and MDA-
MB-231 transfect cells respectively. In which, there was highly significant (**P<0.01 and 
*P<0.05; n=4) down-regulation in their expression respectively as compared with negative 
control, this observation indicates a positive correlation in the expression of NEAT1 and 
MALAT1 transcripts. Unpaired t-test   
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Figure 4.13 The effects of NEAT1 specific ASOs on the basal survival of MCF7 cells. MCF7 
Cells were transfected with either control ASO (negative) or one of the NEAT1 ASOs (N1,1 
and N 1,2). The cells were harvested 48 h post-transfection and re-plated for colony 
forming assay and assessment for cell survival after a further 24h. Muse cell analyser using 
Muse Count & Viability Assay Kit was used to determine the number of total and viable 
cells. (A and B) represent the number of total and viable MCF7 cells at 24h of re-plating 
respectively. There was significant (*P<0.05 n=4) decrease in the cell number. (C) Shows 
the number of colonies formed in long-term clonogenic assays, which revealed no 
significant changes in number of colonies formed as compared to the negative control. (E) 
An example image of clonogenic assay plates after crystal violet staining. Unpaired t-test. 
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Figure 4.14 The effects of ASOs-mediated silencing of NEAT1 on the basal survival of 
MDA-MB-231 cells.  MDA-MB231 cells were transfected with negative ASO or one of the 
NEAT1 ASOs (N1,1 and N1, 2). The cells were harvested 48 h post-transfection and re-
plated for colony forming assay and assessment of cell survival after 24 and 48h. Viable 
cell number and the percentage of apoptosis were measured by flow cytometry. (A) 
Reveals the number of viable MDA-M-B231 cells at 24h which shows  a highly significant 
(**P<0.01 n=4) decrease in the number of viable cells as compared with the negative 
control. (B) Shows the basal apoptosis levels. There was a highly significant (*P<0.05; n=4) 
increase in the percentage of apoptosis particularly in N1,1 ASO transfect cells after 24h of 
cell re-plating. (C) Number of colonies formed in long-term clonogenic assay, which 
revealed a highly significant (**P<0.01) decrease in number of colonies formed as 
compared with the negative control. (D) An example image of clonogenic assay plates 
after crystal violet staining. Unpaired t-test with Welch’s correction. 
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Figure 4.15 The effects of NEAT1 specific ASO on the migration ability of MCF7 and 
MDA-MB-231 breast cancer cells.  The cells were transfected with negative ASO or one of 
the NEAT1 ASO (N1, 1 and N1, 2). Cells were harvested 48h post transfection and re-
plated for further 24h to be 80% -90% confluence. Then a scratch line was done by using 
10 µl pipette tips. The cell migration was determined by measuring the gap distance of the 
scratch line under the light microscope at 0 time, 18 and 36h intervals. (A) Represents the 
gap closure ratio of MCF7 cells. In which, there was a significant (*P<0.05; n=3) decrease 
at 36h of cell re-plating as compared to the negative control. while (B) shows the gap 
closure ratio of MDA-MB-231 cells after 18h of cell re-plating, which was significantly 
(****P<0.0001 n=4) decrease as compared to the negative control. The negative ratio 
indicates the presence of dead cells that prevents the migration of healthy cells. Unpaired 
t-test with Welch’s correction. The magnification 10x and the distance 10 mm.  
 4.3.5 The effects of NEAT1 down-regulation on breast cancer 
cells response to UV and chemotherapeutic drugs 
The influence of NEAT1 silencing on MCF7 and MDA-MB-231 survival was 
examined under the effect of cell death stimuli. Ultraviolet (UV) light exposure has 
been one of the major inducers of apoptosis. UV exposure causes pyrimidine 
dimers and DNA fragmentation leading to cell cycle arrest and induction of 
apoptosis (Dunkern& Kaina, 2002). The effects of NEAT1 silencing on UV-induced 
cell death in breast cancer cells were investigated In MCF7 and MDA-MB-231 
cells. Reduced NEAT1 transcript levels enhanced UV-induced apoptosis (Figure 
4.16 B, Figure 4.17 B) respectively and increase the rate of growth inhibition as 
well as decrease in long term survival (Figure 4.16 A and C, Figure 4.17 A and C) 
respectively. LncRNAs has been reported to affect gene expression and their 
effects can occur in cis (on neighbouring genes) or in trans (on distantly located 
genes) (Vance and Ponting, 2014).  One of the genes located on Chromosome 11 
and on the same cytogenetic band, q13.1 is BCL2 Associated Agonist of Cell 
Death (BAD). BAD is a pro-apoptotic member of the Bcl-2 family. Its effects are 
mediated by its ability to heterodimerize with survival proteins such as Bcl-XL 
leading to the promotion of cell death. The possibility that the increase in cell death 
and inhibition of cell survival induced by UV in NEAT1 silenced cells might be due 
to the change of BAD expression levels, which was investigated. NEAT1 silencing 
enhanced UV- induced cell death and this response was associated with a 
significant increase in the expression levels of BAD (BCL2-Associated Agonist of 
Cell Death). The results showed that the enhancement of UV-induced cells in 
NEAT1 silenced cells was associated with a significant increase in the expression 
levels of BAD (Figure 4.18  A and  B) respectively.  
 Further experiments were carried out to investigate the effects of NEAT1 silencing 
on the response of breast cancer cells to chemotherapeutic drugs. Accordingly, 
the effects of NEAT1 silencing on the response of MCF7 and MDA-MB-231 to 
Docetaxel, 5Fluorouracil (5-FU), Nutlin-3a and Mitoxantrone were examined at 
48h of treatment. Control cells contained 0.25% dimethyl sulphoxide as a vehicle.  
In MCF7 cells, decreased NEAT1 transcript levels enhanced the growth inhibition 
induced by Docetaxel , 5-FU and  Nutlin-3a (Figure 4.19) and had no effects on 
Mitoxantrone induced cell death (result not shown). In MDA-MB-231 breast cancer 
cells, NEAT1 silencing enhanced the cells response to Docetaxel, 5-FU, Nutlin-3a 
and Mitoxantrone (Figure 4.20) 
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Figure 4.16 The effects of NEAT1 specific ASOs on UV-induced cell death MCF7 cells.  Cells 
were transfected by nucleofection using the negative ASO or one of the NEAT1 ASOs (N1,1 
and N1, 2). Cells were harvested 48 h post-transfection and irradiated with UV-C light for 
20s, then re-plated at density of 2x105 cell/well for cell function assessment. The growth 
inhibition ratio calculated according to an equation % Decrease = (basal state – after 
exposing to UV –C)  ÷ basal state × 100 (A) Represents the ratio of growth inhibition after 
exposing to UV irradiation, which was  highly significant (**P<0.01 and *P<0.05; n=4) .(B) 
shows the highly significant (**P<0.01; n=4) increase in ratio of  apoptosis level  using Muse 
cell analyser and Muse cell Annexin V and dead cell kit.  (C) Reveals the effects of UV-C 
irradiation on the long-term cell survival. There was significant (*P<0.05; n=4) decrease in 
number of colonies. (D) An example image of clonogenic assay plates after crystal violet 
staining. Unpaired t-test   
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Figure 4.17 The effects of NEAT1 specific ASOs on UV-induced cell death of  MDA-MB-
231. Cells were transfected by nucleofection using the negative ASO or one of the NEAT1 
ASOs (N1,1 and N1, 2).  Cells were harvested 48 h post-transfection and irradiated with 
UV-C light for 20 s, then re-plated at density of 2x105 cell/well for cell function 
assessment. The growth inhibition ratio calculated according to an equation % Decrease = 
(basal state – after exposing to UV –C)  ÷ basal state × 100.  (A) Represents the ratio of 
growth inhibition after exposing to UV-C irradiation, which was highly significant 
(**P<0.01 and ***P<0.001; n=4). (B) Shows the highly significant (**P<0.01; n=4) increase 
in ratio of  apoptosis levels using Muse cell analyser and Muse cell analyser specific kit for 
Annexin V and dead cell. (C) Revealed the effects of UV-C irradiation on the long-term cell 
survival, there was significant (*P<0.05; n=4) decrease in number of colonies. (D) An 
example image of clonogenic assay plates after crystal violet staining. Unpaired t-test   
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Figure 4.18 Effects of NEAT1 down-regulation on BAD expression levels following UV-C 
irradiation. Cells were transfected with either negative ASO or one of the NEAT1 ASOs 
(N1,1 and N1, 2) . 48h post transfection, the cells were exposed to UV-C irradiation for 20s 
and incubated at 37⁰c and 5% CO2 for 48h. Bad expression levels were determined by RT-
qPCR. Log of base 2 were used to assess the fold of expression change in comparison to 
the expression in the basal status. Meanwhile, the significance in the fold change of the 
expression was determined according to the negative control. (A) Shows the fold increase 
in BAD expression following UV exposure  in  MCF7 cells transfected with NEAT1 ASOs , 
which was highly significant (**P<0.01 and ***P<0.001; n=4) in comparison to the 
negative control. (B) Revealed the fold increase in BAD expression in MDA-MB-231 cells 
transfected with NEAT1 ASOs following UV exposure, which was highly significant 
(**P<0.01 and ***P<0.001;n=4) increase in comparison to negative control. Unpaired t-
test  
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Figure 4.19 Effects of NEAT1 silencing on chemotherapeutic drug-induced death of 
MCF7 breast cancer cells. Cells were transfected with either negative ASO or one of the 
NEAT1 ASOs (N1,1 and N1, 2). Cells were harvested 48 h post-transfection and a density of 
0.8 x105 cell/ml were cultured for minimum 20h in 96 well plate before treating them with 
Docetaxel (10µM), 5-FU (175 µM), Nutlin-3a (2.5 µM) and Mitoxantrone (50 µM) or 
vehicle (0.25% DMSO). Cell viability was assessed by MTS assay after 48h of incubation. 
The results were represented as the percentage of cell growth inhibition versus to control. 
There was significant cytotoxic effect of chemotherapeutic drugs in transfect cells 
(***P<0.001, *P<0.05, n=4). Unpaired t-test with Welch’s correction. 
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Figure 4.20 Effects of NEAT1 silencing on chemotherapeutic drug-induced death of 
MDA-MB-231 breast cancer cells. Cells were transfected with either negative ASO or one 
of the NEAT1 ASOs (N1,1 and N1, 2). Cells were harvested 48 h post-transfection and a 
density of 0.8 x105 cell/ml were cultured for minimum 20h in 96 well plate before treating 
them with Docetaxel (5 µM), 5- FU (100 µM), Nutlin-3a (5 µM) and Mitoxantrone (50 µM) 
or vehicle (25% dimethyl sulphoxide). Cell viability was assessed by MTS assay after 48h of 
incubation. The results were represented as the percentage of cell growth inhibition 
versus to control. There was significant cytotoxic effect of chemotherapeutic drug s in 
transfect cells (**P<0.01, *P<0.05, n=4). Unpaired t-test with Welch’s correction. 
 4.4 Discussion 
Targeted therapies development has transformed the treatment of some breast 
cancer subtypes mainly the hormone receptor-positive and human epidermal 
growth factor receptor 2 (HER2)-positive breast cancer. However, the problems of 
resistance to these therapies still exist (Barrios et al, 2009; Brown et al, 2004, 
Chumakova et al, 2006). Besides, approved targeted therapy for TNBC subtype, 
which lacks oestrogen receptor, progesterone receptor and HER2 amplification 
does not currently exist. This subtype is often highly malignant and shows a strong 
metastatic behaviour and high risk of relapse. Consequently, finding the best 
chemotherapeutic drugs, which leads to longer metastasis free and increase the 
overall survival is a real necessity (O’Reilly et al, 2015).  It is therefore important to 
identify novel therapeutic targets for multiple breast cancer subtypes. An 
increasing number of evidence suggests that lncRNAs regulate many fundamental 
biological processes and therefore may offer new opportunities in developing new 
diagnostic tools and therapeutic approaches to treat the different subtypes of 
breast cancer (Paralkar and Weiss, 2013; Rasool et al,2016). Indeed, NEAT1 is 
already of particular interest in relation to breast cancer, since its expression is up- 
regulated in tumour tissues (Qian et al,  2016; Choudhry et al, 2015). Current 
findings in the hormone receptor-positive and HER2-positive breast cancer cells 
(MCF7) and TNBC cells (MDA-MB-231) demonstrates here that NEAT1 plays an 
important role in regulation the survival of both types of breast cancer cells. Up-
regulation of NEAT1 promoted short and long-term survival and inhibited 
apoptosis in MCF7 cells, whereas the decrease in its expression levels was 
associated with the decrease of cell survival and migration in both types of cells. 
The present study also confirms that a decrease in NEAT1 expression levels is 
 associated with a loss of short term and long term viability. The study also 
demonstrates, for the first time, the presence of a cytoplasmic NEAT1 transcript 
beside to the expression of NEAT1 nuclear transcript.  
In this study, siRNA mediated down-regulation of NEAT1 revealed that NEAT1 is 
required for the survival of breast cancer cells. These results are in agreement 
with other studies which demonstrated the role of NEAT1 lncRNA in promoting cell 
proliferation in different types of cancer such as gastric, colorectal, lung, 
oesophageal, hepatocellular and breast cancer (Ma et al, 2016; Xiong et al, 2017; 
Yu et al,2017; Ke et al ,2016; Peng et al, 2016). siRNA mediated silencing of 
NEAT1 also affected the cell cycle via promoting cell arrest in G0/G1 phase and 
preventing their progression to the S phase. Therefore, this is resulted in a 
noticeable regression in cell proliferation, which was interpreted by a decrease in 
both short and long term cell survival. These results are in agreement with other 
studies which reported the role of NEAT1 lncRNA in regulation of cell cycle 
particularly at G0/G1 and S-phase cells (Li et al, 2016; Wang et al, 2016). For 
instance, Wang et al.  (2016)  reported a regulatory loop of NEAT1/miR-107/CDK6 
that stimulates cell proliferation in laryngeal squamous cell carcinoma (Wang et al, 
2016).  miR-107 related to the miR-103/107 family that act as a tumour suppressor 
in different cancer types (Datta et al, 2012), and CDK6 is a cell cycle regulator 
protein that responsible for the transition phase at G1/S. Therefore, NEAT1 down-
regulation might result in an up-regulation in miR-107, which lead to a decrease in 
the levels of CDK6 protein and hence increase in the number of arresting cells in 
G1 phase (Wang et al, 2016). Ke et al. (2016) have also reported similar results, 
where down-regulation of NEAT1 expression in the same cell lines (MCF-7 and 
MDA-MB-231), inhibited cell growth and induced cell apoptosis. The study 
reported an interaction between NEAT1, miR-548ar-3p and the RNA-binding 
 protein fused in sarcoma/translocated in liposarcoma (FUS/TLS). They found that 
FUS/TLS physically interacts with NEAT1 forming a complex, which is important 
for maintaining the survival of breast cancer cells (Ke et al, 2016). The study also 
reported a regulatory access between miR-548ar and NEAT1. The increase in 
miR-548ar-3p expression was able to decrease NEAT1 expression and promote 
apoptosis. Recent studies have also demonstrated the role of NEAT1 in 
hepatocellular carcinoma (HCC) (Mang et al, 2017).  The study reported an 
elevation of NEAT1 transcript levels in HCC tissues compared with non- 
cancerous liver tissues. Silencing of NEAT1 reduced HCC cell proliferation, 
invasion and migration (Mang et al, 2017). The study also indicated that NEAT1 
regulated Heterogeneous Nuclear Ribonucleoprotein A2 (hnRNP A2) expression. 
Down-regulation of NEAT1 resulted decrease in the expression levels of hnRNP 
A2 and overexpression of hnRNP A2 rescued the proliferation and invasion of 
HCC cells that expressing low levels of NEAT1 (Mang et al, 2017).   
An increasing number of evidence confirms the effects of NEAT1 down-regulation 
on promoting apoptosis and inhibition the cell growth (Lo et al, 2016, Ke et al, 
2016, Mang et al, 2017). The study presented here showed that reduced 
expression levels of NEAT1 leads to a decrease in cell survival and insignificant 
increase in the basal apoptosis levels.  It is highly likely that the time point used to 
determine the apoptosis levels was not appropriate where all the apoptotic cells 
were disintegrated. Apoptosis levels were measured by Annexin V staining. This 
method depends on the interaction of Annexin V, a calcium-dependent 
phospholipid binding protein, with a phosphatidylserine (PS) translocated from the 
internal to the external cell membrane during the early stages of apoptosis (Muse 
TM user’s guide, # MCH100105; Walton et al,1997). Accordingly, there might be 
certain factors affecting the translocation of phosphatidylserine in the outer part of 
 the cell membrane such as the incubation period of transfected cells (Schuffner et 
al, 2002). The variation in the levels of flippase activity, an aminophospholipid 
translocases responsible for translocate PS from the exoplasmic to the 
cytoplasmic faces of the plasma membrane  and the concentration of intracellular 
calcium, might have also affected the results. The flippase and calcium levels are 
responsible for regulating the PS externalization in relation to the type of cancer 
cells where cell lines that show high PS in the outer membrane are characterised 
by low flippase activity and high intracellular calcium and vice versa 
(Vallabhapurapu et al, 2015). MDA-MB-231 breast cancer cells are characterised 
by low PS in the outer membrane because of high flippase activity and low 
concentration of intracellular calcium (Vallabhapurapu et al, 2015) and therefore 
this might explain why the apoptosis level was not affected by the down-regulation 
of NEAT1 expression levels.  
The effects of siRNA mediated silencing of NEAT1 were also confirmed using 
NEAT1 specific modified ASOs. Specific NEAT1 antisense DNA and RNA 
phosphorothioate-modified oligonucleotides containing selective phosphorothioate 
backbone modifications and 2’ O-methyl RNA bases were transfected into breast 
cancer cells. Studies have shown that chemical modifications of ASOs improve 
potency and selectivity by increasing binding affinity of oligonucleotides for their 
complementary sequences. NEAT1 specific ASOs were effective in silencing the 
endogenous levels of NEAT1 in both MCF7 and MDA-MB-231 cells.  In MCF7 
cells, ASO-mediated silencing inhibited short-term survival and cell migration but 
had no significant effects on long-term survival. ASO-mediated silencing of NEAT1 
in MDA-MB-231 resulted in an increase in basal apoptosis levels and inhibited 
both short and long-term viability. Although both ASOs reduced endogenous levels 
of NEAT1, the functional effects of both ASOs were not always consistent and 
 were short-lived. It is possible that higher concentration of ASOs is required in 
order to produce the effects for a longer period (Watts and Corey et al, 2012; 
Bertrand et al, 2002).  The effects of NEAT1 silencing on cell migration have also 
been reported by Song et al. (2017), who described the effects of NEAT1 on 
promoting cell invasion and migration in colorectal cancer. Studies have also 
shown that overexpression of NEAT1 lncRNA leads to suppression of miR-662 
resulting in overexpression of ZEB2 (Zinc finger E-box-binding homeobox 2), a 
transcription protein involved in epithelial-mesenchymal transition process (Song 
et al, 2017). The effects of NEAT1 silencing on cell migration might be also related 
to the low levels of MALAT1 in these cells.  MALAT1 has been reported to be 
involved in promoting the migration of lung cancer cells (Gutschner et al, 2013).   
Using cationic lipid polymer mediated siRNA transfection resulted in an increase in 
NEAT1 expression levels. Further experiments revealed that delivery of NEAT1 
specific siRNAs via lipid polymers resulted in a decrease in the cytoplasmic 
NEAT1 expression levels and an increase in the expression levels of nuclear 
NEAT1.  It is well known that using a lipid polymer-mediated transfection method 
depends on a chemical concept characterised by forming a complex between 
negatively charged nucleic acid and cationic lipid reagent to facilitate their cellular 
uptake (Brazas and Hagstrom, 2005). siRNAs delivered via this method remained 
in the cytoplasm, where it is incorporated with the functional RNA -induced 
silencing complexes (RISC) to start their silencing effects (Brazas and Hagstrom, 
2005). Therefore, the obtained results using this method of transfection in MCF7 
cells were unexpected and suggest that the siRNAs delivered via this method 
remained in the cytoplasm and acted on the cytoplasmic NEAT1 transcript causing 
a reduction of its expression. These results demonstrate that in addition to its 
nuclear location, NEAT1 is also located in cytoplasm and suggest that the 
 cytoplasmic transcript might exert inhibitory effects on the expression of nuclear 
NEAT1.  The decrease in the levels of cytoplasmic NEAT1 transcript levels was 
associated with an overexpression of nuclear NEAT1 and an increase in the 
number of total and viable cells as well as an increase in long-term survival. 
Overexpression of NEAT1 also resulted in a decrease in basal apoptosis levels, 
which appear to be related to the increase in X-inhibitory of apoptosis (XIAP) 
expression levels, a potent enzymatic inhibitor of mammalian caspase (including 
both the extrinsic and the intrinsic caspase pathway) (Eckelman et al, 2006). The 
inhibition of basal apoptosis levels observed in cells overexpressing NEAT1 could 
be due the activation of PI3K/AKT signalling pathway which inhibits the activity of 
the tumour suppressor Phosphatase and tensin homolog (PTEN)  in breast cancer 
(Weng et al, 2001). The other possible cause could be due to the activation of 
ataxia telangiectasia and Rad3-related protein (ATR kinase pathway by NEAT1 
and hence the contribution of this activated pathway in inhibiting P53 (Adriaens et 
al, 2016).  
Overall the results confirmed the oncogenic role of NEAT1 in breast cancer. The 
cell survival effects resulted from elevated NEAT1 expression levels in MCF7 cells 
may be due to correlation between NEAT1 and ERα expression in ER- positive 
tumours. ERα is reported to have positive effects on NEAT1 expression 
particularly in ER- positive tumours where oestrogen plays an important role in 
enhancing the growth and differentiation of mammary epithelium (Girdler and 
Brotherick , 2000). Accordingly, an alteration in ERα mRNA expression might lead 
to the breast cancer formation. The correlation between NEAT1 and ERα was 
demonstrated by Chakravarty et al (2014) in prostate cancer.  The study 
demonstrated the effects of ERα on the expression of NEAT1, which contributes to 
the epigenetic changes of other genes leading to their aberrant expression in 
 prostate cancer (Chakravarty et al, 2014).  The survival effects of NEAT1 may be 
related to the positive correlation of NEAT1 lncRNA with the activation of 
PI3K/AKT ( phosphoinositide 3-kinase / serine/threonine kinase) pathway, a 
signalling pathway activated in basal-like breast tumours and  responsible for 
regulation of cell proliferation, apoptosis and migration (Cancer Genome Atlas 
Network, 2012; Chin et al, 2013). In addition, a direct relation between AKT kinase 
pathway and NEAT1 expression was also confirmed in colorectal cancer where 
down-regulation of NEAT1 leads to inactivation of AKT kinase pathway causing an 
inhibitory effects on cell cycle progression and cell survival (Peng et al, 2016; Chin 
et al.,2013).  
Although the effects of NEAT1 expression on breast cancer cell survival has been 
addressed before in breast cancer cells and other cell types (Choudhry et al, 2015; 
Lo et al, 2016a; Ke et al, 2016; Peng et al, 2016; Mang et al,2017). The 
consequences of its reduced levels on breast cancer cell response to apoptosis 
inducing agents have not been addressed. Here, the results demonstrate that 
reduction in NEAT1 expression levels are associated with increase cell death in 
response to a range of apoptosis-inducing agents (UV-C irradiation, 5-FU, 
docetaxel, and Mitoxantrone (only in MDA-MB-231). The enhancement of UV-
induced inhibition of cell growth by NEAT1 silencing was associated with an 
increase in BCL2 Associated Agonist of Cell Death (BAD) expression levels. 
These results suggest that NEAT1 inhibits the expression of BAD and UV 
irradiation of these cells with NEAT1 silencing relieves such inhibition leading to an 
increase in UV-induced BAD expression resulting in an increase in cell death. The 
results also indicate that NEAT1 affects gene expression and its effects can occur 
in cis as shown by its effects on MALAT1 and BAD.  Although, there was a 
variation in the sensitivity of NEAT1 knockout cells to different chemotherapeutic 
 drugs used in this study, this may be due to variation in the silencing efficiency of 
NEAT1 ASO. The expression level of NEAT1 in transfected cells correlated with 
silencing efficiency of N1,1 and N1,2 ASO , which was more significant in MDA-
MB-231 and MCF7 respectively. NEAT1 appears to be selectively modulate the 
action of chemotherapeutic agents Docetaxel, 5-FU, Nutlin-3a and Mitoxantrone. 
This perhaps related to their differing mechanisms of engagement of the apoptotic 
machinery. Docetaxel is an anti-mitotic drug, 5-FL is an antimetabolite that prevent 
DNA synthesis, Nutlin-3a is Mdm2 antagonist and Mitoxantrone is an antitumour 
antibiotic that affects cell cycle (Longley et al, 2003; Herbst and Khuri, 2003; Tabe 
et al, 2009; Fox, 2004). From a therapeutic perspective, the results suggest that 
reducing cellular NEAT1 levels might improve the cytotoxic activities of 
conventional chemotherapies drugs. However, further experiments are required 
using NEAT1 specific siRNAs and a higher dose of ASOs to investigate in details 
the consequences of NEAT1 down-regulation for breast cancer cell survival 
following treatment with chemotherapeutic agents. 
 
 
 
 
 
 
 
 
 
 
 Chapter highlights  
1. The results suggest that in MCF7 breast cancer cells, NEAT1 is distributed 
in both nuclear and cytoplasm compartments. Down-regulation of 
cytoplasmic NEAT1 levels leads to an increase in the expression of nuclear 
NEAT1, which was associated with an increase in short and long-term 
survival and a decrease in apoptosis.  
 
2. Silencing of NEAT1 decreased short and long-term viability, altered the cell 
cycle and inhibited cell migration of both triple-negative and oestrogen 
receptor-positive cells. 
  
3. Down regulation of NEAT 1 reduced the expression level of its neighbouring 
gene, MALAT1.  
 
4. NEAT1 silencing enhanced UV- induced cell death and this response was 
associated with a significant increase in the expression levels of BAD. 
 
5. NEAT1 silencing enhanced growth inhibition induced by some classical 
chemotherapeutic agents 
 
6. Both ASOs and siRNAs were effective in silencing NEAT1. However, 
functional effects of siRNAs lasted longer than those of ASOs 
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Chapter 5 
The influence of NEAT1 down-
regulation on gene expression in 
breast cancer cells 
 5.1 Introduction 
Various studies confirm the importance of lncRNAs in their contribution via many 
different pathways for regulating the cellular function in health and disease (Yang 
et al, 2012a; Bernard et al, 2010, Batista and Chang, 2013; Han et al, 2017). 
LncRNAs play important roles in regulating multiple aspects of gene transcription, 
often through regulation of transcription factor expression or by recruiting 
regulatory complexes through RNA–protein interactions to influence the 
expression of nearby or distant genes (Batista and Chang, 2013). Many lncRNAs 
have been demonstrated to interact with chromatin at several thousand different 
locations across multiple chromosomes and to modulate large-scale gene 
expression programs (Wang et al, 2011; Vance and  Ponting, 2014). For instance, 
Bernard et al. (2010) has revealed the role of MALAT1 lncRNA in regulating the 
expression of genes that are involved in synapse formation and maintenance. 
Furthermore, lncRNAs can be involved in transcriptional interference, a mechanism that 
regulates gene expression through its regulatory sequences like the activating or blocking 
of the promoter sites (Batista and Chang, 2013). They can exert their effects in integrated 
manner with a set of non-coding and coding RNAs rather than individually such as 
AK123657, BX649059 and BX648207 lncRNAs, which are down-regulated in colorectal 
cancer in versus to normal colorectal tissues, suggesting their protective role in colorectal 
cancer pathology (Hu et al, 2014, Han et al, 2017). 
NEAT1 up-regulation promotes glioma cell proliferation, invasion and migration via 
activating the expression of c-Met gene, which encodes a receptor tyrosine kinase involved 
in cell proliferation and migration via c-Met signalling pathway (Yan et al, 2017, Organ and 
Tsao, 2011). The effects of NEAT1 on MET gene expression were attributed to the ability 
of NEAT1 to act as a sponge to miR-449b-5p, which regulates the expression of c-Met 
 gene (Yan et al, 2017). Additionally, NEAT1 regulates the expression of paraspeckles 
target genes through sequestration of NEAT1 binding transcription factors in the 
paraspeckles (Hirose et al, 2014). NEAT1 knockdown leads to the repression of the 
transcription of several genes including the RNA-specific adenosine deaminase B2 
(ADARB2), such effects were dependent on the sequestration of the paraspeckle protein 
SFPQ (Splicing factor proline/glutamine rich) (Hirose et al, 2014). 
Therefore, the aims of this study are to determine the effects of NEAT1 down-regulation on 
the expression of genes involved in breast cancer and cell cycle, using Breast Cancer and 
Cell Cycle RT2 Profiler™ PCR Arrays. The study also investigated the effects of NEAT1 
down-regulation on global gene expression in breast cancer cells using RNA sequencing. 
 
5.2 Material and methods 
5.2.1 RT2 profiler PCR array 
RT2 profiler PCR array is a combination of using the qRT-PCR and microarray 
analysis. Quantification of gene expression was performed using ready to use 
Human Breast Cancer and Human Cell Cycle RT2 Profiler PCR Arrays (QIAGEN). 
Each array contains primers for 84 tested and 5 housekeeping genes, and controls 
for RT2 and PCR reactions (QIAGEN, 2013). 
RNAs were isolated for MCF7 48h following transfection with NEAT1 ASOs 
(Section 2.2.12). cDNA was synthesised as discussed in Section 2.2.13 and used 
in RT2 profiler PCR array as indicated in Section 2.2.14. After determining the Ct 
value for each well by using the real time cycler software, the results were 
analysed using the Web-based PCR Array Data Analysis software at 
www.SABioscience.com/pcrarraydataanalysis.php. 
 
 5.2.2 RNA Sequencing           
MDA-MB-231 cells were re-plated for 6 h after 48h post-transfection with NEAT1 ASOs 
before isolation of RNAs, according to the protocol described in Section 2.2.12. The quality 
of RNA samples was assessed using gel electrophoresis (Section 2.2.12.1). The RNA 
purity and the concentration were measured by a NanoDrop. RNA with 260/280 nm ratio of 
~ 2 was considered as pure and good quality (Desjardins and Conklin, 2010). 
For RNA-sequencing, samples at a concentration of 3-5μg of total RNA (50 ng/μl 
in 60 μl) were prepared according to the Earlham Institute (Norwich Research 
Park, Norwich, UK) and sent to Earlham Institute on dry ice. The obtained results 
were analysed using the Galaxy Web based platform for bioinformatics analysis, 
IPathway Guide for Next-gen pathway analysis and Reactome pathway database 
 
 
5.3 Results 
5.3.1 Effects of NEAT1 down-regulation on the expression of cell 
cycle and breast cancer genes         
Two RT2 profiler PCR arrays were used to investigate the effects of NEAT1 down-
regulation on the expression of genes involved in the regulation of genes involved 
in cell cycle and breast cancer. One of the arrays used was the Human Cell Cycle 
RT2 Profiler PCR Array, which profiles the expression of 84 genes key to cell cycle 
regulation. This array contains genes that involved in: 1) positive and negative 
regulation of cell cycle, 2) the cell cycle process, 3) the transitions between the cell 
cycle phases, 4) DNA replication, and 5) checkpoints and arrest. The other array 
was the Human Breast Cancer RT2 Profiler PCR Array, which profiles the 
expression of 84 key genes involved in the dysregulation of signal transduction 
and other biological processes involved in breast carcinogenesis. This array 
 includes genes involved in carcinogenesis. 1) signal transduction, 2) angiogenesis, 
3) adhesion, 4) invasion and metastasis, 5) cell cycle regulation, and 6) apoptosis. 
Using the Human Cell Cycle RT2 Profiler PCR Array, revealed the fold changes in 
expression of 84 genes as detected in various stages of cell cycle process (Figure 
5.1). Furthermore, the RT2 profiler PCR data analysis illustrated the effects of 
NEAT1 down-regulation on the expression of specific genes that are responsible 
for regulating each phase of the cell cycle. In which, there was a down-regulation 
in cyclin dependent kinase (CDK4/6) and cyclin dependent kinase regulator 
(CCND1and CCNE1) genes, which are responsible for regulation of G1, S and 
G2/M phases as present in Figure 5.2. Additionally, NEAT1 down-regulation 
resulted in increase the expression of most cell cycle regulatory checkpoint genes, 
which includes ATM, ATR, BRCA1, BRCA2, CDKN1A (p21CIP1, WAF1), 
CDKN1B (P27KIP1), CDKN2A (p16INK4a), CDKN2B (p15INK4b), CHEK2, 
CUL(1-3),KNTC1,RAD1, RAD17, RB1, RBBP8, TP53, RAD3A (Figure 5.3 A). Four 
of these cell cycle regulatory checkpoint genes (ATM, BRCA1, CDKN2B and 
TP53) function as negative regulators of the cell cycle. Reduced NEAT1 levels 
also resulted in the up-regulation of cell cycle negative regulatory genes (Figure 
5.3 B). Two other genes involved in the negative regulation of the cell cycle, RBL1 
and RBL2, were also up-regulated as a result of reduction in NEAT1 expression. 
Moreover, NEAT1 down-regulation has a positive and negative influence on the 
expression of human breast cancer focused genes as illustrated in Figure 5.4.  
Genes that were found to be up-regulated are GTSE1, GTF2H1, GADD45A, 
DNM2, CUL3, CUL2, UBA1, TP53, TFDP2, TFDP1, SUMO1, SERTAD1, RPA3, 
RBL2, RBL1, RBBP8, RB1, RAD9A, RAD51, RAD17, RAD1, PCNA, KPNA2 and 
KNTC1(Figure 5. 5 A). On the other hand, genes that were found to be down-
regulated by the reduction of NEAT1 expression levels include HUS1, MAD2L1, 
 MCM3, MCM4, MKI67, MNAT1, SKP2, CDK4, CDK6, CDH1, GATA3, IGF1R, 
KRT18, KRT19, KRT8, MAPK3, MLH1, MMP9, PYCARD, SLC39A6, TFF3, XBP1 
and E2F4 (Figure 5.5 B).  
At the same time, the RT2 profiler PCR array results revealed list of communal 
genes between human breast cancer and cell cycle that had their expression 
affected by NEAT1 down-regulation, as illustrated in Figure 5.6.  These genes 
include BRCA1, BRCA2, CCND2, CCNE1, CDK2, CDKN1A, TP53, CCND1, 
CDKN2A and MKI67. There was an up-regulation in the levels of BRCA1, BRCA2, 
CDKN1A, CDKN2A and TP53. Genes that showed down-regulation in both arrays 
include CCND1, CCND2, CCNE1, CDK2 and MKI67 (Figure 5.6). 
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Figure 5.1  Cell cycle genes affected by NEAT1 down-regulation. RT 2 profiler PCR array bar 
graph showing the expression profile of 84 focused- cell cycle genes. The average Ct value 
was normalised to a set of 5 own internal housekeeping genes at cut-off was 35. The fold 
change in gene expression was organised according to a cut-off 2. A) Represent the Negative 
regulation. B) Regulation of cell cycle, which controls cell cycle progression, terminal 
differentiation, and apoptosis. C) Cell cycle checkpoint and cell cycle arrest that occurs near 
the end of G1, at the G2/M transition, and during metaphase. . D) M phase. E) G2 phase and 
G2/M transition. F) S phase and DNA replication. G) G1 phase and G1/S transition. The 
analysis of the results was performed using a Web-based PCR Array Data Analysis software at 
www.SABioscience.com/pcrarraydataanalysis.php. 
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Figure 5.2  NEAT1 down-regulation effects on the expression of genes involved in each 
stage of the cell cycle. RT2 profiler PCR array bar graphs show the expression profile of 84 
cell cycle focused- genes. The average Ct value was normalised to a set of 5 own internal 
housekeeping genes at cut-off was 35. The fold regulation in gene expression was organised 
according to a cut-off 2. (A) Represents the list of genes expression relevant to G1 phase of 
cell cycle. (B) Shows the list of genes expression relevant to S phase of cell cycle. (C) Revealed 
the expression of genes responsible for G2/M phase of cell cycle. The analysis of the results 
was carried out through a Web-based PCR Array Data Analysis software at 
www.SABioscience.com/pcrarraydataanalysis.php. 
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Figure 5.3 Cell cycle checkpoint genes affected by the decrease in NEAT1 transcript 
levels. RT2 profiler PCR array bar graphs show the expression profile of  cell cycle focused- 
genes. The fold regulation in gene expression was organised according to a cut-off value 
was 2. (A) Represents the list of genes responsible for regulating the cell cycle 
checkpoints. (B) Shows the expression of genes expression considered as a negative 
regulator of cell cycle. The analysis of the results through a Web-based PCR Array Data 
Analysis software at www.SABioscience.com/pcrarraydataanalysis.php. 
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Figure 5.4 The effects of NEAT1 down-regulation on the expression of breast cancer 
genes. RT2 profiler PCR array bar graphs show the expression profile of 84 focused- 
human breast cancer cells. The average Ct value was normalised to a set of 5 own 
internal housekeeping genes at cut-off was 35. The fold change in gene expression was 
organised according to a cut-off 2. The analysis of the results through a Web-based PCR 
Array Data Analysis software at www.SABioscience.com/pcrarraydataanalysis.php 
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Figure 5.5 Breast cancer genes affected by the silencing of NEAT1 expression levels. RT2 
profiler PCR array bar graphs show the expression profile of 84 focused- human breast 
cancer cells in relevance to NEAT1 down-regulation. The average Ct value was normalised 
to a set of 5 own internal housekeeping genes at cut-off was 35. The fold change in gene 
expression was organised according to a cut-off 2. A) Revealed the genes that show an 
increase in the level of expression. B) Showed the genes which were down-regulated as a 
result of NEAT1 down-regulation.  The analysis of the results using a Web-based PCR Array 
Data Analysis software at: www.SABioscience.com/pcrarraydataanalysis.php. 
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5.3.2 Differential gene Expression using RNA Sequencing 
profiling in MDA-MB-231 cells transfected with NEAT1 
ASOs    
MDA-MB-231 was transfected with negative ASO, NEAT1,1 ASO or NEAT1,2 
ASO and cultured for further 48 h before being trypsinised and  re-plated  for 
further 6 h. Total RNA was isolated from transfected cells following the 6h 
incubation. The RNA sequencing data analysis showed NEAT1 expression (Figure 
Figure 5.6 Bar graph showing the effects of NEAT1 down-regulation on the expression 
profile of genes that are shared between human breast cancer and cell cycle. The 
average Ct value was normalised to a set of 5 own internal housekeeping genes at cut-
off was 35. The fold change in gene expression was organised according to a cut-off 2. 
The analysis of the results through a Web-based PCR Array Data Analysis software at:  
www.SABioscience.com/pcrarraydataanalysis.php. 
 
 5.7, Appendix l). NEAT1 levels were reduced by 35% compared to control only in 
the cells transfected with NEAT1,1 ASO (Figure 5.8). Cells transfected with 
NEAT1,2 showed no significant decrease in the expression levels of NEAT1 
(Figure 5.8).  These results support the previous observation in Chapter 4 that the 
effects of NEAT1 ASOs are short lived and suggest that the levels of NEAT1 have 
returned to the normal endogenous levels at the time of RNA collection.  
Therefore, only the results of RNA sequencing form the cells transfected with 
NEAT1,1 ASO will be described here. The 35% decrease on NEAT1 expression 
levels resulted in the significant (P < 0.05 and Q < 0.05) up-regulation of 67 genes 
(P<0.05) (Figure 5.8 and Table 5.1). There were changes in the fold expression of 
other genes detected by the RT- Profiler, however these changes were not 
significant (P>0.05). These genes includes the negative regulators of the cell cycle 
ATM, BRCA1, CDKN2B and TP53 and the genes affected in both cell cycle and 
breast cancer arrays (BRCA1, BRCA2, CCND2, CCNE1, CDK2, CDKN1A, TP53, 
CCND1, CDKN2A and MKI67). The changes were in the same direction as found 
in the RT profiler arrays.  These results could be due to the fact that the 
expression levels of NEAT1 have started to recover at the time point chosen for 
the RNA collection and this has caused a loss of some of the effects of NEAT1 on 
the gene expression. 
The RNA sequencing data analysis showed a significant (P< 0.05) up-regulation of 
67 genes as presented in Table 5.2, Appendix l  DEGS2, RNF223, HSPB1 and 
ISG15 showed the highest up-regulation levels (Table 5.2, Appendix l). DEGS2 
gene encodes an enzyme involved in the key reaction of the biosynthesis of 
phytosphingolipids including sphingomyelin. Sphingomyelin (SM) and its metabolic 
products ceramide and sphingosine-1-phosphate, are known to have second 
messenger functions in a variety of cellular signalling pathways including 
 apoptosis.  RNF223 is a ring finger protein and HSPB1 is heat-shock protein of 
27 kDa (HSP27) which is reported to be expressed at higher levels during 
oxidative stress in renal tubular cells in acute kidney injury (Matsumoto et al, 
2015).  
 ISG15 gene encodes an ubiquitin-like modifier protein and involved in cellular 
communication and in defence against viral infection (Desai, 2015). Interestingly, 7 
genes located on chromosome 11 were found to be up-regulated. Two of these 
genes (Coiled-Coil Domain Containing 85B and Sjogren Syndrome/Scleroderma 
Autoantigen 1) are located on 11q13.1 the same chromosomal band as NEAT1 
and another one, Nudix Hydrolase 8, on 11q13.2. Another four of these genes are 
located on 11p15.5. These include Tumour Suppressing Subtransferable 
Candidate 4, Plakophilin 3, Ras Association Domain Family Member 7 and 
Ribonuclease / Angiogenin Inhibitor 1. It is also worth noting that Tumour Protein 
P53 Inducible Protein 13 (TP53I13) and BRCA1 Associated ATM Activator 1 
(BRAT1) were found to be up-regulated. The expression of BRAT1 and TP53I13 
are regulated by BARC1 and TP53, respectively. 
Further analysis using IPathway Guide for Next-gen pathway analysis showed that 
the genes affected are implicated in a number of pathways with the most 
significant ones include galactose catabolism, tight junction and Fatty acid (Table 
5.1). Other pathways affected include systemic lupus erythematosus, viral 
carcinogenesis. AMPK and MAPK  signalling pathways, RNA degradation,   VEGF 
signalling pathway, DNA repair, Central carbon metabolism in cancer,  
Sphingolipid metabolism , HIF-1 signalling pathway , and cell cycle. Reactome 
database has identified 11 of the genes to be involved in regulation the immune 
system, 13 in the regulation of metabolism, 5 in signal transduction and 4 in the 
 cellular response to stress (the list of pathways affected by NEAT1 down-
regulation illustrated in Table 5.3, Appendix l) 
 
 
 
     
 
 
 
 
 
 
Figure 5.8 NEAT1 raw reads in the linear scale of NEAT1. Raw reads obtained from 
the RNA sequencing data.   Levels of NEAT1 expression in transfect cells with NEAT1,1 
ASO are lower than those in the negative control (n=3). While, there was no changes 
in NEAT1 expression in transfect cells with NEAT1,2 ASO. The table presents NEAT1 
number of reads in each sample. The diagram was obtained from Integrative 
Genomics Viewer (IGV). 
  
                 
 
 
Table 5.1: Top pathways that have been affected by NEAT1 down-regulation and their  
associated p-values 
 
 
 
 
 
  
 
  
 
 
 
Pathway name  The involved Genes  p-value 
Galactose catabolism 
 
Galactokinase 1(GALK1);  
Phosphofructo-1-Kinase Isozyme 
B (PFKL);  GAA (producing an 
enzyme acid alpha-glucosidase); 
1.567e-4 
Tight junction Scribbled Planar Cell Polarity 
Protein (SCRIB) 
0.02 
Fatty acid 
Biosynthesis 
Fatty Acid Synthase (FASN) 
 
0.05 
Figure 5.9 Volcano plot revealed 67 signiﬁcantly diﬀerentially expressed (DE) genes are 
represented in terms of their measured expression change (x-axis) and the signiﬁcance of 
the change (y-axis). The signiﬁcance is represented in terms of the negative log (base 10) 
of the p-value, so that more signiﬁcant genes are plotted higher on the y-axis. The dotted 
lines represent the thresholds used to select the DE genes: 0.6 for expression change and 
0.05 for significance. https://ipathwayguide.advaitabio.com/report/24273/contrast/294 
 5.4 Discussion 
The work described in this chapter aimed at studying the effects of silencing 
NEAT1 on the expression of genes involved in cell cycle and human breast cancer 
were investigated. RNA sequencing was also carried out to analyse the effects of 
reduced NEAT1 transcript levels on global gene expression in MDA-MB-231 
breast cancer cells. The results revealed that down-regulation of NEAT1 affected 
the expression of genes, which regulate cell cycle and are involved in breast 
cancer.  RNA sequencing identified 67 differentially expressed genes in the RNA 
isolated from cells that had up to 35% reduction in the expression levels of 
NEAT1. These genes are involved in a number of important cellular functions 
Reduction in the NEAT1 expression levels down-regulated six genes involved in 
G1 phase and G1 transition. These include CCND1 (cyclin D1), CCNE1 (cyclin 
E1), CDK4 (cyclin dependent kinase 4), CDK6 (cyclin dependent kinase 6), 
CDC34 (cell division cycle) and SKP2 (S-phase kinase associated protein 2). Both 
CDK4 and CDK6 are involved in the regulation and progression of G1. G1 Phase 
and G1/S transition genes overexpressed as a results of NEAT1 down-regulation 
include CUL1, CUL2 and CUL3 (Cullin 1, 2 and 3) and CDKN1B. Cullins are family 
of NEDD8 targets important in the stabilization and degradation of proteins, such 
as hypoxia-inducible factor (Curtis et al, 2015).  Genes involved in S phase and 
DNA replication were also affected by the silencing of NEAT1 including two genes 
involved in DNA replication, MCM3 and MCM4 (Minichromosomal maintenance 
deficient 3 and 4). Seven genes involved in G2 phase and G2/M transition were 
down-regulated including CCNB1 (Cyclin B1), CCNT2, CCNG1, CCNT1, CDK5R1, 
CCNH (Cyclin H) and CDK7, in addition to seven of these genes were found to be 
up-regulated. 
 Interestingly, expression of six genes involved in cell-cycle negative regulation 
were up-regulated. These genes include ataxia telangiectasia mutated (ATM), 
breast cancer 1 (BRCA1), cyclin dependent kinase inhibitor 2B (CDKN2B), RB 
transcriptional corepressor like 1(RBL1), RB transcriptional corepressor like 2 
(RBL2) and tumour protein P53 (TP53). It is likely that up-regulated expression of 
these genes is the proximal cause for the inhibition of cell-cycle progression 
shown by reducing NEAT1 expression levels.  ATM/ATR kinases are responsible 
for maintaining the DNA integrity via their contribution in DNA repair and 
controlling the cell cycle checkpoints (Maréchal and Zou, 2013). Therefore, 
activation of these pathways leads to the inhibition in cell proliferation and increase 
in the rate of apoptosis (Taylor and Lindsay, 2016). In addition to the above, the 
importance of BRCA1 in regulating cell cycle depends on its ability to encode 
multiple tumour suppressor genes, which are involved in all stages of cell cycle 
(Anderson et al, 1998; Zhang et al, 2016a). The effects of NEAT1 down-regulation 
on the enhancement of the expression of cell cycle regulator gene such BRCA1 
has been demonstrated in by Lo et al. (2016).  This study reported a signalling 
axis involving BRCA1/NEAT1/miR-129-5p/WNT4 which plays a role in breast 
cancer initiation (Lo et al, 2016b). BRCA1 deficient cells were shown to have high 
expression of NEAT1 and this supressed the activity of miR-129-5p by DNA 
methylation at the CpG Island in miR-129 genes. Thus, down-regulation of miR-
129-5p leads to up-regulation of WNT4 that stimulate the oncogenic WNT pathway 
(Lo et al, 2016b).   
The other cell cycle inhibitor up-regulated as a result of reduction in NEAT1 
expression levels is CDKN2B. CDKN2B is a cell cycle inhibitor that forms a 
complex with CDK4 and 6 preventing their effects and hence controlling cell 
proliferation (Suzuki et al, 1995; Kitagawa et al, 2013). Therefore, inactive 
 CDKN2B protein might enhance malignant cell proliferation a fact has been proved 
in different studies (Li et al, 2014a Omura et al, 2000; Hu et al, 2017). Expression 
of CDKN2B was induced by suppression of AKT kinase in oral squamous cell 
carcinoma (Nakashiro et al, 2015). RBL1 and RBL2 (Retinoblastoma 
transcriptional corepressor like 1, 2) code for the p107 and p130 proteins, 
respectively (Henley and Dick, 2012). These proteins are called pocket proteins 
because they contain a conserved domain referred to as the 'pocket' that interacts 
with the LXCXE motif found in viral proteins such as TAg (Henley and Dick, 2012). 
Pocket proteins are thought to be central to the regulation of proliferation in many 
diverse organisms and deregulation of cell cycle control in cancer (Henley and 
Dick, 2012). 
TP53 was also found to be up-regulated as a consequence of NEAT1 down-
regulation. TP53, a tumour suppressor protein, plays an important role in 
regulating the cell cycle, DNA replication and cell division (Vogelstein et al, 2000). 
Therefore, any abnormal expression of TP53 because of gene mutation leads to a 
disturbance in normal cell function, and hence increases the incidence of different 
pathological problems like cancer (Vogelstein et al, 2000).  Usually, TP53 presents 
as inactive protein that become active after phosphorylation by one of the 3 
distinct pathways, which are ATM/CHK2 pathway, ATR kinase pathway, and the 
last one as a consequence to p14 activation due to oncogene stimulation like Ras 
or Myc (Vogelstein et al,2000).  Therefore, activation of these kinases ATM, 
CHK2, ATR, CHK1 protein as a response to DNA damage will promote the 
phosphorylation processes of TP53 (Vogelstein et al, 2000; Schwartz and Rotter, 
1998). Phosphorylated TP53 plays an important role in regulating the cell cycle by 
arresting the cells in G1 phase and preventing them to progress into S phase, an 
action to keep the genome integrity via increasing the possibility of repairing the 
 damaged DNA or enhance the rate of apoptosis (Vogelstein et al, 2000). TP53 
promotes the expression of non-coding genes beside to protein coding genes that 
are responsible for cell cycle arrest, DNA repair and apoptosis (Botcheva et al, 
2011; Blume et al, 2015; Riley et al, 2008). TP53 is reported to induce NEAT1 
expression in CLL (chronic lymphocytic leukaemia) (Botcheva et al, 2011; Blume 
et al, 2015). On the other hand,  NEAT1 expression contribute in regulating the 
TP53- dependent gene expression via increase the formation of paraspeckles, 
which are involved in controlling gene expression and function in editing A-I 
mRNA, transcription and splicing  (Idogawa et al, 2017, Adriaens et al, 2016). 
Idogawa et al. (2017) revealed the importance of NEAT1_2 (long isoform) in 
regulating the TP53- induced gene expression and tumour suppression function. 
Activation of P53 by oncogene stress leads to up-regulation of NEAT1 and 
increase in paraspeckles formation, which in turn attenuate the oncogene-induced 
p53 activation (Adriaens and Marine, 2017), suggesting the important role of 
NEAT1 in regulating p53 protein by a negative feedback loop that is involved in 
attenuating the oncogene- dependent p53 activation. 
NEAT1 down-regulation has also resulted in the overexpression of 24 genes 
involved in breast cancer and the down-regulation of 23 genes. Genes affected 
include genes involved in carcinogenesis, signal transduction, angiogenesis, 
adhesion, invasion and metastasis, cell cycle, and apoptosis. While further 
experiments are required to validate the results obtained with the RT2 ProfilerTM 
PCR Arrays, both cell cycle and breast cancer arrays results confirmed NEAT1 
effects on genes shared by both arrays. The fact that the same genes were 
changed in both arrays confirms the effects of NEAT1 down-regulation on the 
expression of these genes. In both arrays, reduction of NEAT1 expression levels 
resulted in the increase in levels of BRCA1, BRCA2, CDKN1A, CDKN2A and 
 TP53. The decrease in NEAT1 transcript levels led to the down-regulation of the 
expression of CCND2, CCND1, CCNE1 and MKI67.  Overexpression of BRCA1 
leads to co-activation of the p53-mediated gene expression like p21 and GADD45, 
which are involved in supressing cell cycle progression. This elucidates the 
importance of BRCA1 overexpression in activation and stabilization of P53 
signalling pathway (MacLachlan et al, 2002; Yoshida and Miki, 2004). In addition, 
BRCA1 and  BRCA2 play a significant role in repairing of DNA double strand 
brake by homologous recombination (HR) pathway via activation of certain 
proteins, such as ATM, CHK2, ATR, BRCA2, RAD51, RAD50 (Yoshida and Miki, 
2004; Powell and Kachnic, 2003). 
Shen et al. (2017) have previously reported the positive correlation of NEAT1 
lncRNA associated proteins P54nrb and PSF protein and the level of c-Myc mRNA 
translation in stress condition, which is a transcription factor involved in the 
activation of the expression of BRCA1 (Chen et al 2011; Shen et al,2017). 
CDKN1A (p21cip1) belongs to the cyclin dependent kinase inhibitor (CDKI) family 
and inhibits cell-cycle progression by inhibiting CDK2 and CDK4 and by blocking 
DNA replication and repair by binding to PCNA (Harper et al., 1993; Cayrol et al., 
1998). This inhibitor of cell-cycle progression causes arrest at G1, S, and G2 
phases (Harper et al., 1993; Cayrol et al., 1998). CDKN2A also belongs to the 
CDKI family and known as cyclin-dependent kinase Inhibitor 2A (Soto et al, 2005). 
Its role as a tumour suppressor gene is well established.  The down-regulation of 
MKI67 observed suggests that down-regulation of NEAT1 lead to an increase in 
MDA-MB-231 cells entering the resting state (G0) since the gene product for 
MKI67 (Ki-67) encodes KI67, a cell marker linked to proliferation and is present in 
all stages of the cell cycle with the exception of the G0 stage (Gerdes et al, 1984). 
Both CCND2 (Cyclin D2) and CCND1 (Cyclin D1) are frequently deregulated in 
 cancer and are biomarkers of cancer phenotype and disease progression. The 
protein product of CCND2 and CCND1 are able to activate the cyclin- dependent 
kinases CDK4 and CDK6 mediating their oncogenic actions (Musgrove et al., 
2011). 
The results of RNA sequencing revealed changes in the same direction in some 
genes identified using the RT2 profiler arrays; however, the changes were not 
statistically significant due to the fact that the level of expression of NEAT1 was 
returning to its basal levels at the time of RNA collection. However, the RNA 
sequencing results have provided important information and showed that even a 
small decrease in the levels of NEAT1 expression results in changes in the 
expression of a number of genes involved in many cellular function. The reduction 
in NEAT1 expression levels resulted in the up-regulation of 67 genes. These 
differentially expressed genes might be direct targets of NEAT1 or targets of 
genes affected by NEAT1. For example, TP53I13 and were found to be up-
regulated. The expression of BRAT1 and TP53I13 are regulated by BRCA1 and 
TP53, respectively. It is therefore possible that NEAT1 down-regulation causes the 
increase in TP53 and BRCA1 levels, which in turn leads to an increase in the 
expression levels of their target genes. TP53I13 is reported to act as a tumour 
suppressor and its overexpression is known to inhibit tumour cell growth (Hata et 
al, 2004). The protein encoded by BRAT1 interacts with the BRCA1 and ATM 
(ataxia telangiectasia mutated) protein. ATM, BRCA1 and BRAT1 complex 
(BRCA1-associated genome surveillance complex) plays an important role in the 
cellular responses to DNA damage (Low et al, 2015; Aglipay et al, 2006). 
RNA sequencing results confirmed that NEAT1 functions as important cis and 
trans -acting modulator for the expression of protein-coding genes. Seven genes 
located on chromosome 11 were found to be up-regulated as a result of decrease 
 in NEAT1 transcript levels.  Two of these genes are located on 11q13.1 the same 
chromosomal band as NEAT1; one gene is located on 11q13.2. Another four of 
these genes are located on 11p15.5.  The other genes affected by NEAT1 are 
located on different genomic locations across the genome. These results confirm 
that NEAT1 controls gene expression and has an impact on its target genes in cis 
and in trans. Genes affected by NEAT1 down-regulation are implicated in a 
number of pathways with the most significant ones include galactose catabolism, 
tight junction and Fatty acid metabolism. Other pathways affected include systemic 
lupus erythematosus, viral carcinogenesis, AMPK and MAPK signalling, RNA 
degradation, VEGF signalling, DNA repair, central carbon metabolism in cancer , 
sphingolipid metabolism,  HIF-1 signalling pathway, Sphingolipid signalling 
pathway and cell cycle 
Overall, the results presented in this chapter confirm the modulatory effects of 
NEAT1 on gene expression.  The current study supports a role for NEAT1 in the 
regulation the expression of genes involved in regulating the cell cycle, 
proliferation and functions as tumour suppressors. The results also confirm that 
NEAT1 can act in cis to regulate the expression of nearby genes or in trans to 
regulate genes at other genomic locations across the genome. Since no changes 
were seen in the long isoform.  It is therefore possible that NEAT1 short isoform is 
the transcript involved in the regulation of gene expression. Further experiments 
are required to validate the effects of NEAT1 on the expression of the genes 
identified in the present work. 
 
 
 
 Chapter highlights 
1. NEAT1 down-regulation affects the expression of genes involved in 
the regulation of cell cycle checkpoints and promotes the expression 
of genes involved in the negative regulation of the cell cycle. 
 
2. NEAT1 down-regulation leads to increase in the expression of 
BRCA1, BRCA2, CDKN1A, CDKN2A and TP53.  
 
3. Decrease of the NEAT1 transcript levels resulted in the down-
regulation of the expression of CCND2, CCND1, CCNE1 and MKI67 
 
4. NEAT1 down-regulation has a significant impact on the regulation of 
a number of pathways including galactose catabolism, tight junction 
and fatty acid synthesis. 
 
5. The short isoform of NEAT1 may act in cis to regulate the expression 
of nearby genes or in trans to regulate genes at other genomic 
locations across the genome.  
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Chapter 6 
The role of the long non-coding 
RNA MIAT in breast cancer 
 6.1 Introduction 
In addition to NEAT1 and MALAT1, myocardial infarction associated transcript 
(MIAT) is another nuclear lncRNA localised to nuclear bodies. Many studies 
revealed the importance of MIAT in biological cell function and its crucial role in 
certain pathological conditions (Liao et al 2015; Vausort et al 2014; Yan et al. 
2015; Sattari et al.2016). For instance, Ishii et al. (2006) has reported a positive 
relationship between abnormal expression of MIAT and the incidence of 
myocardial infarction. The study has also found a single nucleotide polymorphism 
(SNP) in MIAT gene that leads to its abnormal transcription in patients with 
myocardial infarction (Ishii et al. 2006). Furthermore, MIAT is reported to be 
involved in microvascular regulation and in the control of pathways that are 
responsible for cell proliferation, migration and apoptosis of endothelial cells (Yan 
et al. 2015). MIAT is reported to act as a competing endogenous RNA (ceRNA) 
which is involved in a feedback loop with vascular endothelial growth factor 
(VEGF) and miR-150-5p to regulate endothelial cell function (Yan et al. 2015). 
Accordingly, in normal circumstances, MIAT binds to miRNA150-5p and supress 
its posttranscriptional effects on VEGF mRNA and hence regulating the process of 
endothelial angiogenesis (Yan et al. 2015). 
Recent studies have also implicated MIAT in cancer initiation and progression 
(Crea et al, 2016). MIAT was found to be upregulated in neuroendocrine prostate 
cancer (NEPC) and its up-regulation was associated with Polycomb genes, which 
play a key role in NEPC initiation and progression (Crea et al, 2016).  Moreover, 
MIAT  was suggested to act as a new biomarker for detecting the advance stages 
of chronic lymphocytic leukemia (CLL) (Sattari et al, 2016).  MIAT was found to be 
up-regulated in aggressive forms of CLL and was shown to form a regulatory loop 
 with Oct4 in malignant mature B cell where both molecules are essential for cell 
survival (Sattari et al., 2016).  Overall, these studies suggest an important role for 
MIAT in regulating the survival of some cancer cells. The evidence presented in 
Chapter 3 shows that MIAT is overexpressed in TNBC and suggests that MIAT 
could be implicated in breast cancer. Since the role of MIAT in breast cancer has 
not been investigated yet, the present study aimed to assess the functional effects 
of MIAT down-regulation on the survival of breast cancer cells. 
 
6.2  Materials and Methods 
6.2.1 RNA interference by siRNA  
MCF7 and MDA-MB-231 breast cancer cells were nucleofected with MIAT specific 
siRNAs as described in section 2.2.5. Details of MIAT specific siRNAs are 
presented in Table 2.3. 
 
6.2.2 Assessment of cell survival, apoptosis and cell cycle 
At 48h post transfection, cells were trypsinised and re-plated at 2x105 cells/well in 
6 well plates. Cell survival and apoptosis were determined at 24 h and 48 h post 
re-plating, as described in section 2.2.7.2 and 2.2.7.4.  Long-term survival of 
MCF7 and MDA-MB 231 was determined by counting the violet stained colonies 
that formed after 2-3 weeks of incubation (section 2.2.9).  Cell cycle profile was 
determined 24 h post re-plating according to the protocol described in section 
2.2.8 
 
. 
 6.2.3 Induction of cell death and cell survival assays  
The effect of UV-C irradiation was determined in MCF7 and MDA-MB-231 cells as 
explained in section 2.2.11. Long term survival was assessed by colony forming 
assay and the percentage of apoptosis was determined by flow cytometry and 
measurement of Annexin V (Section 2.2.7.4) at 24h and 48h post-UV irradiation.  
 For drug treatments, siRNA transfected MDA-MB231 cells were re-plated at a 
density of 0.8 x 105 cell/ml in 96 well plates and cultured for 20 h before being 
treated with different types of chemotherapy drugs as described in section 2.2.11. 
The growth inhibitory effect of chemotherapeutic drugs (the cytotoxicity effect) was 
determined at 24h and 48h of drug treatment using the MTS assay (CellTiter 96 
AQueous One Solution Cell Proliferation Assay) and calculated according to this 
equation: 
% of cytotoxicity= 100- [OD490 of treated sample / OD490 of untreated 
sample (vehicle)] x 100 
 
6.2.4 Real time RT-PCR (RT-qPCR) 
The expression levels of MIAT and Oct4 genes were determined using RT-qPCR.  
TaqMan gene expression assays (assay codes Hs99999901_m1 for 18S, 
Hs00402814_m1_for MIAT and Hs0004260367_gH for Oct4 (POU5F1) were 
employed with cDNA prepared by random hexamer priming, as described 
previously in Section 2.2.13. Input amounts of samples were calculated from their 
respective threshold cycle (CT) values, using standard curves generated with each 
assay. Data were expressed relative to 18S rRNA 
 
 6.2.5 Statistical analysis  
Data are presented as mean ± standard error of the mean (S.E.), where (n) 
represent the number of experiments. Statistical analysis was determined by 
Student’s t-test using the GraphPad 7 software. Two-sided P-values were 
calculated, and a probability level of less than 0.05 was chosen for statistical 
significance. 
 
6.3 Results 
6.3.1 The effects of MIAT silencing on the survival of MCF7 breast 
cancer cells 
To examine the effects of reduced MIAT expression on breast cancer cell survival, 
MIAT siRNAs were employed to silence endogenous MIAT expression in MCF7 
cell line; two different siRNAs were employed to reduce the likelihood of ‘off-target’ 
effects. The influence of MIAT silencing on MCF7 cell survival was examined 
under basal conditions and after apoptosis induction by UV.  
In MCF7 cells, siRNAs reduced MIAT transcript levels by up to 70-85% compared 
to control levels (Figure 6.1A). Oct4 is a transcriptional factor reported to promote 
MIAT expression. A positive correlation between MIAT and Oct4 expression levels 
have been reported (Sattari et al, 2016). Therefore, the effects of reduced MIAT 
expression levels on the expression of Oct4 were also determined. Down-
regulation of MIAT was found to be associated with a decrease in the expression 
levels Oct4. In MCF7 transfected cells, Oct4 transcript levels were found to be 70-
80% less than that of control (Figure 6.1B), indicating the positive relationship 
between MIAT and Oct4 expression. 
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MIAT down-regulation caused a small but significant elevation in the total cell 
number of MCF7 cells (Figure 6.2A) and a significant reduction in the number of 
viable cells as shown in Figure 6.2B.  Furthermore, the silencing effects of MIAT 
siRNAs was prominent in long term cell survival, in which there was a highly 
significant decrease in number of colonies formed as detected by long term 
clonogenic assay in Figure 6.2 C and 6.2 D. 
Figure 6.1 The effects of MIAT specific siRNAs on MIAT and OCT4 expression levels in 
MCF7 cells.  MIAT specific siRNAs (M2 and M3) and negative siRNA were nucleofected 
into MCF7 cells. RNA was isolated 72h post-transfection and qRT-PCR was performed. (A) 
Cellular MIAT expression using MIAT assay located at the position 1864. There was a 
highly significant (***P<0.01 and **P<0.01; n=4) down-regulation cells transfected with 
M2 and M3 siRNAs. (B) Expression profile of Oct4 in cells transfected with MIAT siRNAs. 
There was a significant (*P<0.05 and **P<0.01; n=4) decrease in expression level as 
compared to the negative control. (Unpaired t-test)  
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Figure 6.2 The effects of MIAT silencing on the survival of MCF7 cells. MCF7 Cells were 
transfected with negative siRNA or one of the MIAT siRNAs (M2 and M3 siRNAs) using 
nucleofection. Cell survival was assessed 48 h post re-plating.  Flow cytometry was used to 
determine cell number using Muse cell analyser and Muse Count & Viability Assay Kit. (A) 
Number of total MCF7 cells. There was a significant (*P<0.05; n=4) elevation in the total 
number of cells. (B) Number of viable MCF7 cells. There was a significant (*P<0.05; n=4) 
decrease in number of viable cells particularly in those cells transfect with M2 siRNA as 
compared with the negative control. (C) Long term survival. Number of colonies formed in 
long-term clonogenic assays, which showed a significant (*P<0.05 and **P<0.01 n=4) 
decrease for those cells transfected with M2 and M3 siRNAs respectively as compared 
with the negative control. (D) An example images of the clonogenic assay after crystal 
violet staining. (Unpaired t-test)    
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 MIAT down-regulation was also associated in a small but significant increase in 
the levels of basal apoptosis as in Figure 6.3. Together, these observations 
provide an evidence that MIAT regulate cell survival and its down-regulation 
produces growth inhibitory and pro-apoptotic effects on MCF7 breast cancer cells 
(Figure 6.3). 
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Figure 6.3 Effects of MIAT silencing on basal apoptosis in MCF7 cells.  MCF7 Cells were 
transfected with the negative siRNA or one of the MIAT siRNAs (M2 and M3 siRNAs) using 
nucleofection. 72h post-transfection, cells were harvested and re-plated in 6 well plates for a 
further assessment of apoptosis after 24 h.  Muse cell analyser and the Muse Annexin V and 
dead cell kit were used to measure basal apoptosis levels.  The results were compared with 
the negative control.  There was a highly significant (*P<0.01; n=4) increase in the percentage 
of apoptosis in cells transfected with M2 siRNA. Unpaired t-test with Welch’s correction.  
    
 
 Further experiments were carried out to investigate the effects of MIAT silencing 
on the cell cycle profile.  MIAT silencing was associated with an increase in the 
percentage of cells in G1 phase and a concomitant decrease in the percentage of 
cells in S and G2 phases, as illustrated in Figure 6.4 
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Figure 6.4 Effects of MIAT silencing on the cell cycle profile of MCF7 breast cancer cells.  
MCF7 cells were transfected with negative siRNA or one of the MIAT siRNAs (M2 and M3). Cell 
cycle analysis was performed using the Muse cell analyser and the Muse cell cycle kit, which 
involves quantifying DNA content by propidium iodide staining of fixed cells and fluorescence 
flow cytometry. There was a significant (*P<0.05 and ***P<0.001; n=4) elevation in the 
percentage of cells in G0/G1 phase and a significant decrease in percentage of cells in S phase.   
G2/M phase shows a significant (*P<0.05; n=4) reduction in cell ratio particularly those cells 
transfect by M3. (Unpaired t-test) 
 
 
 
 
 
    
 
 6.3.2 The effects of MIAT silencing on the survival of MDA-MB-
231 breast cancer cells 
The effects of MIAT silencing on the TNBC cells MDA-MB-231 were also 
investigated. Transfection of MDA-MB-231 with both MIAT specific siRNAs caused 
up to 6 fold decrease in the endogenous levels of MIAT compared to the cells 
transfected with negative siRNA (Figure 6.5 A).  Similar to MCF7 cells, this 
decrease in MIAT expression levels was associated with a decrease in the 
transcript levels of Oct4 (Figure 6.5 B).  
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Figure 6.5 Effects of MIAT specific siRNAs on MIAT and Oct4 gene expression in MDA-MB-
231 cells. MDA-MB-231 cells were nucleofected with the negative siRNA or one of the MIAT 
siRNAs (M2 and M3). RNA was isolated 72 h following transfection. (A) Cellular MIAT 
expression levels using MIAT assay that located at the position 1864. There was a significant 
(**P<0.01 n=4) down-regulation in cells transfected with M2 and M3 siRNAs. (B) Expression 
levels of Oct4. There was a significant (*P<0.05 and ***P<0.001; n=4) respectively decrease in 
expression level compared to the negative control. (Unpaired t-test) 
 
 The decrease in MIAT expression levels led to a small increase in total cell 
number which was significant with the cells transfected with M2 siRNA and a 
decrease in the number of viable cells (Figure 6.6 A and B) respectively.   MIAT 
silencing also caused a significant reduction in long term survival reflected by the 
decrease in the number of colonies in Figure 6.6 C. MIAT silencing also caused a 
slight but significant increase in basal apoptosis levels (Figure 6.7). 
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Figure 6.6 The effects of MIAT silencing on the survival of MDA-MB-231 cells. Cells were 
transfected with negative siRNA or one of the MIAT siRNAs. Total and viable cell numbers 
were determined using the Muse cell analyser with Muse Count & Viability Assay Kit. (A) The 
number of total MDA-MB 231 cells in which there was a slight but significant (*P<0.05; n=4) 
elevation in total cells. (B) The number of viable MDA-MB-231 cells where a significant 
(*P<0.05; n=4) decrease in number of viable cells in cells transfected with M2 and M3 
compared with the negative control. (C) Colony forming assay. There was a significant 
(***P<0.001 n=4) decrease in the number of colonies for cells transfected with M2 and M3 
siRNAs compared with the negative control. (D) An example image of clonogenic assay plates 
after crystal violet staining. (Unpaired t-test)    
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Analysing the cell cycle profile revealed that MIAT silencing caused an increase in 
the percentage of cells in G0/G1, which was not statistically significant (Figure 
6.8).However, a significant decrease in the cells in S and G2/M phase was 
observed in the cells transfected with MIAT siRNAs (Figure 6.8).  
  
 
Figure 6.7 The effects of MIAT down-regulation on basal apoptosis levels in MDA-MB-231 
cells.  MDA-MB-231 Cells were transfected with the negative siRNA or one of the MIAT siRNAs 
(M2 and M3 siRNAs).  Muse cell analyser using the Muse Annexin V and dead cell kit were 
used to measure the apoptosis levels.  The results were compared with the negative control.  
There was a highly significant (*P<0.01 and *P<0.05; n=4) increase in the percentage of 
apoptosis. Unpaired t-test with Welch’s correction. 
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6.3.3 The effects of MIAT silencing on UV- and chemotherapeutic 
drugs- induced cell death in breast cancer cells 
The previous results confirmed the importance of MIAT transcript levels in the 
control of cell fate. MIAT down-regulation is associated with a decrease in cell 
survival. The next set of experiments examined the effects of MIAT silencing on 
Figure 6.8 Effects of MIAT silencing on the cell cycle profile of MDA-MB-231 breast cancer 
cells.  MDA-MB-231 cells were transfected with negative siRNA or one of the MIAT siRNAs (M2 
and M3 siRNAs). Cells were harvested and re-plated for a further 24h for cell cycle analysis. 
Cell cycle analysis were performed by flow cytometry. There was a significant (*P<0.05 n=4) 
reduction in the percentage of cells in S phase and small but significant decrease in the 
percentage of cells in G2/M phase (*P<0.05; n=4). (Unpaired t-test) 
 the cell death induced by a number of apoptotic stimuli. Transfected cells were 
exposed to UV-C before being assessed for their ability to form colonies, which 
represents the most stringent test of cell viability. MIAT silencing enhanced the 
loss of long term survival induced by UV-C irradiation in MCF7 cells, as 
determined by long-term clonogenic assay (Figure 6.9 A and B).  Similar results 
were obtained with MDA-MB-231.  MIAT silencing in these cells enhanced the loss 
of long term survival induced by UV irradiation (Figure 6.10 A and B) respectively. 
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Figure 6.9 The effects of MIAT silencing on UV-induced cell death in MCF7 cells. MCF7 Cells 
were transfected with negative siRNA or one of the MIAT siRNAs (M2 and M3).  Transfected 
cells were exposed to UV-C irradiation for 20s at dose of 40J/M 2, before being plated for 
clonogenic assay and incubated at 37⁰C and 5% CO 2 for a further 20 days. The effect of UV-C 
irradiation was determined by calculating the percentage of growth inhibition in cell colony. 
(A) Shows the number of colonies, where UV irradiation causes a significant (*P<0.05) 
decrease as compared to the negative control. (B) Revealed the ratio of growth inhibition 
because of irradiation, in which UV irradiation causes a highly significant (**P<0.01) elevation 
in growth inhibition ratio as compared to the negative control.. (Unpaired t-test)   
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Further experiments were carried out to examine the effects of MIAT silencing on 
chemotherapeutic drug action in the TNBC cells MDA-MB-231. Transfected cells 
were treated with Docetaxel, 5-Floururacil (5-FL), Nutlin-3a or Mitoxantrone and 
cell survival was assessed using the MTS assay.  MIAT silencing enhanced the 
sensitivity to these drugs, especially for those cells transfected with M2 siRNA as 
revealed in (Figure 6.11). These results suggest that MIAT plays a crucial role in 
the impaired responses to chemotherapeutic drugs in breast cancer. 
 
 
Figure 6.10 The effects of MIAT silencing on UV-induced cell death in MDA-MB-231 cells. 
MDA-MB-231 Cells were transfected with negative siRNA or one of the MIAT siRNAs (M2 and 
M3).  Transfected cells were exposed to UV-C irradiation for 20s at dose of 40J/M 2 ,before 
being plated for clonogenic assays and incubated at 37⁰C and 5% CO 2 for a further 20 days. 
The effect of UV-C irradiation was determined by calculating the percentage of growth 
inhibition in cell colony. (A) Shows the number of colonies, where UV irradiation causes a 
significant (*P<0.05 and **P<0.01) decrease in number of colonies as compared to the 
negative control. (B) Revealed the ratio of growth inhibition because of irradiation, in which 
UV irradiation causes a significant (*P<0.05 and **P<0.01) elevation in growth inhibition ratio 
as compared to the negative control. (Unpaired t-test)    
  
N e
g a
t iv
e  M
2
M
3
0
1 0
2 0
3 0
4 0
%
 o
f 
g
ro
w
th
 in
h
ib
it
io
n
**
N e
g a
t iv
e  M
2
M
3
0
1 0
2 0
3 0
4 0
%
 o
f 
g
ro
w
th
 in
h
ib
it
io
n
**
*
N e
g a
t iv
e  M
2
M
3
0
1 0
2 0
3 0
4 0
%
 o
f 
g
ro
w
th
 in
h
ib
it
io
n
*
N e
g a
t iv
e  M
2
M
3
0
1 0
2 0
3 0
4 0
%
 o
f 
g
ro
w
th
 in
h
ib
it
io
n
**
N e
g a
t iv
e  M
2
M
3
0
1 0
2 0
3 0
4 0
%
 o
f 
g
ro
w
th
 in
h
ib
it
io
n
****
N e
g a
t iv
e  M
2
M
3
0
1 0
2 0
3 0
4 0
%
 o
f 
g
ro
w
th
 in
h
ib
it
io
n
*
N e
g a
t iv
e  M
2
M
3
0
1 0
2 0
3 0
%
 o
f 
g
ro
w
th
 in
h
ib
it
io
n
***
N e
g a
t iv
e  M
2
M
3
0
1 0
2 0
3 0
%
 o
f 
g
ro
w
th
 in
h
ib
it
io
n
*
     4 8 h
D o c e ta x e l
5 -F U
N u tlin -3 a
M ito x a n tro n
    2 4 h
D o c e ta x e l
5 -F U
N u tlin -3 a
M ito x a n tro n
A ) B )
C )
D )
E ) F )
G ) H )
 
 
 
 
 
 
Figure 6.11 The effects of MIAT reduced expression levels on chemotherapeutic drug-
induced death of TNBC cells.  MDA-MB231 cells were transfected with negative siRNA or one 
of the MIAT siRNAs (M2 and M3).  Transfected cells were harvested and a density of 0.8 x105 
cell/ml and cultured for a minimum 20h in 96 well plates. After that, cells were treated with 
Docetaxel (5 µM), 5-Fluorouracil (100 µM), Nutlin-3a (5 µM) and Mitoxantrone (50 µM) or 
vehicle (25% dimethyl sulphoxide). Cells were incubated in 37⁰ C and 5% of CO2 for a further 
24 and 48h.  Cell viability was assessed using the CellTiter 96® Aqueous One Solution Cell 
Proliferation Assay (MTS assay) and growth inhibition was calculated relative to the control in 
the absence of drug. There was a significant and highly significant (*P<0.05, **P<0.01, 
***P<0.001 and ****P<0.0001) elevation in growth inhibition after 24h and 48h of cell 
treatment. (Unpaired t-test). 
 6.4 Discussion 
The present study demonstrates, for the first time, that MIAT regulates the survival 
and proliferation of oestrogen receptor-positive breast cancer and TNBC cells. The 
study further demonstrates that reduction in MIAT expression is associated with an 
enhanced cell death in response to a range of apoptosis-inducing agents (UV-C 
irradiation, Docetaxel, 5-FU, Nutlin-3a and Mitoxantrone). The results described 
here confirm the positive correlation between the expression MIAT and Oct4 and 
suggest that MIAT regulates the expression of Oct4 pointing to the existence of 
MIAT and Oct4 axis that controls breast cancer cell fate. 
The results revealed that endogenous expression level of MIAT is of critical 
importance for the survival and growth of breast cancer cells. Modulation of the 
expression of MIAT was shown to cause significant and specific effects on the 
survival and proliferation of breast cancer cells. MIAT knockdown in both 
oestrogen receptor positive and TNBC cells was associated with the consistent 
and significant decrease in both short and long term viability and the increase in 
apoptosis levels in the absence of extracellular stimuli. Together, the data 
supports an important role for MIAT in maintaining the delicate balance between 
cell survival and cell death in breast cancer cells and points to an oncogene 
function for this lncRNA in breast cancer. 
 Oct4 is a transcription factor that contributes with MIAT in forming a regulatory 
feedback loop (Sattari et al, 2016; Mohamed et al, 2010; Nobili et al, 2017; Ghosal 
et al, 2013). The relationship between Oct4 and MIAT was first reported in mouse 
ES cells (Mohamed et al., 2010). Gomafu, the mouse homologue of MIAT, has 
been shown to bind to Oct4 gene leading to an increase in its expression and  
Oct4 was also find to bind  and positively regulates Gomafu transcription in mouse 
 ES cells, and thus, they both constitute a regulatory feedback loop (Mohamed et 
al, 2010). Sattari et al (2016) confirmed the existence of a regulatory feedback 
loop between MIAT and Oct4 in aggressive chronic lymphocytic leukaemia and 
that both molecules act on suppressing apoptotic cell death in malignant mature B 
cells. Oct4 overexpression increases the cell proliferation and inhibits the 
apoptosis in myeloid cell with mature B cell phenotype and in cancer stem cell-like 
cells. Oct4 down-regulation increases cell death and inhibits proliferation (Sattari 
et al, 2016; Hu et al, 2008; Wang et al, 2013). The present work also supports the 
existence of a MIAT and Oct4 axis involved in the regulation of breast cancer cell 
survival. It also confirms that MIAT regulates the expression of Oct4 and that both 
molecules are required for breast cancer cell survival. These observations are in 
agreement with a number of studies, which report the important role of MIAT in 
regulating the cell growth and proliferation (Sattari et al, 2016; Yan et al, 2015; 
Shen et al, 2016). MIAT lncRNA may act as a regulator of gene expression at 
transcriptional and post-transcriptional level (Yan et al, 2015). Besides its role as 
co-activator for Oct4 mRNA, MIAT lncRNA is considered as one of a ceRNA, 
where it forms a regulatory feedback loop with miRNA-150-5p and VEGF ( 
vascular endothelial factor) responsible for regulating the biological function of 
endothelial cells (Yan et al, 2015; Mohamed et al, 2010; Yi et al, 2017). Yan et al. 
(2015) also found that MIAT up-regulation leads to a suppression in miRNA-150-
5p (post transcriptionally regulatory factor) resulting in the overexpression of 
VEGF mRNA and hence promoting the angiogenesis (Yan et al, 2015). The 
increase in the basal apoptosis levels caused by the reduced levels of MIAT 
transcripts could be related to the inhibitory role of miRNA 150-5p which prevents 
the expression of AKT mRNA and hence decrease its anti-apoptotic effects (Shen 
et al, 2016). Shen et al (2016) have reported a relationship between AKT and 
 MIAT lncRNA and a role for both molecules in regulating the cell function in human 
lens epithelial cells (HLEC). The study confirmed that knockdown of MIAT in HLEC 
leads to growth inhibitory effects, which can be reversed by an injection of AKT 
activator (Shen et al, 2016).  Recent study has also implicated MIAT in the 
regulation of apoptosis in diabetic retinopathy (DR), a complication of diabetes 
mellitus (Zhang et al. 2017). Recent studies using high glucose stimulated rat 
retinal Müller cells have shown that activation of nuclear factor κB (NF-κB) 
promotes the expression of MIAT (Zhang et al., 2017). The increase in MIAT 
expression was associated with an increase in apoptosis. MIAT suppression 
reversed the high apoptosis induced by high glucose, indicating that MIAT 
suppression might serve as protectant in diabetic retinopathy (Zhang et al, 2017). 
Interestingly, the increase of MIAT expression in high glucose stimulated rat retinal 
Müller cells led to a decrease in the expression levels of miR-29b, a biomarker for 
Diabetic retinopathy. miR-29b regulates the expression of the transcription factor 
SP1 which is involved in PI3K/Akt/Sp1 pathway. The study showed that MIAT 
controlled the cell apoptosis in DR might be partly through absorbing miR-29b and 
inhibiting its function, meanwhile regulating the expression of SP1. Therefore, 
MIAT regulates apoptosis in diabetic retinopathy via a regulatory loop of NF-κB / 
MIAT/ miR-29b / Sp1 (Zhang et al. 2017; Yu et al. 2015).  
MIAT silencing affected the cell cycle profile of breast cancer cells. In MCF7 cells, 
there was an increase in the percentage of cells in G1 suggesting that more cells 
are arrested in G1 and prevented from entering the S and G2/M phases. In MDA-
MB-231, reduction in MIAT expression levels caused a decrease in the number of 
cells in S and G2/M phases but the elevation in G1 phase was not significant.  The 
effects of MIAT down-regulation on the cell cycle might be explained by the effects 
of MIAT silencing on the levels of Oct4. Down-regulation of Oct4 leads to the 
 activation of p21 protein, which regulates cell cycle progression at G1 and S phase 
(Lee et al, 2010). P21 protein is responsible for preventing the continuation of the 
cell cycle, and hence arresting the cells in G1 phase in embryonic stem cells (Lee 
et al, 2010). In addition, miRNA 150-5p overexpression is reported to lead cell 
cycle arrest and an increase in the rate of apoptosis in pancreatic cell cancer (Sun 
et al, 2013). MIAT lncRNA is a ceRNA that represses the miRNA 150-5p and 
therefore its down-regulation might lead to cell cycle arrest by the subsequent 
activation of miRNA150-5p. miRNA150-5p enhances apoptosis and regulates the 
expression of genes involved in the regulation of cell cycle (Sun et al, 2013). 
The consequences of reduced MIAT expression for breast cancer cell survival 
have also been addressed here.  The results demonstrate that reductions in MIAT 
expression are consistently associated with an enhanced cell death in response to 
a range of apoptosis-inducing agents (UV-C irradiation, Docetaxel, 5-Floururacil, 
Nutlin-3a and Mitoxantrone). Reduced MIAT expression enhanced growth 
inhibition induced by UV irradiation in oestrogen receptor-positive breast cancer 
and TNBC cells. TNBC cells transfected with one of the MIAT specific siRNAs (M2 
siRNA) enhanced the growth inhibition induced with the chemotherapy drugs.  
Thus, reduction in endogenous MIAT levels may enhance the responses of breast 
cancer cells to certain death-inducing stimuli, including conventional 
chemotherapeutic agents.  The effects of MIAT down-regulation on increasing the 
sensitivity of TNBC cells to chemotherapy drugs might be caused by the 
decreased levels of Oct4.  Overexpression of Oct4 promotes prostate cancer cells 
resistance against chemotherapy (Linn et al, 2010). At the same time, 
chemotherapy drugs play an important role as a repressor for Oct4 expression and 
hence increase the sensitivity of the cells by inhibition the emergence of drug 
resistance (Yang et al, 2012b).  The fact that only one MIAT siRNA caused an 
 enhanced response to chemotherapeutic drugs might be due to the fact that 
siRNA down-regulation of MIAT with the M3 siRNA lasted for a short time. 
Previous studies have reported that, for unknown reason, it is very difficult to 
silence MIAT with high efficiency using siRNAs (Mohamed et al, 2010). This was 
first showed in ES cell study (Mohamed et al, 2010) and later in malignant mature 
B cells (Sattari et al. 2016). Sattari et al (2016) reported up to 50% reduction in 
MIAT expression levels after repetition the transfection for three times. The study 
also reported an increased in apoptosis levels in the malignant B cells transfected 
with MIAT siRNAs.  Similar approach was used during the course of this study 
where transfection with MIAT siRNAs was repeated two times within a 24h 
interval. No difference in the extent of MIAT down-regulation was observed when 
compared to the cells transfected with MIAT siRNAs once.   Although further study 
by applying different approach for MIAT silencing is needed to further determine 
the functions of MIAT in breast cancer cell survival, the present study indicates 
that MIAT may play an oncogenic role in breast cancer.  
 
 
 
 
 
 
 
 
 Chapter highlights 
1. MIAT down-regulation suppresses the expression of Oct4 transcripts. 
2. MIAT down-regulation leads to the decrease in the short and long-term survival 
of oestrogen receptor-positive breast cancer and TNBC cells. These effects 
were associated with an increase in the rate of basal apoptosis levels. 
3. MIAT down-regulation enhances the response of oestrogen receptor-positive 
breast cancer and TNBC cells to UV-induced cell death. 
4. MIAT down-regulation increases the sensitivity of TNBC to chemotherapeutic 
drugs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7 
General Discussion and 
Concluding Remarks 
 Breast cancer is a heterogeneous disease characterised by abnormal growth in 
breast tissues. It represents the most common worldwide disease and the leading 
cause of death among women in less developed countries (Cancer, I.A.F.R.O, 
2013). The aetiology of breast cancer is attributed to a certain factors including 
hereditary, hormonal, reproductive in addition to environmental factors, like diet, 
life style, smoking and occupational exposure (Debruin and Josephy, 2002). 
Therefore, understanding these risk factors and their roles in genetic and 
epigenetic modulation might lead to establishing new methods for determining the 
prognostic and therapeutic biomarkers that play an important role in breast cancer 
management. Many studies have investigated the role of long noncoding RNAs 
(lncRNAs) in different types of cancer, including breast cancer (Su et al, 2014; 
Zhang et al, 2016 c; Jiang et al, 2016 a). LncRNAs are a major component of the 
human transcriptome and are increasingly recognised to play essential regulatory 
roles in essential biological processes and consequently their dysregulation may 
contribute in many human diseases, including cancer (Liz and Esteller, 2016). 
Indeed, many lncRNAs have been identified to play important role in cancer and it 
is now widely acknowledged that many more lncRNAs are likely to be of crucial 
importance in the pathogenesis of the disease. Therefore, gaining better insights 
into lncRNA biology may lead to better understanding to pathological 
characteristics and mechanisms and thereby provide novel opportunities for the 
diagnosis and treatment of this important disease. 
Of particular, interest in this regard, the two lncRNAs NEAT1 and MIAT, which are 
associated with sub-nuclear structures, with an increasing number of evidence 
implicating them in the pathogenetic mechanisms of different types of cancer. To 
illustrate these points, the work reported in this thesis focuses on the role of these 
two lncRNAs in breast cancer. 
 7.1The role of Nuclear enriched abundant transcript 1 
(NEAT1) in breast cancer 
7.1.1 Expression of NEAT1 in breast cancer  
NEAT1 is encoded by gene located on chromosome 11q13.1. It is a nuclear-
restricted lncRNA where it constitutes the essential structural element of the 
paraspeckles, sub-nuclear domains implicated in mRNA nuclear retention 
(Hutchinson et al, 2007; Bond and Fox, 2009). The role of NEAT1 in cancer has 
been controversial with some studies reporting an oncogenic role and others 
suggesting that NEAT1 is a tumour suppressor. However, many studies confirmed 
that NEAT1 is overexpressed in different types of human cancers and its high 
expression in the cancerous tissues is shown to be associated with prognosis and 
overall survival in a number of cancers (Adriaens, 2016; Chakravarty et al, 2014; 
Choudhry et al, 2015).  
According to comprehensive gene expression studies, the expression level of 
lncRNAs is characterised to be tissue- and disease- specific and lower than 
protein coding genes (Derrien et al, 2012). Such patterns of tissue- and disease- 
specific expression made many lncRNAs potential candidates to be used as 
diagnostic and prognostic biomarkers and for monitoring therapeutic responses 
(Fu et al, 2016; Malih et al, 2016). HOTAIR, H19 and KCNQ1OT1 lncRNAs have 
been considered as important biomarkers in breast cancer diagnosis. HOTAIR and 
H19 are reported to show high expression levels in invasive carcinoma (IC) rather 
than ductal carcinoma in situ (DCIS), while HOTAIR and KCNQ1 Opposite 
Strand/Antisense Transcript 1 (KCNQ1OT1) lncRNAs show high expression in 
tumour cells (IC) (Zhang et al, 2015). The current study confirms that NEAT1 is 
overexpressed in human breast cancer. While previous studies have reported an 
 increased in NEAT1 expression levels in different types of tumours (Qian et 
al, 2016; Choudhry et al,2015; Adriaens et al, 2016), the current study reveals for 
the first time that the expression patterns of the long and short isoforms of NEAT1 
isoforms differ in breast cancer. NEAT1_1 short isoform was found to be 
significantly up-regulated in breast cancer and its expression was specifically 
elevated in advance stages of breast cancer and in ER, PR +ve, HER –ve 
molecular subtype. On the other hand, the expression levels of NEAT1 long 
isoform were found to be slightly decreased in all the stages, such decrease in the 
levels of NEAT1_2 was statistically insignificant apart from the levels in TNBC 
where the decrease was found to be significant.   
Variation in the expression of NEAT1 isoforms has been reported previously and 
studies have shown that the expression of these isoforms is cell specific 
(Nakagawa et al, 2011). The short isoform NEAT1 _1 is widely and ubiquitously 
expressed, whereas the expression profile of NEAT1 _2 is found to be restricted to 
a sub-population of cells originated from certain tissues such intestinal epithelium 
(Nakagawa et al, 2011). In addition, Chai et al. (2016) reported that HuR, an RNA 
binding protein and miR-124-3p are responsible for regulation of NEAT1_1 
expression and stability in ovarian cancer (Chai et al, 2016). Evidence suggests 
that HuR promotes ovarian cancer cells growth and invasion by enhancing the 
overexpression of NEAT1 _1, whilst miR-124-3p suppresses the expression of 
NEAT1 _1 leading to the inhibition of ovarian cancer cell growth (Chai et al, 2016). 
Additionally, an oncogenic role of NEAT1 in colorectal cancer has also been 
reported (Wu et al, 2015). NEAT1_1 was found to be overexpressed in advanced 
stages and in metastatic tissues (Wu et al, 2015). Overexpression of NEAT1 _1 is 
also associated with poor prognosis because of its role in enhancing cell growth 
and invasion (Wu et al, 2015; Li et al, 2017b).   
  Interestingly, NEAT1_1 overexpression was found to be highly predominant in 
samples from breast cancer with the molecular subtype ER, PR +ve and HER -ve 
and down-regulated in triple negative cells. Such observations might be related to 
the effects of oestrogen receptor overexpression in this molecular subtype of 
breast cancer, particularly ERα, which regulates the expression of different genes 
in breast cancer including the expression of NEAT1 (Chakravarty et al, 2014). ERα 
also regulates NEAT1 expression in prostate cancer (Chakravarty et al, 2014; 
Romano et al, 2010; Lin et al, 2004). ERα-dependent NEAT1 overexpression 
leads to the chromatin modification, which is responsible for guiding NEAT1 
transcripts to the promoting sites and activating the expression of target genes 
(Chakravarty et al, 2014).  
MALAT1/NEAT2 is located approximately 55 kb from NEAT1. MALAT1 is 
implicated in the pathology of many cancers including lung cancer (Ji et al, 2003).  
MALAT1 is overexpressed in different types of solid tumours such as lung, breast, 
colon, hepatocarcinoma, pancreatic and prostate cancer and its overexpression 
has been shown to increase cell proliferation and promotes invasion and 
metastasis (Tripathi et al, 2013; Meseure et al, 2016;   Ma et al, 2015). Abnormal 
expression of MALAT1 affects the alternative splicing of pre-mRNA leading to an 
aberrant expression of genes that are responsible for cell cycle regulation, thereby 
enhancing the proliferation of tumour cells (Tripathi et al, 2013). The present work 
also showed that MALAT1 expression is elevated in breast cancer samples and 
such increase was found significant in the ER,PR +ve and HER –ve breast cancer 
molecular subtype. MALAT1 is also an oestrogen dependent transcript and its 
expression in breast and prostate cancer is regulated by oestrogen receptors 
namely ERα / ERβ, respectively (Aiello et al, 2016). This explains the increased 
expression of MALAT1 in this molecular subtype of breast cancer. The present 
 study also showed that the expression of MALAT1 in breast cancer samples 
correlated positively with NEAT1 expression. Evidence of positive correlation 
between the expression of NEAT1 and MALAT1 has been reported previously 
(Naganuma and Hirose, 2013; Nakagawa et al, 2012).  Such correlation between 
the expression of the two genes suggests that coordinate dysregulation of these 
two lncRNAs might play an important role in cancer. Their differential expression 
according to breast cancer stages and molecular subtypes indicates that these two 
lncRNAs could potentially be used as markers for prognosis prediction and 
targeted therapy of breast cancer. 
 
7.1.2 Effects of modulation of NEAT1 expression levels on breast 
cancer cell survival 
One of the aims of the current study was to investigate the effects of NEAT1 
silencing on the survival of breast cancer cells. Lipid polymers mediated 
transfection of NEAT1 specific siRNAs into MCF7 cells led to an unexpected 
increase in the expression levels of both NEAT1 isoforms. Further experiments 
revealed that NEAT1 siRNAs delivered using the lipid polymers were effective in 
silencing the cytoplasmic NEAT1 transcripts and in increasing the expression 
levels of nuclear NEAT1. These results demonstrated that cellular NEAT1 
transcripts reside in the cytoplasm and nucleus and suggested that the 
cytoplasmic NEAT1 transcript might exert negative feedback on the expression of 
nuclear NEAT1. Therefore, a decrease in the expression of cytoplasmic NEAT1 
was associated with an increase in the expression levels of the nuclear NEAT1. 
The increase in the expression of nuclear NEAT1 resulted in an increase in short 
and long-term survival and a decrease in apoptosis. Such observations suggested 
 that NEAT1 might function as an oncogene. Nucleofection mediated delivery of 
NEAT1 siRNAs resulted in down-regulation of NEAT1 transcript levels. The 
reduced level of NEAT1 transcripts was associated with decreased short and long-
term viability. Reduction in NEAT1 endogenous levels altered the cell cycle and 
inhibited cell migration of both triple-negative and oestrogen receptor-positive 
cells, confirming the oncogenic role of NEAT1 in these cells. ASOs mediated 
silencing confirmed these observations and provided further evidence that NEAT1 
is required for survival in these breast cancer cells.  
A number of studies have confirmed the oncogenic role of NEAT1 and reported 
the effects of NEAT1 overexpression in promoting cell proliferation and 
suppression of apoptosis (Ma et al, 2016; Xiong et al,2017; Yu et al, 2017; Ke et 
al, 2016; Peng et al, 2016). Studies have also reported the effects of NEAT1 
down-regulation on inhibition cell growth and survival (Ke et al, 2016; Lo et al, 
2016a). The oncogenic property of NEAT1 might be attributed to its role as 
transcriptional regulator. NEAT1 accumulates at the chromatin site of target genes 
and causes epigenetic modification, which in turn leads to overexpression of these 
genes, as reported in prostate cancer (Chakravarty et al, 2014). The other 
possible explanation of NEAT1 effects might be due to its property as competing 
endogenous RNA (ceRNA) which acts as a sponge for miR-377-3p leading to up- 
upregulation of  the E2F3 gene in non-small cell lung cancer (NSCLC) and hence 
increases the activity of E2F3 signalling pathway, which is responsible for 
promoting cell proliferation (Sun et al, 2016). Additionally, Wang et al, (2016) 
found a regulatory NEAT1/miR-107/CDK6 loop which stimulates cell proliferation 
in laryngeal squamous cell carcinoma (Wang et al, 2016).  NEAT1 in these cells 
causes suppression to miR-107 and enhances the activity of CDK6 that leads to 
cell cycle progression (Wang et al., 2016b).  
 Down-regulation of NEAT1 led to a significant decrease in the short and long term 
survival of TNBC cancer cells. Such effects might be related to the positive 
correlation of NEAT1 lncRNA with the activation of PI(3)K/AKT pathway, which is 
found to be highly activated in basal-like breast tumours  (Chin et al, 2013). 
Activation of PI3K/AKT pathway promotes survival and increase cell proliferation 
and migration.  Peng et al. (2016) reported a direct relation between AKT kinase 
pathway and NEAT1 expression in colorectal cancer (Peng et al, 2016). In which, 
downregulation of NEAT1 leads to inactivation of AKT kinase pathway that has a 
direct impact on the cell cycle, cell survival and apoptosis (Peng et al, 2016; Chin 
et al, 2013). 
Reduced transcripts levels of NEAT1 led to an alteration in the cell cycle profile of 
breast cancer cells. The effects of NEAT1 down-regulation on the expression of 
some genes involved in the regulation of cell cycle as shown in Chapter 5, might 
be responsible for the alteration of cell cycle profile. Reduced NEAT1 levels 
supressed the expression of cell cycle positive regulators and increased the 
expression of genes involved in the negative regulation of cell cycle. Negative 
regulator of cell cycle cause arresting of the cells in G1 phase and prevent cell 
cycle progression to S phase (Yang et al, 2017b; Wang et al, 2016 ; Li et al, 2016; 
Li et al, 2017a).   
Reduced levels of NEAT1 expression were associated with a decrease in 
migration ability of the cells and a reduction in levels of MALAT1 expression. The 
reduction in MALAT1 expression supports the finding in chapter 3 where positive 
correlation was found between NEAT1 and MALAT1 in breast cancer samples. 
The effects of NEAT1 silencing on migration could be attributed to the low 
expression of MALAT1. MALAT1 promotes the migration of cancerous cells, a fact 
confirmed by Gutschner (2013). In addition, Song et al, (2017) confirmed the role 
 of NEAT1 in promoting cell invasion and migration in colorectal cancer. Increased 
levels of NEAT1 lead to the suppression of miR-662 and hence overexpression of 
Zinc finger E-box-binding homeobox 2 (ZEB2), a transcription protein that involved 
in epithelial-mesenchymal transition process (Song et al, 2017).  
The current study investigated the consequences of reduced NEAT1 expression 
levels on cell death induced by a number of apoptotic stimuli. Reduction in NEAT1 
expression levels is consistently associated with an increased cell death in 
response to a range of apoptosis agents including UV-C irradiation, Docetaxel 
(anti-mitotic drug), 5-FU (antimetabolite that prevent DNA synthesis), Nutlin-3a 
(Mdm2 antagonist) and Mitoxantrone (antitumor antibiotic, a cell cycle specific 
drug) (Longley et al, 2003; Herbst and Khuri, 2003; Tabe et al., 2009; Fox, 2004).     
Down-regulation of NEAT1 enhanced the breast cancer cells response to UV-
induced cell death and such response was associated with a significant increase 
in the expression levels of pro-apoptotic gene BAD. Reduced expression of 
NEAT1 had positive impact upon the responses of breast cancer cells to some of 
these conventional therapeutic agents, which could explain why NEAT1 
overexpression is associated with poor prognosis in cancer patients (Yang et al, 
2017a).  Future experiments are required to study the effects of NEAT1 down-
regulation on the breast cancer cell response to PI3K/mTOR inhibitors since 
NEAT1 is reported to be involved in the activation of PI(3)K/AKT pathway ( Zhu et 
al, 2008).   
Overall the present study support an important role for NEAT1 in the control of 
breast cancer cell survival and suggests that NEAT1 may act as an oncogene in 
breast cancer cells.  
 
 7.1.3 Effects of NEAT1 on gene expression 
Two strategies were used to investigate the effects of NEAT1 silencing on breast 
cancer cell gene expression. Breast Cancer and Cell Cycle RT2 Profiler™ PCR 
arrays were used to investigate the effects of NEAT1 silencing on the genes 
involved in cell cycle regulation and breast cancer. RNA sequencing was also 
used to study the effects of NEAT1 silencing on global gene expression in breast 
cancer cells.   
NEAT1 silencing has resulted in the change of expression of a number of genes 
involved in the control of cell cycle and breast cancer. Interestingly, the reduction 
in NEAT1 expression level affected the expression of genes involved in the 
regulation of cell cycle checkpoints and enhanced the expression of genes 
involved in the negative regulation of the cell cycle. These genes include BRCA1, 
BRCA2, CDKN1A, CDKN2A and TP53.  BRCA1, BRCA2 and TP53 are among six 
genes that confer a high risk for hereditary breast cancer. The others are PTEN, 
CDH1, and STK11. Germline mutations in these genes are the most common 
known causes of hereditary breast cancer (Walsh et al, 2006). BRCA1 and 
BRCA2 play important role in the regulation of transcription, DNA damage repair 
and recombination, control of cell cycle checkpoint apoptosis (Yoshida and Miki, 
2004; Powell and Kachnic,  2003 ). A signalling pathway involving 
BRCA1/NEAT1/miR-129-5p/WNT4 is important in breast cancer initiation (Lo et al, 
2016b). BRCA1 deficient cells induce the expression of NEAT1 and this supress 
the activity of miR-129-5p by DNA methylation at the CpG Island in miR-129 
genes. Down-regulation of miR-129-5p leads to upregulation of WNT4 which 
stimulates the oncogenic WNT pathway (Lo et al, 2016b). At the same time, 
overexpression of BRCA1 leads to co-activation of the Tp53-mediated gene 
 expression like p21 and GADD45 that contribute to the inhibition of  the cell cycle 
progression (MacLachlan et al, 2002; Yoshida and Miki, 2004).   
TP53 is a tumour suppressor that plays an essential role in the cellular response 
to DNA damage and in the induction of apoptosis, cell cycle arrest and DNA repair 
(Vogelstein et al, 2000; Isik et al, 2014). The fact that down-regulation of NEAT1 
leads to the overexpression of such important tumour suppressor genes provides 
further evidence about the importance of NEAT1 in the pathogenesis of breast 
cancer. Up-regulation of CDKN1A and CDKN2A expression in cell with reduced 
NEAT1 levels provides evidence that NEAT1 is involved in the regulation of cell 
cycle and cell proliferation. CDKN1A and CDKN2A are cyclin dependent kinase 
inhibitors. The sequential activation of cyclin and cyclin dependent kinases 
complexes controls the transition from phase G1 to the phase S of the cell cycle 
(Ekholm and Reed, 2000). These complexes phosphorylate and inactivate the 
negative regulators of G1 transition into S phase such as members of the 
retinoblastoma protein (Rb) family. The inactivation of Rb protein results in the 
induction of E2F (E2 factor)-regulated gene expression and cell proliferation. 
CDKN1A and CDKN2A binds and inhibits the function of these complexes leading 
to the inhibition of progression from G1 to S phase (Ekholm and Reed, 2000).   
One the other hand, decrease of the NEAT1 transcript levels led to the down-
regulation of the expression of CCND2, CCND1, CCNE1 and MKI67. CCND1 and 
CCND2 belong to the D-type cyclin family (Patil et al, 2009). Both genes play 
important role in promoting the cell transition from G1 to S phase (Patil et al, 
2009). Cyclin E, the protein encoded by CCNE1, is the main regulator for transition 
from G1 to S phase. CCNE1 is a known oncogene in many types of cancer and 
has been associated with gene amplifications in various types of malignancies 
(Pils et al, 2014). The protein encoded by MKI67, Ki67, is a marker of cell 
 proliferation.  Therefore, the decrease in the expression of these genes further 
supports a role for NEAT1 in increasing cell proliferation and survival.  
RNA sequencing provided interesting information on the role of NEAT1 in the 
regulation of gene expression despite the fact that the levels of NEAT1 were 
reduced by only 35% at the time of RNA collection. Tumour suppressor genes 
were found up-regulated as a result of reduced NEAT1 levels. These include 
Interferon-Stimulated Gene 15 (ISG15), Tumour Suppressing Subtransferable 
Candidate (TSSC4) and Tumor Protein P53 Inducible Protein 13 (TP53I13). 
BRCA1 Associated ATM Activator 1 (BRAT1), which is involved in DNA damage 
response was also found to be up-regulated.  A number of genes involved in the 
regulation of immune response, systemic lupus erythematosus and viral 
carcinogenesis were also up-regulated. A functional role of NEAT1 in controlling 
the innate immune response to viral and microbial infection have already been 
reported. NEAT1 expression is induced in HIV-1 infected T cells as well as 
influenza virus and herpes simplex virus infected epithelial cells (Geng et al, 
2016). NEAT1 down-regulation affected genes involved in galactose catabolism, 
tight junction, fatty acid sphingolipid metabolism. Previous studies have supported 
a role for NEAT1 in PPARγ2 splicing during adipogenesis (Chen, 2016). Most 
importantly, the RNA sequencing data has confirmed that the short isoform of 
NEAT1 may act in cis to regulate the expression of nearby genes or in trans to 
regulate genes at other genomic locations across the genome. 
While ASOs were effective at causing more than 75% silencing of NEAT1 
endogenous levels (Southwell et al, 2014), the RNA sequencing results confirmed 
that unlike the siRNAs, the silencing effects of these ASOs were short lived. 
Challenges in silencing lncRNAs have been previously reported due to their 
varying subcellular localisations, with some residing predominantly in the nucleus, 
 the cytoplasm or in both compartments. siRNAs have been successfully used to 
silence cytoplasmic lncRNAs. Their ability to silence nuclear lncRNAs is largely 
dependent on the method of transfection as shown in chapter 3. The work 
presented in chapter 3 showed that nucleofection of siRNAs resulted in the 
silencing of NEAT1 levels. NEAT1 specific ASOs also down-regulated NEAT1 
endogenous levels but their effects appeared to be short lived with the NEAT1 
levels recovered by the time the RNA was collected for sequencing.  The use of 
antisense LNA™ GapmeRs would have been more efficient at silencing NEAT1. 
GapmeRs are recommended as an excellent alternative to siRNA for silencing 
nuclear lncRNAs and are taken up by the cells without transfection reagents 
(Watts and Corey, 2012). Combining Antisense LNA™ GapmeRs and siRNA 
reagents have also been shown to have additive effects for the lncRNAs present in 
both nuclear and cytoplasmic compartments (Lennox and Behlke, 2015) .  
Overall, the results presented in chapter 3 confirm that the expression of NEAT1 
short isoform is elevated in breast cancer. Chapter 4 provides evidence that 
NEAT1 plays an important role in the regulation of breast cancer cell fate. The 
results confirmed that reduced level of NEAT1 is associated with loss of short and 
term survival and an increase in basal apoptosis in TNBC cells.  The data 
presented in Chapter 5 indicate that NEAT1 regulates gene expression in breast 
cancer cells. Collectively the results suggest that NEAT1 plays a critical role in 
various cellular functions and the process of breast cancer.  A recent study based 
on 560 whole- human genome sequences has identified NEAT1 as one of the 
genes that carries driver mutations in breast cancer (Nik-Zainal et al, 2016). These 
findings, together with the evidence presented in this thesis further highlight the 
importance of NEAT1 in the pathogenesis of breast cancer. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
 7.2 The role of Myocardial infarction associated 
transcript (MIAT) in breast cancer 
MIAT gene is mapped to human chromosome 22q12.1. The gene consists of 5 
exons and highly expressed in the nervous system and retinal tissues (Sone et al, 
2007; Sattari et al, 2016). The clinical importance of MIAT was highlighted by its 
association with the susceptibility to myocardial infarction (Ishii et al, 2006; Liao et 
al, 2016). Evidence implicating MIAT in cancer is now emerging. Recent studies 
reported an increase in MIAT expression levels in neuroendocrine prostate cancer,  
an androgen receptor (AR)-negative metastatic neoplasm (Crea et al.,2016) and in 
an aggressive form of chronic lymphocytic leukemia (CLL) (Sattari et al, 2016).  
The work in Chapter 6 aimed to investigate the role of MIAT in breast cancer. 
Initial studies reported in Chapter 3 involved the analysis of MIAT expression level 
in the breast cancer samples suggested that MIAT might be down-regulated in 
stages III-IV of the disease and its level showed a significant increase in TNBC 
samples. Similar to neuroendocrine prostate cancer where MIAT is up-regulated, 
TNBC is characterised by negative endocrine receptors and is highly metastatic 
with poor prognosis (Zhang et al, 2012). Jin et al. (2017) reported positive 
correlation between tumour necrosis factor (TNFα), a pro-inflammatory cytokine 
that promote tumour growth, and MIAT in osteogenic differentiation of human 
adipose-derived stem cells (Jin et al, 2017). However, further experiments are 
required to confirm the increase of MIAT levels in TNBC due to the small sample 
size. Some samples in stage I and II showed high expression of MIAT, therefore a 
correlation analysis between the expression of MIAT and NEAT1 short and long 
isoforms was carried out. The results showed a positive correlation between the 
expression of both NEAT1 isoforms and MIAT. Such observations might due to the 
 effects of MIAT on promoting the expression of Oct4. An Oct4/NEAT1/MALAT1 
axis has been reported in lung cancer where Oct4 promotes and enhances the 
expression of NEAT1 and MALAT1 lncRNAs via Oct4/NEAT1/MALAT1 pathway 
(Nobili et al, 2017; Jen et al, 2017). Oct4 is overexpressed in MDA-MB-231 cells 
and therefore it might promote the expression of NEAT1/MALAT1 in TNBC (Ling 
et al, 2012).  
Nucleofection of MIAT specific siRNAs into MCF7 and MDA-MB-231 resulted in 
significant decrease in MIAT expression levels. The decrease in MIAT expression 
levels was associated with a decrease in Oct4 levels, in agreement with other 
studies in other cell types.  Such positive correlation between the expression of 
Oct4 and MIAT has been reported previously in aggressive CLL (Sattari et al, 
2016; Mohamed et al, 2010). Both genes are up-regulated in CLL and are 
essential for the survival and apoptosis resistance of these cells.  
Down-regulation of MIAT resulted in an increase in basal apoptosis and a 
decrease in short and long term survival of breast cancer cells. These 
observations suggest that MIAT plays important role in promoting cell survival and 
proliferation, as shown in CLL and neuroendocrine prostate cancer (Sattari et 
al.2016; Yan et al. 2015; Shen et al. 2016). MIAT is reported to regulate gene 
expression at transcriptional and post-transcriptional levels (Yan et al, 2015). 
Besides its role as co-activator for Oct4 mRNA, MIAT is considered as one of a 
competing endogenous RNA (ceRNA), where it form a regulatory feedback loop 
with miRNA-150-5p and vascular endothelial factor (VEGF) which is responsible 
for regulating the biological function of endothelial cell  (Yan et al. 2015; Mohamed 
et al. 2010; Yi et al. 2017). Yan et al. (2015) found that up-regulation of MIAT 
suppresses miRNA-150-5 which results in overexpression of VEGF mRNA and 
hence promoting angiogenesis.  
 MIAT silencing altered the cell cycle profile and caused an increase in percentage 
of cells in G1 phase and a subsequent decrease in the cells in G2/M phase. These 
observations might be due to the fact that reduced MIAT expression level is 
associated with decreased levels of Oct4. Suppression of Oct4 expression leads 
to the activation of p21 protein, a cell cycle regulatory protein at G1/S phase (Lee 
et al, 2010).  Active p21 inhibits cell cycle progression leading to the arrest of cells 
in G1 phase (Lee et al, 2010). In addition, the inhibitory effects of MIAT on the cell 
cycle progress might be mediated by miRNA150-5p. The decrease in MIAT 
expression leads to the increase in the levels of miRNA150-5p which results in the 
inactivation of genes involved in the progression of cell cycle (Bueno and 
Malumbres, 2011).  
Reduced levels of MIAT lncRNA enhanced cell growth inhibition induced by UV-C 
irradiation in breast cancer cells and chemotherapeutic drugs such as Docetaxel, 
5-FU, Nutlin-3a and Mitoxantrone.  The diverse nature of the apoptotic stimuli 
affected by MIAT silencing in TNBC cells which include the DNA damaging agent 
(UV-C irradiation), an MDM2 inhibitor (Nutlin-3a), a microtubule stabilising agent 
(Docetaxel) and a topoisomerase II inhibitor/DNA intercalating agent 
(Mitoxantrone), indicates that MIAT is involved in a late and common step of 
activation the apoptotic machinery by these cell death stimuli.  
Overall, the results indicate that the lncRNA MIAT is involved in breast cancer and 
is required for cell survival. Reduced levels of MIAT result in the loss of survival 
and the increase in basal apoptosis, suggesting that MIAT may act as an 
oncogene. In agreement with these findings, Luan et al. (2017) reported that MIAT 
expression is increased in breast cancer cell lines and advanced breast tumours 
and its overexpression is associated with TNM stage and lymph node metastasis. 
Consistent with the data presented in Chapter 6, Luan et al. (2017) showed that 
 reduced levels of MIAT promoted breast cancer cell apoptosis and inhibited cell 
proliferation, migration, and in vivo tumour growth (Luan et al, 2017). Future 
studies will be required to investigate the mechanism (s) by which MIAT regulates 
cell survival and its potential use as biomarker and specific therapeutic target. 
 
7.3 Concluding remarks   
The work presented in this thesis show that NEAT1 and MIAT lncRNAs are key 
regulators of breast cell survival. Future work should explore the effects of NEAT1 
and MIAT silencing on the breast cancer cell response to PI3K/mTOR inhibitors 
and other agents used in the management of breast cancer. Different approaches 
to silence the two lncRNAs should be also explored such as CRISPR-Cas9 
genome editing and antisense LNA™ GapmeRs. Both approaches are 
recommended for silencing nuclear lncRNAs. Future work should also involve the 
identification of the proteins that directly interact with them. This will provide better 
understanding of their functions and an insight into their molecular mechanisms. 
The direct interacting proteins of each lncRNA can be identified using RNA 
antisense purification with mass spectrometry (RAP-MS) (Rinn and Ule, 2014; Chu 
et al, 2015; Yang et al, 2015). The method involves crosslinking cells through 
ultraviolet irradiation to fix endogenous RNA-protein complexes. RNA protein 
complexes are then purified through hybrid capture with biotinylated antisense 
oligonucleotides and proteins that interact with the target RNA can be identified by 
quantitative mass spectrometry. An alternative approach to identify the interacting 
proteins could be the use of protein microarrays, which have been recently used to 
identify the binding of proteins with a specific RNA in vitro (Siprashvili et al, 2012). 
 
 Other recent work has supported these findings and identified several other 
lncRNAs that act in the same or opposite direction to control cell fate in breast 
cells. These include the oncogenes HOTAIR, XIST, MALAT and H19 and the 
tumour suppressor GAS5 (Reviewed by Cerk et al, 2016). Together these findings 
highlight the importance of lncRNAs in breast cancer and demonstrate that 
lncRNAs can regulate cell proliferation and cell survival by suppressing or 
promoting cell death, suggesting a key role for these molecular regulators. 
Therefore, better understanding of the functions of these lncRNAs and the 
mechanisms by which such lncRNAs regulate cell death and survival will 
undoubtedly aid in the development of optimised breast cancer therapies in the 
future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
                              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
 
 ADRIAENS, C. & MARINE, J.-C. 2017. NEAT1-containing Paraspeckles: central 
hubs in stress response and tumor formation. Cell Cycle, 16, 137-138. 
 
ADRIAENS, C., STANDAERT, L., BARRA, J., LATIL, M., VERFAILLIE, A., 
KALEV, P., BOECKX, B., WIJNHOVEN, P. W., RADAELLI, E. & VERMI, W. 2016. 
p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate 
replication stress response and chemosensitivity. Nature Medicine. 
 
AGLIPAY, J. A., MARTIN, S. A., TAWARA, H., LEE, S. W. & OUCHI, T. 2006. 
ATM activation by ionizing radiation requires BRCA1-associated BAAT1. Journal 
of Biological Chemistry, 281, 9710-9718. 
 
AIELLO, A., BACCI, L., RE, A., RIPOLI, C., PIERCONTI, F., PINTO, F., MASETTI, 
R., GRASSI, C., GAETANO, C. & BASSI, P. F. 2016. MALAT1 and HOTAIR Long 
Non-Coding RNAs Play Opposite Role in Estrogen-Mediated Transcriptional 
Regulation in Prostate Cancer Cells. Scientific Reports, 6. 
 
ALUIGI, M., FOGLI, M., CURTI, A., ISIDORI, A., GRUPPIONI, E., CHIODONI, C., 
COLOMBO, M. P., VERSURA, P., D'ERRICO‐GRIGIONI, A. & FERRI, E. 2006. 
Nucleofection is an efficient non-viral transfection technique for human bone 
marrow–derived mesenchymal stem cells. Stem cells, 24, 454-461. 
 
AMARAL, P. P. & MATTICK, J. S. 2008. Noncoding RNA in development. 
Mammalian Genome, 19, 454-492. 
 
AMBION 2007a. silencer® Negative Control ,#1 siRNA,  Applied Biosystems. 
http://tools.lifetechnologies.com/content/sfs/manuals/sp_4635.pdf. 
 
AMBION, I. 2007b. silencer® Negative Control ,#1 siRNA, Applied Biosystems  
http://tools.lifetechnologies.com/content/sfs/manuals/sp_4635.pdf [Accessed]. 
 
AMIT, I., GARBER, M., CHEVRIER, N., LEITE, A. P., DONNER, Y., 
EISENHAURE, T., GUTTMAN, M., GRENIER, J. K., LI, W. & ZUK, O. 2009. 
 Unbiased reconstruction of a mammalian transcriptional network mediating 
pathogen response. Science, 326, 257-263. 
 
ANDERSON, S. F., SCHLEGEL, B. P., NAKAJIMA, T., WOLPIN, E. S. & PARVIN, 
J. D. 1998. BRCA1 protein is linked to the RNA polymerase II holoenzyme 
complex via RNA helicase A. Nature genetics, 19(3), pp.254-256 
 
APREA, J., PRENNINGER, S., DORI, M., GHOSH, T., MONASOR, L. S., 
WESSENDORF, E., ZOCHER, S., MASSALINI, S., ALEXOPOULOU, D. & 
LESCHE, M. 2013. Transcriptome sequencing during mouse brain development 
identifies long non‐coding RNAs functionally involved in neurogenic commitment. 
The EMBO journal, 32, 3145-3160. 
. 
ARUN, G., DIERMEIER, S., AKERMAN, M., CHANG, K.-C., WILKINSON, J. E., 
HEARN, S., KIM, Y., MACLEOD, A. R., KRAINER, A. R. & NORTON, L. 2016. 
Differentiation of mammary tumors and reduction in metastasis upon Malat1 
lncRNA loss. Genes & development, 30, 34-51. 
 
BADVE, S., DABBS, D. J., SCHNITT, S. J., BAEHNER, F. L., DECKER, T., 
EUSEBI, V., FOX, S. B., ICHIHARA, S., JACQUEMIER, J. & LAKHANI, S. R. 
2011. Basal-like and triple-negative breast cancers: a critical review with an 
emphasis on the implications for pathologists and oncologists. Modern pathology, 
24, 157-167. 
 
BAGARIA, S. P., RAY, P. S., SIM, M.-S., YE, X., SHAMONKI, J. M., CUI, X. & 
GIULIANO, A. E. 2014. Personalizing breast cancer staging by the inclusion of 
ER, PR, and HER2. JAMA surgery, 149, 125-129. 
 
BAO, T. & DAVIDSON, N. E. 2008. Gene expression profiling of breast cancer. 
Advances in surgery, 42, 249. 
 
BARNES, C. J. & KUMAR, R. 2004. Biology of the epidermal growth factor 
receptor family. Molecular Targeting and Signal Transduction, pp.1-13. 
 
 BARRIOS, C., SAMPAIO, C., VINHOLES, J. & CAPONERO, R. 2009. What is the 
role of chemotherapy in estrogen receptor-positive, advanced breast cancer? 
Annals of oncology, 20, 1157-1162. 
 
BARRY, G., BRIGGS, J., VANICHKINA, D., POTH, E., BEVERIDGE, N., RATNU, 
V., NAYLER, S., NONES, K., HU, J. & BREDY, T. 2014. The long non-coding 
RNA Gomafu is acutely regulated in response to neuronal activation and involved 
in schizophrenia-associated alternative splicing. Molecular psychiatry, 19, 486-
494. 
 
BARRY, G., BRIGGS, J. A., DO WON HWANG, S. P. N., FORTUNA, P. R., 
JONKHOUT, N., DACHET, F., MAAG, J. L., MESTDAGH, P., SINGH, E. M. & 
AVESSON, L. 2017. The long non-coding RNA NEAT1 is responsive to neuronal 
activity and is associated with hyperexcitability states. Scientific Reports, 7, 
p.40127. 
 
BASAK, P., CHATTERJEE, S., WEGER, S., BRUCE, M. C., MURPHY, L. C. & 
RAOUF, A. 2015. Estrogen regulates luminal progenitor cell differentiation through 
H19 gene expression. Endocrine-related cancer, 22, 505-517. 
 
BATISTA, P. J. & CHANG, H. Y. 2013. Long noncoding RNAs: cellular address 
codes in development and disease. Cell, 152, 1298-1307. 
 
BENSON, J. R. 2003. The TNM staging system and breast cancer. The lancet 
oncology, 4, 56-60. 
 
BEREZHNA, S. Y., SUPEKOVA, L., SUPEK, F., SCHULTZ, P. G. & DENIZ, A. A. 
2006. siRNA in human cells selectively localizes to target RNA sites. Proceedings 
of the National Academy of Sciences, 103, 7682-7687. 
 
BERNARD, D., PRASANTH, K. V., TRIPATHI, V., COLASSE, S., NAKAMURA, T., 
XUAN, Z., ZHANG, M. Q., SEDEL, F., JOURDREN, L. & COULPIER, F. 2010. A 
long nuclear‐retained non‐coding RNA regulates synaptogenesis by modulating 
gene expression. The EMBO journal, 29, 3082-3093. 
 BERTEAUX, N., LOTTIN, S., MONTÉ, D., PINTE, S., QUATANNENS, B., COLL, 
J., HONDERMARCK, H., CURGY, J.-J., DUGIMONT, T. & ADRIAENSSENS, E. 
2005. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation 
through positive control by E2F1. Journal of biological chemistry, 280, 29625-
29636. 
 
BERTRAND, J.-R., POTTIER, M., VEKRIS, A., OPOLON, P., MAKSIMENKO, A. & 
MALVY, C. 2002. Comparison of antisense oligonucleotides and siRNAs in cell 
culture and in vivo. Biochemical and biophysical research communications, 296, 
1000-1004. 
 
BERTUCCI, F., FINETTI, P., CERVERA, N., CHARAFE-JAUFFRET, E., 
MAMESSIER, E., ADÉLAÏDE, J., DEBONO, S., HOUVENAEGHEL, G., 
MARANINCHI, D. & VIENS, P. 2006. Gene expression profiling shows medullary 
breast cancer is a subgroup of basal breast cancers. Cancer Research, 66, 4636-
4644. 
 
BIAMONTI, G. & VOURC’H, C. 2010. Nuclear stress bodies. Cold Spring Harbor 
perspectives in biology, 2, a000695. 
 
BISWAS, A. & DESAI, K. V. 2017. The LncRNA HOTAIR-expression, regulation 
and function in cancer. The Nucleus, pp.1-10 
 
BLUME, C., HOTZ-WAGENBLATT, A., HÜLLEIN, J., SELLNER, L., JETHWA, A., 
STOLZ, T., SLABICKI, M., LEE, K., SHARATHCHANDRA, A. & BENNER, A. 
2015. p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. 
Leukemia, 29(10). 
 
BOLTON, E.M., TUZOVA, A.V., WALSH, A.L., LYNCH, T. and PERRY, A.S., 
2014. Noncoding RNAs in prostate cancer: the long and the short of it. Clinical 
Cancer Research, 20(1), pp.35-43. 
 
BONASIO, R., TU, S. & REINBERG, D. 2010. Molecular signals of epigenetic 
states. Science, 330, 612-616. 
 BOND, C. S. & FOX, A. H. 2009. Paraspeckles: nuclear bodies built on long 
noncoding RNA. The Journal of cell biology, 186, 637-644. 
 
BORST, M. J. & INGOLD, J. A. 1993. Metastatic patterns of invasive lobular 
versus invasive ductal carcinoma of the breast. Surgery, 114, 637-41; discussion 
641-2. 
 
BOTCHEVA, K., MCCORKLE, S. R., MCCOMBIE, W., DUNN, J. J. & 
ANDERSON, C. W. 2011. Distinct p53 genomic binding patterns in normal and 
cancer-derived human cells. Cell cycle, 10, 4237-4249. 
 
BRAZAS, R. M. & HAGSTROM, J. E. 2005. Delivery of Small Interfering RNA to 
Mammalian Cells in Culture by Using Cationic Lipid⧸ Polymer-Based Transfection 
Reagents. Methods in enzymology, 392, 112-124. 
 
BRENTON, J. D., CAREY, L. A., AHMED, A. A. & CALDAS, C. 2005. Molecular 
Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical 
Application? Journal of Clinical Oncology, 23, 7350-7360. 
 
BRIERLEY, J., GOSPODAROWICZ, M. & O'SULLIVAN, B. 2016. The principles of 
cancer staging. Ecancermedicalscience. 10 
 
BROSNAN, C. A. & VOINNET, O. 2009. The long and the short of noncoding 
RNAs. Current opinion in cell biology, 21, 416-425. 
 
BROWN, I., SHALLI, K., MCDONALD, S. L., MOIR, S. E., HUTCHEON, A. W., 
HEYS, S. D. & SCHOFIELD, A. C. 2004. Reduced expression of p27 is a novel 
mechanism of docetaxel resistance in breast cancer cells. Breast Cancer 
Research, 6(5), p.R601. 
 
BUENO, M. J. & MALUMBRES, M. 2011. MicroRNAs and the cell cycle. 
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1812, 592-601. 
 
 CABILI, M. N., TRAPNELL, C., GOFF, L., KOZIOL, M., TAZON-VEGA, B., 
REGEV, A. & RINN, J. L. 2011. Integrative annotation of human large intergenic 
noncoding RNAs reveals global properties and specific subclasses. Genes & 
development, 25, 1915-1927. 
 
CAILLEAU, R., YOUNG, R., OLIVE, M. & REEVES, W. 1974. Breast tumor cell 
lines from pleural effusions. Journal of the National Cancer Institute, 53, 661-674. 
 
CAREY, L. A., PEROU, C. M., LIVASY, C. A., DRESSLER, L. G., COWAN, D., 
CONWAY, K., KARACA, G., TROESTER, M. A., TSE, C. K. & EDMISTON, S. 
2006. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer 
Study. Jama, 295, 2492-2502. 
 
CAYROL, C., KNIBIEHLER, M. & DUCOMMUN, B. 1998. p21 binding to PCNA 
causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene, 16(3). 
 
CERK, S., SCHWARZENBACHER, D., ADIPRASITO, J. B., STOTZ, M., 
HUTTERER, G. C., GERGER, A., LING, H., CALIN, G. A. & PICHLER, M. 2016. 
Current Status of Long Non-Coding RNAs in Human Breast Cancer. International 
Journal of Molecular Sciences, 17, 1485. 
 
CHAI, Y., LIU, J., ZHANG, Z. & LIU, L. 2016. HuR‐regulated lncRNA NEAT1 
stability in tumorigenesis and progression of ovarian cancer. Cancer medicine, 5, 
1588-1598. 
 
CHAKRAVARTY, D., SBONER, A., NAIR, S. S., GIANNOPOULOU, E., LI, R., 
HENNIG, S., MOSQUERA, J. M., PAUWELS, J., PARK, K. & KOSSAI, M. 2014. 
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of 
prostate cancer. Nature communications, 5  
 
CHEN, L.-L. & CARMICHAEL, G. G. 2009. Altered nuclear retention of mRNAs 
containing inverted repeats in human embryonic stem cells: functional role of a 
nuclear noncoding RNA. Molecular cell, 35, 467-478. 
 
 CHEN, X., KONG, J., MA, Z., GAO, S. & FENG, X. 2015. Up regulation of the long 
non-coding RNA NEAT1 promotes esophageal squamous cell carcinoma cell 
progression and correlates with poor prognosis. American journal of cancer 
research, 5, 2808. 
 
CHEN, Y., XU, J., BOROWICZ, S., COLLINS, C., HUO, D. & OLOPADE, O. I. 
2011. c-Myc activates BRCA1 gene expression through distal promoter elements 
in breast cancer cells. BMC cancer, 11, 246. 
 
CHEN, Z. 2016. Progress and prospects of long noncoding RNAs in lipid 
homeostasis. Molecular metabolism, 5, 164-170. 
 
CHIAPPETTA, G., AVANTAGGIATO, V., VISCONTI, R., FEDELE, M., BATTISTA, 
S., TRAPASSO, F., MERCIAI, B. M., FIDANZA, V., GIANCOTTI, V. & SANTORO, 
M. 1996. High level expression of the HMGI (Y) gene during embryonic 
development. Oncogene, 13, 2439-2446. 
 
CHIAPPETTA, G., MANFIOLETTI, G., PENTIMALLI, F., ABE, N., DI BONITO, M., 
VENTO, M. T., GIULIANO, A., FEDELE, M., VIGLIETTO, G. & SANTORO, M. 
2001. High mobility group HMGI (Y) protein expression in human colorectal 
hyperplastic and neoplastic diseases. International journal of cancer, 91, 147-151. 
 
CHIN, Y. R., YOSHIDA, T., MARUSYK, A., BECK, A. H., POLYAK, K. & TOKER, 
A. 2013. Targeting Akt3 signaling in triple-negative breast cancer. Cancer 
research. 
 
CHISHOLM, K. M., WAN, Y., LI, R., MONTGOMERY, K. D., CHANG, H. Y. & 
WEST, R. B. 2012. Detection of long non-coding RNA in archival tissue: 
correlation with polycomb protein expression in primary and metastatic breast 
carcinoma. PloS one, 7, e47998. 
 
CHOMCZYNSKI, P. & SACCHI, N. 1987. Single-step method of RNA isolation by 
acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical 
biochemistry, 162, 156-159. 
 CHOUDHRY, H., ALBUKHARI, A., MOROTTI, M., HAIDER, S., MORALLI, D., 
SMYTHIES, J., SCHÖDEL, J., GREEN, C. M., CAMPS, C. & BUFFA, F. 2015. 
Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent 
transcriptional activation of NEAT1 leading to cancer cell survival. Oncogene, 34, 
4482-4490. 
 
CHU, C., QU, K., ZHONG, F. L., ARTANDI, S. E. & CHANG, H. Y. 2011. Genomic 
maps of long noncoding RNA occupancy reveal principles of RNA-chromatin 
interactions. Molecular cell, 44, 667-678. 
 
CHU, C., SPITALE, R.C. and CHANG, H.Y., 2015. Technologies to probe 
functions and mechanisms of long noncoding RNAs. Nature structural & molecular 
biology, 22(1), pp.29-35. 
 
CHUMAKOVA, O. V., LIOPO, A. V., EVERS, B. M. & ESENALIEV, R. O. 2006. 
Effect of 5-fluorouracil, Optison and ultrasound on MCF-7 cell viability. Ultrasound 
in medicine & biology, 32, 751-758. 
 
CLARK, M. B. & MATTICK, J. S. Long noncoding RNAs in cell biology.  Seminars 
in cell & developmental biology, 2011. Elsevier, 366-376. 
 
CLEMSON, C. M., HUTCHINSON, J. N., SARA, S. A., ENSMINGER, A. W., FOX, 
A. H., CHESS, A. & LAWRENCE, J. B. 2009. An architectural role for a nuclear 
noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. 
Molecular cell, 33, 717-726. 
 
COCCIA, E. M., CICALA, C., CHARLESWORTH, A., CICCARELLI, C., ROSSI, 
G., PHILIPSON, L. & SORRENTINO, V. 1992. Regulation and expression of a 
growth arrest-specific gene (gas5) during growth, differentiation, and development. 
Molecular and cellular biology, 12, 3514-3521. 
 
CORNELIS, G., SOUQUERE, S., VERNOCHET, C., HEIDMANN, T. & PIERRON, 
G. 2016. Functional conservation of the lncRNA NEAT1 in the ancestrally diverged 
marsupial lineage: Evidence for NEAT1 expression and associated paraspeckle 
 assembly during late gestation in the opossum Monodelphis domestica. RNA 
biology, 13, 826-836. 
 
CREA, F., VENALAINEN, E., CI, X., CHENG, H., PIKOR, L., PAROLIA, A., XUE, 
H., SAIDY, N. R. N., LIN, D. & LAM, W. 2016. The role of epigenetics and long 
noncoding RNA MIAT in neuroendocrine prostate cancer. 
 
CURTIS, V. F., EHRENTRAUT, S. F., CAMPBELL, E. L., GLOVER, L. E., 
BAYLESS, A., KELLY, C. J., KOMINSKY, D. J. & COLGAN, S. P. 2015. 
Stabilization of HIF through inhibition of Cullin-2 neddylation is protective in 
mucosal inflammatory responses. The FASEB Journal, 29, 208-215. 
 
CUTULI, B., DE LAFONTAN, B., KIROVA, Y., AUVRAY, H., TALLET, A., 
AVIGDOR, S., BRUNAUD, C. & DELVA, C. 2015. Lobular carcinoma in situ ( 
LCIS) of the breast: is long- term outcome similar to ductal carcinoma in situ ( 
DCIS)? Analysis of 200 cases. Radiation oncology (London, England), 10, 110. 
 
DARLINGTON, A. J. 2015. Anatomy of the Breast. In Digital Mammography. (pp. 
3-10). Springer International Publishing. 
 
DATTA, J., SMITH, A., LANG, J. C., ISLAM, M., DUTT, D., TEKNOS, T. N. & 
PAN, Q. 2012. microRNA-107 functions as a candidate tumor-suppressor gene in 
head and neck squamous cell carcinoma by downregulation of protein kinase Cϵ. 
Oncogene, 31, 4045-4053. 
 
DEBRUIN, L. S. & JOSEPHY, P. D. 2002. Perspectives on the chemical etiology 
of breast cancer. Environmental health perspectives, 110, 119. 
 
DENG, Z., NORSEEN, J., WIEDMER, A., RIETHMAN, H. & LIEBERMAN, P. M. 
2009. TERRA RNA binding to TRF2 facilitates heterochromatin formation and 
ORC recruitment at telomeres. Molecular cell, 35, 403-413. 
 
DENIZ, E. & ERMAN, B. 2017. Long noncoding RNA (lincRNA), a new paradigm 
in gene expression control. Functional & integrative genomics, 17, 135-143. 
 DERRIEN, T., JOHNSON, R., BUSSOTTI, G., TANZER, A., DJEBALI, S., 
TILGNER, H., GUERNEC, G., MARTIN, D., MERKEL, A. & KNOWLES, D. G. 
2012. The GENCODE v7 catalogue of human long noncoding RNAs: analysis of 
their gene structure, evolution, and expression. Genome research, 22, 1775-1789. 
 
DESAI, S. D. 2015. ISG15: A double edged sword in cancer. Oncoimmunology, 
4(12), p.e1052935  
 
DESJARDINS, P. & CONKLIN, D. 2010. NanoDrop microvolume quantitation of 
nucleic acids. Journal of visualized experiments: JoVE, (45). 
 
DINGER, M. E., AMARAL, P. P., MERCER, T. R., PANG, K. C., BRUCE, S. J., 
GARDINER, B. B., ASKARIAN-AMIRI, M. E., RU, K., SOLDÀ, G. & SIMONS, C. 
2008. Long noncoding RNAs in mouse embryonic stem cell pluripotency and 
differentiation. Genome research, 18, 1433-1445. 
 
DUNKERN, T. R. & KAINA, B. 2002. Cell proliferation and DNA breaks are 
involved in ultraviolet light-induced apoptosis in nucleotide excision repair-deficient 
Chinese hamster cells. Molecular biology of the cell, 13, 348-361. 
 
ECKELMAN, B. P., SALVESEN, G. S. & SCOTT, F. L. 2006. Human inhibitor of 
apoptosis proteins: why XIAP is the black sheep of the family. EMBO reports, 7, 
988-994. 
 
EKHOLM, S. V. & REED, S. I. 2000. Regulation of G 1 cyclin-dependent kinases 
in the mammalian cell cycle. Current opinion in cell biology, 12, 676-684. 
 
EL MESSAOUDI-AUBERT, S., NICHOLLS, J., MAERTENS, G. N., BROOKES, S., 
BERNSTEIN, E. & PETERS, G. 2010. Role for the MOV10 RNA helicase in 
polycomb-mediated repression of the INK4a tumor suppressor. Nature structural & 
molecular biology, 17, 862-868. 
 
ELLIS, H. & MAHADEVAN, V. 2013. Anatomy and physiology of the breast. 
Surgery (Oxford). 31(1), pp.11-14 
 ELLIS, M. J., DING, L., SHEN, D., LUO, J., SUMAN, V. J., WALLIS, J. W., VAN 
TINE, B. A., HOOG, J., GOIFFON, R. J. & GOLDSTEIN, T. C. 2012. Whole 
genome analysis informs breast cancer response to aromatase inhibition. Nature, 
486, 353. 
 
ELSTON, C. W., ELLIS, I. O. & PINDER, S. E. 1999. Pathological prognostic 
factors in breast cancer. Critical reviews in oncology/hematology, 31, 209-223. 
 
EMBERLEY, E., HUANG, G.-J., HAMEDANI, M. K., CZOSNEK, A., ALI, D., 
GROLLA, A., LU, B., WATSON, P. H., MURPHY, L. C. & LEYGUE, E. 2003. 
Identification of new human coding steroid receptor RNA activator isoforms. 
Biochemical and biophysical research communications, 301, 509-515. 
 
FISH, J. E., MATOUK, C. C., YEBOAH, E., BEVAN, S. C., KHAN, M., PATIL, K., 
OHH, M. & MARSDEN, P. A. 2007. Hypoxia-inducible expression of a natural cis-
antisense transcript inhibits endothelial nitric-oxide synthase. Journal of Biological 
Chemistry, 282, 15652-15666. 
 
FLYNN, R. L., CENTORE, R. C., O’SULLIVAN, R. J., RAI, R., TSE, A., 
SONGYANG, Z., CHANG, S., KARLSEDER, J. & ZOU, L. 2011. TERRA and 
hnRNPA1 orchestrate an RPA-to-POT1 switch on telomeric single-stranded DNA. 
Nature, 471, 532. 
 
FONG, K.-W., LI, Y., WANG, W., MA, W., LI, K., QI, R. Z., LIU, D., SONGYANG, 
Z. & CHEN, J. 2013. Whole-genome screening identifies proteins localized to 
distinct nuclear bodies. J Cell Biol, 203, 149-164. 
 
FOX, A. H. & LAMOND, A. I. 2010. Paraspeckles. Cold Spring Harbor 
perspectives in biology, 2(7), p.a000687. 
 
FOX, E. J. 2004. Mechanism of action of mitoxantrone. Neurology, 63(12 suppl 6), 
pp.S15-S18 
 
 FU, X., RAVINDRANATH, L., TRAN, N., PETROVICS, G. & SRIVASTAVA, S. 
2006. Regulation of apoptosis by a prostate-specific and prostate cancer-
associated noncoding gene, PCGEM1. DNA and cell biology, 25, 135-141. 
 
FU, X.-L., LIU, D.-J., YAN, T.-T., YANG, J.-Y., YANG, M.-W., LI, J., HUO, Y.-M., 
LIU, W., ZHANG, J.-F. & HONG, J. 2016. Analysis of long non-coding RNA 
expression profiles in pancreatic ductal adenocarcinoma. Scientific Reports, 6, 
p.33535.. 
 
GABOS, Z., SINHA, R., HANSON, J., CHAUHAN, N., HUGH, J., MACKEY, J. R. & 
ABDULKARIM, B. 2006. Prognostic significance of human epidermal growth factor 
receptor positivity for the development of brain metastasis after newly diagnosed 
breast cancer. Journal of Clinical Oncology, 24, 5658-5663. 
 
GALUPA, R. & HEARD, E. 2015. X-chromosome inactivation: new insights into cis 
and trans regulation. Current opinion in genetics & development, 31, 57-66. 
GAO, C., ZHANG, J., WANG, Q. & REN, C. 2016. Overexpression of lncRNA 
NEAT1 mitigates multidrug resistance by inhibiting ABCG2 in leukemia. Oncology 
letters, 12, 1051-1057. 
 
GATZA, M. L. & CAREY, L. A. 2016. Another Breast Cancer Entity Confirmed 
Genomics of Invasive Lobular Breast Cancer. American Society of Clinical 
Oncology Alexandria, 1838-1839. 
 
GENG, H. & TAN, X.-D. 2016. Functional diversity of long non-coding RNAs in 
immune regulation. Genes & diseases, 3, 72-81. 
. 
GERDES, J., LEMKE, H., BAISCH, H., WACKER, H.-H., SCHWAB, U. & STEIN, 
H. 1984. Cell cycle analysis of a cell proliferation-associated human nuclear 
antigen defined by the monoclonal antibody Ki-67. The Journal of Immunology, 
133, 1710-1715. 
 
 GERNAPUDI, R., WOLFSON, B., ZHANG, Y., YAO, Y., YANG, P., ASAHARA, H. 
& ZHOU, Q. 2016. MicroRNA 140 promotes expression of long noncoding RNA 
NEAT1 in adipogenesis. Molecular and cellular biology, 36, 30-38. 
 
GHOSAL, S., DAS, S. & CHAKRABARTI, J. 2013. Long noncoding RNAs: new 
players in the molecular mechanism for maintenance and differentiation of 
pluripotent stem cells. Stem cells and development, 22, 2240-2253. 
 
GIBB, E. A., BROWN, C. J. & LAM, W. L. 2011a. The functional role of long non-
coding RNA in human carcinomas. Molecular cancer, 10(1), p.38. 
 
GIBB, E. A., VUCIC, E. A., ENFIELD, K. S., STEWART, G. L., LONERGAN, K. M., 
KENNETT, J. Y., BECKER-SANTOS, D. D., MACAULAY, C. E., LAM, S. & 
BROWN, C. J. 2011b. Human cancer long non-coding RNA transcriptomes. PloS 
one, 6(10), p.e25915.  
 
GINGER, M. R., SHORE, A. N., CONTRERAS, A., RIJNKELS, M., MILLER, J., 
GONZALEZ-RIMBAU, M. F. & ROSEN, J. M. 2006. A noncoding RNA is a 
potential marker of cell fate during mammary gland development. Proceedings of 
the National Academy of Sciences, 103, 5781-5786. 
 
GIRDLER, F. & BROTHERICK, I. 2000. The oestrogen receptors (ERα and ERβ) 
and their role in breast cancer: a review. The Breast, 9, 194-200. 
 
GODINHO, M., MEIJER, D., SETYONO‐HAN, B., DORSSERS, L. C. & VAN 
AGTHOVEN, T. 2011. Characterization of BCAR4, a novel oncogene causing 
endocrine resistance in human breast cancer cells. Journal of cellular physiology, 
226, 1741-1749. 
 
GODINHO, M. F., SIEUWERTS, A., LOOK, M., MEIJER, D., FOEKENS, J., 
DORSSERS, L. & VAN AGTHOVEN, T. 2010. Relevance of BCAR4 in tamoxifen 
resistance and tumour aggressiveness of human breast cancer. British journal of 
cancer, 103, 1284. 
 
 GUO, F., LI, Y., LIU, Y., WANG, J., LI, Y. & LI, G. 2010. Inhibition of metastasis-
associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells 
suppresses cell proliferation and invasion. Acta Biochim Biophys Sin, 42, 224-229. 
. 
GUO, S., CHEN, W., LUO, Y., REN, F., ZHONG, T., RONG, M., DANG, Y., FENG, 
Z. & CHEN, G. 2015. Clinical implication of long non-coding RNA NEAT1 
expression in hepatocellular carcinoma patients. International journal of clinical 
and experimental pathology, 8(5), p.5395. 
 
GUPTA, R. A., SHAH, N., WANG, K. C., KIM, J., HORLINGS, H. M., WONG, D. 
J., TSAI, M.-C., HUNG, T., ARGANI, P. & RINN, J. L. 2010. Long noncoding RNA 
HOTAIR reprograms chromatin state to promote cancer metastasis. Nature, 464, 
1071. 
 
GUTIERREZ, C. & SCHIFF, R. 2011. HER2: biology, detection, and clinical 
implications. Archives of pathology & laboratory medicine, 135, 55-62. 
 
GUTSCHNER, T., BAAS, M. & DIEDERICHS, S. 2011. Noncoding RNA gene 
silencing through genomic integration of RNA destabilizing elements using zinc 
finger nucleases. Genome research, 21, 1944-1954. 
 
GUTSCHNER, T., HÄMMERLE, M., EIßMANN, M., HSU, J., KIM, Y., HUNG, G., 
REVENKO, A., ARUN, G., STENTRUP, M. & GROß, M. 2013. The noncoding 
RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer 
cells. Cancer research, 73, 1180-1189. 
 
GUTTMAN, M. & RINN, J. L. 2012. Modular regulatory principles of large non-
coding RNAs. Nature, 482, 339-346. 
 
HAN, J., LIU, S., SUN, Z., ZHANG, Y., ZHANG, F., ZHANG, C., SHANG, D., 
YANG, H., SU, F. & XU, Y. 2017. LncRNAs2Pathways: Identifying the pathways 
influenced by a set of lncRNAs of interest based on a global network propagation 
method. Scientific Reports, 7. 
 
 HANAHAN, D. & WEINBERG, R. A. 2000. The hallmarks of cancer. Cell, 100, 57-
70. 
 
HARPER, J. W., ADAMI, G. R., WEI, N., KEYOMARSI, K. & ELLEDGE, S. J. 
1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-
dependent kinases. Cell, 75, 805-816. 
 
HATA, T., OGAWA, T., YOKOYAMA, T.-A., FUKUSHIGE, S., HORII, A. & 
FURUKAWA, T. 2004. DSCP1, a novel TP53-inducible gene, is upregulated by 
strong genotoxic stresses and its overexpression inhibits tumor cell growth in vitro. 
International journal of oncology, 24, 513-520. 
 
HAYES, E. L. & LEWIS-WAMBI, J. S. 2015. Mechanisms of endocrine resistance 
in breast cancer: an overview of the proposed roles of noncoding RNA. Breast 
Cancer Research, 17, 40. 
 
HE, Y., VOGELSTEIN, B., VELCULESCU, V. E., PAPADOPOULOS, N. & 
KINZLER, K. W. 2008. The antisense transcriptomes of human cells. Science, 
322, 1855-1857. 
 
HENLEY, S. A. & DICK, F. A. 2012. The retinoblastoma family of proteins and 
their regulatory functions in the mammalian cell division cycle. Cell division, 7, 10. 
HERBST, R. S. & KHURI, F. R. 2003. Mode of action of docetaxel–a basis for 
combination with novel anticancer agents. Cancer treatment reviews, 29, 407-415. 
 
HESSELBERTH, J. R. 2013. Lives that introns lead after splicing. Wiley 
Interdisciplinary Reviews: RNA, 4, 677-691. 
 
HIROSE, T., VIRNICCHI, G., TANIGAWA, A., NAGANUMA, T., LI, R., KIMURA, 
H., YOKOI, T., NAKAGAWA, S., BÉNARD, M. & FOX, A. H. 2014. NEAT1 long 
noncoding RNA regulates transcription via protein sequestration within subnuclear 
bodies. Molecular biology of the cell, 25, 169-183. 
 
 HU, Q., CHEN, X., LIU, S., WEN, R., YUAN, X., XU, D., LIU, G. & WEN, F. 2017. 
Methylation of CDKN2B CpG islands is associated with upregulated telomerase 
activity in children with acute lymphoblastic leukemia. Oncology Letters, 13, 2115-
2120. 
 
HU, T., LIU, S., BREITER, D. R., WANG, F., TANG, Y. & SUN, S. 2008. Octamer 
4 small interfering RNA results in cancer stem cell–like cell apoptosis. Cancer 
research, 68, 6533-6540. 
 
HU, Y., CHEN, H.-Y., YU, C.-Y., XU, J., WANG, J.-L., QIAN, J., ZHANG, X. & 
FANG, J.-Y. 2014. A long non-coding RNA signature to improve prognosis 
prediction of colorectal cancer. Oncotarget, 5, 2230. 
 
HUANG, Y.-S., CHANG, C.-C., LEE, S.-S., JOU, Y.-S. & SHIH, H.-M. 2016. Xist 
reduction in breast cancer upregulates AKT phosphorylation via HDAC3-mediated 
repression of PHLPP1 expression. Oncotarget, 7, 43256. 
 
HUARTE, M., GUTTMAN, M., FELDSER, D., GARBER, M., KOZIOL, M. J., 
KENZELMANN-BROZ, D., KHALIL, A. M., ZUK, O., AMIT, I. & RABANI, M. 2010. 
A large intergenic noncoding RNA induced by p53 mediates global gene 
repression in the p53 response. Cell, 142, 409-419. 
 
HUDSON, T. J. 2011. Cancer genome variation in children, adolescents, and 
young adults. Cancer, 117, 2262-2267. 
 
HUNG, T. & CHANG, H. Y. 2010. Long noncoding RNA in genome regulation: 
prospects and mechanisms. RNA biology, 7, 582-585. 
 
HUNG, T., WANG, Y., LIN, M. F., KOEGEL, A. K., KOTAKE, Y., GRANT, G. D., 
HORLINGS, H. M., SHAH, N., UMBRICHT, C. & WANG, P. 2011. Extensive and 
coordinated transcription of noncoding RNAs within cell-cycle promoters. Nature 
genetics, 43, 621-629. 
 
 HUTCHINSON, J. N., ENSMINGER, A. W., CLEMSON, C. M., LYNCH, C. R., 
LAWRENCE, J. B. & CHESS, A. 2007. A screen for nuclear transcripts identifies 
two linked noncoding RNAs associated with SC35 splicing domains. BMC 
genomics, 8(1), p.39.. 
 
IDOGAWA, M., OHASHI, T., SASAKI, Y., NAKASE, H. & TOKINO, T. 2017. Long 
non‐coding RNA NEAT1 is a transcriptional target of p53 and modulates p53‐
induced transactivation and tumor‐suppressor function. International Journal of 
Cancer, 140, 2785-2791. 
 
IMAMURA, K., IMAMACHI, N., AKIZUKI, G., KUMAKURA, M., KAWAGUCHI, A., 
NAGATA, K., KATO, A., KAWAGUCHI, Y., SATO, H. & YONEDA, M. 2014. Long 
noncoding RNA NEAT1-dependent SFPQ relocation from promoter region to 
paraspeckle mediates IL8 expression upon immune stimuli. Molecular cell, 53, 
393-406. 
 
ISHII, N., OZAKI, K., SATO, H., MIZUNO, H., SAITO, S., TAKAHASHI, A., 
MIYAMOTO, Y., IKEGAWA, S., KAMATANI, N. & HORI, M. 2006. Identification of 
a novel non-coding RNA, MIAT that confers risk of myocardial infarction. Journal 
of human genetics, 51, 1087-1099. 
 
ISHIZUKA, A., HASEGAWA, Y., ISHIDA, K., YANAKA, K. & NAKAGAWA, S. 
2014. Formation of nuclear bodies by the lncRNA Gomafu‐associating proteins 
Celf3 and SF1. Genes to Cells, 19, 704-721. 
 
ISIK, A., PEKER, K., FIRAT, D., YILMAZ, B., SAYAR, I., IDIZ, O., CAKIR, C., 
DEMIRYILMAZ, I. & YILMAZ, I. 2014. Importance of metastatic lymph node ratio 
in non-metastatic, lymph node-invaded colon cancer: A clinical trial. Medical 
science monitor: international medical journal of experimental and clinical 
research, 20, 1369. 
 
JEN, J., TANG, Y.-A., LU, Y.-H., LIN, C.-C., LAI, W.-W. & WANG, Y.-C. 2017. 
Oct4 transcriptionally regulates the expression of long non-coding RNAs NEAT1 
and MALAT1 to promote lung cancer progression. Molecular Cancer, 16, 104. 
 JI, P., DIEDERICHS, S., WANG, W., BÖING, S., METZGER, R., SCHNEIDER, P. 
M., TIDOW, N., BRANDT, B., BUERGER, H. & BULK, E. 2003. MALAT-1, a novel 
noncoding RNA, and thymosin [beta] 4 predict metastasis and survival in early-
stage non-small cell lung cancer. Oncogene, 22, 8031. 
 
JIANG, Y.-Z., LIU, Y.-R., XU, X.-E., JIN, X., HU, X., YU, K.-D. & SHAO, Z.-M. 
2016a. Transcriptome analysis of triple-negative breast cancer reveals an 
integrated mRNA-lncRNA signature with predictive and prognostic value. Cancer 
research, 76, 2105-2114. 
 
JIANG, Q., SHAN, K., QUN-WANG, X., ZHOU, R.-M., YANG, H., LIU, C., LI, Y.-J., 
YAO, J., LI, X.-M. & SHEN, Y. 2016b. Long non-coding RNA-MIAT promotes 
neurovascular remodeling in the eye and brain. Oncotarget, 7, 49688-49698. 
 
JIN, C., ZHENG, Y., HUANG, Y., LIU, Y., JIA, L. & ZHOU, Y. 2017. Long non‐
coding RNA MIAT knockdown promotes osteogenic differentiation of human 
adipose derived stem cells. Cell Biology International. 
 
JOHNSON, R. 2012. Long non-coding RNAs in Huntington's disease 
neurodegeneration. Neurobiology of disease, 46, 245-254. 
KANHERE, A. & JENNER, R. G. 2012. Noncoding RNA localisation mechanisms 
in chromatin regulation. Silence, 3, 2. 
 
KE, H., ZHAO, L., FENG, X., XU, H., ZOU, L., YANG, Q., SU, X., PENG, L. & 
JIAO, B. 2016. NEAT1 is required for survival of breast cancer cells through FUS 
and miR-548. Gene regulation and systems biology, 10, 11. 
 
KERR, J. F., WYLLIE, A. H. & CURRIE, A. R. 1972. Apoptosis: a basic biological 
phenomenon with wide-ranging implications in tissue kinetics. British journal of 
cancer, 26, 239. 
 
KHAITAN, D., DINGER, M. E., MAZAR, J., CRAWFORD, J., SMITH, M. A., 
MATTICK, J. S. & PERERA, R. J. 2011. The melanoma‐upregulated long 
 noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer research, 
71, 3852-3862. 
 
KHALIL, A. M., GUTTMAN, M., HUARTE, M., GARBER, M., RAJ, A., MORALES, 
D. R., THOMAS, K., PRESSER, A., BERNSTEIN, B. E. & VAN OUDENAARDEN, 
A. 2009. Many human large intergenic noncoding RNAs associate with chromatin-
modifying complexes and affect gene expression. Proceedings of the National 
Academy of Sciences, 106, 11667-11672. 
 
KINO, T., HURT, D. E., ICHIJO, T., NADER, N. & CHROUSOS, G. P. 2010. 
Noncoding RNA Gas5 is a growth arrest and starvation-associated repressor of 
the glucocorticoid receptor. Science signaling, 3(107), p.ra8. 
 
KITAGAWA, M., KITAGAWA, K., KOTAKE, Y., NIIDA, H. & OHHATA, T. 2013. 
Cell cycle regulation by long non-coding RNAs. Cellular and molecular life 
sciences, 70, 4785-4794. 
 
KLINGE, C. M., JERNIGAN, S., MATTINGLY, K., RISINGER, K. & ZHANG, J. 
2004. Estrogen response element-dependent regulation of transcriptional 
activation of estrogen receptors α and β by coactivators and corepressors. Journal 
of molecular endocrinology, 33, 387-410. 
 
KOTAKE, Y., NAKAGAWA, T., KITAGAWA, K., SUZUKI, S., LIU, N., KITAGAWA, 
M. & XIONG, Y. 2011. Long non-coding RNA ANRIL is required for the PRC2 
recruitment to and silencing of p15INK4B tumor suppressor gene. Oncogene, 30, 
1956-1962. 
. 
LAI, M.-C., YANG, Z., ZHOU, L., ZHU, Q.-Q., XIE, H.-Y., ZHANG, F., WU, L.-M., 
CHEN, L.-M. & ZHENG, S.-S. 2012. Long non-coding RNA MALAT-1 
overexpression predicts tumor recurrence of hepatocellular carcinoma after liver 
transplantation. Medical oncology, 29, 1810-1816. 
 
 LANZ, R. B., MCKENNA, N. J., ONATE, S. A., ALBRECHT, U., WONG, J., TSAI, 
S. Y., TSAI, M.-J. & O’MALLEY, B. W. 1999. A steroid receptor coactivator, SRA, 
functions as an RNA and is present in an SRC-1 complex. Cell, 97, 17-27. 
 
LATORRE, E., CARELLI, S., RAIMONDI, I., D'AGOSTINO, V., CASTIGLIONI, I., 
ZUCAL, C., MORO, G., LUCIANI, A., GHILARDI, G. & MONTI, E. 2016. The 
Ribonucleic Complex HuR-MALAT1 Represses CD133 Expression and 
Suppresses Epithelial–Mesenchymal Transition in Breast Cancer. Cancer 
research, 76, 2626-2636. 
 
LAVORGNA, G., DAHARY, D., LEHNER, B., SOREK, R., SANDERSON, C. M. & 
CASARI, G. 2004. In search of antisense. Trends in biochemical sciences, 29, 88-
94. 
 
LAYFIELD, D., MOHAMUD, M., ODOFIN, O., WALSH, C., ROYLE, G. & 
CUTRESS, R. 2015. Tumour grade on core biopsy and evidence of axillary 
involvement on ultrasound predicts response in elderly co-morbid patients treated 
with primary hormone therapy for oestrogen receptor positive breast carcinoma. 
The Surgeon, 13, 61-68. 
 
LEE, J., GO, Y., KANG, I., HAN, Y.-M. & KIM, J. 2010. Oct-4 controls cell-cycle 
progression of embryonic stem cells. Biochemical Journal, 426, 171-181. 
 
LENNOX, K. A. & BEHLKE, M. A. 2015. Cellular localization of long non-coding 
RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic 
acids research, 44, 863-877. 
 
LESTRADE, L. & WEBER, M. J. 2006. snoRNA-LBME-db, a comprehensive 
database of human H/ACA and C/D box snoRNAs. Nucleic acids research, 34, 
D158-D162. 
 
LEYGUE, E., DOTZLAW, H., WATSON, P. H. & MURPHY, L. C. 1999. Expression 
of the steroid receptor RNA activator in human breast tumors. Cancer Research, 
59, 4190-4193. 
 LI, C. H. & CHEN, Y. 2013. Targeting long non-coding RNAs in cancers: progress 
and prospects. The international journal of biochemistry & cell biology, 45, 1895-
1910. 
 
LI, H., ZHENG, P., XU, P., LI, Z. & HAN, Q. 2017a. Long non-coding RNA NEAT1 
promotes human clear cell kidney carcinoma progression through negative 
regulation of miR-129-5p. INTERNATIONAL JOURNAL OF CLINICAL AND 
EXPERIMENTAL PATHOLOGY, 10, 6692-6700. 
 
LI, J., BI, L., LIN, Y., LU, Z. & HOU, G. 2014a. Clinicopathological significance and 
potential drug target of p15INK4B in multiple myeloma. Drug design, development 
and therapy, 8, 2129. 
 
LI, J.-T., WANG, L.-F., ZHAO, Y.-L., YANG, T., LI, W., ZHAO, J., YU, F., WANG, 
L., MENG, Y.-L. & LIU, N.-N. 2014b. Nuclear factor of activated T cells 5 
maintained by Hotair suppression of miR-568 upregulates S100 calcium binding 
protein A4 to promote breast cancer metastasis. Breast Cancer Research, 16(5), 
p.454. 
 
LI, L., FENG, T., LIAN, Y., ZHANG, G., GAREN, A. & SONG, X. 2009. Role of 
human noncoding RNAs in the control of tumorigenesis. Proceedings of the 
National Academy of Sciences, 106, 12956-12961. 
 
LI, R., HARVEY, A. R., HODGETTS, S. I. & FOX, A. H. 2017b. Functional 
dissection of NEAT1 using genome editing reveals substantial localization of the 
NEAT1_1 isoform outside paraspeckles. RNA, 23, 872-881. 
 
LI, Z., WEI, D., YANG, C., SUN, H., LU, T. & KUANG, D. 2016. Overexpression of 
long noncoding RNA, NEAT1 promotes cell proliferation, invasion and migration in 
endometrial endometrioid adenocarcinoma. Biomedicine & Pharmacotherapy, 84, 
244-251. 
 
 LIANG, C.-C., PARK, A. Y. & GUAN, J.-L. 2007. In vitro scratch assay: a 
convenient and inexpensive method for analysis of cell migration in vitro. Nature 
protocols, 2, 329-333. 
 
LIAO, J., HE, Q., LI, M., CHEN, Y., LIU, Y. & WANG, J. 2016. LncRNA MIAT: 
Myocardial infarction associated and more. Gene, 578, 158-161. 
 
LIAO, K., XIA, B., ZHUANG, Q.-Y., HOU, M.-J., ZHANG, Y.-J., LUO, B., QIU, Y., 
GAO, Y.-F., LI, X.-J. & CHEN, H.-F. 2015. Parthenolide inhibits cancer stem-like 
side population of nasopharyngeal carcinoma cells via suppression of the NF-
κB/COX-2 pathway. Theranostics, 5(3), p.302. 
 
LIEDTKE, C., MAZOUNI, C., HESS, K. R., ANDRÉ, F., TORDAI, A., MEJIA, J. A., 
SYMMANS, W. F., GONZALEZ-ANGULO, A. M., HENNESSY, B. & GREEN, M. 
2008. Response to neoadjuvant therapy and long-term survival in patients with 
triple-negative breast cancer. Journal of clinical oncology, 26, 1275-1281. 
 
LIN, A., LI, C., XING, Z., HU, Q., LIANG, K., HAN, L., WANG, C., HAWKE, D. H., 
WANG, S. & ZHANG, Y. 2016. The LINK-A lncRNA Activates Normoxic HIF1α 
Signaling in Triple-negative Breast Cancer. Nature cell biology, 18(2), pp.213-224.. 
 
LIN, C.-Y., STRÖM, A., VEGA, V. B., KONG, S. L., YEO, A. L., THOMSEN, J. S., 
CHAN, W. C., DORAY, B., BANGARUSAMY, D. K. & RAMASAMY, A. 2004. 
Discovery of estrogen receptor α target genes and response elements in breast 
tumor cells. Genome biology, 5(9), p.R66. 
 
LING, G.-Q., CHEN, D.-B., WANG, B.-Q. & ZHANG, L.-S. 2012. Expression of the 
pluripotency markers Oct3/4, Nanog and Sox2 in human breast cancer cell lines. 
Oncology letters, 4, 1264-1268. 
 
LINN, D. E., YANG, X., SUN, F., XIE, Y., CHEN, H., JIANG, R., CHEN, H., 
CHUMSRI, S., BURGER, A. M. & QIU, Y. 2010. A role for OCT4 in tumor initiation 
of drug-resistant prostate cancer cells. Genes & cancer, 1, 908-916. 
 
 LIU, H., LI, J., KOIRALA, P., DING, X., CHEN, B., WANG, Y., WANG, Z., WANG, 
C., ZHANG, X. & MO, Y.-Y. 2016. Long non-coding RNAs as prognostic markers 
in human breast cancer. Oncotarget, 7(15), p.20584. 
 
LIZ, J. & ESTELLER, M. 2016. LncRNAs and microRNAs with a role in cancer 
development. Biochimica et Biophysica Acta (BBA)-Gene Regulatory 
Mechanisms, 1859, 169-176. 
 
LO, P.-K., WOLFSON, B. & ZHOU, Q. 2016a. Cellular, physiological and 
pathological aspects of the long non-coding RNA NEAT1. Frontiers in Biology, 11, 
413-426. 
 
LO, P.-K., ZHANG, Y., WOLFSON, B., GERNAPUDI, R., YAO, Y., DURU, N. & 
ZHOU, Q. 2016b. Dysregulation of the BRCA1/long non-coding RNA NEAT1 
signaling axis contributes to breast tumorigenesis. Oncotarget, 7(40), p.65067. 
 
LONGLEY, D. B., HARKIN, D. P. & JOHNSTON, P. G. 2003. 5-fluorouracil: 
mechanisms of action and clinical strategies. Nature Reviews Cancer, 3, 330-338. 
 
LOTTIN, S., ADRIAENSSENS, E., DUPRESSOIR, T., BERTEAUX, N., 
MONTPELLIER, C., COLL, J., DUGIMONT, T. & CURGY, J. J. 2002. 
Overexpression of an ectopic H19 gene enhances the tumorigenic properties of 
breast cancer cells. Carcinogenesis, 23, 1885-1895. 
 
LOURO, R., SMIRNOVA, A. S. & VERJOVSKI-ALMEIDA, S. 2009. Long intronic 
noncoding RNA transcription: expression noise or expression choice? Genomics, 
93, 291-298. 
 
LOW, L.-H., CHOW, Y.-L., LI, Y., GOH, C.-P., PUTZ, U., SILKE, J., OUCHI, T., 
HOWITT, J. & TAN, S.-S. 2015. Nedd4 family interacting protein 1 (Ndfip1) is 
required for ubiquitination and nuclear trafficking of BRCA1-associated ATM 
activator 1 (BRAT1) during the DNA damage response. Journal of Biological 
Chemistry, 290, 7141-7150. 
 
 LUAN, T., ZHANG, X., WANG, S., SONG, Y., ZHOU, S., LIN, J., AN, W., YUAN, 
W., YANG, Y. & CAI, H. 2017. Long non-coding RNA MIAT promotes breast 
cancer progression and functions as ceRNA to regulate DUSP7 expression by 
sponging miR-155-5p. Oncotarget, 8(44), p.76153. 
 
LV, M., XU, P., WU, Y., HUANG, L., LI, W., LV, S., WU, X., ZENG, X., SHEN, R. & 
JIA, X. 2016. LncRNAs as new biomarkers to differentiate triple negative breast 
cancer from non-triple negative breast cancer. Oncotarget, 7(11), p.13047  
 
MA, X.-Y., WANG, J.-H., WANG, J.-L., MA, C. X., WANG, X.-C. & LIU, F.-S. 2015. 
Malat1 as an evolutionarily conserved lncRNA plays a positive role in regulating 
proliferation and maintaining undifferentiated status of early-stage hematopoietic 
cells. BMC genomics, 16(1), p.676. 
 
MA, Y., LIU, L., YAN, F., WEI, W., DENG, J. & SUN, J. 2016. Enhanced 
expression of long non-coding RNA NEAT1 is associated with the progression of 
gastric adenocarcinomas. World Journal of Surgical Oncology, 14(1), p.41. 
 
MACLACHLAN, T. K., TAKIMOTO, R. & EL-DEIRY, W. S. 2002. BRCA1 directs a 
selective p53-dependent transcriptional response towards growth arrest and DNA 
repair targets. Molecular and cellular biology, 22, 4280-4292. 
 
MACÉA, J. R. & FREGNANI, J. H. T. G. 2006. Anatomy of the Thoracic Wall, 
Axilla and Breast. Int. j. morphol, 24, 691-704. 
 
MALIH, S., SAIDIJAM, M. & MALIH, N. 2016. A brief review on long noncoding 
RNAs: a new paradigm in breast cancer pathogenesis, diagnosis and therapy. 
Tumor Biology, 37, 1479-1485. 
. 
MANG, Y., LI, L., RAN, J., ZHANG, S., LIU, J., LI, L., CHEN, Y., LIU, J., GAO, Y. 
& REN, G. 2017b. long noncoding rna NEAT1 promotes cell proliferation and 
invasion by regulating hnrnP a2 expression in hepatocellular carcinoma cells. 
OncoTargets and therapy, 10, p.1003.  
 
 MARCHESE, F. P. & HUARTE, M. 2014. Long non-coding RNAs and chromatin 
modifiers: their place in the epigenetic code. Epigenetics, 9, 21-26. 
 
MARTIANOV, I., RAMADASS, A., BARROS, A. S., CHOW, N. & AKOULITCHEV, 
A. 2007. Repression of the human dihydrofolate reductase gene by a non-coding 
interfering transcript. Nature, 445, 666-670. 
 
MARÉCHAL, A. & ZOU, L. 2013. DNA damage sensing by the ATM and ATR 
kinases. Cold Spring Harbor perspectives in biology, 5(9), p.a012716  
 
MATOUK, I. J., DEGROOT, N., MEZAN, S., AYESH, S., ABU-LAIL, R., 
HOCHBERG, A. & GALUN, E. 2007. The H19 non-coding RNA is essential for 
human tumor growth. PloS one, 2(9), p.e845 
 
MATSUMOTO, T., URUSHIDO, M., IDE, H., ISHIHARA, M., HAMADA-ODE, K., 
SHIMAMURA, Y., OGATA, K., INOUE, K., TANIGUCHI, Y. & TAGUCHI, T. 2015. 
Small heat shock protein beta-1 (HSPB1) is upregulated and regulates autophagy 
and apoptosis of renal tubular cells in acute kidney injury. PloS one, 10(5), 
p.e0126229 
 
MATTICK, J. S. & GAGEN, M. J. 2001. The evolution of controlled multitasked 
gene networks: the role of introns and other noncoding RNAs in the development 
of complex organisms. Molecular Biology and Evolution, 18, 1611-1630. 
 
MATTICK, J. S. & MAKUNIN, I. V. 2006. Non-coding RNA. Human molecular 
genetics, 15, R17-R29. 
 
MAZO, A., HODGSON, J. W., PETRUK, S., SEDKOV, Y. & BROCK, H. W. 2007. 
Transcriptional interference: an unexpected layer of complexity in gene regulation. 
Journal of cell science, 120, 2755-2761. 
 
MEIJER, D., VAN AGTHOVEN, T., BOSMA, P. T., NOOTER, K. & DORSSERS, L. 
C. 2006. Functional screen for genes responsible for tamoxifen resistance in 
human breast cancer cells. Molecular Cancer Research, 4, 379-386. 
 MENG, J., LI, P., ZHANG, Q., YANG, Z. & FU, S. 2014. A four-long non-coding 
RNA signature in predicting breast cancer survival. Journal of Experimental & 
Clinical Cancer Research, 33(1), p.84.  
 
MERCER, T. R., DINGER, M. E. & MATTICK, J. S. 2009. Long non-coding RNAs: 
insights into functions. Nature Reviews Genetics, 10, 155-159 
. 
MERCER, T. R., QURESHI, I. A., GOKHAN, S., DINGER, M. E., LI, G., MATTICK, 
J. S. & MEHLER, M. F. 2010. Long noncoding RNAs in neuronal-glial fate 
specification and oligodendrocyte lineage maturation. BMC neuroscience, 11, 14. 
 
MESEURE, D., VACHER, S., LALLEMAND, F., ALSIBAI, K. D., HATEM, R., 
CHEMLALI, W., NICOLAS, A., DE KONING, L., PASMANT, E. & CALLENS, C. 
2016. Prognostic value of a newly identified MALAT1 alternatively spliced 
transcript in breast cancer. British journal of cancer .114(12), pp.1395-1404. 
 
MOHAMED, J. S., GAUGHWIN, P. M., LIM, B., ROBSON, P. & LIPOVICH, L. 
2010. Conserved long noncoding RNAs transcriptionally regulated by Oct4 and 
Nanog modulate pluripotency in mouse embryonic stem cells. Rna, 16, 324-337. 
 
MORAN, V. A., PERERA, R. J. & KHALIL, A. M. 2012. Emerging functional and 
mechanistic paradigms of mammalian long non-coding RNAs. Nucleic acids 
research, 40, 6391-6400. 
 
MORRIS, K. V. 2009. Long antisense non-coding RNAs function to direct 
epigenetic complexes that regulate transcription in human cells. Epigenetics, 4, 
296-301. 
 
MORRIS, K. V., SANTOSO, S., TURNER, A.-M., PASTORI, C. & HAWKINS, P. G. 
2008. Bidirectional transcription directs both transcriptional gene activation and 
suppression in human cells. PLoS genetics, 4(11), p.e1000258. 
 
MOURTADA-MAARABOUNI, M., HASAN, A. M., FARZANEH, F. & WILLIAMS, G. 
T. 2010. Inhibition of human T-cell proliferation by mammalian target of rapamycin 
 (mTOR) antagonists requires noncoding RNA growth-arrest-specific transcript 5 
(GAS5). Molecular pharmacology, 78, 19-28. 
 
MOURTADA-MAARABOUNI, M., HEDGE, V. L., KIRKHAM, L., FARZANEH, F. & 
WILLIAMS, G. T. 2008. Growth arrest in human T-cells is controlled by the non-
coding RNA growth-arrest-specific transcript 5 (GAS5). Journal of cell science, 
121, 939-946. 
 
MOURTADA-MAARABOUNI, M., PICKARD, M., HEDGE, V., FARZANEH, F. & 
WILLIAMS, G. 2009. GAS5, a non-protein-coding RNA, controls apoptosis and is 
downregulated in breast cancer. Oncogene, 28, 195-208. 
 
MULLER, A. J., CHATTERJEE, S., TERESKY, A. & LEVINE, A. J. 1998. The gas5 
gene is disrupted by a frameshift mutation within its longest open reading frame in 
several inbred mouse strains and maps to murine chromosome 1. Mammalian 
genome, 9, 773-774 
. 
MURTHY, U. S. & RANGARAJAN, P. N. 2010. Identification of protein interaction 
regions of VINC/NEAT1/Men epsilon RNA. FEBS letters, 584, 1531-1535. 
 
MUSE, U. G., #MCH100106 4600-3387MAN [B] MUSE CELL CYCLE KIT USER'S 
GUIDE.https://www.emdmillipore.com/CA/en/product/Muse-Cell-Cycle-Assay-
Kit,MM_NF-MCH100106?_ga=2.201384465.1405426301.1496230800-
1415377981.1496230800. 
 
MUSE, U. S. G., #MCH100102 4600-3373MAN [B] MCH100102 & MCH600103 
MUSE COUNT  & VIABILITY KIT USER'S GUIDE. www.millipore.com. 
 
MUSE, U. S. G., #MCH100105 4600-3384MAN [B]  ANNEXIN V & DEAD CELL 
KIT 100 TEST USER'S GUIDE. www.millipore.com. 
 
MUSGROVE, E. A., CALDON, C. E., BARRACLOUGH, J., STONE, A. & 
SUTHERLAND, R. L. 2011. Cyclin D as a therapeutic target in cancer. Nature 
reviews. Cancer, 11(8), pp.558-572 
 NAGANO, T., MITCHELL, J. A., SANZ, L. A., PAULER, F. M., FERGUSON-
SMITH, A. C., FEIL, R. & FRASER, P. 2008. The Air noncoding RNA 
epigenetically silences transcription by targeting G9a to chromatin. Science, 322, 
1717-1720. 
 
NAGANUMA, T. & HIROSE, T. 2013. Paraspeckle formation during the biogenesis 
of long non-coding RNAs. RNA biology, 10, 456-461. 
 
NAGANUMA, T., NAKAGAWA, S., TANIGAWA, A., SASAKI, Y. F., GOSHIMA, N. 
& HIROSE, T. 2012. Alternative 3′‐end processing of long noncoding RNA initiates 
construction of nuclear paraspeckles. The EMBO journal, 31, 4020-4034. 
 
NAKAGAWA, S., IP, J. Y., SHIOI, G., TRIPATHI, V., ZONG, X., HIROSE, T. & 
PRASANTH, K. V. 2012. Malat1 is not an essential component of nuclear speckles 
in mice. Rna, 18, 1487-1499. 
 
NAKAGAWA, S., NAGANUMA, T., SHIOI, G. & HIROSE, T. 2011. Paraspeckles 
are subpopulation-specific nuclear bodies that are not essential in mice. The 
Journal of cell biology, jcb. 201011110. 
 
NAKAGAWA, S., SHIMADA, M., YANAKA, K., MITO, M., ARAI, T., TAKAHASHI, 
E., FUJITA, Y., FUJIMORI, T., STANDAERT, L. & MARINE, J.-C. 2014. The 
lncRNA Neat1 is required for corpus luteum formation and the establishment of 
pregnancy in a subpopulation of mice. Development, 141, 4618-4627. 
 
NAKASHIRO, K.-I., TANAKA, H., GODA, H., IWAMOTO, K., TOKUZEN, N., 
HARA, S., ONODERA, J., FUJIMOTO, I., HINO, S. & HAMAKAWA, H. 2015. 
Identification of Akt1 as a potent therapeutic target for oral squamous cell 
carcinoma. International journal of oncology, 47, 1273-1281. 
 
NETWORK, C. G. A. 2012. Comprehensive molecular portraits of human breast 
tumors. Nature, 490(7418), pp.61-70. 
 
 NEVILLE, M. C. & NEIFERT, M. R. 1983. An Introduction to Lactation and Breast-
Feeding. Lactation. Springer. 
 
NG, L. J., CROPLEY, J. E., PICKETT, H. A., REDDEL, R. R. & SUTER, C. M. 
2009. Telomerase activity is associated with an increase in DNA methylation at the 
proximal subtelomere and a reduction in telomeric transcription. Nucleic acids 
research, 37, 1152-1159. 
 
NGUYEN, V. T., KISS, T., MICHELS, A. A. & BENSAUDE, O. 2001. 7SK small 
nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature, 
414(6861), pp.322-325  
 
NIE, L., Wu, H.J., Hsu, J.M., Chang, S.S., LaBaff, A.M., Li, C.W., Wang, Y., Hsu, 
J.L. and Hung, M.C., 2012. Long non-coding RNAs: versatile master regulators of 
gene expression and crucial players in cancer. American journal of translational 
research, 4(2), p.127. 
 
NIK-ZAINAL, S., DAVIES, H., STAAF, J., RAMAKRISHNA, M., GLODZIK, D., 
ZOU, X., MARTINCORENA, I., ALEXANDROV, L. B., MARTIN, S. & WEDGE, D. 
C. 2016. Landscape of somatic mutations in 560 breast cancer whole-genome 
sequences. Nature, 534, 47-54. 
 
NOBILI, L., RONCHETTI, D., TAIANA, E. & NERI, A. 2017. Long non-coding 
RNAs in B-cell malignancies: a comprehensive overview. Oncotarget, 8(36), 
p.60605.  
 
OHNISHI, Y., TANAKA, T., YAMADA, R., SUEMATSU, K., MINAMI, M., FUJII, K., 
HOKI, N., KODAMA, K., NAGATA, S. & HAYASHI, T. 2000. Identification of 187 
single nucleotide polymorphisms (SNPs) among 41 candidate genes for ischemic 
heart disease in the Japanese population. Human genetics, 106, 288-292. 
 
OMURA-MINAMISAWA, M., DICCIANNI, M. B., BATOVA, A., CHANG, R. C., 
BRIDGEMAN, L. J., YU, J., PULLEN, J., BOWMAN, W. P. & ALICE, L. Y. 2000. 
Universal inactivation of both p16 and p15 but not downstream components is an 
 essential event in the pathogenesis of T-cell acute lymphoblastic leukemia. Clinical 
Cancer Research, 6, 1219-1228. 
 
ORGAN, S. L. & TSAO, M.-S. 2011. An overview of the c-MET signalling pathway. 
Therapeutic advances in medical oncology, 3, S7-S19. 
 
OSBORNE, C., WILSON, P. & TRIPATHY, D. 2004. Oncogenes and tumor 
suppressor genes in breast cancer: potential diagnostic and therapeutic 
applications. The oncologist, 9, 361-377. 
 
O’REILLY, E. A., GUBBINS, L., SHARMA, S., TULLY, R., GUANG, M. H. Z., 
WEINER-GORZEL, K., MCCAFFREY, J., HARRISON, M., FURLONG, F. & KELL, 
M. 2015. The fate of chemoresistance in triple negative breast cancer (TNBC). 
BBA clinical, 3, 257-275. 
 
PACHNIS, V., BELAYEW, A. & TILGHMAN, S. M. 1984. Locus unlinked to alpha-
fetoprotein under the control of the murine raf and Rif genes. Proceedings of the 
National Academy of Sciences, 81, 5523-5527. 
 
PAGEAU, G. J., HALL, L. L., GANESAN, S., LIVINGSTON, D. M. & LAWRENCE, 
J. B. 2007. The disappearing Barr body in breast and ovarian cancers. Nature 
reviews. Cancer, 7(8), pp.628-633. 
 
PARALKAR, V. R. & WEISS, M. J. 2013. Long noncoding RNAs in biology and 
haematopoiesis. Blood, 121, 4842-4846. 
 
PASMANT, E., LAURENDEAU, I., HÉRON, D., VIDAUD, M., VIDAUD, D. & 
BIECHE, I. 2007. Characterization of a germ-line deletion, including the entire 
INK4/ARF locus, in a melanoma-neural system tumor family: identification of 
ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. 
Cancer research, 67, 3963-3969. 
 
PATIL, M. A., LEE, S. A., MACIAS, E., LAM, E. T., XU, C., JONES, K. D., HO, C., 
RODRIGUEZ-PUEBLA, M. & CHEN, X. 2009. Role of Cyclin D1 as a Mediator of 
 c-Met–and β-Catenin–Induced Hepatocarcinogenesis. Cancer research, 69, 253-
261. 
 
PENG, W., WANG, Z. & FAN, H. 2016. LncRNA NEAT1 Impacts Cell Proliferation 
and Apoptosis of Colorectal Cancer via Regulation of Akt Signalling. Pathology & 
Oncology Research, 3(23), pp.651-656.  
 
PEROU, C. M., SØRLIE, T., EISEN, M. B., VAN DE RIJN, M., JEFFREY, S. S., 
REES, C. A., POLLACK, J. R., ROSS, D. T., JOHNSEN, H. & AKSLEN, L. A. 
2000. Molecular portraits of human breast tumours. Nature, 406, 747-752. 
 
PETROVICS, G., ZHANG, W., MAKAREM, M., STREET, J. P., CONNELLY, R., 
SUN, L., SESTERHENN, I. A., SRIKANTAN, V., MOUL, J. W. & SRIVASTAVA, S. 
2004. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-
promoting function, is associated with high-risk prostate cancer patients. 
Oncogene, 23(2), pp.605-611.. 
 
PICKARD, M. R. & WILLIAMS, G. T. 2014. Regulation of apoptosis by long non-
coding RNA GAS5 in breast cancer cells: implications for chemotherapy. Breast 
cancer research and treatment, 145, 359-370. 
 
PILECZKI, V., BRAICU, C., GHERMAN, C. D. & BERINDAN-NEAGOE, I. 2012. 
TNF-α gene knockout in triple negative breast cancer cell line induces apoptosis. 
International journal of molecular sciences, 14, 411-420. 
 
PILS, D., BACHMAYR-HEYDA, A., AUER, K., SVOBODA, M., AUNER, V., 
HAGER, G., OBERMAYR, E., REINER, A., REINTHALLER, A. & SPEISER, P. 
2014. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced 
stage serous ovarian cancer patients–A study of the OVCAD consortium. 
European journal of cancer, 50, 99-110. 
 
PINDER, S. E. 2010. Ductal carcinoma in situ (DCIS): pathological features, 
differential diagnosis, prognostic factors and specimen evaluation. Modern 
Pathology, 23, S8-S13. 
 PONJAVIC, J., PONTING, C. P. & LUNTER, G. 2007. Functionality or 
transcriptional noise? Evidence for selection within long noncoding RNAs. 
Genome research, 17, 556-565. 
 
POWELL, S. N. & KACHNIC, L. A. 2003. Roles of BRCA1 and BRCA2 in 
homologous recombination, DNA replication fidelity and the cellular response to 
ionizing radiation. Oncogene 22(37), pp.5784-5791.  
 
PRASANTH, K. V. & SPECTOR, D. L. 2007. Eukaryotic regulatory RNAs: an 
answer to the ‘genome complexity’conundrum. Genes & development, 21, 11-42. 
 
PRENSNER, J. R., IYER, M. K., BALBIN, O. A., DHANASEKARAN, S. M., CAO, 
Q., BRENNER, J. C., LAXMAN, B., ASANGANI, I. A., GRASSO, C. S. & 
KOMINSKY, H. D. 2011. Transcriptome sequencing across a prostate cancer 
cohort identifies PCAT-1, an unannotated lincRNA implicated in disease 
progression. Nature biotechnology, 29, 742-749. 
 
PROMEGA celltiter-96-aqueous-one-solution-cell-proliferation-assay-system-
protocol. https://www.promega.com/-/media/files/resources/protocols/technical-
bulletins/0/celltiter-96-aqueous-one-solution-cell-proliferation-assay-system-
protocol.pdf. 
 
QIAGEN 2010. HiPerFect Transfection Reagent Handbook [Online]. Available: 
https://www.qiagen.com/gb/shop/rnai/hiperfect-transfection-reagent [Accessed]. 
 
QIAGEN 2006. Purification of cytoplasmic RNA from animal cells using the 
RNeasy® Mini Kit. http://www.qiagen.com/ts/msds.asp. 
 
QIAGEN 2008. RNase-Free Water. 
https://www.qiagen.com/ch/resources/resourcedetail?id=93a4bb4b-596a-4779-
bab8-32e9a196a7e3&lang=en. 
 
QIAGEN 2010. HiPerFect Transfection Reagent Handbook, Sample and Assay 
Technologies. 
 https://www.qiagen.com/us/resources/download.aspx?id=c475824e-3da5-40b6-
9870-1752ffb015a6&lang=en. Fifth Edition  
 
QIAGEN. 2013. RT2 Profiler PCR Array Handbook [Online]. Available: 
http://www.qiagen.com [Accessed]. 
 
QIAGEN, # PAHS-131Z, P.-Z. Human Breast Cancer RT² Profiler PCR Array,. 
https://www.qiagen.com/us/shop/genes-and-pathways/complete.../breast-cancer/. 
QIAGEN, # PAHS-020Z, P.-Z. RT² Profiler™ PCR Array Human Cell Cycle, 
 
QIAN, K., LIU, G., TANG, Z., HU, Y., FANG, Y., CHEN, Z. & XU, X. 2016. The 
long non-coding RNA NEAT1 interacted with miR-101 modulates breast cancer 
growth by targeting EZH2. Archives of Biochemistry and Biophysics. 
 
QU, H. & FANG, X. 2013. A brief review on the Human Encyclopedia of DNA 
Elements (ENCODE) project. Genomics, proteomics & bioinformatics, 11, 135-
141. 
 
QUINN, J. J. & CHANG, H. Y. 2016. Unique features of long non-coding RNA 
biogenesis and function. Nature Reviews. Genetics, 17(1), pp.47-62.  
 
RAHO, G., BARONE, V., ROSSI, D., PHILIPSON, L. & SORRENTINO, V. 2000. 
The gas 5 gene shows four alternative splicing patterns without coding for a 
protein. Gene, 256, 13-17. 
 
RAKHA, E., EL-SAYED, M., MENON, S., GREEN, A., LEE, A. & ELLIS, I. 2008. 
Histologic grading is an independent prognostic factor in invasive lobular 
carcinoma of the breast. Breast Cancer Res Treat, 111, 121-127. 
 
RAKHA, E. A. & GREEN, A. R. 2017. Molecular classification of breast cancer: 
what the pathologist needs to know. Pathology. 49(2), pp.111-119. 
 
 RAO, S.-Q., HU, H.-L., YE, N., SHEN, Y. & XU, Q. 2015. Genetic variants in long 
non-coding RNA MIAT contribute to risk of paranoid schizophrenia in a Chinese 
Han population. Schizophrenia research, 166, 125-130. 
 
RAPICAVOLI, N. A., POTH, E. M. & BLACKSHAW, S. 2010. The long noncoding 
RNA RNCR2 directs mouse retinal cell specification. BMC developmental biology, 
10(1), p.49. 
 
RASOOL, M., MALIK, A., ZAHID, S., ASHRAF, M. A. B., QAZI, M. H., ASIF, M., 
ZAHEER, A., ARSHAD, M., RAZA, A. & JAMAL, M. S. 2016. Non-coding RNAs in 
cancer diagnosis and therapy. Non-coding RNA Research, 1, 69-76. 
 
RAVASI, T., SUZUKI, H., PANG, K. C., KATAYAMA, S., FURUNO, M., 
OKUNISHI, R., FUKUDA, S., RU, K., FRITH, M. C. & GONGORA, M. M. 2006. 
Experimental validation of the regulated expression of large numbers of non-
coding RNAs from the mouse genome. Genome research, 16, 11-19. 
 
RAVEH, E., MATOUK, I. J., GILON, M. & HOCHBERG, A. 2015. The H19 Long 
non-coding RNA in cancer initiation, progression and metastasis–a proposed 
unifying theory. Molecular cancer, 14(1), p.184.  
 
REDFERN, A. D., COLLEY, S. M., BEVERIDGE, D. J., IKEDA, N., EPIS, M. R., LI, 
X., FOULDS, C. E., STUART, L. M., BARKER, A. & RUSSELL, V. J. 2013. RNA-
induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA 
binding nuclear receptor coregulators. Proceedings of the National Academy of 
Sciences, 110, 6536-6541. 
 
REDON, S., REICHENBACH, P. & LINGNER, J. 2010. The non-coding RNA 
TERRA is a natural ligand and direct inhibitor of human telomerase. Nucleic acids 
research, 38, 5797-5806. 
 
REN, S., WANG, F., SHEN, J., SUN, Y., XU, W., LU, J., WEI, M., XU, C., WU, C. 
& ZHANG, Z. 2013. Long non-coding RNA metastasis associated in lung 
 adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker 
for diagnosing prostate cancer. European journal of cancer, 49, 2949-2959. 
 
RHEINBAY, E., PARASURAMAN, P., GRIMSBY, J., TIAO, G., ENGREITZ, J. M., 
KIM, J., LAWRENCE, M. S., TAYLOR-WEINER, A., RODRIGUEZ-CUEVAS, S. & 
ROSENBERG, M. 2017. Recurrent and functional regulatory mutations in breast 
cancer. Nature. 547(7661), pp.55-60 
 
RILEY, T., SONTAG, E., CHEN, P. & LEVINE, A. 2008. Transcriptional control of 
human p53-regulated genes. Nature reviews. Molecular cell biology, 9(5), pp.402-
412. 
 
RINN, J. L., KERTESZ, M., WANG, J. K., SQUAZZO, S. L., XU, X., BRUGMANN, 
S. A., GOODNOUGH, L. H., HELMS, J. A., FARNHAM, P. J. & SEGAL, E. 2007. 
Functional demarcation of active and silent chromatin domains in human HOX loci 
by noncoding RNAs. Cell, 129, 1311-1323. 
 
RINN, J.L. and ULE, J., 2014. 'Oming in on RNA–protein interactions. Genome 
biology, 15(1), p.401. 
 
ROMANO, A., ADRIAENS, M., KUENEN, S., DELVOUX, B., DUNSELMAN, G., 
EVELO, C. & GROOTHUIS, P. 2010. Identification of novel ER-α target genes in 
breast cancer cells: Gene-and cell-selective co-regulator recruitment at target 
promoters determines the response to 17β-estradiol and tamoxifen. Molecular and 
cellular endocrinology, 314, 90-100. 
 
ROSS, J. S., FLETCHER, J. A., LINETTE, G. P., STEC, J., CLARK, E., AYERS, 
M., SYMMANS, W. F., PUSZTAI, L. & BLOOM, K. J. 2003. The Her-2/neu gene 
and protein in breast cancer 2003: biomarker and target of therapy. The 
oncologist, 8, 307-325. 
 
ROSSIGNOL, F., VACHÉ, C. & CLOTTES, E. 2002. Natural antisense transcripts 
of hypoxia-inducible factor 1alpha are detected in different normal and tumour 
human tissues. Gene, 299, 135-140. 
 SAINSBURY, J., ANDERSON, T., MORGAN, D. & DIXON, J. 1994. ABC of breast 
diseases. Breast cancer. BMJ: British Medical Journal, 309(6962), p.1150. 
 
SASAKI, Y. T., IDEUE, T., SANO, M., MITUYAMA, T. & HIROSE, T. 2009. 
MENε/β noncoding RNAs are essential for structural integrity of nuclear 
paraspeckles. Proceedings of the National Academy of Sciences, 106, 2525-2530. 
 
SATTARI, A., SIDDIQUI, H., MOSHIRI, F., NGANKEU, A., NAKAMURA, T., 
KIPPS, T. J. & CROCE, C. M. 2016. Upregulation of long noncoding RNA MIAT in 
aggressive form of chronic lymphocytic leukemias. Oncotarget, 7, 54174-54182. 
 
SCHMIDT, L. H., SPIEKER, T., KOSCHMIEDER, S., HUMBERG, J., JUNGEN, D., 
BULK, E., HASCHER, A., WITTMER, D., MARRA, A. & HILLEJAN, L. 2011. The 
long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung 
cancer and induces migration and tumor growth. Journal of thoracic oncology, 6, 
1984-1992. 
 
SCHNEIDER, C., KING, R. M. & PHILIPSON, L. 1988. Genes specifically 
expressed at growth arrest of mammalian cells. Cell, 54, 787-793. 
 
SCHUFFNER, A., MORSHEDI, M., VAAMONDE, D., DURAN, E. H. & 
OEHNINGER, S. 2002. Effect of different incubation conditions on 
phosphatidylserine externalization and motion parameters of purified fractions of 
highly motile human spermatozoa. Journal of andrology, 23, 194-201. 
 
SCHWARTZ, D. & ROTTER, V. 1998. P53-dependent cell cycle control: response 
to genotoxic stress.  Seminars in cancer biology, Academic Press. 8,(5), pp. 325-
336).  
 
SCHWARTZ, J. C., YOUNGER, S. T., NGUYEN, N.-B., HARDY, D. B., MONIA, B. 
P., COREY, D. R. & JANOWSKI, B. A. 2008. Antisense transcripts are targets for 
activating small RNAs. Nature structural & molecular biology, 15, 842-848. 
 
 SHAY, J. W. & WRIGHT, W. E. 2000. Hayflick, his limit, and cellular ageing. 
Nature reviews Molecular cell biology, 1, 72-76. 
 
SHEN, W., LIANG, X.-H., SUN, H., DE HOYOS, C. L. & CROOKE, S. T. 2017. 
Depletion of NEAT1 lncRNA attenuates nucleolar stress by releasing sequestered 
P54nrb and PSF to facilitate c-Myc translation. PloS one, 12(3), p.e0173494  
 
SHEN, Y., DONG, L. F., ZHOU, R. M., YAO, J., SONG, Y. C., YANG, H., JIANG, 
Q. & YAN, B. 2016. Role of long non‐coding RNA MIAT in proliferation, apoptosis 
and migration of lens epithelial cells: a clinical and in vitro study. Journal of cellular 
and molecular medicine, 20, 537-548. 
 
SIPRASHVILI, Z., WEBSTER, D.E., KRETZ, M., JOHNSTON, D., RINN, J.L., 
CHANG, H.Y. and KHAVARI, P.A., 2012. Identification of proteins binding coding 
and non-coding human RNAs using protein microarrays. BMC genomics, 13(1), 
p.633. 
. 
SMID, M., WANG, Y., ZHANG, Y., SIEUWERTS, A. M., YU, J., KLIJN, J. G. M., 
FOEKENS, J. A. & MARTENS, J. W. M. 2008. Subtypes of Breast Cancer Show 
Preferential Site of Relapse. Cancer Research, 68, 3108-3114. 
SONE, M., HAYASHI, T., TARUI, H., AGATA, K., TAKEICHI, M. & NAKAGAWA, 
S. 2007. The mRNA-like noncoding RNA Gomafu constitutes a novel nuclear 
domain in a subset of neurons. J Cell Sci, 120, 2498-2506. 
 
SONG, B., YAN, J., LIU, C. & ZHOU, H. 2017. Long non-coding RNA NEAT1 
promotes metastasis via enhancing ZEB2 by sponging miR-662 in colorectal 
cancer. Int J Clin Exp Pathol, 10, 4470-4478. 
 
SOTO, J. L., CABRERA, C. M., SERRANO, S. & LÓPEZ-NEVOT, M. Á. 2005. 
Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, 
CDKN1A, CDKN2A, and CDKN2B. BMC cancer, 5(1), p.36.  
 
 SOULE, H., VAZQUEZ, J., LONG, A., ALBERT, S. & BRENNAN, M. 1973. A 
human cell line from a pleural effusion derived from a breast carcinoma. Journal of 
the National Cancer Institute, 51, 1409-1416. 
 
SOUTHWELL, A. L., SKOTTE, N. H., KORDASIEWICZ, H. B., ØSTERGAARD, M. 
E., WATT, A. T., CARROLL, J. B., DOTY, C. N., VILLANUEVA, E. B., 
PETOUKHOV, E. & VAID, K. 2014. In vivo evaluation of candidate allele-specific 
mutant huntingtin gene silencing antisense oligonucleotides. Molecular Therapy, 
22, 2093-2106. 
 
SPADARO, P. A., FLAVELL, C. R., WIDAGDO, J., RATNU, V. S., TROUP, M., 
RAGAN, C., MATTICK, J. S. & BREDY, T. W. 2015. Long noncoding RNA-
directed epigenetic regulation of gene expression is associated with anxiety-like 
behavior in mice. Biological psychiatry, 78, 848-859. 
 
SPECTOR, D. L. 2017. The Role of Long Non-Coding RNAs in Nuclear 
Organization and Disease. The FASEB Journal, 31(1 Supplement), pp.255-2. 
 
STANDAERT, L., ADRIAENS, C., RADAELLI, E., VAN KEYMEULEN, A., 
BLANPAIN, C., HIROSE, T., NAKAGAWA, S. & MARINE, J.-C. 2014. The long 
noncoding RNA Neat1 is required for mammary gland development and lactation. 
Rna, 20, 1844-1849. 
 
SU, F., LI, D., ZENG, M. and SONG, E., 2015. A Cytoplasmic NF-kB Interacting 
Long Noncoding RNA Blocks IkB Phosphorylation and Suppresses Breast Cancer 
Metastasis. Cancer Cell, 27, pp.370-381. 
 
SU, X., MALOUF, G. G., CHEN, Y., ZHANG, J., YAO, H., VALERO, V., 
WEINSTEIN, J. N., SPANO, J.-P., MERIC-BERNSTAM, F. & KHAYAT, D. 2014. 
Comprehensive analysis of long non-coding RNAs in human breast cancer clinical 
subtypes. Oncotarget, 5, 9864-9876. 
 
 SUN, C., LI, S., ZHANG, F., XI, Y., WANG, L., BI, Y. & LI, D. 2016. Long non-
coding RNA NEAT1 promotes non-small cell lung cancer progression through 
regulation of miR-377-3p-E2F3 pathway. Oncotarget, 7, 51784-51814. 
 
SUN, H., WANG, G., PENG, Y., ZENG, Y., ZHU, Q.-N., LI, T.-L., CAI, J.-Q., 
ZHOU, H.-H. & ZHU, Y.-S. 2015. H19 lncRNA mediates 17β-estradiol-induced cell 
proliferation in MCF-7 breast cancer cells. Oncology reports, 33, 3045-3052. 
 
SUN, Y., JIN, X., ZHANG, T., JIA, C. & CHEN, J. 2013. MiR-150-5p inhibits the 
proliferation and promoted apoptosis of pancreatic cancer cells. Zhonghua bing li 
xue za zhi Chinese journal of pathology, 42, 460-464. 
 
SUNWOO, H., DINGER, M. E., WILUSZ, J. E., AMARAL, P. P., MATTICK, J. S. & 
SPECTOR, D. L. 2009. MEN ε/β nuclear-retained non-coding RNAs are up-
regulated upon muscle differentiation and are essential components of 
paraspeckles. Genome research. 
 
SUZUKI, H., ZHOU, X., YIN, J., LEI, J., JIANG, H. Y., SUZUKI, Y., CHAN, T., 
HANNON, G. J., MERGNER, W. J. & ABRAHAM, J. M. 1995. Intragenic mutations 
of CDKN2B and CDKN2A in primary human esophageal cancers. Human 
molecular genetics, 4, 1883-1887. 
 
SØRENSEN, K. P., THOMASSEN, M., TAN, Q., BAK, M., COLD, S., BURTON, 
M., LARSEN, M. J. & KRUSE, T. A. 2013. Long non-coding RNA HOTAIR is an 
independent prognostic marker of metastasis in estrogen receptor-positive primary 
breast cancer. Breast cancer research and treatment, 142, 529-536. 
 
SØRLIE, T., PEROU, C. M., TIBSHIRANI, R., AAS, T., GEISLER, S., JOHNSEN, 
H., HASTIE, T., EISEN, M. B., VAN DE RIJN, M. & JEFFREY, S. S. 2001. Gene 
expression patterns of breast carcinomas distinguish tumor subclasses with 
clinical implications. Proceedings of the National Academy of Sciences, 98, 10869-
10874. 
 
 TABE, Y., SEBASIGARI, D., JIN, L., RUDELIUS, M., DAVIES-HILL, T., MIYAKE, 
K., MIIDA, T., PITTALUGA, S. & RAFFELD, M. 2009. MDM2 antagonist nutlin-3 
displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clinical 
Cancer Research, 15, 933-942. 
 
TAFT, R. J., PANG, K. C., MERCER, T. R., DINGER, M. & MATTICK, J. S. 2010. 
Non‐coding RNAs: regulators of disease. The Journal of pathology, 220, 126-139. 
 
TAYLOR, E. M. & LINDSAY, H. D. 2016. DNA replication stress and cancer: 
cause or cure? Future Oncology, 12, 221-237. 
 
TOLLERVEY, J. R., CURK, T., ROGELJ, B., BRIESE, M., CEREDA, M., KAYIKCI, 
M., KÖNIG, J., HORTOBÁGYI, T., NISHIMURA, A. L. & ŽUPUNSKI, V. 2011. 
Characterizing the RNA targets and position-dependent splicing regulation by 
TDP-43. Nature neuroscience, 14, 452-458. 
. 
TRIPATHI, V., ELLIS, J. D., SHEN, Z., SONG, D. Y., PAN, Q., WATT, A. T., 
FREIER, S. M., BENNETT, C. F., SHARMA, A. & BUBULYA, P. A. 2010. The 
nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by 
modulating SR splicing factor phosphorylation. Molecular cell, 39, 925-938. 
 
TRIPATHI, V., SHEN, Z., CHAKRABORTY, A., GIRI, S., FREIER, S. M., WU, X., 
ZHANG, Y., GOROSPE, M., PRASANTH, S. G. & LAL, A. 2013. Long noncoding 
RNA MALAT1 controls cell cycle progression by regulating the expression of 
oncogenic transcription factor B-MYB. PLoS Genet, 9(3), p.e1003368. 
 
TSAI, M.-C., MANOR, O., WAN, Y., MOSAMMAPARAST, N., WANG, J. K., LAN, 
F., SHI, Y., SEGAL, E. & CHANG, H. Y. 2010. Long noncoding RNA as modular 
scaffold of histone modification complexes. Science, 329, 689-693. 
 
TSAI, M.-C., SPITALE, R. C. & CHANG, H. Y. 2011. Long intergenic noncoding 
RNAs: new links in cancer progression. Cancer research, 71, 3-7. 
 
 TSUIJI, H., YOSHIMOTO, R., HASEGAWA, Y., FURUNO, M., YOSHIDA, M. & 
NAKAGAWA, S. 2011. Competition between a noncoding exon and introns: 
Gomafu contains tandem UACUAAC repeats and associates with splicing factor‐1. 
Genes to Cells, 16, 479-490. 
 
TURASHVILI, G., BOUCHAL, J., BAUMFORTH, K., WEI, W., DZIECHCIARKOVA, 
M., EHRMANN, J., KLEIN, J., FRIDMAN, E., SKARDA, J. & SROVNAL, J. 2007. 
Novel markers for differentiation of lobular and ductal invasive breast carcinomas 
by laser microdissection and microarray analysis. BMC cancer, 7. 
 
TUTUNEA-FATAN, E., MAJUMDER, M., XIN, X. & LALA, P. K. 2015. The role of 
CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis. 
Molecular cancer, 14(1), p.35. 
 
TUZLALI, S. 2016. Pathology of Breast Cancer. In: AYDINER, A., İĞCI, A. & 
SORAN, A. (eds.) Breast Disease: Diagnosis and Pathology. Cham: Springer 
International Publishing. pp 241-266.  
 
UCHIDA, T., ROSSIGNOL, F., MATTHAY, M. A., MOUNIER, R., COUETTE, S., 
CLOTTES, E. & CLERICI, C. 2004. Prolonged hypoxia differentially regulates 
hypoxia-inducible factor (HIF)-1α and HIF-2α expression in lung epithelial cells 
IMPLICATION OF NATURAL ANTISENSE HIF-1α. Journal of Biological 
Chemistry, 279, 14871-14878. 
 
UK, C. R. 2014. Breast cancer statistics [Online]. Available: 
http://www.cancerresearchuk.org/health [Accessed]. 
 
VALLABHAPURAPU, S. D., BLANCO, V. M., SULAIMAN, M. K., 
VALLABHAPURAPU, S. L., CHU, Z., FRANCO, R. S. & QI, X. 2015. Variation in 
human cancer cell external phosphatidylserine is regulated by flippase activity and 
intracellular calcium. Oncotarget, 6(33), p.34375 
. 
VAN DEN BRANDT, P. & GOLDBOHM, R. 2002. Breast cancer and 
breastfeeding: collaborative reanalysis of individual data from 47 epidemiological 
 studies in 30 countries, including 50302 women with breast cancer and 96973 
women without the disease. Collaborative Group on Hormonal Factors in Breast 
Cancer. Lancet, 360, 187-195. 
 
VANCE, K. W. & PONTING, C. P. 2014. Transcriptional regulatory functions of 
nuclear long noncoding RNAs. Trends in Genetics, 30, 348-355. 
 
VAUSORT, M., WAGNER, D. R. & DEVAUX, Y. 2014. Long Noncoding RNAs in 
Patients With Acute Myocardial Infarction Novelty and Significance. Circulation 
research, 115, 668-677. 
. 
VIALE, G. 2012. The current state of breast cancer classification. Annals of 
Oncology, 23, x207-x210. 
 
VIDAL, M., PARÉ, L. & PRAT, A. 2016. Molecular Classification of Breast Cancer. 
Management of Breast Diseases. Springer. 203-219 
 
VISINTIN, R. & AMON, A. 2000. The nucleolus: the magician’s hat for cell cycle 
tricks. Current opinion in cell biology, 12, 372-377. 
 
VODUC, K. D., CHEANG, M. C., TYLDESLEY, S., GELMON, K., NIELSEN, T. O. 
& KENNECKE, H. 2010. Breast cancer subtypes and the risk of local and regional 
relapse. Journal of Clinical Oncology, 28, 1684-1691. 
 
VOGELSTEIN, B., LANE, D. & LEVINE, A. J. 2000. Surfing the p53 network. 
Nature, 408, 307-310. 
 
WALSH, T., CASADEI, S., COATS, K. H., SWISHER, E., STRAY, S. M., 
HIGGINS, J., ROACH, K. C., MANDELL, J., LEE, M. K. & CIERNIKOVA, S. 2006. 
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high 
risk of breast cancer. Jama, 295, 1379-1388. 
 
 WALTON, M., SIRIMANNE, E., REUTELINGSPERGER, C., WILLIAMS, C., 
GLUCKMAN, P. & DRAGUNOW, M. 1997. Annexin V labels apoptotic neurons 
following hypoxia‐ischemia. Neuroreport, 8, 3871-3875. 
. 
WANG, J., YE, C., XIONG, H., SHEN, Y., LU, Y., ZHOU, J. & WANG, L. 2017a 
Dysregulation of long non-coding RNA in breast cancer: an overview of 
mechanism and clinical implication. Oncotarget, 8(3), p.5508. 
 
WANG, K. C. & CHANG, H. Y. 2011. Molecular mechanisms of long noncoding 
RNAs. Molecular cell, 43, 904-914. 
. 
WANG, P., WU, T., ZHOU, H., JIN, Q., HE, G., YU, H., XUAN, L., WANG, X., 
TIAN, L. & SUN, Y. 2016. Long noncoding RNA NEAT1 promotes laryngeal 
squamous cell cancer through regulating miR-107/CDK6 pathway. Journal of 
Experimental & Clinical Cancer Research, 35(1), p.22 
 
WANG, X., RUAN, Y., WANG, X., ZHAO, W., JIANG, Q., JIANG, C., ZHAO, Y., 
XU, Y., SUN, F. & ZHU, Y. 2017b. Long intragenic non‐coding RNA lincRNA‐p21 
suppresses development of human prostate cancer. Cell proliferation, 50(2). 
 
WANG, Y.-D., CAI, N., WU, X., CAO, H., XIE, L. & ZHENG, P. 2013. OCT4 
promotes tumorigenesis and inhibits apoptosis of cervical cancer cells by miR-
125b/BAK1 pathway. Cell death & disease, 4, e760. 
 
WATTS, J. K. & COREY, D. R. 2012. Silencing disease genes in the laboratory 
and the clinic. The Journal of pathology, 226, 365-379. 
 
WEAKLEY, S. M., WANG, H., YAO, Q. & CHEN, C. 2011. Expression and function 
of a large non-coding RNA gene XIST in human cancer. World journal of surgery, 
35, 1751-1756. 
 
WEIGELT, B., GEYER, F. C., NATRAJAN, R., LOPEZ‐GARCIA, M. A., AHMAD, 
A. S., SAVAGE, K., KREIKE, B. & REIS‐FILHO, J. S. 2010. The molecular 
underpinning of lobular histological growth pattern: a genome‐wide transcriptomic 
 analysis of invasive lobular carcinomas and grade‐and molecular subtype‐
matched invasive ductal carcinomas of no special type. The Journal of pathology, 
220, 45-57. 
 
WENG, L.-P., GIMM, O., KUM, J. B., SMITH, W. M., ZHOU, X.-P., WYNFORD-
THOMAS, D., LEONE, G. & ENG, C. 2001. Transient ectopic expression of PTEN 
in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell 
death. Human molecular genetics, 10, 251-258. 
 
WEST, M., BLANCHETTE, C., DRESSMAN, H., HUANG, E., ISHIDA, S., SPANG, 
R., ZUZAN, H., OLSON, J. A., MARKS, J. R. & NEVINS, J. R. 2001. Predicting the 
clinical status of human breast cancer by using gene expression profiles. 
Proceedings of the National Academy of Sciences, 98, 11462-11467. 
 
WHITMAN, G. J., SHEPPARD, D. G., PHELPS, M. J. & GONZALES, B. N. 2006. 
Breast cancer staging.  Seminars in roentgenology, WB Saunders, 91-104. 
 
WILLIAMS, G. T. & FARZANEH, F. 2012. Are snoRNAs and snoRNA host genes 
new players in cancer? Nature reviews cancer, 12, 84-88. 
 
WILLIAMS, G. T., HUGHES, J. P., STONEMAN, V., ANDERSON, C. L., 
MCCARTHY, N. J., MOURTADA-MAARABOUNI, M., PICKARD, M., HEDGE, V. 
L., TRAYNER, I. & FARZANEH, F. 2006. Isolation of genes controlling apoptosis 
through their effects on cell survival. Gene therapy & molecular biology, 10, 255. 
 
WILUSZ, J.E., SUNWOO, H. and SPECTOR, D.L., 2009. Long noncoding RNAs: 
functional surprises from the RNA world. Genes & development, 23(13), pp.1494-
1504. 
 
WINN, J. S., BAKER, M. G., FANOUS, I. S., SLACK-DAVIS, J. K., ATKINS, K. A. 
& DILLON, P. M. 2016. Lobular Breast Cancer and Abdominal Metastases: A 
Retrospective Review and Impact on Survival. Oncology, 91, 135-142. 
 
 WU, W., WAGNER, E. K., HAO, Y., RAO, X., DAI, H., HAN, J., CHEN, J., 
STORNIOLO, A. M. V., LIU, Y. & HE, C. 2016. Tissue-specific Co-expression of 
Long Non-coding and Coding RNAs Associated with Breast Cancer. Scientific 
Reports, 6, p.32731 
 
WU, Y., YANG, L., ZHAO, J., LI, C., NIE, J., LIU, F., ZHUO, C., ZHENG, Y., LI, B. 
& WANG, Z. 2015. Nuclear-enriched abundant transcript 1 as a diagnostic and 
prognostic biomarker in colorectal cancer. Molecular cancer, 14, 191. 
 
WU, Z.-Q., LI, X.-Y., HU, C. Y., FORD, M., KLEER, C. G. & WEISS, S. J. 2012. 
Canonical Wnt signaling regulates Slug activity and links epithelial–mesenchymal 
transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. 
Proceedings of the National Academy of Sciences, 109, 16654-16659. 
 
XING, Z., LIN, A., LI, C., LIANG, K., WANG, S., LIU, Y., PARK, P. K., QIN, L., 
WEI, Y. & HAWKE, D. H. 2014. LncRNA directs cooperative epigenetic regulation 
downstream of chemokine signals. Cell, 159, 1110-1125. 
 
XIONG, D.-D., FENG, Z.-B., CEN, W.-L., ZENG, J.-J., LIANG, L., TANG, R.-X., 
GAN, X.-N., LIANG, H.-W., LI, Z.-Y. & CHEN, G. 2017. The clinical value of 
lncRNA NEAT1 in digestive system malignancies: A comprehensive investigation 
based on 57 microarray and RNA-seq datasets. Oncotarget, 8, 17665. 
 
XU, S., WANG, P., YOU, Z., MENG, H., MU, G., BAI, X., ZHANG, G., ZHANG, J. 
& PANG, D. 2016. The long non-coding RNA EPB41L4A-AS2 inhibits tumor 
proliferation and is associated with favourable prognoses in breast cancer and 
other solid tumors. Oncotarget, 7, 20704. 
 
QU, X., DU, Y., SHU, Y., GAO, M., SUN, F., LUO, S., YANG, T., ZHAN, L., YUAN, 
Y., CHU, W. and PAN, Z., 2017. MIAT is a pro-fibrotic long non-coding rna 
governing cardiac fibrosis in post-infarct myocardium. Scientific reports, 7, 
p.42657.  
 
 YAMASHITA, A., IZUMI, N., KASHIMA, I., OHNISHI, T., SAARI, B., KATSUHATA, 
Y., MURAMATSU, R., MORITA, T., IWAMATSU, A. & HACHIYA, T. 2009. SMG-8 
and SMG-9, two novel subunits of the SMG-1 complex, regulate remodelling of the 
mRNA surveillance complex during nonsense-mediated mRNA decay. Genes & 
development, 23, 1091-1105. 
 
YAN, B., LIU, J., YAO, J., LI, X., WANG, X., LI, Y., TAO, Z., SONG, Y., CHEN, Q. 
& JIANG, Q. 2015. LncRNA-MIAT regulates microvascular dysfunction by 
functioning as a competing endogenous RNA. Circulation research, 
CIRCRESAHA. 114.305510. 
 
YAN, M.-D., HONG, C.-C., LAI, G.-M., CHENG, A.-L., LIN, Y.-W. & CHUANG, S.-
E. 2005. Identification and characterization of a novel gene Saf transcribed from 
the opposite strand of Fas. Human molecular genetics, 14, 1465-1474. 
 
YAN, R., WANG, K., PENG, R., WANG, S., CAO, J., WANG, P. & SONG, C. 
2016. Genetic variants in lncRNA SRA and risk of breast cancer. Oncotarget, 7, 
22486. 
 
YAN, Y., SKLIRIS, G. P., PENNER, C., CHOONIEDASS-KOTHARI, S., COOPER, 
C., NUGENT, Z., BLANCHARD, A., WATSON, P. H., MYAL, Y. & MURPHY, L. C. 
2009. Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic 
marker for estrogen receptor-positive/node-negative/younger breast cancer 
patients. Breast Cancer Research, 11, R67. 
 
YAN, Y., XU, Z., LI, Z., SUN, L. & GONG, Z. 2017. An insight into the increasing 
role of lncRNAs in the pathogenesis of gliomas. Frontiers in Molecular 
Neuroscience, 10. 
 
YANG, C., LI, Z., LI, Y., XU, R., WANG, Y., TIAN, Y. & CHEN, W. 2017a. Long 
non-coding RNA NEAT1 overexpression is associated with poor prognosis in 
cancer patients: a systematic review and meta-analysis. Oncotarget, 8, 2672. 
 
 YANG, J.-H., LI, J.-H., JIANG, S., ZHOU, H. & QU, L.-H. 2012a. ChIPBase: a 
database for decoding the transcriptional regulation of long non-coding RNA and 
microRNA genes from ChIP-Seq data. Nucleic acids research, 41, D177-D187. 
 
YANG, L., LIN, C., LIU, W., ZHANG, J., OHGI, K. A., GRINSTEIN, J. D., 
DORRESTEIN, P. C. & ROSENFELD, M. G. 2011a. ncRNA-and Pc2 methylation-
dependent gene relocation between nuclear structures mediates gene activation 
programs. Cell, 147, 773-788. 
 
YANG, S., ZHENG, J., MA, Y., ZHU, H., XU, T., DONG, K. & XIAO, X. 2012b. 
Oct4 and Sox2 are overexpressed in human neuroblastoma and inhibited by 
chemotherapy. Oncology reports, 28, 186-192. 
 
YANG, Y., WEN, L. and ZHU, H., 2015. Unveiling the hidden function of long non-
coding RNA by identifying its major partner-protein. Cell & bioscience, 5(1), p.59. 
 
YANG, X., XIAO, Z., DU, X., HUANG, L. & DU, G. 2017b. Silencing of the long 
non-coding RNA NEAT1 suppresses glioma stem-like properties through 
modulation of the miR-107/CDK6 pathway. Oncology reports, 37, 555-562. 
 
YANG, Z., ZHOU, L., WU, L.-M., LAI, M.-C., XIE, H.-Y., ZHANG, F. & ZHENG, S.-
S. 2011b. Overexpression of long non-coding RNA HOTAIR predicts tumor 
recurrence in hepatocellular carcinoma patients following liver transplantation. 
Annals of surgical oncology, 18, 1243-1250. 
 
YANG, Z., ZHU, Q., LUO, K. & ZHOU, Q. 2001. The 7SK small nuclear RNA 
inhibits the CDK9/cyclin T1 kinase to control transcription. Nature, 414, 317. 
 
YAO, H., BRICK, K., EVRARD, Y., XIAO, T., CAMERINI-OTERO, R. D. & 
FELSENFELD, G. 2010. Mediation of CTCF transcriptional insulation by DEAD-
box RNA-binding protein p68 and steroid receptor RNA activator SRA. Genes & 
development, 24, 2543-2555. 
 
 YAP, K. L., LI, S., MUÑOZ-CABELLO, A. M., RAGUZ, S., ZENG, L., MUJTABA, 
S., GIL, J., WALSH, M. J. & ZHOU, M.-M. 2010. Molecular interplay of the 
noncoding RNA ANRIL and methylated histone H3 lysine 27 by Polycomb CBX7 in 
transcriptional silencing of INK4a. Molecular cell, 38, 662-674. 
 
YERSAL, O. & BARUTCA, S. 2014. Biological subtypes of breast cancer: 
Prognostic and therapeutic implications. World journal of clinical oncology, 5, 412. 
 
YI, F., SHANG, Y., LI, B., DAI, S., WU, W., CHENG, L. & WANG, X. 2017. 
LncRNA MIAT promotes P19 cells differentiation into cardiomyocytes by sponging 
miR-150. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL 
PATHOLOGY, 10, 3662-3670. 
 
YOSHIDA, K. & MIKI, Y. 2004. Role of BRCA1 and BRCA2 as regulators of DNA 
repair, transcription, and cell cycle in response to DNA damage. Cancer science, 
95, 866-871. 
 
YU, J., LUO, H., LI, N. & DUAN, X. 2015. Suppression of Type I Collagen 
Expression by miR-29b Via PI3K, Akt, and Sp1 Pathway, Part II: An In Vivo 
InvestigationMiR-29b Controls In Vivo Expression of Type I Collagen. Investigative 
ophthalmology & visual science, 56, 6019-6028. 
 
YU, X., LI, Z., ZHENG, H., CHAN, M. T. & WU, W. K. K. 2017. NEAT1: A novel 
cancer‐related long non‐coding RNA. Cell proliferation. 
 
ZEMEL, S., BARTOLOMEI, M. S. & TILGHMAN, S. M. 1992. Physical linkage of 
two mammalian imprinted genes, H19 and insulin–like growth factor 2. Nature 
genetics, 2, 61-65. 
 
ZHANG, H., LIU, H., CHEN, Y., YANG, X., WANG, P., LIU, T., DENG, M., QIN, B., 
CORREIA, C. & LEE, S. 2016a. A cell cycle-dependent BRCA1–UHRF1 cascade 
regulates DNA double-strand break repair pathway choice. Nature 
communications, 7, 10201. 
 
 ZHANG, J., CHEN, M., CHEN, J., LIN, S., CAI, D., CHEN, C. & CHEN, Z. 2017a. 
Long non-coding RNA MIAT acts as a biomarker in diabetic retinopathy by 
absorbing miR-29b and regulating cell apoptosis. Bioscience reports, 37, 
BSR20170036. 
 
ZHANG, L., HAO, C., DONG, G. & TONG, Z. 2012. Analysis of clinical features 
and outcome of 356 triple-negative breast cancer patients in China. Breast Care, 
7, 13-17. 
 
ZHANG, M., WU, W., WANG, Z. & WANG, X. 2017b. LncRNA NEAT1 is closely 
related with progression of breast cancer via promoting proliferation and emt. Eur. 
Rev. Med. Pharmacol. Sci, 21, 1020-1026. 
 
ZHANG, M. H., MAN, H. T., ZHAO, X. D., DONG, N. & MA, S. L. 2014a. Estrogen 
receptor-positive breast cancer molecular signatures and therapeutic potentials 
(Review). Biomedical reports, 2, 41-52. 
 
ZHANG, X.-Q., SUN, S., LAM, K.-F., KIANG, K. M.-Y., PU, J. K.-S., HO, A. S.-W., 
LUI, W.-M., FUNG, C.-F., WONG, T.-S. & LEUNG, G. K.-K. 2013. A long non-
coding RNA signature in glioblastoma multiforme predicts survival. Neurobiology 
of disease, 58, 123-131. 
 
ZHANG, Y., HE, Q., HU, Z., FENG, Y., FAN, L., TANG, Z., YUAN, J., SHAN, W., 
LI, C. & HU, X. 2016b. Long noncoding RNA LINP1 regulates repair of DNA 
double-strand breaks in triple-negative breast cancer. Nature structural & 
molecular biology, 23, 522-530. 
 
ZHANG, Y., WAGNER, E. K., GUO, X., MAY, I., CAI, Q., ZHENG, W., HE, C. & 
LONG, J. 2016c. Long intergenic non-coding RNA expression signature in human 
breast cancer. Scientific Reports, 6. 
 
ZHANG, Z., WEAVER, D. L., OLSEN, D., PENG, Z., ASHIKAGA, T. & EVANS, M. 
F. 2015. Long non-coding RNA chromogenic in situ hybridisation signal pattern 
 correlation with breast tumour pathology. Journal of clinical pathology, jclinpath-
2015-203275. 
ZHU, N., GU, L., LI, F. & ZHOU, M. 2008. Inhibition of the Akt/survivin pathway 
synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia 
cells. Molecular cancer therapeutics, 7, 1101-1109. 
 
 
 
 
 
 
. 
 
 
 
 
 267 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Appendix 
 Appendix l 
 
Table 5.2 The 67-signiﬁcantly diﬀerentially expressed genes as illustrated by 
https://ipathwayguide.advaitabio.com/report/24273/contrast/294.  
symbol Name Genomic 
location 
Fold 
change 
p- value 
DEGS2 Delta 4-Desaturase, Sphingolipid 2 14q32.2 10 5.000 e-5 
RNF223 Ring Finger Protein 223 1p36.33 10 5.000 e-5 
HSPB1 Heat Shock Protein Family B (Small) Member 1 7q11.23 4.932 1.000e-4 
ISG15 ISG15 Ubiquitin-Like Modifier 1p36.33 5.243 1.000e4 
RPLP1 Ribosomal Protein Lateral Stalk Subunit P1 15q23 2.885 2.000e-4 
MIF Macrophage Migration Inhibitory Factor 22q11.23 6.349 4.000e-4 
CYBA Cytochrome B-245 Alpha Chain 16q24.2 3.201 6.000e-4 
C14orf80 Chromosome 14 Open Reading Frame 80 14q32.33 4.039 0.001 
LINC00116 Long Intergenic Non-Protein Coding RNA 116 2q13 4.106 0.003 
CHPF Chondroitin Polymerizing Factor 2q35 2.801 0.004 
CRIP2 Cysteine Rich Protein 2 14q32.33 5.012 0.004 
C8orf55 Thioesterase Superfamily Member 6 8q24.3 2.439 0.004 
NUBP2 Nucleotide Binding Protein 2 16p13.3 4.271 0.005 
H2AFJ H2A Histone Family Member J 12p12.3 2.768 0.006 
RPUSD1 RNA Pseudouridylate Synthase Domain Containing 1 16p13.3 4.303 0.006 
DPP7 Dipeptidyl Peptidase 7 9q34.3 3.303 0.006 
H1FX H1 Histone Family Member X 3q21.3 2.76 0.007 
PPDPF Pancreatic Progenitor Cell Differentiation And 
Proliferation Factor 
20q13.33 2.536 0.007 
GALK1 Galactokinase 1 17q25.1 4.042 0.007 
C9orf16 Chromosome 9 Open Reading Frame 16 9q34.11 3.896 0.007 
PPP1R16A Protein Phosphatase 1 Regulatory Subunit 16A 8q24.3 3.407 0.007 
MFSD3 Major Facilitator Superfamily Domain Containing 3 8q24.3 4.349 0.008 
PARP10 Poly(ADP-Ribose) Polymerase Family Member 10 8q24.3 3.107 0.009 
SCRIB Scribbled Planar Cell Polarity Protein 8q24.3 2.370 0.009 
TFF1 Trefoil Factor 1 21q22.3 2.307 0.014 
MRPL41 Mitochondrial Ribosomal Protein L41 9q34.3 2.912 0.014 
C9orf142 Chromosome 9 Open Reading Frame 142 9q34.3 2.864 0.014 
C9orf24 Chromosome 9 Open Reading Frame 24 9p13.3 3.933 0.015 
SPDEF SAM Pointed Domain Containing ETS Transcription 
Factor 
6p21.31 2.339 0.016 
CCDC85B Coiled-Coil Domain Containing 85B 11q13.1 4.161 0.018 
FBXL14 F-Box And Leucine Rich Repeat Protein 14 12p13.33 2.96 0.019 
PFKL Phosphofructokinase, Liver Type 21q22.3 1.703 0.02 
TSSC4 Tumor Suppressing Subtransferable Candidate 4 11p15.5 2.457 0.02 
E4F1 E4F Transcription Factor 1 16p13.3 2.659 0.021 
PKP3 Plakophilin 3 11p15.5 1.935 0.022 
FAM195B MAPK Regulated Corepressor Interacting Protein 1 17q25.3 2.86 0.022 
FBXL15 F-Box And Leucine Rich Repeat Protein 15 10q24.32 2.408 0.023 
NTHL1 Nth Like DNA Glycosylase 1 16p13.3 2.55 0.025 
BTBD2 BTB Domain Containing 2 19p13.3 2.523 0.027 
ALKBH7 AlkB Homolog 7 19p13.3 2.523 0.027 
FBXL14 F-Box And Leucine Rich Repeat Protein 14 12p13.33 2.96 0.019 
PFKL Phosphofructokinase, Liver Type 21q22.3 1.703 0.02 
FAM100A UBA Like Domain Containing 1 16p13.3 2.886 0.023 
ZNF598 Zinc Finger Protein 598 16p13.3 2.582 0.023 
FKBP8 FK506 Binding Protein 8 19p13.11 2.285 0.024 
 SSSCA1 Sjogren Syndrome/Scleroderma Autoantigen 1 11q13.1 2.484 0.027 
MED16 Mediator Complex Subunit 16 19p13.3 2.489 0.028 
RASSF7 Ras Association Domain Family Member 7 11p15.5 1.999 0.032 
FAM195A MAPK Regulated Corepressor Interacting Protein 2 16p13.3 2.247 0.032 
SCAND1 SCAN Domain Containing 1 20q11.23 4.419 0.033 
POLRMT RNA Polymerase Mitochondrial 19p13.3 2.331 0.034 
TP53I13 Tumor Protein P53 Inducible Protein 13 17q11.2 2.249 0.034 
DGCR6L DiGeorge Syndrome Critical Region Gene 6 Like 22q11.21 2.245 0.035 
FLYWCH2 FLYWCH Family Member 2 16p13.3 2.212 0.036 
RPS15 Ribosomal Protein S15 19p13.3 2.241 0.038 
MRPL55 Mitochondrial Ribosomal Protein L55 1q42.13 2.346 0.039 
BRAT1 BRCA1 Associated ATM Activator 1 7p22.3 1.815 0.039 
NPDC1 Neural Proliferation, Differentiation And Control 1 9q34.3 2.258 0.04 
MVD Mevalonate Diphosphate Decarboxylase 16q24.2 2.38 0.04 
ISG20 Interferon Stimulated Exonuclease Gene 20 15q26.1 2.188 0.042 
BCL7C BCL Tumor Suppressor 7C 16p11.2 2.227 0.044 
COMTD1 Catechol-O-Methyltransferase Domain Containing 1 10q22.2 2.732 0.045 
NUDT8 Nudix Hydrolase 8 11q13.2 10 0.047 
TIGD5 Tigger Transposable Element Derived 5 8q24.3 2.745 0.048 
ANAPC11 Anaphase Promoting Complex Subunit 11 17q25.3 2.130 0.048 
RNH1 Ribonuclease/Angiogenin Inhibitor 1 11p15.5 1.834 0.049 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 5.3 NEAT1 downregulation effect on biological pathway as detected by Reactome 
database  
Pathway name Submitted 
entities found 
Pathway name 
Submitted 
entities 
found 
Activation of gene 
 expression by SREBF (SREBP) 
FASN;MVD 
Mitochondrial translation  
termination 
MRPL41;MR
PL55 
Regulation of cholesterol 
 biosynthesis by SREBP 
(SREBF) 
FASN;MVD 
Mitochondrial translation  
elongation 
MRPL41;MR
PL55 
Defective GALK1 can cause 
 Galactosemia II (GALCT2) 
GALK1 Influenza Infection 
RPS15;RPLP1
;ISG15 
Mitochondrial transcription 
 initiation 
POLRMT Metabolism of steroids FASN;MVD 
Transcription from 
mitochondrial 
 promoters 
POLRMT 
Mitochondrial translation 
initiation 
MRPL41;MR
PL55 
Glycogen storage disease 
 type II (GAA) 
GAA 
Interleukin-12 family 
signalling 
MIF 
Lysosomal glycogen 
 catabolism 
GAA Phosphorylation of the APC/C ANAPC11 
Recognition and association 
 of DNA glycosylase with site 
 containing an affected 
pyrimidine 
NTHL1 Peptide chain elongation RPS15;RPLP1 
ChREBP activates metabolic 
 gene expression 
FASN 
Inactivation of APC/C via 
direct inhibition of the APC/C 
complex 
ANAPC11 
Displacement of DNA  
glycosylase by APEX1 
NTHL1 
Inhibition of the proteolytic 
activity of APC/C required for 
the onset of anaphase by 
mitotic spindle checkpoint 
components 
ANAPC11 
Attachment of GPI  
anchor to uPAR 
GPAA1 
Nonsense Mediated Decay 
(NMD) independent of the 
Exon Junction Complex (EJC) 
RPS15;RPLP1 
Gene and protein expression 
 by JAK-STAT signalling after 
 Interleukin-12 stimulation 
MIF Mitochondrial translation 
MRPL41;MR
PL55 
Cross-presentation of 
 particulate exogenous 
 antigens (phagosomes) 
CYBA 
Conversion from 
APC/C:Cdc20 to APC/C:Cdh1 
in late anaphase 
ANAPC11 
Transcriptional activation 
 of mitochondrial biogenesis 
POLRMT 
Eukaryotic Translation 
Elongation 
RPS15;RPLP1 
Galactose catabolism GALK1 Translation 
MRPL41;RPS
15;RPLP1;M
RPL55 
Senescence-Associated  
Secretory Phenotype (SASP) 
H2AFJ;ANAPC1
1 
Glycogen storage diseases GAA 
Depyrimidination NTHL1 
Formation of a pool of free 
40S subunits 
RPS15;RPLP1 
 Neutrophil degranulation 
PFKL;DPP7;GA
A;CYBA;MIF 
Negative regulators of 
DDX58/IFIH1 signalling 
ISG15 
Cleavage of the damaged  
pyrimidine  
NTHL1 
Interferon alpha/beta 
signalling 
ISG20;ISG15 
Base-Excision Repair, AP Site 
Formation 
NTHL1 Metabolism of carbohydrates 
PFKL;CHPF;G
AA;GALK1 
Synthesis of Dolichyl-
phosphate 
MVD 
Diseases associated with 
glycosylation precursor 
biosynthesis 
GALK1 
Viral mRNA Translation RPS15;RPLP1 HSF1 activation HSPB1 
APC-Cdc20 mediated 
degradation of Nek2A 
ANAPC11 Glycogen metabolism GAA 
RHO GTPases Activate 
NADPH Oxidases 
CYBA 
PRC2 methylates histones 
and DNA 
H2AFJ 
Chondroitin sulfate 
biosynthesis 
CHPF 
 NS1 Mediated Effects on 
Host Pathways 
ISG15 
Selenocysteine synthesis RPS15;RPLP1 
SIRT1 negatively regulates 
rRNA expression 
H2AFJ 
L13a-mediated translational 
silencing of Ceruloplasmin 
expression 
RPS15;RPLP1 Attenuation phase HSPB1 
Glycogen breakdown 
(glycogenolysis) 
GAA 
Resolution of Abasic Sites (AP 
sites) 
NTHL1 
SRP-dependent 
cotranslational protein 
targeting to membrane 
RPS15;RPLP1 
ERCC6 (CSB) and EHMT2 
(G9a) positively regulate 
rRNA expression 
H2AFJ 
GTP hydrolysis and joining of 
the 60S ribosomal subunit 
RPS15;RPLP1 
Vitamin B5 (pantothenate) 
metabolism 
FASN 
Nonsense-Mediated Decay 
(NMD) 
RPS15;RPLP1 DNA methylation H2AFJ 
Nonsense Mediated Decay 
(NMD) enhanced by the Exon 
Junction Complex (EJC) 
RPS15;RPLP1 
Negative regulators of 
DDX58/IFIH1 signalling 
ISG15 
VEGFA-VEGFR2 Pathway HSPB1;CYBA 
Interferon alpha/beta 
signalling 
ISG20;ISG15 
signalling by BMP MIF Metabolism of carbohydrates 
PFKL;CHPF;G
AA;GALK1 
Mitochondrial biogenesis POLRMT 
Diseases associated with 
glycosylation precursor 
biosynthesis 
GALK1 
Eukaryotic Translation 
Initiation 
RPS15;RPLP1 HSF1 activation HSPB1 
Cap-dependent Translation 
Initiation 
RPS15;RPLP1 Glycogen metabolism GAA 
RNA Polymerase I Promoter 
Opening 
H2AFJ 
PRC2 methylates histones 
and DNA 
H2AFJ 
Host Interactions with 
Influenza Factors 
ISG15 
Auto degradation of Cdh1 by 
Cdh1:APC/C 
ANAPC11 
Activated PKN1 stimulates 
transcription of AR (androgen 
receptor) regulated genes 
H2AFJ 
Translation initiation complex 
formation 
RPS15 
 KLK2 and KLK3 
Influenza Viral RNA 
Transcription and Replication 
RPS15;RPLP1 
RNA Polymerase I Chain 
Elongation 
H2AFJ 
Class I MHC mediated antigen 
processing & presentation 
FBXL15;CYBA;F
BXL14;ANAPC1
1 
Cellular Senescence 
H2AFJ;ANAP
C11 
Antigen processing: 
Ubiquitination & Proteasome 
degradation 
FBXL15;FBXL14
;ANAPC11 
Detoxification of Reactive 
Oxygen Species 
CYBA 
ROS, RNS production in 
phagocytes 
CYBA Cellular responses to stress 
H2AFJ;HSPB
1;CYBA;ANA
PC11 
RMTs methylate histone 
arginines 
H2AFJ 
Ribosomal scanning and start 
codon recognition 
RPS15 
Deposition of new CENPA-
containing nucleosomes at 
the centromere 
H2AFJ 
Asymmetric localization of 
PCP proteins 
SCRIB 
Nucleosome assembly H2AFJ 
Regulation of expression of 
SLITs and ROBOs 
RPS15;RPLP1 
Formation of the ternary 
complex, and subsequently, 
the 43S complex 
RPS15 
AUF1 (hnRNP D0) binds and 
destabilizes mRNA 
HSPB1 
Condensation of Prophase 
Chromosomes 
H2AFJ 
HSF1-dependent 
transactivation 
HSPB1 
Selenoamino acid 
metabolism 
RPS15;RPLP1 
APC/C:Cdc20 mediated 
degradation of Securing 
ANAPC11 
DNA Damage Bypass ISG15 
Activation of the mRNA upon 
binding of the cap-binding 
complex and eIFs, and 
subsequent binding to 43S 
RPS15 
Influenza Life Cycle RPS15;RPLP1 
Formation of the beta-
catenin:TCF trans activating 
complex 
H2AFJ 
Meiotic recombination H2AFJ 
Regulation of APC/C 
activators between G1/S and 
early anaphase 
ANAPC11 
Major pathway of rRNA 
processing in the nucleolus 
and cytosol 
RPS15;RPLP1 
Amino acid synthesis and 
interconversion 
(transamination) 
PPP1R16A 
rRNA processing in the 
nucleus and cytosol 
RPS15;RPLP1 
RNA Polymerase I Promoter 
Clearance 
H2AFJ 
DNA Damage/Telomere 
Stress Induced Senescence 
H2AFJ 
Antiviral mechanism by IFN-
stimulated genes 
ISG15 
APC/C:Cdh1 mediated 
degradation of Cdc20 and 
other APC/C:Cdh1 targeted 
proteins in late mitosis/early 
G1 
ANAPC11 ISG15 antiviral mechanism ISG15 
Cdc20:Phospho-APC/C 
mediated degradation of 
Cyclin A 
ANAPC11 
NoRC negatively regulates 
rRNA expression 
H2AFJ 
 Cholesterol biosynthesis MVD Signaling by ROBO receptors RPS15;RPLP1 
APC:Cdc20 mediated 
degradation of cell cycle 
proteins prior to satisfation 
of the cell cycle checkpoint 
ANAPC11 Nicotinate metabolism PARP10 
Chondroitin 
sulfate/dermatan sulfate 
metabolism 
CHPF Neddylation 
FBXL15;FBXL
14 
APC/C:Cdc20 mediated 
degradation of mitotic 
proteins 
ANAPC11 
RNA Polymerase I 
Transcription 
H2AFJ 
Activation of APC/C and 
APC/C:Cdc20 mediated 
degradation of mitotic 
proteins 
ANAPC11 
DDX58/IFIH1-mediated 
induction of interferon-
alpha/beta 
ISG15 
RUNX1 regulates genes 
involved in megakaryocyte 
differentiation and platelet 
function 
H2AFJ rRNA processing RPS15;RPLP1 
Telomere Maintenance H2AFJ 
APC/C-mediated degradation 
of cell cycle proteins 
ANAPC11 
Transcriptional regulation by 
small RNAs 
H2AFJ 
Regulation of mitotic cell 
cycle 
ANAPC11 
Fatty acyl-CoA biosynthesis FASN 
Negative epigenetic 
regulation of rRNA expression 
H2AFJ 
Sphingolipid de novo 
biosynthesis 
DEGS2 Meiosis H2AFJ 
Positive epigenetic regulation 
of rRNA expression 
H2AFJ 
Metabolism of water-soluble 
vitamins and cofactors 
PARP10;FAS
N 
RHO GTPases activate PKNs H2AFJ 
Regulation of mRNA stability 
by proteins that bind AU-rich 
elements 
HSPB1 
Diseases of carbohydrate 
metabolism 
GAA 
Cellular responses to external 
stimuli 
H2AFJ;HSPB
1;CYBA;ANA
PC11 
Post-translational 
modification: synthesis of 
GPI-anchored proteins 
GPAA1 PCP/CE pathway SCRIB 
Activation of anterior HOX 
genes in hindbrain 
development during early 
embryogenesis 
H2AFJ 
Regulation of lipid 
metabolism by Peroxisome 
proliferator-activated 
receptor alpha (PPARalpha) 
MED16 
Activation of HOX genes 
during differentiation 
H2AFJ M Phase 
H2AFJ;ANAP
C11 
Interferon Signaling ISG20;ISG15 
Glycosaminoglycan 
metabolism 
CHPF 
Reproduction H2AFJ 
Antigen processing-Cross 
presentation 
CYBA 
RHO GTPase Effectors H2AFJ;CYBA Adaptive Immune System 
NPDC1;FBXL
15;CYBA;FBX
L14;ANAPC1
 1 
Synthesis of substrates in N-
glycan biosynthesis 
MVD Diseases of glycosylation GALK1 
Cellular response to heat 
stress 
HSPB1 
Separation of Sister 
Chromatids 
ANAPC11 
Mitotic Prophase H2AFJ 
Ub-specific processing 
proteases 
FKBP8 
Formation of the cornified 
envelope 
PKP3 Mitotic Anaphase ANAPC11 
Glucose metabolism PFKL 
Mitotic Metaphase and 
Anaphase 
ANAPC11 
Signalling by WNT H2AFJ;SCRIB 
Metabolism of amino acids 
and derivatives 
RPS15;RPLP1
;PPP1R16A 
Epigenetic regulation of gene 
expression 
H2AFJ 
TCF dependent signalling in 
response to WNT 
H2AFJ 
Integration of energy 
metabolism 
FASN Diseases of metabolism GAA 
Organelle biogenesis and 
maintenance 
POLRMT Signalling by Rho GTPases H2AFJ;CYBA 
Infectious disease 
RPS15;RPLP1;IS
G15 
Keratinization PKP3 
DNA Repair NTHL1;ISG15 Innate Immune System 
PFKL;DPP7;G
AA;CYBA;ISG
15;MIF 
Sphingolipid metabolism DEGS2 Metabolism of lipids 
FASN;MVD;D
EGS2;MED16 
  
Cell surface interactions at 
the vascular wall 
MIF 
Metabolism of vitamins and 
cofactors 
PARP10;FASN Chromatin organization H2AFJ 
Biosynthesis of the N-glycan 
precursor (dolichol lipid-
linked oligosaccharide, LLO) 
and transfer to a nascent 
protein 
MVD Chromosome Maintenance H2AFJ 
Beta-catenin independent 
WNT signalling 
SCRIB 
RUNX1 regulates 
transcription of genes 
involved in differentiation of 
HSCs 
H2AFJ 
PPARA activates gene 
expression 
MED16 MAPK6/MAPK4 signalling HSPB1 
Gene Silencing by RNA H2AFJ 
Transcriptional regulation of 
white adipocyte 
differentiation 
MED16 
Signaling by TGF-beta family 
members 
MIF Glycolysis PFKL 
Oxidative Stress Induced 
Senescence 
H2AFJ Mitotic Spindle Checkpoint ANAPC11 
Immune System 
NPDC1;ISG20;P
FKL;DPP7;GAA;
FBXL15;CYBA;I
Regulation of HSF1-mediated 
heat shock response 
HSPB1 
  
 
 
SG15;MIF;FBXL
14;ANAPC11 
Chromatin modifying 
enzymes 
H2AFJ Deubiquitination FKBP8 
Developmental Biology 
RPS15;H2AFJ;R
PLP1;PKP3; 
imm16 
Metabolism of RNA 
RPS15;RPLP1
;HSPB1 
Transcriptional regulation by 
RUNX1 
H2AFJ Cell Cycle, Mitotic 
H2AFJ;ANAP
C11 
Cell Cycle Checkpoints ANAPC11 
Immunoregulatory 
interactions between a 
Lymphoid and a non-
Lymphoid cell 
NPDC1 
Axon guidance RPS15;RPLP1 Cell Cycle 
H2AFJ;ANAP
C11 
Signaling by Receptor 
Tyrosine Kinases 
HSPB1;CYBA 
Asparagine N-linked 
glycosylation 
MVD 
MAPK family signaling 
cascades 
HSPB1 Metabolism of proteins 
MRPL41;RPS
15;GPAA1;R
PLP1;FKBP8;
MVD;FBXL15
;FBXL14;MR
PL55 
Cytokine signalling in Immune 
system 
ISG20;ISG15; 
MIF 
Fatty acid metabolism FASN 
Metabolism 
CHPF;GAA;RPL
P1;PPP1R16A;
MED16;NUBP2
;RPS15;PARP10
;PFKL;FASN;MV
D;DEGS2;GALK
1 
Disease 
RPS15;RPLP1
;GAA;ISG15;
GALK1 
Signaling by Interleukins MIF 
Post-translational protein 
modification 
GPAA1;FKBP
8;MVD;FBXL
15;FBXL14 
Hemostasis MIF Nicotinamide salvaging PARP10 
Gene expression 
(Transcription) 
H2AFJ;POLRMT
;MED16 
Base Excision Repair NTHL1 
Generic Transcription 
Pathway 
H2AFJ;MED16 
B-WICH complex positively 
regulates rRNA expression 
H2AFJ 
RNA Polymerase II 
Transcription 
H2AFJ;MED16 Meiotic synapsis H2AFJ 
Signal Transduction 
H2AFJ;HSPB1;S
CRIB;CYBA;MIF 
  
  
Figure 5.7 Log scale to show the coverage (grey bars) over the NEAT1 short and long isoform. 
The diagram was obtained from Integrative Genomics Viewer (IGV). 
 
 
 
 
 
 
 
